omeprazole has been researched along with Gastroesophageal Reflux in 1085 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Gastroesophageal Reflux: Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gastroesophageal reflux was observed in 55% (11/20) of control dogs, 55% (11/20) of dogs receiving omeprazole once and 47% (7/15) of dogs receiving omeprazole twice." | 9.41 | Effect of two different pre-anaesthetic omeprazole protocols on gastroesophageal reflux incidence and pH in dogs. ( Boscan, P; Bryan, S; Fukushima, K; Krause, L; Lotti, F; Twedt, D; Vaca, C; Warrit, K, 2021) |
| "Forty-five participants were randomised (23 to omeprazole, 22 to placebo), with 40 (20 in each group) having cough monitoring before and after treatment." | 9.30 | Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis. ( Dutta, P; Forbes, R; Forrest, IA; Funston, W; Griffin, SM; Jones, R; Mossop, H; Pearson, J; Ryan, V; Sen, S; Simpson, AJ; Smith, JA; Ward, C, 2019) |
| "We investigated whether the prokinetic activity of mosapride, a 5-hydroxytryptamine 4 receptor agonist, in combination with proton pump inhibitor (PPI) would ameliorate symptoms of gastroesophageal reflux disease (GERD) in Japanese patients." | 9.19 | Randomized controlled trial comparing the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in gastroesophageal reflux disease. ( Hirata, Y; Isomura, Y; Koike, K; Yamada, A; Yamaji, Y; Yoshida, S, 2014) |
| "To compare pharmacokinetics between immediate and delayed-release omeprazole in patients with GERD associated with gastroparesis." | 9.14 | Pharmacokinetic profile of immediate-release omeprazole in patients with gastro-oesophageal reflux associated with gastroparesis. ( Eversmann, J; Mann, S; Wo, JM, 2010) |
| "Melatonin has a role in the improvement of Gastro-esophageal reflux disease when used alone or in combination with omeprazole." | 9.14 | The potential therapeutic effect of melatonin in Gastro-Esophageal Reflux Disease. ( Abbas, AM; El-Gendy, AA; Kandil, TS; Mousa, AA, 2010) |
| "To estimate the effect of double omeprazole dose on the course of angina pectoris and treadmill stress test in patients with coronary artery disease (CAD), using double-blind, crossover randomised, placebo-controlled study design." | 9.13 | The effect of double dose of omeprazole on the course of angina pectoris and treadmill stress test in patients with coronary artery disease--a randomised, double-blind, placebo controlled, crossover trial. ( Budzyński, J; Fabisiak, J; Kłopocka, M; Majer, M; Pulkowski, G; Suppan, K; Swiatkowski, M, 2008) |
| "We investigated whether the treatment of gastrooesophageal reflux with omeprazole is able to decrease apnoea attacks." | 9.12 | Obstructive sleep apnoea is improved by a prolonged treatment of gastrooesophageal reflux with omeprazole. ( Bortolotti, M; Gentilini, L; Giovannini, M; Morselli, C, 2006) |
| "Out of 45 patients referred for unexplained chronic persistent cough, 36 had at least one of the GI investigations (endoscopy, 24-h esophageal pH-metry and a 4-week trial of proton pump inhibitor (PPI) therapy) positive and were randomly assigned to receive either 30 mg lansoprazole o." | 9.12 | Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough: a comparison between two different daily doses of lansoprazole. ( Baldi, F; Cappiello, R; Cavoli, C; Ghersi, S; Roda, E; Torresan, F, 2006) |
| "The objective of the open, randomised, four-period crossover study was to compare the time of onset of effect of sodium alginate (SA), omeprazole, ranitidine and control, based on oesophageal and intragastric pH and to determine any correlation between reflux symptoms and episodes in volunteers suffering from occasional gastro-oesophageal reflux." | 9.12 | Rapid onset of effect of sodium alginate on gastro-oesophageal reflux compared with ranitidine and omeprazole, and relationship between symptoms and reflux episodes. ( Bryan, J; Dettmar, PW; Little, SL; Sykes, J, 2006) |
| "To evaluate symptom improvement in 53 children (aged 5-11 years) with endoscopically proven gastroesophageal reflux disease (GERD) treated with pantoprazole (10, 20 and 40 mg) using the GERD Assessment of Symptoms in Pediatrics Questionnaire." | 9.12 | Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. ( Bishop, PR; Comer, GM; Gremse, D; Soffer, EF; Tolia, V; Tsou, VM, 2006) |
| "We sought to evaluate safety and efficacy of IV pantoprazole when used as initial therapy in patients with gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) in a double-blind, placebo-controlled, randomized, parallel-group study." | 9.12 | Intravenous pantoprazole as initial treatment in patients with gastroesophageal reflux disease and a history of erosive esophagitis: a randomized clinical trial. ( Field, B; Hogan, DL; Lynn, RB; Metz, DC; Pratha, V, 2006) |
| " The primary objective was to compare the efficacy of rabeprazole (20 mg) and omeprazole (20 mg) regarding onset of heartburn control during the first 7 days of treatment in patients with erosive oesophagitis." | 9.12 | Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment. ( Bytzer, P; Kennerly, P; Miller, N; Morocutti, A; Ravic, M, 2006) |
| "Twenty-nine asthmatics, not taking steroids regularly, underwent respiratory symptom measurements, 24-h dual-probe pH monitoring, and challenges with methacholine and capsaicin." | 9.12 | Omeprazole reduces the response to capsaicin but not to methacholine in asthmatic patients with proximal reflux. ( Benini, L; Bonella, F; Brotto, E; Corradini, G; De Iorio, F; Ferrari, M; Lo Cascio, V; Locatelli, F; Tacchella, N; Vantini, I, 2007) |
| "To study the effect of combined omeprazole (Ome) and domperidone (Dom) therapy on asthma symptoms and pulmonary function in asthmatics with gastroesophageal reflux." | 9.12 | Effect of omeprazole and domperidone on adult asthmatics with gastroesophageal reflux. ( Bondi, E; Daga, MK; Sachdev, GK; Sharma, B; Sharma, M, 2007) |
| "Omeprazole is an effective treatment for gastroesophageal reflux in children younger than 2 years." | 9.12 | Omeprazole for gastroesophageal reflux disease in the first 2 years of life: a dose-finding study with dual-channel pH monitoring. ( Bishop, J; Furman, M; Thomson, M, 2007) |
| " This prospective randomised study aimed to investigate whether H pylori eradication can influence gastritis and its sequelae during long term omeprazole therapy for gastro-oesophageal reflux disease (GORD)." | 9.11 | Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. ( Dent, J; Festen, HP; Goldfain, D; Havu, N; Klinkenberg-Knol, EC; Kolkman, JJ; Kuipers, EJ; Lamm, M; Nelis, GF; Snel, P; Walan, A; Zeitoun, P, 2004) |
| "Studies of the pharmacokinetics of omeprazole in children with gastroesophageal reflux disease (GERD) remain scarce despite the vast number of reports on its efficacy." | 9.11 | Pharmacokinetics of omeprazole in healthy adults and in children with gastroesophageal reflux disease. ( Alvarez, F; Brazier, JL; Drouin, E; Dubuc, MC; Ducharme, MP; Marier, JF, 2004) |
| "To compare the effect of lansoprazole 30 mg and 15 mg once daily on the 24-h oesophageal and intragastric pH profiles in Chinese patients with gastro-oesophageal reflux disease." | 9.11 | Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease. ( Chan, AO; Hu, WH; Huang, JQ; Hui, WM; Lai, KC; Lam, CL; Lam, KF; Lam, SK; Wong, BC; Wong, NY; Wong, WM; Xia, HH, 2004) |
| "In a population with laryngitis, the aim is to determine whether (a) omeprazole 20 mg tds (3 months) improves symptoms and laryngitis, and (b) the outcome in response to potent acid suppression can be predicted by esophageal and/or pharyngeal parameters during ambulatory pH monitoring or by other pretreatment variables." | 9.11 | Predictors of outcome in an open label, therapeutic trial of high-dose omeprazole in laryngitis. ( Brake, HM; Cole, IE; Cook, IJ; Maclean, JC; Szczesniak, MM; Williams, RB, 2004) |
| "To determine the clinical value of an empirical trial of high-dose lansoprazole in detecting patients with gastro-oesophageal reflux disease-related non-cardiac chest pain." | 9.11 | The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial. ( Bautista, J; Briseno, M; Cui, H; Fass, R; Fullerton, H, 2004) |
| " pylori infection on effectiveness of rabeprazole in primary and secondary care patients with gastro-oesophageal reflux disease." | 9.11 | Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness? ( Bergmans, P; Boer, WA; Geldof, H; Hazelhoff, B; Smout, AJ; Tytgat, GN; Wit, NJ, 2004) |
| "Gastro-oesophageal reflux disease patients (349) with endoscopically documented healed erosive oesophagitis (grade 0 or 1) were randomly assigned to receive pantoprazole (10, 20 or 40 mg/q." | 9.11 | Prevention of erosive oesophagitis relapse with pantoprazole. ( Bochenek, W; Fraga, P; Mack, M; Richter, JE; Sabesin, SM, 2004) |
| "To compare the effect of esomeprazole 40 mg with lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg on intragastric pH during single and repeated dosing in four separate studies in patients with symptoms of gastro-oesophageal reflux disorder (GERD)." | 9.11 | Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. ( Lind, T; Röhss, K; Wilder-Smith, C, 2004) |
| "To assess the efficacy and safety of lansoprazole in the treatment of adolescents with symptomatic, endoscopically proven, non-erosive gastroesophageal reflux disease and erosive esophagitis." | 9.11 | Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease. ( Fiedorek, S; Gold, BD; Gremse, D; Huang, B; Lee, C; Stolle, J; Tolia, V, 2005) |
| "In controlled clinical trials, rabeprazole effectively improves symptoms and heals oesophageal erosions in patients with gastro-oesophageal reflux disease (GORD)." | 9.11 | Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study. ( Archimandritis, AJ; Avgerinos, A; Kouklakis, G; Nikolopoulou, V; Paraskevas, E; Triantafillidis, JK; Tsianos, E, 2005) |
| "To investigate the efficacy of famotidine and omeprazole in the treatment of gastro-oesophageal reflux disease, especially non-erosive gastro-oesophageal reflux disease." | 9.11 | Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease. ( Fujita, F; Itoh, K; Itoh, M; Joh, T; Kataoka, H; Kubota, E; Mori, Y; Nakao, H; Ogasawara, N; Ohara, H; Oshima, T; Sasaki, M; Sobue, S; Tanida, S; Togawa, S; Wada, T; Yamada, T, 2005) |
| "To compare the efficacy of famotidine and omeprazole in Japanese patients with non-erosive gastro-oesophageal reflux disease by a prospective randomized multicentre trial." | 9.11 | Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease. ( Arakawa, T; Chono, S; Fujiwara, Y; Higuchi, K; Kitada, K; Kobayashi, K; Nakagawa, K; Nebiki, H; Oshitani, N; Satoh, H; Tominaga, K; Uno, H; Watanabe, T, 2005) |
| "Thirty-six patients with nocturnal gastro-oesophageal reflux disease symptoms received immediate-release omeprazole and pantoprazole in this open-label, randomized-crossover trial." | 9.11 | Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. ( Bagin, R; Castell, D; Goldlust, B; Hepburn, B; Major, J, 2005) |
| "The objective of this study was to determine the incidence of gastroesophageal reflux disease (GERD) in bronchial asthma and the role of omeprazole for asthmatics with symptoms of GERD." | 9.11 | Gastroesophageal reflux disease in bronchial asthma and the response to omeprazole. ( Gaur, SN; Gopal, B; Singhal, P, 2005) |
| "Daily asthma symptoms, albuterol use, peak expiratory flow, FEV1, FVC, and investigator-assessed asthma symptoms at 24 weeks did not improve significantly with lansoprazole treatment compared to placebo." | 9.11 | Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. ( Ballard, ED; Huang, B; Leung, FW; Littner, MR; Samra, NK, 2005) |
| "Therapeutic trials with high-dose lansoprazole and omeprazole have been shown to be sensitive clinical tools for diagnosing patients with gastro-oesophageal reflux disease-related non-cardiac chest pain." | 9.11 | The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. ( Cui, H; Dickman, R; Emmons, S; Esquivel, RF; Fass, R; Hernández, D; Sewell, J, 2005) |
| "To compare the efficacy and safety of on-demand lansoprazole 15 mg and placebo treatment in patients with gastro-oesophageal reflux." | 9.11 | Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg. ( Bigard, MA; Genestin, E, 2005) |
| "The purpose of this study was to assess the rapidity of symptom relief and 4-week efficacy of rabeprazole 20 mg in patients with moderately severe nonerosive gastroesophageal reflux disease." | 9.11 | Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. ( Johanson, J; Jokubaitis, L; Kahrilas, PJ; Mao, L; Miner, P; Sloan, S, 2005) |
| " We tested whether esomeprazole-induced healing of gastroesophageal reflux disease (GERD) is related to CYP2C19 genotype." | 9.11 | Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. ( Hofmann, U; Klotz, U; Leodolter, A; Malfertheiner, P; Schaeffeler, E; Schwab, M; Treiber, G, 2005) |
| "To evaluate the effect of omeprazole treatment on the symptoms and lesions of patients with posterior laryngitis (PL)." | 9.10 | Posterior laryngitis: effects of treatment with omeprazole alone. ( Argüelles-Arias, F; Carmona, I; Galera-Ruiz, H; Herrerías, JM; Muñoz-Borje, F; Rodríguez-Téllez, M, 2002) |
| "Eighteen men and 24 women, aged 22 to 77 years, who presented with recurrent chest pain complaints of a noncardiac etiology, as determined by rest/stress perfusion imaging with technetium Tc99m sestamibi (MIBI), were enrolled in a prospective, double-blinded, placebo-controlled, crossover trial using high-dose omeprazole." | 9.10 | Short course of omeprazole: a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour esophageal pH monitoring. ( Arezo, S; Crofts, T; DeCosta, G; Everett, S; Gennings, C; Jesse, R; Pandak, WM; Siuta, M; Zfass, A, 2002) |
| "To investigate the prevalence of gastroesophageal reflux disease (GERD) among patients with bronchial asthma (BA) and to determine the effects of omeprazole therapy on the outcome of asthma in patients with GERD." | 9.10 | [Clinico-functional evaluation of the efficacy of treating gastroesophageal reflux disease combined with bronchial asthma with omeprazole]. ( Agapova, NR; Busarova, GA; Maev, IV; Samsonov, AA, 2002) |
| "To investigate whether pantoprazole (20 mg/d) produces significantly greater symptom control than ranitidine (300 mg/d) in patients with gastro-oesophageal reflux disease (GORD)." | 9.10 | Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care. ( Katelaris, P; Moore, MG; Sprogis, A; Talley, NJ, 2002) |
| ": Fifty patients with complicated or atypical gastro-oesophageal reflux disease were randomly assigned to receive 30 mg lansoprazole (n = 26) or 40 mg pantoprazole (n = 24) once daily." | 9.10 | Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. ( De Micheli, E; Frazzoni, M; Grisendi, A; Savarino, V, 2003) |
| "To compare the efficacy and safety of two doses of rabeprazole with 20 mg omeprazole in the maintenance treatment of erosive gastro-oesophageal reflux disease over 5 years." | 9.10 | A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. ( Bardhan, KD; Fiocca, R; Humphries, TJ; Miller, N; Morocutti, A; Rindi, G; Thjodleifsson, B, 2003) |
| "Treatment with lansoprazole is a useful test in diagnosing endoscopy-negative gastro-oesophageal reflux disease in Chinese patients with non-cardiac chest pain." | 9.10 | Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. ( Chan, CK; Chen, WH; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Lau, CP; Wong, BC; Wong, NY; Wong, WM; Xia, HH, 2003) |
| "To assess the efficacy of lansoprazole for the relief of symptoms due to gastroesophageal reflux disease (GERD) in children 1 to 11 years of age." | 9.10 | Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. ( Book, L; Ferry, G; Gunasekaran, T; Huang, B; Keith, R; Tolia, V, 2002) |
| "To evaluate the pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability of lansoprazole in adolescents between 12 and 17 years of age with gastroesophageal reflux disease (GERD)." | 9.10 | Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. ( Chiu, YL; Fitzgerald, J; Gremse, D; Gunasekaran, T; Gupta, S; Karol, M; Keith, R; Pan, WJ, 2002) |
| "To evaluate the pharmacokinetics and pharmacodynamics of lansoprazole in children between 1 and 11 years of age with gastroesophageal reflux disease (GERD)." | 9.10 | Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. ( Book, L; Chiu, YL; Gremse, D; Gunasekaran, T; Karol, M; Pan, WJ; Pilmer, B; Tolia, V; Winter, H, 2002) |
| " Both pantoprazole and placebo resulted in a marked improvement in laryngitis scores (decrease of 8." | 9.10 | Effect of pantoprazole on the course of reflux-associated laryngitis: a placebo-controlled double-blind crossover study. ( Eherer, AJ; Friedrich, G; Habermann, W; Hammer, HF; Kiesler, K; Krejs, GJ, 2003) |
| " Patients with GERD, characterized by heartburn that had occurred 4 or more times per week for at least 6 months, were treated for 28 days with either pantoprazole 40 mg once daily or nizatidine 150 mg twice daily." | 9.10 | Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine. ( Armstrong, D; Paré, P; Pericak, D; Pyzyk, M, 2003) |
| "The GABA(B) receptor agonist baclofen improves duodenal reflux and associated reflux symptoms that persist during PPI therapy." | 9.10 | Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. ( Janssens, J; Koek, GH; Lerut, T; Sifrim, D; Tack, J, 2003) |
| "To assess the efficacy of omeprazole in treating irritable infants with gastroesophageal reflux and/or esophagitis." | 9.10 | Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. ( Davidson, GP; Heddle, ML; Hirte, C; Lines, DR; Moore, DJ; Tao, BS, 2003) |
| "The purpose of this study is a comparative assessment of the clinical efficiency of Omeprazole and Esomeprazole in patients suffering from bronchial asthma (BA) with associated gastroesophageal reflux disease (GERD)." | 9.10 | [Use of omeprazole and esomeprazole in patients suffering from bronchial asthma with associated gastroesophageal reflux disease]. ( Balashova, NN; Maev, IV; Shchekina, MI; Viuchnova, ES, 2003) |
| "Lansoprazole and omeprazole are widely used proton pump inhibitors for the management of gastro-oesophageal reflux." | 9.10 | Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison. ( De Micheli, E; Frazzoni, M; Grisendi, A; Savarino, V, 2002) |
| "Rabeprazole has a faster onset of antisecretory action than omeprazole, and it is of interest to determine whether this translates into faster symptom relief in patients with gastro-oesophageal reflux disease." | 9.10 | A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. ( Blum, AL; Bytzer, P; Holtmann, G; Loeffler, V; Metz, M, 2002) |
| "In this randomised, double-blind, multicentre study, conducted at 27 European sites, the efficacy and safety of rabeprazole and omeprazole were compared in patients with erosive or ulcerative gastro-oesophageal reflux disease (GERD)." | 9.09 | Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. ( Beker, JA; Bell, NE; Dekkers, CP; Gabryelewicz, A; Humphries, TJ; Thjodleifsson, B, 1999) |
| "Because improvement in quality of life (QoL) is an important therapeutic goal in patients with heartburn but without esophagitis, the aim of the present study was to compare the impact of omeprazole 20 mg or 10 mg daily with that of placebo on QoL in patients with heartburn as the predominant symptom." | 9.09 | Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. ( Anker-Hansen, O; Carlsson, R; Glise, H; Havelund, T; Hernqvist, H; Junghard, O; Lauritsen, K; Lind, T; Lundell, L; Pedersen, SA; Stubberöd, A; Wiklund, I, 1999) |
| "Strenuous exercise exacerbates gastro-oesophageal reflux and symptoms and this may be diminished by antisecretory medication with omeprazole." | 9.09 | The effect of omeprazole on gastro-oesophageal reflux and symptoms during strenuous exercise. ( Akkermans, LM; Bol, E; De Kort, AF; De Vries, WR; Mosterd, WL; Peters, HP; Van Berge Henegouwen, GP; Van Krevelen, H, 1999) |
| "Better control of gastric acid secretion with omeprazole appeared to decrease the need for dilatation of oesophageal strictures complicating gastro-oesophageal reflux disease in our hospital-based endoscopy service." | 9.09 | Omeprazole therapy decreases the need for dilatation of peptic oesophageal strictures. ( Barbezat, GO; Lubcke, R; Schlup, M, 1999) |
| "To evaluate the diagnostic accuracy of a trial of a high-dose proton pump inhibitor (the omeprazole test) in detecting gastroesophageal reflux disease (GERD) in patients with heartburn symptoms." | 9.09 | Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. ( Camargo, E; Fass, R; Fennerty, MB; Gralnek, IM; Johnson, C; Ofman, JJ; Sampliner, RE, 1999) |
| "To investigate the prevalence of gastroesophageal reflux (GER) among patients with asthma and to determine the effect of omeprazole on the outcome of asthma in patients with GER." | 9.09 | Gastroesophageal reflux in asthmatics: A double-blind, placebo-controlled crossover study with omeprazole. ( Hietanen, EK; Kiljander, TO; Salomaa, ER; Terho, EO, 1999) |
| "This 1-year study compared the cost effectiveness of omeprazole and ranitidine when used as initial therapy in an intermittent treatment strategy for the management of patients with symptomatic gastro-oesophageal reflux disease with or without erosive oesophagitis." | 9.09 | Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease. ( Bardhan, KD; Bigard, MA; Carlsson, J; Fulton, C; Gillon, K; Hosie, J; Müller-Lissner, S; Peacock, R; Ponce, J; Porro, GB; Scott, M; Stålhammar, NO; Weir, DG, 1999) |
| "The aim of the present study was to investigate whether not only omeprazole but also lansoprazole leads to hypertrophy of the parietal cells of the gastric mucosa." | 9.09 | Treatment with lansoprazole also induces hypertrophy of the parietal cells of the stomach. ( Alexandridis, T; Meining, A; Seifert, E; Stolte, M, 2000) |
| "The aim of this study was to assess the ability of pantoprazole to maintain gastric acid suppression in patients with gastroesophageal reflux disease who are switched from an oral (p." | 9.09 | Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. ( Lew, E; Martin, P; Maton, PN; Metz, DC; Paul, J; Pisegna, JR; Pratha, V, 2000) |
| "To compare the efficacy of 20 mg with 40 mg pantoprazole in maintaining symptomatic and endoscopic remission in patients with gastro-oesophageal reflux disease (GORD)." | 9.09 | Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease. ( Fumagalli, I; Hotz, J; Lühmann, R; Plein, K; Schneider, A; Wurzer, H, 2000) |
| "05) lower percentages of days and nights with heartburn, less pain severity of both day and night heartburn, fewer days of antacid use, and smaller amounts of antacid use compared with patients who were treated with ranitidine or placebo." | 9.09 | Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. ( Campbell, DR; Fludas, C; Huang, B; Kahrilas, PJ; Richter, JE, 2000) |
| "In this double-blind crossover study, 38 patients with gastro-oesophageal reflux disease (GERD) symptoms were randomized to esomeprazole 40 and 20 mg and omeprazole 20 mg once daily for 5 days." | 9.09 | Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease. ( Andersson, T; Hasselgren, G; Holmberg, J; Jonsson, A; Kylebäck, A; Lind, T; Röhss, K; Rydberg, L, 2000) |
| "To compare clinical, health-related quality of life (HRQL), and medical cost outcomes in patients with symptomatic gastroesophageal reflux disease (GERD) receiving omeprazole sodium or ranitidine hydrochloride treatment." | 9.09 | Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia. ( Kaplan-Machlis, B; Revicki, DA; Spiegler, GE; Zodet, MW, 2000) |
| "The objective of this study was to compare the efficacy and safety of the proton pump inhibitor rabeprazole to that of the histamine-2 (H2)-receptor antagonist ranitidine in the treatment of erosive gastroesophageal reflux disease." | 9.09 | Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group. ( Farley, A; Humphries, TJ; Wruble, LD, 2000) |
| "The efficacy of antireflux surgery (ARS) and omeprazole treatment in the control of gastrooesophageal reflux disease (GORD) are well established." | 9.09 | Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study Group. ( Blomqvist, A; Hatlebakk, JG; Janatuinen, E; Lamm, M; Levander, K; Lundell, L; Miettinen, P; Myrvold, HE; Nyström, P; Pedersen, SA; Thor, K; Wiklund, I, 2000) |
| "To evaluate the efficacy and tolerability of rabeprazole 10 mg and 20 mg versus placebo for the prevention of endoscopically demonstrable relapse in patients previously diagnosed with erosive or ulcerative gastro-oesophageal reflux disease (GORD) who had no oesophageal erosions or ulcerations at study entry." | 9.09 | Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group. ( Birbara, C; Breiter, J; Hahne, W; Perdomo, C, 2000) |
| "To evaluate and compare the pharmacodynamic effects of IY-81149 and omeprazole on gastric pH in patients with gastroesophageal reflux disease." | 9.09 | A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease. ( Boileau, F; Cho, KD; Goldwater, R; Jung, WT; Kim, DY; Lee, SM; Park, DW; Periclou, AP, 2000) |
| "We evaluated the effectiveness and safety profile of 10 and 20 mg of rabeprazole, a new proton pump inhibitor, once daily versus placebo in preventing endoscopic and symptomatic relapse for up to 1 yr among patients with healed erosive or ulcerative gastroesophageal reflux disease (GERD)." | 9.09 | Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group. ( Barth, J; Caos, A; Dayal, Y; Moskovitz, M; Niecestro, R; Perdomo, C, 2000) |
| "To determine efficacy of lansoprazole, a relatively new proton pump inhibitor, on symptoms and oesophagitis in a group of children with gastro-oesophageal reflux disease refractory to H2 receptor antagonists." | 9.09 | Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. ( Cucchiara, S; De Rosa, I; Franco, MT; Iula, VD; Salvia, G; Spadaro, R; Terrin, G, 2000) |
| "A total of 318 gastroesophageal reflux patients whose erosive esophagitis was healed in a comparative study of esomeprazole 40 mg, 20 mg, or omeprazole 20 mg, were randomized to maintenance therapy with once daily esomeprazole 40 mg, 20 mg, or 10 mg, or placebo in a U." | 9.09 | Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. ( Benjamin, SB; Damico, D; Goldstein, JL; Hamelin, B; Johnson, DA; Lamet, M; Vakil, NB; Whipple, J, 2001) |
| "In patients with gastroesophageal reflux disease (GERD), esomeprazole, the S-isomer of omeprazole, has demonstrated pharmacological and clinical benefits beyond those seen with the racemic parent compound." | 9.09 | Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. ( Breiter, JR; Hamelin, B; Hwang, C; Johanson, J; Kahrilas, PJ; Levine, JG; Marino, V; Maton, P; Richter, JE, 2001) |
| "Patients diagnosed with idiopathic chronic laryngitis were randomized to receive either lansoprazole 30 mg p." | 9.09 | Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. ( Buchner, A; El-Serag, HB; Gavin, M; Inadomi, JM; Lee, P; McCarthy, DM, 2001) |
| "To investigate whether pantoprazole also reduces bile reflux and whether this is paralleled by a change in oesophageal motility." | 9.09 | Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis. ( Brundler, R; Gaia, C; Gut, A; Halter, F; Inauen, W; Netzer, P, 2001) |
| "When routinely checking patients receiving omeprazole treatment for gastro-oesophageal reflux, we have been finding patients with surprisingly low nocturnal gastric pH." | 9.08 | Morning or evening dosage of omeprazole for gastro-oesophageal reflux disease? ( Aggestrup, S; Hendel, J; Hendel, L, 1995) |
| "Six hundred and four patients with endoscopically proven oesophagitis and a recent history of heartburn were randomly assigned to receive lansoprazole 30 mg or omeprazole 20 mg daily for 4-8 weeks." | 9.08 | Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. ( Mee, AS; Rowley, JL, 1996) |
| "To investigate the effect of the potent gastric acid inhibitor omeprazole 40 mg orally daily on peak expiratory flow rate (PEFR), asthma symptoms and histamine bronchial responsiveness in adult patients with both asthma and GOR." | 9.08 | Adult asthma and gastro-oesophageal reflux: the effects of omeprazole therapy on asthma. ( Kronborg, IJ; Robinson, P; Teichtahl, H; Yeomans, ND, 1996) |
| "Previous studies have demonstrated greater efficacy for omeprazole compared with cimetidine in patients with endoscopically verified oesophagitis, but excluded the substantial group of gastro-oesophageal reflux disease (GERD) patients with reflux symptoms but without endoscopic abnormality." | 9.08 | Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. ( Axon, AT; Bate, CM; Emmas, CE; Green, JR; Murray, FE; Taylor, MD; Tildesley, G, 1997) |
| "Following endoscopy 424 patients presenting with heartburn as the predominant symptom of gastro-oesophageal reflux disease were randomized to treatment with omeprazole 20 or 10 mg once daily, or cisapride 10 mg four times daily, in a double-blind, double-dummy, parallel group, multicentre study." | 9.08 | Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. ( Barthelemy, P; Galmiche, JP; Hamelin, B, 1997) |
| " This study assessed 20 mg omeprazole daily (OM20), 10 mg omeprazole daily (OM10), and 150 mg ranitidine (RAN) twice daily for symptom relief in gastro-oesophageal reflux disease (GORD)." | 9.08 | Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. ( Hole, J; Newland, RD; Patel, AC; Turbitt, ML; Venables, TL; Wilcock, C, 1997) |
| "To determine the diagnostic value of empirical treatment with omeprazole in the diagnosis of gastroesophageal reflux disease (GERD)." | 9.08 | Omeprazole as a diagnostic tool in gastroesophageal reflux disease. ( Dieleman, LA; Festen, HP; Jansen, EH; Klinkenberg-Knol, EC; Kuipers, EJ; Meuwissen, SG; Schenk, BE; Schrijver, M; Tuynman, HA, 1997) |
| " pylori and with gastro-oesophageal reflux disease we investigated the gastritis parameters in antral and corpus mucosa before and after 2, 6 and 12 months of treatment with 15 or 30 mg lansoprazole or 20 mg omeprazole/day." | 9.08 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. ( Alexandridis, T; Meining, A; Schmitz, JM; Seifert, E; Stolte, M, 1998) |
| "After endoscopy, patients without endoscopic oesophagitis were randomized to omeprazole 20 mg (Ome20), omeprazole 10 mg (Ome10) or placebo once daily for 4 weeks (n = 261) and those with oesophagitis (except circumferential/ulcerative) were randomized to receive either Ome20 or Ome10 once daily for 4 weeks (n = 277)." | 9.08 | Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. ( Carlsson, R; Dalväg, A; de Groot, G; Dent, J; Hatlebakk, J; Haug, K; Junghard, O; Riley, S; Sheikh, R; van Oudvorst, A; Watts, R; Wiklund, I, 1998) |
| "Rabeprazole, a new proton pump inhibitor, was studied in patients with acid-peptic-related diseases (duodenal ulcer, gastric ulcer, GERD) in three placebo-controlled, double-blind, randomized clinical trials." | 9.08 | Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. ( Bassion, S; Cloud, ML; Enas, N; Humphries, TJ, 1998) |
| " The aim of this study was to evaluate the efficacy of the omeprazole test (OT) in diagnosing gastroesophageal reflux (GERD) in patients with NCCP and estimate the potential cost savings of this strategy compared with conventional diagnostic evaluations." | 9.08 | The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. ( Camargo, E; Fass, R; Fennerty, MB; Gralnek, IM; Johnson, C; Ofman, JJ; Sampliner, RE, 1998) |
| "After healing and symptom relief had been obtained on open therapy with lansoprazole 30 mg daily, 103 patients with reflux oesophagitis grade 1 or 2 were randomized to maintenance therapy with lansoprazole 15 or 30 mg daily, and time until recurrence of symptoms and/or endoscopic changes was recorded." | 9.08 | Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole. ( Berstad, A; Hatlebakk, JG, 1997) |
| "The aim of this study was to determine if omeprazole improves pulmonary function and quality of life in asthmatics with gastroesophageal reflux." | 9.08 | Omeprazole improves peak expiratory flow rate and quality of life in asthmatics with gastroesophageal reflux. ( Levin, TR; McQuaid, KR; Sperling, RM, 1998) |
| " is more effective than cimetidine 800 mg nocte in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis." | 9.08 | Omeprazole is more effective than cimetidine in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis. ( Axon, AT; Bate, CM; Emmas, C; Green, JR; Murrays, FE; Owen, SM; Taylor, MD; Tildesley, G, 1998) |
| " However, little is known about the effect of omeprazole on duodenogastric reflux (DGR) and duodenogastro-oesophageal reflux (DGOR)." | 9.08 | Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus. ( Anggiansah, A; Manifold, DK; Marshall, RE; Owen, WA; Owen, WJ, 1998) |
| "Lansoprazole (LAN) and omeprazole (OME) heal esophagitis effectively and to similar extents, but LAN has a faster effect on the relief of symptoms of gastroesophageal reflux." | 9.08 | Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease. ( Hammarlund, B; Iwarzon, M; Janczewska, I; Sagar, M; Seensalu, R; Sjöstedt, S, 1998) |
| "Eleven adult patients with nocturnal asthma, and gastro-oesophageal reflux documented by endoscopy or ambulatory oesophageal pH monitoring completed a double-blind cross-over study (4 week treatment, one week run-in and cross-over periods) comparing the effects of omeprazole 20 mg daily and placebo on asthma control assessed by symptoms, peak expiratory flow rate and bronchodilator usage." | 9.07 | Omeprazole in the treatment of asthmatics with nocturnal symptoms and gastro-oesophageal reflux: a placebo-controlled cross-over study. ( Butland, RJ; Ford, GA; Oliver, PS; Prior, JS; Wilkinson, SP, 1994) |
| "To determine whether the patients with refractory posterior laryngitis respond to treatment with omeprazole." | 9.07 | Omeprazole for the treatment of posterior laryngitis. ( Hanson, D; Kahrilas, PJ; Kamel, PL, 1994) |
| "Omeprazole, a potent inhibitor of acid secretion, is effective in adults with severe gastroesophageal reflux, but no such data are available on children." | 9.07 | Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. ( Gunasekaran, TS; Hassall, EG, 1993) |
| "Twenty-five patients with systemic sclerosis and severe gastro-oesophageal reflux disease were treated with 20-80 mg omeprazole daily for up to 5 years." | 9.07 | Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis. ( Hage, E; Hendel, J; Hendel, L; Stentoft, P, 1992) |
| "To define the optimum doses of omeprazole appropriate for acute and long-term therapy of patients with gastro-oesophageal reflux disease, 24-h oesophageal pH was measured in 12 patients with symptomatic reflux and an abnormal 24-h oesophageal acid exposure time (greater than 6%) in a randomized, double-blind, four-way crossover study comparing the effects of omeprazole 10, 20, or 40 mg/day and placebo." | 9.07 | Effect of different doses of omeprazole on 24-hour oesophageal acid exposure in patients with gastro-oesophageal reflux. ( Allen, ML; Bradstreet, TE; Cagliola, AJ; Humphries, TJ; Maton, PN; McIntosh, D; Robinson, M, 1991) |
| "To assess the available literature regarding the efficacy of omeprazole/sodium bicarbonate in gastroesophageal reflux patients." | 8.98 | Efficacy of omeprazole/sodium bicarbonate treatment in gastroesophageal reflux disease: a systematic review. ( Higuera-de-la-Tijera, F, 2018) |
| " This meta-analysis sought to assess the clinical and safety profiles of esomeprazole versus omeprazole at pharmacologically equivalent doses in healing gastroesophageal reflux disease (GERD), peptic ulcer disease and eradicating Helicobacter pylori (H." | 8.91 | Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection. ( Dan, YY; Khoo, AL; Lim, BP; Lin, L; Teng, M; Wu, TS; Zhao, YJ, 2015) |
| "This study aims to evaluate the effectiveness and tolerability of esomeprazole and omeprazole in patients with gastroesophageal reflux disease (GERD)." | 8.91 | Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis. ( Liu, L; Qi, Q; Wang, R; Wang, S; Zhao, F, 2015) |
| " Omeprazole is a drug widely used in the treatment of gastroesophageal reflux disease and peptic ulcer disease." | 8.82 | [Acute interstitial nephritis associated with omeprazole therapy]. ( Calvo, C; García, H; Hernández-Jaras, J; Maduell, F; Rovira, RE; Torregrosa, E, 2004) |
| "To compare the safety and efficacy of pantoprazole, placebo and the H2 antagonist nizatidine in relieving symptoms in patients with erosive oesophagitis." | 8.82 | Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. ( Bochenek, WJ; Fraga, PD; Mack, ME; Metz, DC, 2004) |
| "The older proton pump inhibitor (PPI) omeprazole and the newer PPIs lansoprazole, rabeprazole, and pantoprazole are approved for the acute and maintenance treatment of gastroesophageal reflux disease (GERD)." | 8.81 | Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. ( Caro, JJ; Salas, M; Ward, A, 2001) |
| "Pantoprazole is a new proton pump inhibitor indicated for the treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD) and is available in both oral and intravenous (IV) formulations." | 8.80 | Clinical experience with pantoprazole in gastroesophageal reflux disease. ( Avner, DL, 2000) |
| "To review gastroesophageal reflux disease (GERD) and its treatment, with emphasis on the use and place of omeprazole, a proton pump inhibitor." | 8.79 | Comparative role of omeprazole in the treatment of gastroesophageal reflux disease. ( Hara, DS; Joe, RH; Skoutakis, VA, 1995) |
| "Several studies have clearly demonstrated that omeprazole is highly efficacious in the management of patients with gastro-oesophageal reflux disease." | 8.77 | Management of gastro-oesophageal reflux disease. Are there alternatives to omeprazole? ( Klinkenberg-Knol, EC; Meuwissen, SG, 1989) |
| "In this prospective open-label comparative observational study, gastroesophageal reflux disease (GERD) patients were evaluated using 24-h dual-channel pH-impedance monitoring while on dexlansoprazole (60 mg, n = 39) and omeprazole (20 mg, n = 41) to study the degree of gastric acid suppression, esophageal acid exposure, and NAB (primary outcome measures)." | 8.12 | Nocturnal acid breakthrough and esophageal acidification during treatment with dexlansoprazole as compared to omeprazole in patients with gastroesophageal reflux disease. ( Blaachandran, A; Ghoshal, UC; Misra, A; Rai, S, 2022) |
| "To evaluate the efficacy and safety of baclofen for treatment of refractory gastroesophageal reflux-induced chronic cough (GERC) unresponsive to standard anti-reflux therapy." | 7.79 | Therapeutic efficacy of baclofen in refractory gastroesophageal reflux-induced chronic cough. ( Chen, Q; Liang, SW; Lv, HJ; Qiu, ZM; Xu, XH; Yang, ZM; Yu, L, 2013) |
| "To determine treatment satisfaction in patients with gastro-oesophageal reflux disease (GORD) when switched to esomeprazole." | 7.75 | Patient satisfaction with switching to esomeprazole from existing proton pump inhibitor therapy for gastro-oesophageal reflux disease: an observational, multicentre study. ( Groeneveld, L; Hoogendoorn, RJ; Kwee, JA, 2009) |
| "Resistance to proton pump inhibitors (PPI) in gastroesophageal reflux disease (GERD), which has been described in patients treated with omeprazole, could explain some exceptional cases of treatment failure and the need for surgery." | 7.73 | [Gastroesophageal reflux disease refractory to esomeprazole]. ( Ortiz, V; Ponce, J; Velasco, MJ, 2005) |
| "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease." | 7.73 | Lansoprazole-associated collagenous colitis: a case report. ( Höbling, W; Kirchgatterer, A; Knoflach, P; Rammer, M, 2005) |
| "Helicobacter pylori eradication was recommended for the prevention of atrophic gastritis in gastroesophageal reflux disease (GERD) patients on long-term omeprazole treatment." | 7.73 | Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients. ( Celikel, CA; Giral, A; Kalayci, C; Ozdogan, O; Tözün, N; Ulusoy, NB, 2005) |
| "To define the prevalence of gastroesophageal reflux disease (GERD) in mild persistent asthma and to value the effect of pantoprazole therapy on asthmatic symptoms." | 7.73 | Asthma and gastroesophageal reflux disease: effect of long-term pantoprazole therapy. ( Areni, A; Calabrese, C; Di Febo, G; Fabbri, A; Scialpi, C; Zahlane, D, 2005) |
| "Twenty-nine children with moderate to severe erosive oesophagitis and abnormal oesophageal bile reflux were studied before and after treatment with omeprazole 1 mg/kg per day." | 7.73 | Treatment of oesophageal bile reflux in children: the results of a prospective study with omeprazole. ( Brecelj, J; Heuschkel, R; Homan, M; Orel, R, 2006) |
| "From a cohort of 114 consecutive patients with bronchial asthma, 53 patients agreed to participate in the study and were treated with rabeprazole 20mg daily for 8 weeks during an asymptomatic, stable period with no exacerbations of their asthma." | 7.72 | A proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal reflux. ( Ashida, S; Fujiki, S; Hosaki, Y; Mitsunobu, F; Mizuno, M; Okada, H; Okamoto, M; Shiratori, Y; Tanizaki, Y; Tsugeno, H, 2003) |
| "Our aims were to describe clinical characteristics of patients with chronic posterior laryngitis and to predict the response to omeprazole therapy." | 7.72 | Manifestations of gastroesophageal reflux and response to omeprazole therapy in patients with chronic posterior laryngitis: an evaluation based on clinical practice. ( Bastida, G; Bau, I; Garrigues, V; Gisbert, L; Nos, P; Ortiz, V; Ponce, J, 2003) |
| " The patient had initiated treatment with oral pantoprazole 40 mg/d for gastroesophageal reflux 2 months prior to admission." | 7.72 | Acute interstitial nephritis due to pantoprazole. ( Ra, A; Tobe, SW, 2004) |
| "Omeprazole therapy is effective in children with gastroesophageal reflux disease." | 7.72 | [Effectiveness of omeprazole therapy in children with gastroesophageal reflux diseases(GERD)]. ( Czerwionka-Szaflarska, M; Kuczyńska, R; Mierzwa, G, 2004) |
| "In this randomized multicenter trial with a 5-year followup, we found antireflux surgery to be more effective than omeprazole in controlling gastroesophageal reflux disease as measured by the treatment failure rates." | 7.71 | Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. ( Carlsson, J; Hatlebakk, JG; Julkonen, R; Lamm, M; Levander, K; Liedman, B; Lundell, L; Miettinen, P; Myrvold, HE; Pedersen, SA; Wiklund, I, 2001) |
| "Omeprazole is an effective long-term drug for gastroesophageal reflux disease after failed fundoplication in children." | 7.71 | Omeprazole maintenance therapy for gastroesophageal reflux disease after failure of fundoplication. ( Blair, GK; Israel, DM; Pashankar, D, 2001) |
| "To compare the efficacy of laparoscopic fundoplication and lansoprazole in abolishing abnormal reflux in patients with gastro-oesophageal reflux disease." | 7.71 | Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison. ( De Micheli, E; Frazzoni, M; Grisendi, A; Lanzani, A; Melotti, G, 2002) |
| "To evaluate the cost effectiveness of on-demand treatment with esomeprazole 20mg compared with two alternative omeprazole treatment strategies for the long-term management of patients with gastro-oesophageal reflux disease (GORD) without oesophagitis." | 7.71 | Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies. ( Green, J; Higgins, A; Junghard, O; Wahlqvist, P, 2002) |
| " pylori status of patients with gastroesophageal reflux disease (GERD) affects the severity of disease and the efficacy of omeprazole therapy to maintain disease remission, we conducted this study." | 7.70 | Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. ( Eskes, SA; Klinkenberg-Knol, EC; Kuipers, EJ; Meuwissen, SG; Schenk, BE, 1999) |
| "Recent evidence suggests that an empiric trial of omeprazole (the "omeprazole test") is sensitive and specific for diagnosing gastroesophageal reflux disease (GERD) as the cause of noncardiac chest pain." | 7.70 | The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. ( Fass, R; Fennerty, MB; Gralnek, IM; Ofman, JJ; Udani, J, 1999) |
| "To determine if patients perceived a difference in the efficacy, side effects, and value of omeprazole versus lansoprazole for gastroesophageal reflux disease (GERD) maintenance therapy after a formulary conversion, and to evaluate the costs of the conversion." | 7.70 | Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy. ( Condra, LJ; Marcus, D; Morreale, AP; Stolley, SN, 1999) |
| " We report data from patients with refractory reflux esophagitis who were undergoing maintenance therapy with >/=20 mg omeprazole daily for a mean period of 6." | 7.70 | Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. ( Dent, J; Frame, MH; Havu, N; Klinkenberg-Knol, EC; Lloyd, D; Mitchell, B; Nelis, F; Prichard, P; Romàn, J; Snel, P; Walan, A, 2000) |
| "To compare the omeprazole test to ambulatory 24-h oesophageal pH monitoring in diagnosing GERD in symptomatic patients using endoscopically proven erosive oesophagitis as a gold standard." | 7.70 | The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. ( Camargo, L; Fass, R; Fennerty, MB; Ofman, JJ; Sampliner, RE; Wendel, C, 2000) |
| "Lansoprazole intolerance requiring omeprazole conversion occurred in 5% of veterans on proton pump inhibitor therapy for chronic gastro-oesophageal reflux disease (GERD) symptoms and in 10% of patients with prior omeprazole success." | 7.70 | Clinical and fiscal impact of lansoprazole intolerance in veterans with gastro-oesophageal reflux disease. ( Fass, R; Gerson, LB; Hatton, BN; Jones, W; Pulliam, G; Ryono, R; Sampliner, RE; Triadafilopoulos, G, 2000) |
| "In patients undergoing long-term treatment with omeprazole, tiny gastric polyps, described histologically as glandular cysts, have occasionally been reported." | 7.69 | Observation of gastric glandular cysts in the corpus mucosa of the stomach under omeprazole treatment. ( Armbrecht, U; Bethke, B; Goldbrunner, P; Lütke, A; Rabast, U; Seifert, E; Stolte, M, 1995) |
| "To test our standard dosing regimen in omeprazole treatment of gastro-oesophageal reflux disease (GORD) and to determine whether 'non-responders' could be pinpointed." | 7.69 | Monitoring of omeprazole treatment in gastro-oesophageal reflux disease. ( Aggestrup, S; Hage, E; Hendel, J; Hendel, L; Nielsen, OH, 1996) |
| "Patients were evaluated with a history, physical examination, esophageal manometry, upper endoscopy, and 24-hour pH-metry for determination of the presence of absence of underlying gastroesophageal reflux disease and then received an empiric trial of oral omeprazole therapy (20 mg twice daily for 1 month)." | 7.69 | Pilot study of the oral omeprazole test for reflux laryngitis. ( Childs, ML; Metz, DC; Ruiz, C; Weinstein, GS, 1997) |
| "Empiric omeprazole therapy is a reasonable, initial approach to patients with suspected gastroesophageal reflux-related posterior laryngitis." | 7.69 | Empiric trial of high-dose omeprazole in patients with posterior laryngitis: a prospective study. ( Delgaudio, JM; Grist, WJ; Gussack, G; Waring, JP; Wo, JM, 1997) |
| " To investigate the effect of omeprazole and higher-than-presently-recommended doses of H2-blockers, we evaluated gastric acidity and gastroesophageal reflux in 17 patients with severe-moderate esophagitis before and after treatment with 300 mg ranitidine twice daily or 20 mg omeprazole once daily." | 7.68 | Effect of omeprazole and high doses of ranitidine on gastric acidity and gastroesophageal reflux in patients with moderate-severe esophagitis. ( Fiorucci, S; Morelli, A; Santucci, L, 1990) |
| "The role of gastro-esophageal reflux disease (GERD) in poorly controlled asthma is often mentioned, but published studies have presented discordant results." | 7.11 | Does omeprazole improve asthma-control in poorly-controlled asthmatic children with gastro-esophageal reflux. ( Benhassine, F; Laid, Y; Nafissa Benhalla, K; Smati, L; Yagoubi, A, 2022) |
| "The incidence of gastroesophageal reflux disease (GERD) is higher in patients with cystic fibrosis (CF) than in the general population." | 7.01 | Effect of omeprazole on symptoms of gastroesophageal reflux disease in children with cystic fibrosis. A randomized, double-blind, placebo-controlled trial. ( Banaszkiewicz, A; Dziekiewicz, M; Lisowska, A; Mielus, M; Radzikowski, A; Sands, D; Walkowiak, J, 2021) |
| "Gastroesophageal reflux disease (GERD) as one of the most common ailments of gastrointestinal system diminishes quality of life and impairs physical functioning and work productivity." | 7.01 | Effect of rose oil on Gastroesophageal Reflux Disease in comparison with omeprazole: A double-blind controlled trial. ( Adel Mehraban, MS; Ahmadian-Attari, MM; Shakeri, R; Shirbeigi, L; Shirzad, M; Tabarrai, M; Taghizadeh Kashani, LM, 2021) |
| "Omeprazole is a proton pump inhibitor that is used in acid suppression therapy in infants." | 6.94 | Rectal Omeprazole in Infants With Gastroesophageal Reflux Disease: A Randomized Pilot Trial. ( Bestebreurtje, P; de Koning, BAE; de Wildt, SN; Knibbe, CAJ; Plötz, FB; Roeleveld, N; Tibboel, D; van de Ven, CP; van Groen, B, 2020) |
| "Pre-anesthetic administration of 2 PO doses of omeprazole at a dosage of 1." | 6.84 | Prevalence of Gastroesophageal Reflux in Cats During Anesthesia and Effect of Omeprazole on Gastric pH. ( Belafsky, PC; Della Maggiore, A; Fulton, A; Garcia, RS; Marks, SL; Osborn, JM; Pierce, T; Pypendop, BH; Walker, VJ, 2017) |
| "Twice-daily dosing of proton pump inhibitor (PPI), the standard therapy for gastro-oesophageal reflux disease (GERD), is an effective therapy for GERD in SSc." | 6.84 | Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial. ( Chunlertrith, K; Foocharoen, C; Mahakkanukrauh, A; Mairiang, P; Namvijit, S; Nanagara, R; Suwannaroj, S; Wantha, O, 2017) |
| " The mean time to onset of the first 24-h heartburn-free period after initial dosing was 2." | 6.77 | Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial. ( Bigard, MA; Childs, M; Decaudin, A; Liard, F; McVey, D; Pouchain, D, 2012) |
| "Gastroesophageal reflux disease (GERD) is a common disorder." | 6.73 | Dilated intercellular spaces in gastroesophageal reflux disease patients and the changes of intercellular spaces after omeprazole treatment. ( Lin, SR; Xue, Y; Zhou, LY, 2008) |
| "The diagnosis of GERD was established on the presence of mucosal breaks at endoscopy and/or an abnormal esophageal 24-h pH test." | 6.72 | Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting. ( Aygalenq, P; Bonnot-Marlier, S; des Varannes, SB; Galmiche, JP; Le Rhun, M; Lequeux, Y; Masliah, C; Sacher-Huvelin, S; Vavasseur, F, 2006) |
| "The diagnosis of GERD was established by the method of Los Angeles classification including mucosal minimum change of Grade M and questionnaire for the diagnosis of reflux disease (QUEST) score." | 6.72 | A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease. ( Dobashi, K; Ishizuka, T; Kawamura, O; Kobayashi, S; Kusano, M; Mori, M; Ohki, I; Shimizu, Y; Shimoyama, Y; Sunaga, N; Tokushima, M; Utsugi, M, 2006) |
| "Melatonin has known inhibitory activities on gastric acid secretion and nitric oxide biosynthesis." | 6.72 | Regression of gastroesophageal reflux disease symptoms using dietary supplementation with melatonin, vitamins and aminoacids: comparison with omeprazole. ( Pereira, Rde S, 2006) |
| " Furthermore, the data indicate that 1-week treatment with a once-daily dosage is sufficient to ensure adequate diagnosis." | 6.71 | One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease. ( Edin, R; Falk, A; Hatlebakk, JG; Johnsson, F; Klintenberg, AC; Román, J; Stubberöd, A; Toth, E, 2003) |
| "Gastroesophageal reflux disease (GERD) is characterized by heartburn and related symptoms that are distressing to patients and interfere with everyday functioning and well-being." | 6.71 | Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. ( Damiano, A; Johanson, J; Siddique, R; Sloan, S; Xu, X, 2003) |
| " These data suggest that administration of a PPI before the evening meal maximizes acid control and would be the preferred dosing schedule in GERD patients, particularly those with nocturnal symptoms." | 6.71 | Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. ( McCallum, RW; Olyaee, M; Pehlivanov, ND; Sarosiek, I, 2003) |
| "Nineteen endoscopically confirmed GERD patients and 38 dyspepsia-free controls were invited to receive EGG recording." | 6.71 | Stomach myoelectrical response of patients with gastroesophageal reflux disease receiving omeprazole treatment. ( Chang, FY; Chen, CY; Jiun, KL; Lee, SD; Lu, CL; Luo, JC; Wu, HC, 2003) |
| "Pantoprazole was also significantly more efficacious in controlling all gastrointestinal symptoms of GERD." | 6.71 | Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease. ( Fischer, R; van Rensburg, C; van Zyl, J; Vieweg, W, 2004) |
| "Fifty-five patients (17 with nonerosive GERD and 38 with low-grade esophagitis) were treated with rabeprazole, 20 mg/day." | 6.71 | On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. ( Argüello, L; Bastida, G; Garrigues, V; Ortiz, V; Ponce, J; Ponce, M, 2004) |
| "In patients with nonerosive GERD there was no significant difference in symptomatic response to either regimen (17/20 in group A and 7/9 in group B responded; P = 0." | 6.71 | Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. ( Ahuja, V; Kashyap, PC; Madan, K; Sharma, MP, 2004) |
| "Both rabeprazole doses were significantly superior to placebo in preventing relapse of heartburn frequency and improving patient quality of life." | 6.71 | Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. ( Barth, J; Breiter, J; Caos, A; Perdomo, C, 2005) |
| "Esomeprazole 20 mg was superior to placebo for on-demand treatment of GORD; a higher dose did not confer additional clinical benefit." | 6.70 | Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. ( Armstrong, D; Bardhan, KD; Carlsson, RG; Chen, S; Giaffer, M; Green, JR; Hasselgren, GS; O'Kane, KP; Talley, NJ; Venables, TL, 2002) |
| " Safety for all study participants was monitored by adverse event reports and laboratory evaluations." | 6.70 | Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. ( Fitzgerald, J; Hassall, E; Huang, B; Kane, R; Pilmer, B; Tolia, V, 2002) |
| "Most patients with gastro-oesophageal reflux disease (GERD), regardless of endoscopic status, suffer symptomatic relapse within 6 months of stopping acid suppressant therapy." | 6.70 | Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. ( Bang, C; Delle, M; Junghard, O; Lauritsen, K; Lind, T; Moum, B; Omland, TM; Schulz, T; Talley, NJ; Tunturi-Hihnala, H, 2001) |
| "Despite a high prevalence of mild gastroesophageal reflux disease (GERD), few studies investigated efficacy and safety of proton pump inhibitors in this indication." | 6.70 | Comparison of pantoprazole 20 mg to ranitidine 150 mg b.i.d. in the treatment of mild gastroesophageal reflux disease. ( Biedermann, A; Kaspari, S; Mey, J, 2001) |
| "Pantoprazole once daily was superior to nizatidine b." | 6.70 | Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. ( Armstrong, D; Paré, P; Pericak, D; Pyzyk, M, 2001) |
| "Esomeprazole was well tolerated." | 6.70 | Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. ( Hasselgren, G; Hedenström, H; Röhss, K, 2002) |
| "Both rabeprazole doses were significantly superior to the placebo with respect to time to the first 24-h heartburn-free interval (2." | 6.70 | Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. ( Filippone, J; Jokubaitis, L; Miner, P; Orr, W; Sloan, S, 2002) |
| "Symptoms of gastro-oesophageal reflux are common, and currently available methods for diagnosing reflux disease are expensive and uncomfortable for the patient." | 6.69 | One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. ( Bengtsson, L; Hernqvist, H; Johnsson, F; Solhaug, JH; Weywadt, L, 1998) |
| "Acid gastro-oesophageal reflux may aggravate respiratory symptoms in patients with asthma and chronic obstructive pulmonary disease (COPD) by increasing airway hyperresponsiveness through vagally-mediated pathways." | 6.69 | No effects of high-dose omeprazole in patients with severe airway hyperresponsiveness and (a)symptomatic gastro-oesophageal reflux. ( Boeree, MJ; Kleibeuker, JH; Peters, FT; Postma, DS, 1998) |
| "Gastroesophageal reflux is frequently found in patients with chest pain despite normal coronary anatomy, but little data on the effect of specific medication exist." | 6.69 | Effect of omeprazole in patients with chest pain and normal coronary anatomy: initial experience. ( Anggiansah, A; Chambers, J; Cooke, R; Owen, W, 1998) |
| "677 patients with gastro-oesophageal reflux disease." | 6.69 | Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. ( Bardhan, KD; Bianchi Porro, G; Bigard, MA; Fulton, C; Gillon, KR; Hosie, J; Müller-Lissner, S; Peacock, RA; Ponce, J; Scott, M; Weir, DG, 1999) |
| "Twenty-three patients were evaluated for gastroesophageal reflux disease; six (26%) were eventually determined to have an acid-related cough." | 6.69 | A prospective evaluation of esophageal testing and a double-blind, randomized study of omeprazole in a diagnostic and therapeutic algorithm for chronic cough. ( Kavuru, MS; Ours, TM; Richter, JE; Schilz, RJ, 1999) |
| "Lansoprazole was superior to famotidine in reducing the thickness of esophageal wall." | 6.69 | Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux. ( Aibe, T; Eto, S; Fujisaki, T; Iida, T; Matsuoka, H; Mine, S; Morimoto, I; Tabata, T; Tanaka, Y; Yamada, S, 2000) |
| "Twenty-one patients completed both treatment periods." | 6.69 | Chronic cough and gastro-oesophageal reflux: a double-blind placebo-controlled study with omeprazole. ( Hietanen, EK; Kiljander, TO; Salomaa, ER; Terho, EO, 2000) |
| "Rabeprazole 20 mg in two different dosing schedules is as effective as omeprazole 20 mg QD with regard to efficacy and tolerability in patients with erosive GERD." | 6.69 | Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease. ( Cohen, G; Delchier, JC; Humphries, TJ, 2000) |
| "Gastro-oesophageal reflux disease (GORD) is a frequent cause for consultation in general practice and is a chronically relapsing disease." | 6.68 | Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice. ( Copeman, MB; Hole, J; Newland, RD; Patel, AC; Turbitt, ML; Venables, TL, 1997) |
| "Gastroesophageal reflux (GER) occurs in 22-66% of patients with noncardiac chest pain (NCCP)." | 6.68 | Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. ( Achem, SR; Burton, L; Castell, DO; Kolts, BE; MacMath, T; Mohr, D; Richter, J, 1997) |
| "Pantoprazole is a benzimidazole derivative which selectively inhibits the proton pump H+." | 6.68 | One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis. ( Koop, H; Maier, C; Mössner, J; Porst, H; Schneider, A; Wübbolding, H, 1997) |
| "Gastroesophageal reflux (GER) is common among patients with asthma, and it has been speculated that high GER may exacerbate asthma in some." | 6.67 | Does omeprazole (Prilosec) improve respiratory function in asthmatics with gastroesophageal reflux? A double-blind, placebo-controlled crossover study. ( Freeman, SR; McNally, PR; Meier, JH; Perry, M; Punja, M; Spaulding, HS; Stocker, N; Sudduth, RH, 1994) |
| "This review provides an update on the following points: pharmacokinetic profile and metabolism of ilaprazole in relation to its pharmacodynamic properties; comparative data on the pharmacokinetics and pharmacodynamics of ilaprazole with currently available PPIs; and implications for studies on the therapeutic efficacy of ilaprazole in GERD." | 6.49 | The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment. ( Blandizzi, C; de Bortoli, N; Giacchino, M; Marchi, S; Martinucci, I; Savarino, E; Savarino, V, 2013) |
| "Pantoprazole has an excellent safety record and shows only minor interaction with other drugs." | 6.43 | Role of pantoprazole in the treatment of gastro-oesophageal reflux disease. ( Beglinger, C; Lehmann, FS, 2005) |
| "Lansoprazole is a proton pump inhibitor that inactivates the H(+)/K(+)-ATPase pump in parietal cells, thus inhibiting gastric acid secretion and increasing intragastric pH." | 6.43 | Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents. ( Croom, KF; Scott, LJ, 2005) |
| "Gastroesophageal reflux disease (GERD) is associated with several symptoms, such as heartburn, belching, and regurgitation, which arise from esophageal exposure to gastric acid." | 6.42 | Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease. ( Sloan, S, 2003) |
| "Gastro-oesophageal reflux disease (GERD) is an increasing health problem in developed countries and is associated with enormous costs in terms of reduced quality of life, loss of productivity, health expenses and mortality." | 6.42 | Review of rabeprazole in the treatment of gastro-oesophageal reflux disease. ( Thjodleifsson, B, 2004) |
| "Rabeprazole is a second generation PPI with rapid onset of action that quickly relieves symptoms of GERD." | 6.42 | Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease. ( Goh, KL; Lim, PW, 2004) |
| "Omeprazole is a well studied proton pump inhibitor that reduces gastric acid secretion." | 6.40 | Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. ( Langtry, HD; Wilde, MI, 1998) |
| "Omeprazole has been shown to have a good long-term safety profile, as evaluated in these trials." | 6.39 | Long-term treatment of gastro-oesophageal reflux disease with omeprazole. ( Lundell, L, 1994) |
| "To treat symptoms of gastroesophageal reflux disease, omeprazole was replaced with famotidine, and the visual hallucinations did not recur after the omeprazole had been discontinued." | 5.62 | Omeprazole-induced Visual Hallucinations: A Case Report. ( Kim, GS; Nunez, T; Vargas, E, 2021) |
| "Gastroesophageal reflux disease is widely reported most prevalent disease of the gastrointestinal tract." | 5.48 | Comparative Study of Alginate and Omeprazole in Symptomatic Treatment of Non-erosive Gastroesophageal Reflux Disease. ( Ahmed, F; Akhter, A; Alam, MS; Banik, RK; Chowdhury, M; Haque, A; Saha, SK; Saifullah, AM; Shil, BC, 2018) |
| "Gastroesophageal reflux was observed in 55% (11/20) of control dogs, 55% (11/20) of dogs receiving omeprazole once and 47% (7/15) of dogs receiving omeprazole twice." | 5.41 | Effect of two different pre-anaesthetic omeprazole protocols on gastroesophageal reflux incidence and pH in dogs. ( Boscan, P; Bryan, S; Fukushima, K; Krause, L; Lotti, F; Twedt, D; Vaca, C; Warrit, K, 2021) |
| "The combination of bronchial asthma with pathology of the digestive tract--one of the most frequent, clinically diverse and difficult, which complicates its course." | 5.39 | [Comparison of the effectiveness of omeprazole and pantoprazole treatment of gastroesophageal reflux disease in patients with asthma]. ( Popadynets', IR, 2013) |
| "Gastroesophageal reflux disease (GERD) has a prevalence of 10% to 20% in the pediatric population." | 5.37 | [Gastric acid suppression of a new oral powder omeprazole suspension for infants with gastroesophageal reflux disease. A pilot study]. ( Busoni, V; Caruso, N; Donato, G; Naisberg, G; Orsi, M, 2011) |
| "pylori-infected gastro-oesophageal reflux disease patients does not increase or accelerate gastric autoimmunity." | 5.33 | Long-term acid suppression by omeprazole in gastro-oesophageal reflux disease patients does not lead to anti-gastric autoantibody production. ( Aar, A; Appelmelk, BJ; Bergman, MP; Faller, G; Klinkenberg-Knol, EC; Kuipers, EJ; Lakhai, W; Vandenbroucke-Grauls, CM, 2005) |
| "The effect of gastro-oesophageal reflux on sleep and sleep quality is highly controversial." | 5.33 | The effect of gastro-oesophageal reflux and omeprazole on key sleep parameters. ( Banwait, KS; Cohen, S; Dimarino, AJ; Dimarino, M; Doghramji, K; Eschinger, E; Greenberg, A, 2005) |
| "In most patients with GERD esophagitis is not detected by endoscopy, which represents GERD with a negative endoscopy or non-erosive reflux disease (NERD)." | 5.33 | Efficacy of low-dose lansoprazole in the treatment of non-erosive gastrooesophageal reflux disease. Influence of infection by Helicobacter pylori. ( Castro Fernández, M; García Díaz, E; Lamas Rojas, E; Larraona, JL; Núñez Hospital, D; Pallarés Querol, M; Rodríguez Hornillo, MC, 2006) |
| "Rabeprazole is a PPI whose metabolism shows fewer interactions compared to other PPIs." | 5.33 | Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastresophageal reflux disease. ( Giannini, EG; Savarino, V; Testa, R, 2006) |
| "Thirty one patients with gastroesophageal reflux disease were treated with a daily oral dose of 20 mg OMP for 28 days." | 5.33 | [Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease]. ( Choi, SK; Joo, YE; Kim, HS; Kim, SJ; Lee, WS; Park, CH; Rew, JS; Sohn, YH, 2006) |
| "Gastroesophageal reflux (GER) is a common episode in pediatric patients with severe motor and intellectual disabilities (SMID) and occasionally leads to a severe clinical state accompanied with nausea, hematemesis, melena, wheezing, pneumonia, anemia and/or failure to thrive." | 5.32 | Treatment of gastric hemorrhage by pulverized omeprazole and antacid--concomitant administration via a nasogastric tube. ( Kinoshita, E; Mukai, S; Ohtani, H; Sawada, Y; Yamaguchi, T, 2004) |
| "A total of 65 patients with GERD (grades A-D) completed treatment with lansoprazole, by taking 30 mg orally once a day for 8 weeks." | 5.31 | Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. ( Furuta, T; Futami, H; Hanai, H; Honda, S; Iida, T; Ishizaki, T; Kajimura, M; Ohashi, K; Sato, Y; Shirai, N; Takayanagi, S; Takeuchi, K; Watanabe, F; Yamada, M, 2002) |
| "Patients with erosive gastroesophageal reflux disease participating in an open-label, 8-week study completed the SF-36 Health Survey before and after treatment with rabeprazole." | 5.31 | Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease. ( Bhattacharjya, A; Damiano, AM; Johanson, JF; Jokubaitis, L; Murthy, A; Siddique, R, 2002) |
| "Both PPIs are approved for the treatment of gastroesophageal reflux disease (GERD) and are commonly converted in therapeutic interchange programs." | 5.31 | Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole. ( Ehlert, DA; Geurkink, EA; Nelson, WW; Reichelderfer, M; Vermeulen, LC, 2000) |
| "A total of 23 patients with reflux esophagitis underwent 24-h intragastric and intraesophageal pH-metry after 7, 90, and 180 days of continued dosing with 20 mg of omeprazole once daily before breakfast." | 5.31 | Stability of gastric secretory inhibition during 6-month treatment with omeprazole in patients with gastroesophageal reflux disease. ( Berstad, A; Hatlebakk, JG; Tefera, S, 2001) |
| "Patients who were referred to Veterans Affairs (VA) gastroenterology clinics for PPI-refractory heartburn received 20 mg of omeprazole twice daily for 2 weeks, and those with persistent heartburn underwent endoscopy, esophageal biopsy, esophageal manometry, and multichannel intraluminal impedance-pH monitoring." | 5.30 | Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn. ( Biswas, K; Castell, DO; Chan, BS; Chey, WD; Davis-Karim, A; Dunbar, KB; Fernando, RS; Gellad, ZF; Genta, RM; Ghaferi, AA; Huang, GD; Hunter, JG; Jackson, CS; Jones, KM; Kaz, AM; Kim, AW; Kim, T; Lagoo-Deenadayalan, S; Laine, L; Lee, R; Lieberman, D; Lo, WK; Mashimo, H; Melton, SD; Murthy, UK; Paski, SC; Pearl, JP; Pham, TH; Provenzale, D; Rubenstein, JH; Sanchez, VM; Serpi, T; Smith, BR; Souza, RF; Spechler, SJ; Tatum, RP; von Rosenvinge, EC; Wallen, JM; Warren, SR, 2019) |
| "Patients with persistent heartburn symptoms ≥ 3 times per week treated with omeprazole 20 mg daily were enrolled and randomized to commonly recommended dosing or continued suboptimal dosing of omeprazole." | 5.30 | Optimal Omeprazole Dosing and Symptom Control: A Randomized Controlled Trial (OSCAR Trial). ( Perzynski, AT; Votruba, M; Waghray, A; Waghray, N; Wolfe, MM, 2019) |
| "Forty-five participants were randomised (23 to omeprazole, 22 to placebo), with 40 (20 in each group) having cough monitoring before and after treatment." | 5.30 | Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis. ( Dutta, P; Forbes, R; Forrest, IA; Funston, W; Griffin, SM; Jones, R; Mossop, H; Pearson, J; Ryan, V; Sen, S; Simpson, AJ; Smith, JA; Ward, C, 2019) |
| "The therapeutic approach to gastroesophageal reflux disease (GERD) in intellectually disabled individuals has not been studied extensively." | 5.30 | Gastroesophageal reflux disease in intellectually disabled individuals: leads for diagnosis and the effect of omeprazole therapy. ( Bohmer, CJ; Devillé, WL; Klinkenberg-Knol, EC; Meuwissen, SG; Niezen-de Boer, MC; Tuynman, HA; Voskuil, JH, 1997) |
| "Laryngeal manifestations of gastroesophageal reflux disease are thought to be prevalent in our society." | 5.30 | Laryngeal manifestations of gastroesophageal reflux before and after treatment with omeprazole. ( Searl, JP; Shaw, GY, 1997) |
| "Symptomatic gastroesophageal reflux is a common complication of pregnancy and lactation." | 5.30 | Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation. ( Armstrong, D; Marshall, JK; Thompson, AB, 1998) |
| "Both omeprazole and endoscopy were compared to pH monitoring as the 'gold standard' for the diagnosis of GERD and the cost per correct diagnosis with omeprazole was pound47 (95% CI: pound40- pound59) compared to pound480 (95% CI: pound396- pound608) with endoscopy." | 5.30 | Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease. ( Bate, CM; Chapman, RW; Durnin, AT; Riley, SA; Taylor, MD, 1999) |
| "Gastroesophageal reflux disease (GERD) is known to cause a variety of symptoms that lead a patient to seek otolaryngologic care." | 5.29 | Gastroesophageal reflux laryngitis resistant to omeprazole therapy. ( Bough, ID; Castell, DO; Gideon, RM; Hills, JR; Sataloff, RT; Spiegel, JR, 1995) |
| "In patients with Barrett's esophagus, LES pressure was considerably lower and percentage exposure to acid was considerably higher than in either patients with esophagitis or controls (p less than 0." | 5.28 | Effect of omeprazole on gastroesophageal reflux in Barrett's esophagus. ( Farroni, F; Fiorucci, S; Morelli, A; Pelli, MA; Santucci, L, 1989) |
| "Zegerid (on demand immediate-release omeprazole and sodium bicarbonate combination therapy) has demonstrated earlier absorption and more rapid pH change compared with Losec (standard enteric coated omeprazole), suggesting more rapid clinical relief of heartburn." | 5.20 | Challenges of correlating pH change with relief of clinical symptoms in gastro esophageal reflux disease: a phase III, randomized study of Zegerid versus Losec. ( Gruss, HJ; Jones, D; Ng Kwet Shing, R; Reguła, J; Walker, D, 2015) |
| "In infants with a clinical presentation suggestive of chronic GER-related cough, the use of omeprazole and bethanacol appears to be viable therapeutic option." | 5.16 | [A pilot trial on the treatment of gastroesophageal reflux-related cough in infants]. ( Adamko, DJ; Jones, AB; Majaesic, CM; Skappak, C, 2012) |
| "Omeprazole is one of the most frequently prescribed drugs in patients with gastroesophageal reflux disease (GERD)." | 5.16 | Effects of omeprazole consumption on serum levels of trace elements. ( Amiriani, T; Badeleh, M; Besharat, S; Joshaghani, H; Molana, A; Roshandel, G; Vaghari, G, 2012) |
| "To investigate whether overweight/obesity (BMI≥25 kg/m(2)) affects rabeprazole clinical efficacy versus omeprazole in patients with erosive esophagitis (EE)." | 5.15 | Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole. ( Casalini, S; Coudsy, B; DeLemos, B; Li, H; LoCoco, J; Pace, F; Pelosini, I; Scarpignato, C; Sun, Y; Xiang, J, 2011) |
| "To compare the effects of immediate-release omeprazole and 2 different delayed-release proton pump inhibitors on 24-hour intragastric acidity in gastroesophageal reflux disease patients." | 5.14 | Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD. ( Bagin, RG; Ballard, ED; Gautille, TC; Howden, CW; Koch, FK, 2009) |
| "Esomeprazole may be more effective than omeprazole, lansoprazole, and pantoprazole for the rapid relief of heartburn symptoms and acid reflux symptoms in patients with reflux esophagitis." | 5.14 | Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. ( Zheng, RN, 2009) |
| "To compare pharmacokinetics between immediate and delayed-release omeprazole in patients with GERD associated with gastroparesis." | 5.14 | Pharmacokinetic profile of immediate-release omeprazole in patients with gastro-oesophageal reflux associated with gastroparesis. ( Eversmann, J; Mann, S; Wo, JM, 2010) |
| "Administration of mosapride citrate in addition to omeprazole improved gastro-esophageal reflux and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying." | 5.14 | The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying. ( Futagami, S; Gudis, K; Horie, A; Iwakiri, K; Kawagoe, T; Kawami, N; Sakamoto, C; Shimpuku, M; Shindo, T; Tanaka, Y, 2010) |
| "Melatonin has a role in the improvement of Gastro-esophageal reflux disease when used alone or in combination with omeprazole." | 5.14 | The potential therapeutic effect of melatonin in Gastro-Esophageal Reflux Disease. ( Abbas, AM; El-Gendy, AA; Kandil, TS; Mousa, AA, 2010) |
| "Patients with heartburn for at least 2 days a week during the month before entry into the study and no endoscopic signs of a mucosal break (grade M or N according to Hoshihara's modification of the Los Angeles classification) were randomly assigned to one of three groups (omeprazole 10 mg or 20 mg, or placebo) once daily for 4 weeks." | 5.13 | Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease. ( Chiba, T; Chikama, T; Inokuchi, H; Kawamura, S; Murakami, A; Serizawa, H; Tanabe, S; Tsuru, T; Uemura, N; Umezu, T; Urata, T; Yamamoto, M; Yamauchi, M; Yoshida, T; Yurino, N, 2008) |
| "To estimate the effect of double omeprazole dose on the course of angina pectoris and treadmill stress test in patients with coronary artery disease (CAD), using double-blind, crossover randomised, placebo-controlled study design." | 5.13 | The effect of double dose of omeprazole on the course of angina pectoris and treadmill stress test in patients with coronary artery disease--a randomised, double-blind, placebo controlled, crossover trial. ( Budzyński, J; Fabisiak, J; Kłopocka, M; Majer, M; Pulkowski, G; Suppan, K; Swiatkowski, M, 2008) |
| "We investigated whether the treatment of gastrooesophageal reflux with omeprazole is able to decrease apnoea attacks." | 5.12 | Obstructive sleep apnoea is improved by a prolonged treatment of gastrooesophageal reflux with omeprazole. ( Bortolotti, M; Gentilini, L; Giovannini, M; Morselli, C, 2006) |
| "Out of 45 patients referred for unexplained chronic persistent cough, 36 had at least one of the GI investigations (endoscopy, 24-h esophageal pH-metry and a 4-week trial of proton pump inhibitor (PPI) therapy) positive and were randomly assigned to receive either 30 mg lansoprazole o." | 5.12 | Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough: a comparison between two different daily doses of lansoprazole. ( Baldi, F; Cappiello, R; Cavoli, C; Ghersi, S; Roda, E; Torresan, F, 2006) |
| "The objective of the open, randomised, four-period crossover study was to compare the time of onset of effect of sodium alginate (SA), omeprazole, ranitidine and control, based on oesophageal and intragastric pH and to determine any correlation between reflux symptoms and episodes in volunteers suffering from occasional gastro-oesophageal reflux." | 5.12 | Rapid onset of effect of sodium alginate on gastro-oesophageal reflux compared with ranitidine and omeprazole, and relationship between symptoms and reflux episodes. ( Bryan, J; Dettmar, PW; Little, SL; Sykes, J, 2006) |
| "To evaluate symptom improvement in 53 children (aged 5-11 years) with endoscopically proven gastroesophageal reflux disease (GERD) treated with pantoprazole (10, 20 and 40 mg) using the GERD Assessment of Symptoms in Pediatrics Questionnaire." | 5.12 | Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. ( Bishop, PR; Comer, GM; Gremse, D; Soffer, EF; Tolia, V; Tsou, VM, 2006) |
| "Omeprazole treats gastro-oesophageal reflux disease (GORD) by inhibition of acid secretion whereas alginate based reflux suppressants work by forming a low density raft of near neutral pH which floats on the stomach contents and physically impedes gastro-oesophageal reflux." | 5.12 | Administration of an alginate based gastric reflux suppressant on the bioavailability of omeprazole. ( Baxter, T; Choubey, S; Dettmar, PW; Hampson, FC; Jain, A; Little, SL, 2006) |
| "We sought to evaluate safety and efficacy of IV pantoprazole when used as initial therapy in patients with gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) in a double-blind, placebo-controlled, randomized, parallel-group study." | 5.12 | Intravenous pantoprazole as initial treatment in patients with gastroesophageal reflux disease and a history of erosive esophagitis: a randomized clinical trial. ( Field, B; Hogan, DL; Lynn, RB; Metz, DC; Pratha, V, 2006) |
| " The primary objective was to compare the efficacy of rabeprazole (20 mg) and omeprazole (20 mg) regarding onset of heartburn control during the first 7 days of treatment in patients with erosive oesophagitis." | 5.12 | Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment. ( Bytzer, P; Kennerly, P; Miller, N; Morocutti, A; Ravic, M, 2006) |
| "Patients with chronic GORD and oesophagitis verified at endoscopy were allocated to treatment with omeprazole (154 patients) or antireflux surgery (144)." | 5.12 | Seven-year follow-up of a randomized clinical trial comparing proton-pump inhibition with surgical therapy for reflux oesophagitis. ( Hatlebakk, JG; Lundell, L; Malm, A; Miettinen, P; Myrvold, HE; Sutherland, I; Walan, A; Wallin, L, 2007) |
| "Twenty-nine asthmatics, not taking steroids regularly, underwent respiratory symptom measurements, 24-h dual-probe pH monitoring, and challenges with methacholine and capsaicin." | 5.12 | Omeprazole reduces the response to capsaicin but not to methacholine in asthmatic patients with proximal reflux. ( Benini, L; Bonella, F; Brotto, E; Corradini, G; De Iorio, F; Ferrari, M; Lo Cascio, V; Locatelli, F; Tacchella, N; Vantini, I, 2007) |
| " After appropriate assessment with esophageal manometry and 24 h ambulatory pHmetry, patients with documented gastroesophageal reflux disease (GERD) were treated with omeprazole continuously." | 5.12 | Single-session, graded esophageal dilation without fluoroscopy in outpatients with lower esophageal (Schatzki's) rings: a prospective, long-term follow-up study. ( Bergele, C; Mantides, A; Sgouros, SN; Stefanidis, G; Vassiliadis, K; Vlachogiannakos, J, 2007) |
| "To study the effect of combined omeprazole (Ome) and domperidone (Dom) therapy on asthma symptoms and pulmonary function in asthmatics with gastroesophageal reflux." | 5.12 | Effect of omeprazole and domperidone on adult asthmatics with gastroesophageal reflux. ( Bondi, E; Daga, MK; Sachdev, GK; Sharma, B; Sharma, M, 2007) |
| "We used pooled data from two 4-week studies of patients with gastroesophageal reflux disease (but without endoscopically verified esophagitis) randomized either to esomeprazole (20 or 40 mg) or to omeprazole 20 mg." | 5.12 | Effect of baseline symptom severity on patient-reported outcomes in gastroesophageal reflux disease. ( Junghard, O; Wiklund, IK, 2007) |
| " This prospective randomised study aimed to investigate whether H pylori eradication can influence gastritis and its sequelae during long term omeprazole therapy for gastro-oesophageal reflux disease (GORD)." | 5.11 | Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. ( Dent, J; Festen, HP; Goldfain, D; Havu, N; Klinkenberg-Knol, EC; Kolkman, JJ; Kuipers, EJ; Lamm, M; Nelis, GF; Snel, P; Walan, A; Zeitoun, P, 2004) |
| "To compare the effect of lansoprazole 30 mg and 15 mg once daily on the 24-h oesophageal and intragastric pH profiles in Chinese patients with gastro-oesophageal reflux disease." | 5.11 | Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease. ( Chan, AO; Hu, WH; Huang, JQ; Hui, WM; Lai, KC; Lam, CL; Lam, KF; Lam, SK; Wong, BC; Wong, NY; Wong, WM; Xia, HH, 2004) |
| "In a population with laryngitis, the aim is to determine whether (a) omeprazole 20 mg tds (3 months) improves symptoms and laryngitis, and (b) the outcome in response to potent acid suppression can be predicted by esophageal and/or pharyngeal parameters during ambulatory pH monitoring or by other pretreatment variables." | 5.11 | Predictors of outcome in an open label, therapeutic trial of high-dose omeprazole in laryngitis. ( Brake, HM; Cole, IE; Cook, IJ; Maclean, JC; Szczesniak, MM; Williams, RB, 2004) |
| "To determine the clinical value of an empirical trial of high-dose lansoprazole in detecting patients with gastro-oesophageal reflux disease-related non-cardiac chest pain." | 5.11 | The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial. ( Bautista, J; Briseno, M; Cui, H; Fass, R; Fullerton, H, 2004) |
| " pylori infection on effectiveness of rabeprazole in primary and secondary care patients with gastro-oesophageal reflux disease." | 5.11 | Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness? ( Bergmans, P; Boer, WA; Geldof, H; Hazelhoff, B; Smout, AJ; Tytgat, GN; Wit, NJ, 2004) |
| " The aim of this study was to estimate the effects of gastric acid output suppression with rabeprazole on course of angina pectoris and results of the treadmill stress test in patients with CAD." | 5.11 | Suppression of gastric acid production may improve the course of angina pectoris and the results of treadmill stress test in patients with coronary artery disease. ( Budzyński, J; Fabisiak, J; Kłopocka, M; Majer, M; Morawski, W; Pulkowski, G; Suppan, K; Swiatkowski, M, 2004) |
| "Gastro-oesophageal reflux disease patients (349) with endoscopically documented healed erosive oesophagitis (grade 0 or 1) were randomly assigned to receive pantoprazole (10, 20 or 40 mg/q." | 5.11 | Prevention of erosive oesophagitis relapse with pantoprazole. ( Bochenek, W; Fraga, P; Mack, M; Richter, JE; Sabesin, SM, 2004) |
| "To compare the effect of esomeprazole 40 mg with lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg on intragastric pH during single and repeated dosing in four separate studies in patients with symptoms of gastro-oesophageal reflux disorder (GERD)." | 5.11 | Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. ( Lind, T; Röhss, K; Wilder-Smith, C, 2004) |
| "We followed up 295 pregnancies exposed to omeprazole [233 in the first trimester (T1)], 62 to lansoprazole (55 in T1) and 53 to pantoprazole (47 in T1), and compared pregnancy outcome to that of 868 European Network of Teratology Information Services controls." | 5.11 | The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. ( Arnon, J; Clementi, M; De Santis, M; Diav-Citrin, O; Malm, H; Ornoy, A; Robert-Gnansia, E; Schaefer, C; Shechtman, S; Valti, E; van Tonningen, MR, 2005) |
| "To assess the efficacy and safety of lansoprazole in the treatment of adolescents with symptomatic, endoscopically proven, non-erosive gastroesophageal reflux disease and erosive esophagitis." | 5.11 | Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease. ( Fiedorek, S; Gold, BD; Gremse, D; Huang, B; Lee, C; Stolle, J; Tolia, V, 2005) |
| "Two hundred and forty-three patients received rabeprazole (20 mg or 10 mg) or omeprazole (20 mg) once daily for up to 5 years, for gastro-oesophageal reflux disease and 51% completed the whole 5 year period." | 5.11 | Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. ( Fiocca, R; Jacobs, A; Miller, N; Morocutti, A; Rindi, G; Thjodleifsson, B, 2005) |
| "In controlled clinical trials, rabeprazole effectively improves symptoms and heals oesophageal erosions in patients with gastro-oesophageal reflux disease (GORD)." | 5.11 | Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study. ( Archimandritis, AJ; Avgerinos, A; Kouklakis, G; Nikolopoulou, V; Paraskevas, E; Triantafillidis, JK; Tsianos, E, 2005) |
| "To investigate the efficacy of famotidine and omeprazole in the treatment of gastro-oesophageal reflux disease, especially non-erosive gastro-oesophageal reflux disease." | 5.11 | Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease. ( Fujita, F; Itoh, K; Itoh, M; Joh, T; Kataoka, H; Kubota, E; Mori, Y; Nakao, H; Ogasawara, N; Ohara, H; Oshima, T; Sasaki, M; Sobue, S; Tanida, S; Togawa, S; Wada, T; Yamada, T, 2005) |
| "To compare the efficacy of famotidine and omeprazole in Japanese patients with non-erosive gastro-oesophageal reflux disease by a prospective randomized multicentre trial." | 5.11 | Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease. ( Arakawa, T; Chono, S; Fujiwara, Y; Higuchi, K; Kitada, K; Kobayashi, K; Nakagawa, K; Nebiki, H; Oshitani, N; Satoh, H; Tominaga, K; Uno, H; Watanabe, T, 2005) |
| "Thirty-six patients with nocturnal gastro-oesophageal reflux disease symptoms received immediate-release omeprazole and pantoprazole in this open-label, randomized-crossover trial." | 5.11 | Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. ( Bagin, R; Castell, D; Goldlust, B; Hepburn, B; Major, J, 2005) |
| " We investigated the heartburn symptoms of patients with gastro-oesophageal reflux disease during sequential treatment with 40 mg of famotidine or 15 mg of lansoprazole to clarify whether H." | 5.11 | Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole. ( Adachi, K; Amano, Y; Fujishiro, H; Furuta, K; Hashimoto, T; Hattori, S; Ishihara, S; Kinoshita, Y; Komazawa, Y; Mihara, T, 2005) |
| "The objective of this study was to determine the incidence of gastroesophageal reflux disease (GERD) in bronchial asthma and the role of omeprazole for asthmatics with symptoms of GERD." | 5.11 | Gastroesophageal reflux disease in bronchial asthma and the response to omeprazole. ( Gaur, SN; Gopal, B; Singhal, P, 2005) |
| "Heartburn, regurgitation and dysphagia were hardly found in any group at 8 weeks after 15 mg or 30 mg lansoprazole treatment." | 5.11 | Management of symptoms in step-down therapy of gastroesophageal reflux disease. ( Iida, T; Kishikawa, H; Mine, S; Tabata, T; Tanaka, Y, 2005) |
| "Omeprazole treatment did not improve asthma symptoms or lung function in children with asthma and GORD." | 5.11 | Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease. ( Bentsen, BS; Carlsen, KC; Closs, O; Handeland, M; Holm, HK; Johannesdottir, GB; Knudsen, PK; Sandvik, L; Størdal, K, 2005) |
| "To compare safety and efficacy of on-demand pantoprazole 20 mg/40 mg versus placebo in the long-term management of patients with mild gastroesophageal reflux disease (GERD) after heartburn relief." | 5.11 | On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trial. ( Bohuschke, M; Dekkers, CP; Gatz, G; Körner, T; Scholten, T; Schütze, K, 2005) |
| "Daily asthma symptoms, albuterol use, peak expiratory flow, FEV1, FVC, and investigator-assessed asthma symptoms at 24 weeks did not improve significantly with lansoprazole treatment compared to placebo." | 5.11 | Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. ( Ballard, ED; Huang, B; Leung, FW; Littner, MR; Samra, NK, 2005) |
| "Therapeutic trials with high-dose lansoprazole and omeprazole have been shown to be sensitive clinical tools for diagnosing patients with gastro-oesophageal reflux disease-related non-cardiac chest pain." | 5.11 | The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. ( Cui, H; Dickman, R; Emmons, S; Esquivel, RF; Fass, R; Hernández, D; Sewell, J, 2005) |
| "To compare the efficacy and safety of on-demand lansoprazole 15 mg and placebo treatment in patients with gastro-oesophageal reflux." | 5.11 | Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg. ( Bigard, MA; Genestin, E, 2005) |
| "This study aimed to determine whether dysphagia associated with gastroesophageal reflux disease was effectively treated with rabeprazole, a proton pump inhibitor." | 5.11 | Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor. ( Danjo, A; Fujimoto, K; Hara, M; Iwakiri, R; Kikkawa, A; Oda, K; Ootani, A; Sakata, H; Shimoda, R; Tsunada, S; Watanabe, K, 2005) |
| "The purpose of this study was to assess the rapidity of symptom relief and 4-week efficacy of rabeprazole 20 mg in patients with moderately severe nonerosive gastroesophageal reflux disease." | 5.11 | Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. ( Johanson, J; Jokubaitis, L; Kahrilas, PJ; Mao, L; Miner, P; Sloan, S, 2005) |
| " We tested whether esomeprazole-induced healing of gastroesophageal reflux disease (GERD) is related to CYP2C19 genotype." | 5.11 | Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. ( Hofmann, U; Klotz, U; Leodolter, A; Malfertheiner, P; Schaeffeler, E; Schwab, M; Treiber, G, 2005) |
| "To evaluate the effect of omeprazole treatment on the symptoms and lesions of patients with posterior laryngitis (PL)." | 5.10 | Posterior laryngitis: effects of treatment with omeprazole alone. ( Argüelles-Arias, F; Carmona, I; Galera-Ruiz, H; Herrerías, JM; Muñoz-Borje, F; Rodríguez-Téllez, M, 2002) |
| "Eighteen men and 24 women, aged 22 to 77 years, who presented with recurrent chest pain complaints of a noncardiac etiology, as determined by rest/stress perfusion imaging with technetium Tc99m sestamibi (MIBI), were enrolled in a prospective, double-blinded, placebo-controlled, crossover trial using high-dose omeprazole." | 5.10 | Short course of omeprazole: a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour esophageal pH monitoring. ( Arezo, S; Crofts, T; DeCosta, G; Everett, S; Gennings, C; Jesse, R; Pandak, WM; Siuta, M; Zfass, A, 2002) |
| "To investigate the prevalence of gastroesophageal reflux disease (GERD) among patients with bronchial asthma (BA) and to determine the effects of omeprazole therapy on the outcome of asthma in patients with GERD." | 5.10 | [Clinico-functional evaluation of the efficacy of treating gastroesophageal reflux disease combined with bronchial asthma with omeprazole]. ( Agapova, NR; Busarova, GA; Maev, IV; Samsonov, AA, 2002) |
| "To investigate whether pantoprazole (20 mg/d) produces significantly greater symptom control than ranitidine (300 mg/d) in patients with gastro-oesophageal reflux disease (GORD)." | 5.10 | Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care. ( Katelaris, P; Moore, MG; Sprogis, A; Talley, NJ, 2002) |
| "Pantoprazole is a proton pump inhibitor approved for the treatment of erosive oesophagitis and gastro-oesophageal reflux disease." | 5.10 | Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study. ( Bochenek, W; DeVault, K; Kovacs, TO; Miska, D; Wilcox, CM, 2002) |
| ": Fifty patients with complicated or atypical gastro-oesophageal reflux disease were randomly assigned to receive 30 mg lansoprazole (n = 26) or 40 mg pantoprazole (n = 24) once daily." | 5.10 | Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. ( De Micheli, E; Frazzoni, M; Grisendi, A; Savarino, V, 2003) |
| "To compare the efficacy and safety of two doses of rabeprazole with 20 mg omeprazole in the maintenance treatment of erosive gastro-oesophageal reflux disease over 5 years." | 5.10 | A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. ( Bardhan, KD; Fiocca, R; Humphries, TJ; Miller, N; Morocutti, A; Rindi, G; Thjodleifsson, B, 2003) |
| "Treatment with lansoprazole is a useful test in diagnosing endoscopy-negative gastro-oesophageal reflux disease in Chinese patients with non-cardiac chest pain." | 5.10 | Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. ( Chan, CK; Chen, WH; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Lau, CP; Wong, BC; Wong, NY; Wong, WM; Xia, HH, 2003) |
| "To assess the efficacy of lansoprazole for the relief of symptoms due to gastroesophageal reflux disease (GERD) in children 1 to 11 years of age." | 5.10 | Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. ( Book, L; Ferry, G; Gunasekaran, T; Huang, B; Keith, R; Tolia, V, 2002) |
| "To evaluate the pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability of lansoprazole in adolescents between 12 and 17 years of age with gastroesophageal reflux disease (GERD)." | 5.10 | Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. ( Chiu, YL; Fitzgerald, J; Gremse, D; Gunasekaran, T; Gupta, S; Karol, M; Keith, R; Pan, WJ, 2002) |
| "To evaluate the pharmacokinetics and pharmacodynamics of lansoprazole in children between 1 and 11 years of age with gastroesophageal reflux disease (GERD)." | 5.10 | Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. ( Book, L; Chiu, YL; Gremse, D; Gunasekaran, T; Karol, M; Pan, WJ; Pilmer, B; Tolia, V; Winter, H, 2002) |
| "To compare the efficacy and tolerability of pantoprazole 40 mg and omeprazole MUPS 40 mg in patients with moderate to severe gastroesophageal reflux disease (GERD)." | 5.10 | Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study. ( Bohuschke, M; Costa Neves, B; Fumagalli, I; Gatz, G; Körner, T; Schütze, K; van Leendert, RJ, 2003) |
| " Both pantoprazole and placebo resulted in a marked improvement in laryngitis scores (decrease of 8." | 5.10 | Effect of pantoprazole on the course of reflux-associated laryngitis: a placebo-controlled double-blind crossover study. ( Eherer, AJ; Friedrich, G; Habermann, W; Hammer, HF; Kiesler, K; Krejs, GJ, 2003) |
| "To investigate the occurrence of gastro-oesophageal reflux and acid breakthrough during polygraphically monitored sleep under conditions of powerful acid suppression with omeprazole 20 mg b." | 5.10 | The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity. ( Harnish, MJ; Orr, WC, 2003) |
| "Oesophageal pH and heartburn severity were determined in 27 GERD subjects at baseline and on days 1, 2 and 8 of treatment with 20 mg omeprazole or 20 mg rabeprazole in a randomized, two-way crossover fashion." | 5.10 | Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux disease patients treated with a proton-pump inhibitor. ( Gardner, JD; Miner, PB; Robinson, M; Sloan, S, 2003) |
| " Patients with GERD, characterized by heartburn that had occurred 4 or more times per week for at least 6 months, were treated for 28 days with either pantoprazole 40 mg once daily or nizatidine 150 mg twice daily." | 5.10 | Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine. ( Armstrong, D; Paré, P; Pericak, D; Pyzyk, M, 2003) |
| "The GABA(B) receptor agonist baclofen improves duodenal reflux and associated reflux symptoms that persist during PPI therapy." | 5.10 | Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. ( Janssens, J; Koek, GH; Lerut, T; Sifrim, D; Tack, J, 2003) |
| "To assess the efficacy of omeprazole in treating irritable infants with gastroesophageal reflux and/or esophagitis." | 5.10 | Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. ( Davidson, GP; Heddle, ML; Hirte, C; Lines, DR; Moore, DJ; Tao, BS, 2003) |
| "The purpose of this study is a comparative assessment of the clinical efficiency of Omeprazole and Esomeprazole in patients suffering from bronchial asthma (BA) with associated gastroesophageal reflux disease (GERD)." | 5.10 | [Use of omeprazole and esomeprazole in patients suffering from bronchial asthma with associated gastroesophageal reflux disease]. ( Balashova, NN; Maev, IV; Shchekina, MI; Viuchnova, ES, 2003) |
| "Gastric and oesophageal pH were determined in 26 subjects with gastro-oesophageal reflux disease at baseline and on days 1, 2 and 8 of treatment with 20 mg omeprazole or 20 mg rabeprazole in a randomized, two-way cross-over fashion." | 5.10 | The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis. ( Gallo-Torres, H; Gardner, JD; Miner, PB; Robinson, M; Sloan, S, 2003) |
| "The research was aimed at evaluating the efficiency of the inhibitor of the Rabeprazole (Pariet) proton pump in the therapy of the gastroesophageal reflux disease (GERD) with extra esophagus manifestations, and the presence of pains in the chest not caused by cardiac diseases." | 5.10 | [Evaluation of the efficacy of pariet in patients with gastroesophageal reflux disease with thoracic pain not connected with cardiac disease]. ( Danilin, MS; Kucheriavyĭ, IuA; Maev, IV, 2003) |
| "This randomized, open-label, comparative five-way crossover study evaluated the 24-h intragastric pH profile of oral esomeprazole 40 mg, lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg, and rabeprazole 20 mg once daily in 34 Helicobacter pylori-negative patients aged 18-60 yr with symptoms of gastroesophageal reflux disease." | 5.10 | Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. ( Chen, Y; Katz, PO; Miner, P; Sostek, M, 2003) |
| " In 16 subjects with chronic heartburn, 24-hr gastric and esophageal pH were measured at baseline and again after six days of 20 mg omeprazole alone at 08:00 hr followed by placebo, 75 mg ranitidine, or 20 mg omeprazole at 22:00 hr." | 5.10 | Control of nocturnal gastric acidity: a role for low dose bedtime ranitidine to supplement daily omeprazole. ( Ciociola, AA; Filinto, J; Gardner, JD; Miner, PB; Robinson, M; Rodriguez-Stanley, S; Zubaidi, S, 2002) |
| "Lansoprazole and omeprazole are widely used proton pump inhibitors for the management of gastro-oesophageal reflux." | 5.10 | Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison. ( De Micheli, E; Frazzoni, M; Grisendi, A; Savarino, V, 2002) |
| "The 'Future of Acid Suppression Therapy' (FAST) trial evaluated, in actual clinical practice, the timing of symptom relief, changes in symptom severity, health-related quality of life and safety in endoscopically confirmed erosive gastro-oesophageal reflux disease treated with rabeprazole." | 5.10 | Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. ( Fitzgerald, S; Hegedus, R; Jokubaitis, L; Murthy, A; Robinson, M, 2002) |
| " Rabeprazole is a new proton pump inhibitor that is effective in treating gastro-oesophageal reflux disease (GERD)." | 5.10 | Integrated acidity and rabeprazole pharmacology. ( Barth, JA; Gardner, JD; Hahne, WF; Perdomo, C; Robinson, M; Rodriguez-Stanley, S; Sloan, S, 2002) |
| "Rabeprazole has a faster onset of antisecretory action than omeprazole, and it is of interest to determine whether this translates into faster symptom relief in patients with gastro-oesophageal reflux disease." | 5.10 | A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. ( Blum, AL; Bytzer, P; Holtmann, G; Loeffler, V; Metz, M, 2002) |
| "Fifty patients with complications or atypical manifestations of gastro-oesophageal reflux disease were given lansoprazole, 30 mg once daily." | 5.10 | Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression. ( De Micheli, E; Frazzoni, M; Grisendi, A; Savarino, V, 2002) |
| "In this randomised, double-blind, multicentre study, conducted at 27 European sites, the efficacy and safety of rabeprazole and omeprazole were compared in patients with erosive or ulcerative gastro-oesophageal reflux disease (GERD)." | 5.09 | Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. ( Beker, JA; Bell, NE; Dekkers, CP; Gabryelewicz, A; Humphries, TJ; Thjodleifsson, B, 1999) |
| "Because improvement in quality of life (QoL) is an important therapeutic goal in patients with heartburn but without esophagitis, the aim of the present study was to compare the impact of omeprazole 20 mg or 10 mg daily with that of placebo on QoL in patients with heartburn as the predominant symptom." | 5.09 | Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. ( Anker-Hansen, O; Carlsson, R; Glise, H; Havelund, T; Hernqvist, H; Junghard, O; Lauritsen, K; Lind, T; Lundell, L; Pedersen, SA; Stubberöd, A; Wiklund, I, 1999) |
| "A hypothesis suggesting that profound acid inhibition therapy facilitates and hastens the development of gastric glandular atrophy in patients infected with Helicobacter pylori was investigated in this randomized study comparing omeprazole therapy with antireflux surgery (ARS) for chronic gastroesophageal reflux disease (GERD)." | 5.09 | Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. ( Andersson, A; Hattlebakk, J; Havu, N; Janatuinen, E; Levander, K; Liedman, B; Lundell, L; Miettinen, P; Myrvold, HE; Nyström, P; Pedersen, SA; Thor, K, 1999) |
| "Strenuous exercise exacerbates gastro-oesophageal reflux and symptoms and this may be diminished by antisecretory medication with omeprazole." | 5.09 | The effect of omeprazole on gastro-oesophageal reflux and symptoms during strenuous exercise. ( Akkermans, LM; Bol, E; De Kort, AF; De Vries, WR; Mosterd, WL; Peters, HP; Van Berge Henegouwen, GP; Van Krevelen, H, 1999) |
| "Better control of gastric acid secretion with omeprazole appeared to decrease the need for dilatation of oesophageal strictures complicating gastro-oesophageal reflux disease in our hospital-based endoscopy service." | 5.09 | Omeprazole therapy decreases the need for dilatation of peptic oesophageal strictures. ( Barbezat, GO; Lubcke, R; Schlup, M, 1999) |
| "To evaluate the diagnostic accuracy of a trial of a high-dose proton pump inhibitor (the omeprazole test) in detecting gastroesophageal reflux disease (GERD) in patients with heartburn symptoms." | 5.09 | Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. ( Camargo, E; Fass, R; Fennerty, MB; Gralnek, IM; Johnson, C; Ofman, JJ; Sampliner, RE, 1999) |
| "To investigate the prevalence of gastroesophageal reflux (GER) among patients with asthma and to determine the effect of omeprazole on the outcome of asthma in patients with GER." | 5.09 | Gastroesophageal reflux in asthmatics: A double-blind, placebo-controlled crossover study with omeprazole. ( Hietanen, EK; Kiljander, TO; Salomaa, ER; Terho, EO, 1999) |
| "This 1-year study compared the cost effectiveness of omeprazole and ranitidine when used as initial therapy in an intermittent treatment strategy for the management of patients with symptomatic gastro-oesophageal reflux disease with or without erosive oesophagitis." | 5.09 | Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease. ( Bardhan, KD; Bigard, MA; Carlsson, J; Fulton, C; Gillon, K; Hosie, J; Müller-Lissner, S; Peacock, R; Ponce, J; Porro, GB; Scott, M; Stålhammar, NO; Weir, DG, 1999) |
| "The aim of the present study was to investigate whether not only omeprazole but also lansoprazole leads to hypertrophy of the parietal cells of the gastric mucosa." | 5.09 | Treatment with lansoprazole also induces hypertrophy of the parietal cells of the stomach. ( Alexandridis, T; Meining, A; Seifert, E; Stolte, M, 2000) |
| "The aim of this study was to assess the ability of pantoprazole to maintain gastric acid suppression in patients with gastroesophageal reflux disease who are switched from an oral (p." | 5.09 | Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. ( Lew, E; Martin, P; Maton, PN; Metz, DC; Paul, J; Pisegna, JR; Pratha, V, 2000) |
| "The aim of this study was to compare the efficacy and tolerability of low dose pantoprazole (20 mg) (a gastric proton pump inhibitor) with standard dose ranitidine (300 mg) (a histamine-receptor antagonist), in their ability to relieve symptoms and heal oesophageal lesions associated with gastrooesophageal reflux disease (GORD)." | 5.09 | Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: a randomized, double-blind, parallel, and multicentre study. ( Bethke, T; de K Grundling, H; Fischer, R; O'Keefe, SJ; Retief, FJ; Theron, I; van Rensburg, CJ; van Zyl, JH, 2000) |
| "To compare the efficacy of 20 mg with 40 mg pantoprazole in maintaining symptomatic and endoscopic remission in patients with gastro-oesophageal reflux disease (GORD)." | 5.09 | Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease. ( Fumagalli, I; Hotz, J; Lühmann, R; Plein, K; Schneider, A; Wurzer, H, 2000) |
| "05) lower percentages of days and nights with heartburn, less pain severity of both day and night heartburn, fewer days of antacid use, and smaller amounts of antacid use compared with patients who were treated with ranitidine or placebo." | 5.09 | Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. ( Campbell, DR; Fludas, C; Huang, B; Kahrilas, PJ; Richter, JE, 2000) |
| "In this double-blind crossover study, 38 patients with gastro-oesophageal reflux disease (GERD) symptoms were randomized to esomeprazole 40 and 20 mg and omeprazole 20 mg once daily for 5 days." | 5.09 | Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease. ( Andersson, T; Hasselgren, G; Holmberg, J; Jonsson, A; Kylebäck, A; Lind, T; Röhss, K; Rydberg, L, 2000) |
| "The objective of this study was to compare the efficacy and safety of the proton pump inhibitor rabeprazole to that of the histamine-2 (H2)-receptor antagonist ranitidine in the treatment of erosive gastroesophageal reflux disease." | 5.09 | Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group. ( Farley, A; Humphries, TJ; Wruble, LD, 2000) |
| "The efficacy of antireflux surgery (ARS) and omeprazole treatment in the control of gastrooesophageal reflux disease (GORD) are well established." | 5.09 | Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study Group. ( Blomqvist, A; Hatlebakk, JG; Janatuinen, E; Lamm, M; Levander, K; Lundell, L; Miettinen, P; Myrvold, HE; Nyström, P; Pedersen, SA; Thor, K; Wiklund, I, 2000) |
| "To evaluate the efficacy and tolerability of rabeprazole 10 mg and 20 mg versus placebo for the prevention of endoscopically demonstrable relapse in patients previously diagnosed with erosive or ulcerative gastro-oesophageal reflux disease (GORD) who had no oesophageal erosions or ulcerations at study entry." | 5.09 | Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group. ( Birbara, C; Breiter, J; Hahne, W; Perdomo, C, 2000) |
| "To evaluate and compare the pharmacodynamic effects of IY-81149 and omeprazole on gastric pH in patients with gastroesophageal reflux disease." | 5.09 | A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease. ( Boileau, F; Cho, KD; Goldwater, R; Jung, WT; Kim, DY; Lee, SM; Park, DW; Periclou, AP, 2000) |
| "The aim of this dose-response study was to compare the effectiveness of 10 mg, 20 mg, and 40 mg of pantoprazole with that of placebo tablets in the healing and symptom relief of gastroesophageal reflux disease associated with erosive esophagitis, and to determine the optimal dose." | 5.09 | Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. ( Bochenek, W; Richter, JE, 2000) |
| "We evaluated the effectiveness and safety profile of 10 and 20 mg of rabeprazole, a new proton pump inhibitor, once daily versus placebo in preventing endoscopic and symptomatic relapse for up to 1 yr among patients with healed erosive or ulcerative gastroesophageal reflux disease (GERD)." | 5.09 | Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group. ( Barth, J; Caos, A; Dayal, Y; Moskovitz, M; Niecestro, R; Perdomo, C, 2000) |
| "Omeprazole is well tolerated, highly effective, and safe for treatment of erosive esophagitis and symptoms of gastroesophageal reflux in children, including children in whom antireflux surgery or other medical therapy has failed." | 5.09 | Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. ( Dalväg, A; Hassall, E; Israel, D; Junghard, O; Lundborg, P; Radke, M; Shepherd, R; Sköld, B, 2000) |
| "To determine efficacy of lansoprazole, a relatively new proton pump inhibitor, on symptoms and oesophagitis in a group of children with gastro-oesophageal reflux disease refractory to H2 receptor antagonists." | 5.09 | Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. ( Cucchiara, S; De Rosa, I; Franco, MT; Iula, VD; Salvia, G; Spadaro, R; Terrin, G, 2000) |
| "A total of 318 gastroesophageal reflux patients whose erosive esophagitis was healed in a comparative study of esomeprazole 40 mg, 20 mg, or omeprazole 20 mg, were randomized to maintenance therapy with once daily esomeprazole 40 mg, 20 mg, or 10 mg, or placebo in a U." | 5.09 | Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. ( Benjamin, SB; Damico, D; Goldstein, JL; Hamelin, B; Johnson, DA; Lamet, M; Vakil, NB; Whipple, J, 2001) |
| "Forty-five patients with long segment Barrett esophagus were treated in a randomized 2-year follow-up study with either omeprazole 40 mg b." | 5.09 | Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus. ( de Jager-Krikken, A; Ganesh, S; Karrenbeld, A; Kleibeuker, JH; Klinkenberg-Knol, EC; Kuipers, EJ; Lamers, CB; Peters, FT; Sluiter, WJ, 2000) |
| "In patients with gastroesophageal reflux disease (GERD), esomeprazole, the S-isomer of omeprazole, has demonstrated pharmacological and clinical benefits beyond those seen with the racemic parent compound." | 5.09 | Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. ( Breiter, JR; Hamelin, B; Hwang, C; Johanson, J; Kahrilas, PJ; Levine, JG; Marino, V; Maton, P; Richter, JE, 2001) |
| "Patients diagnosed with idiopathic chronic laryngitis were randomized to receive either lansoprazole 30 mg p." | 5.09 | Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. ( Buchner, A; El-Serag, HB; Gavin, M; Inadomi, JM; Lee, P; McCarthy, DM, 2001) |
| "The aim of the study was to investigate which features predict favourable response to omeprazole therapy in asthmatics with gastro-oesophageal reflux (GER)." | 5.09 | Asthma and gastro-oesophageal reflux: can the response to anti-reflux therapy be predicted? ( Helenius, H; Hietanen, E; Kiljander, T; Liippo, K; Salomaa, ER; Terho, EO, 2001) |
| "Our objective was to compare four management strategies for heartburn: therapy with an H2-receptor antagonist (ranitidine), therapy with a proton pump inhibitor (lansoprazole), crossover from ranitidine to lansoprazole ("step-up" therapy), and crossover from lansoprazole to ranitidine ("step-down" therapy)." | 5.09 | Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies. ( Freston, JW; Henning, JM; Howden, CW; Huang, B; Lukasik, N, 2001) |
| "Rabeprazole has been shown to be more potent and faster than other proton pump inhibitors in in vitro studies and highly effective in decreasing oesophageal acid exposure in patients with gastro-oesophageal reflux disease (GERD)." | 5.09 | Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole. ( Avasthy, N; Ducrottè, P; Fournet, J; Galmiche, JP; Humphries, TJ; Rampal, P; Zerbib, F, 2001) |
| "To investigate whether pantoprazole also reduces bile reflux and whether this is paralleled by a change in oesophageal motility." | 5.09 | Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis. ( Brundler, R; Gaia, C; Gut, A; Halter, F; Inauen, W; Netzer, P, 2001) |
| "To measure 24-h ambulatory oesophageal pH data in patients with gastro-oesophageal reflux disease prior to, during and after acute treatment with comparable doses of omeprazole and ranitidine." | 5.08 | Patterns of 24-hour oesophageal acid exposure after acute withdrawal of acid suppression. ( Grossman, MR; Mellow, MH; Orr, WC, 1995) |
| "To identify patients with gastroesophageal reflux disease (GERD) who, despite omeprazole 20 mg b." | 5.08 | Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. ( Castell, DO; Johnston, BT; Just, RJ; Leite, LP, 1996) |
| "When routinely checking patients receiving omeprazole treatment for gastro-oesophageal reflux, we have been finding patients with surprisingly low nocturnal gastric pH." | 5.08 | Morning or evening dosage of omeprazole for gastro-oesophageal reflux disease? ( Aggestrup, S; Hendel, J; Hendel, L, 1995) |
| "Six hundred and four patients with endoscopically proven oesophagitis and a recent history of heartburn were randomly assigned to receive lansoprazole 30 mg or omeprazole 20 mg daily for 4-8 weeks." | 5.08 | Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. ( Mee, AS; Rowley, JL, 1996) |
| "To investigate the effect of the potent gastric acid inhibitor omeprazole 40 mg orally daily on peak expiratory flow rate (PEFR), asthma symptoms and histamine bronchial responsiveness in adult patients with both asthma and GOR." | 5.08 | Adult asthma and gastro-oesophageal reflux: the effects of omeprazole therapy on asthma. ( Kronborg, IJ; Robinson, P; Teichtahl, H; Yeomans, ND, 1996) |
| " Eighty-eight patients with healed erosive/ulcerative oesophagitis and relief of heartburn after pre-treatment with omeprazole received maintenance treatment." | 5.08 | Efficacy of a pectin-based anti-reflux agent on acid reflux and recurrence of symptoms and oesophagitis in gastro-oesophageal reflux disease. ( Aalykke, C; Havelund, T; Rasmussen, L, 1997) |
| "Previous studies have demonstrated greater efficacy for omeprazole compared with cimetidine in patients with endoscopically verified oesophagitis, but excluded the substantial group of gastro-oesophageal reflux disease (GERD) patients with reflux symptoms but without endoscopic abnormality." | 5.08 | Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. ( Axon, AT; Bate, CM; Emmas, CE; Green, JR; Murray, FE; Taylor, MD; Tildesley, G, 1997) |
| "Following endoscopy 424 patients presenting with heartburn as the predominant symptom of gastro-oesophageal reflux disease were randomized to treatment with omeprazole 20 or 10 mg once daily, or cisapride 10 mg four times daily, in a double-blind, double-dummy, parallel group, multicentre study." | 5.08 | Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. ( Barthelemy, P; Galmiche, JP; Hamelin, B, 1997) |
| " This study assessed 20 mg omeprazole daily (OM20), 10 mg omeprazole daily (OM10), and 150 mg ranitidine (RAN) twice daily for symptom relief in gastro-oesophageal reflux disease (GORD)." | 5.08 | Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. ( Hole, J; Newland, RD; Patel, AC; Turbitt, ML; Venables, TL; Wilcock, C, 1997) |
| "To determine the diagnostic value of empirical treatment with omeprazole in the diagnosis of gastroesophageal reflux disease (GERD)." | 5.08 | Omeprazole as a diagnostic tool in gastroesophageal reflux disease. ( Dieleman, LA; Festen, HP; Jansen, EH; Klinkenberg-Knol, EC; Kuipers, EJ; Meuwissen, SG; Schenk, BE; Schrijver, M; Tuynman, HA, 1997) |
| " pylori and with gastro-oesophageal reflux disease we investigated the gastritis parameters in antral and corpus mucosa before and after 2, 6 and 12 months of treatment with 15 or 30 mg lansoprazole or 20 mg omeprazole/day." | 5.08 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. ( Alexandridis, T; Meining, A; Schmitz, JM; Seifert, E; Stolte, M, 1998) |
| "After endoscopy, patients without endoscopic oesophagitis were randomized to omeprazole 20 mg (Ome20), omeprazole 10 mg (Ome10) or placebo once daily for 4 weeks (n = 261) and those with oesophagitis (except circumferential/ulcerative) were randomized to receive either Ome20 or Ome10 once daily for 4 weeks (n = 277)." | 5.08 | Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. ( Carlsson, R; Dalväg, A; de Groot, G; Dent, J; Hatlebakk, J; Haug, K; Junghard, O; Riley, S; Sheikh, R; van Oudvorst, A; Watts, R; Wiklund, I, 1998) |
| "Rabeprazole, a new proton pump inhibitor, was studied in patients with acid-peptic-related diseases (duodenal ulcer, gastric ulcer, GERD) in three placebo-controlled, double-blind, randomized clinical trials." | 5.08 | Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. ( Bassion, S; Cloud, ML; Enas, N; Humphries, TJ, 1998) |
| " The aim of this study was to evaluate the efficacy of the omeprazole test (OT) in diagnosing gastroesophageal reflux (GERD) in patients with NCCP and estimate the potential cost savings of this strategy compared with conventional diagnostic evaluations." | 5.08 | The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. ( Camargo, E; Fass, R; Fennerty, MB; Gralnek, IM; Johnson, C; Ofman, JJ; Sampliner, RE, 1998) |
| "After healing and symptom relief had been obtained on open therapy with lansoprazole 30 mg daily, 103 patients with reflux oesophagitis grade 1 or 2 were randomized to maintenance therapy with lansoprazole 15 or 30 mg daily, and time until recurrence of symptoms and/or endoscopic changes was recorded." | 5.08 | Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole. ( Berstad, A; Hatlebakk, JG, 1997) |
| "The aim of this study was to determine if omeprazole improves pulmonary function and quality of life in asthmatics with gastroesophageal reflux." | 5.08 | Omeprazole improves peak expiratory flow rate and quality of life in asthmatics with gastroesophageal reflux. ( Levin, TR; McQuaid, KR; Sperling, RM, 1998) |
| " is more effective than cimetidine 800 mg nocte in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis." | 5.08 | Omeprazole is more effective than cimetidine in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis. ( Axon, AT; Bate, CM; Emmas, C; Green, JR; Murrays, FE; Owen, SM; Taylor, MD; Tildesley, G, 1998) |
| "In our study omeprazole was superior to either lansoprazole or pantoprazole in the maintenance treatment of complicated gastro-oesophageal reflux disease." | 5.08 | A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis. ( Diehl, KL; Geyer, P; Jaspersen, D; Martens, E; Schoeppner, H, 1998) |
| "elucidate the mechanisms that lead to severe hypergastrinaemia during long-term omeprazole therapy for gastro-oesophageal reflux disease (GERD)." | 5.08 | Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. ( Biemond, I; Bloemena, E; Festen, HP; Jansen, EH; Klinkenberg-Knol, EC; Kuipers, EJ; Lamers, CB; Meuwissen, SG; Nelis, GF; Schenk, BE, 1998) |
| " However, little is known about the effect of omeprazole on duodenogastric reflux (DGR) and duodenogastro-oesophageal reflux (DGOR)." | 5.08 | Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus. ( Anggiansah, A; Manifold, DK; Marshall, RE; Owen, WA; Owen, WJ, 1998) |
| " However, lansoprazole appears to have a more rapid onset of reduction of acid gastro-oesophageal reflux than omeprazole over a 48 h period." | 5.08 | Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis. ( Burnham, WR; Kamm, MA; Newton, M, 1998) |
| "Thirteen patients with esophagitis were given omeprazole for 90 days." | 5.08 | Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients. ( Arnestad, JS; Brenna, E; Qvigstad, G; Waldum, HL, 1998) |
| "Lansoprazole (LAN) and omeprazole (OME) heal esophagitis effectively and to similar extents, but LAN has a faster effect on the relief of symptoms of gastroesophageal reflux." | 5.08 | Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease. ( Hammarlund, B; Iwarzon, M; Janczewska, I; Sagar, M; Seensalu, R; Sjöstedt, S, 1998) |
| "Eleven adult patients with nocturnal asthma, and gastro-oesophageal reflux documented by endoscopy or ambulatory oesophageal pH monitoring completed a double-blind cross-over study (4 week treatment, one week run-in and cross-over periods) comparing the effects of omeprazole 20 mg daily and placebo on asthma control assessed by symptoms, peak expiratory flow rate and bronchodilator usage." | 5.07 | Omeprazole in the treatment of asthmatics with nocturnal symptoms and gastro-oesophageal reflux: a placebo-controlled cross-over study. ( Butland, RJ; Ford, GA; Oliver, PS; Prior, JS; Wilkinson, SP, 1994) |
| "To determine whether the patients with refractory posterior laryngitis respond to treatment with omeprazole." | 5.07 | Omeprazole for the treatment of posterior laryngitis. ( Hanson, D; Kahrilas, PJ; Kamel, PL, 1994) |
| "Omeprazole, a potent inhibitor of acid secretion, is effective in adults with severe gastroesophageal reflux, but no such data are available on children." | 5.07 | Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. ( Gunasekaran, TS; Hassall, EG, 1993) |
| "Twenty-five patients with systemic sclerosis and severe gastro-oesophageal reflux disease were treated with 20-80 mg omeprazole daily for up to 5 years." | 5.07 | Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis. ( Hage, E; Hendel, J; Hendel, L; Stentoft, P, 1992) |
| "We used decision analysis to assess the clinical and economic effects of three treatments--phase 1 therapy alone or combined with omeprazole or ranitidine hydrochloride therapy--for patients with persistent, symptomatic grade 2 or higher gastroesophageal reflux disease." | 5.07 | Cost and quality effects of alternative treatments for persistent gastroesophageal reflux disease. ( Bloom, BS; Fendrick, AM; Hillman, AL; Schwartz, JS, 1992) |
| "To define the optimum doses of omeprazole appropriate for acute and long-term therapy of patients with gastro-oesophageal reflux disease, 24-h oesophageal pH was measured in 12 patients with symptomatic reflux and an abnormal 24-h oesophageal acid exposure time (greater than 6%) in a randomized, double-blind, four-way crossover study comparing the effects of omeprazole 10, 20, or 40 mg/day and placebo." | 5.07 | Effect of different doses of omeprazole on 24-hour oesophageal acid exposure in patients with gastro-oesophageal reflux. ( Allen, ML; Bradstreet, TE; Cagliola, AJ; Humphries, TJ; Maton, PN; McIntosh, D; Robinson, M, 1991) |
| "Twenty-two consecutive patients with gastroesophageal reflux and erosive or ulcerative esophagitis entered a double-blind, randomized study comparing the effect of 20 mg omeprazole once daily with that of 150 mg ranitidine twice daily on esophageal acidity." | 5.06 | The effect of omeprazole or ranitidine treatment on 24-hour esophageal acidity in patients with reflux esophagitis. ( Enbom, H; Lönroth, H; Lundell, L; Ruth, M; Sandberg, N; Sandmark, S, 1988) |
| " This meta-analysis sought to assess the clinical and safety profiles of esomeprazole versus omeprazole at pharmacologically equivalent doses in healing gastroesophageal reflux disease (GERD), peptic ulcer disease and eradicating Helicobacter pylori (H." | 4.91 | Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection. ( Dan, YY; Khoo, AL; Lim, BP; Lin, L; Teng, M; Wu, TS; Zhao, YJ, 2015) |
| "This study aims to evaluate the effectiveness and tolerability of esomeprazole and omeprazole in patients with gastroesophageal reflux disease (GERD)." | 4.91 | Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis. ( Liu, L; Qi, Q; Wang, R; Wang, S; Zhao, F, 2015) |
| "To determine the role of omeprazole treatment in crying infants under the age of 1 year in whom acid gastroesophageal reflux is suspected and to study the evidence for efficacy, prescribing behaviour and side effects of this medicine, which is not registered for use in infants." | 4.86 | [Omeprazole of limited value in crying babies]. ( Blokpoel, RG; Broos, N; de Jong-van den Berg, LT; de Vries, TW, 2010) |
| "Esomeprazole (Nexium); S-omeprazole) is a single optical isomer proton-pump inhibitor (PPI) approved for the management of reflux oesophagitis, the symptomatic treatment of gastro-oesophageal reflux disease (GORD), the prevention and healing of NSAID-associated gastric ulcer disease (and the prevention of NSAID-associated duodenal ulcers in the UK), the treatment of Helicobacter pylori infection and associated duodenal ulcer disease (and prevention of relapse of H." | 4.84 | Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults. ( Blick, SK; Croxtall, JD; Keating, GM; Lyseng-Williamson, KA; McKeage, K, 2008) |
| " We report 3 cases of anaphylactic reactions induced by lansoprazole or ranitidine diagnosed in a population of 8304 first-referral patients over a 13-year period." | 4.83 | Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature. ( Bozkurt, B; Demirkan, K; Kalyoncu, AF; Karakaya, G, 2006) |
| " Omeprazole is a drug widely used in the treatment of gastroesophageal reflux disease and peptic ulcer disease." | 4.82 | [Acute interstitial nephritis associated with omeprazole therapy]. ( Calvo, C; García, H; Hernández-Jaras, J; Maduell, F; Rovira, RE; Torregrosa, E, 2004) |
| " Pharmacodynamic results have also suggested that rabeprazole may be better suited than omeprazole as on-demand therapy for symptomatic gastro-oesophageal reflux disease." | 4.82 | Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole. ( Horn, J, 2004) |
| "To compare the safety and efficacy of pantoprazole, placebo and the H2 antagonist nizatidine in relieving symptoms in patients with erosive oesophagitis." | 4.82 | Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. ( Bochenek, WJ; Fraga, PD; Mack, ME; Metz, DC, 2004) |
| " To evaluate the efficacy of the new PPI rabeprazole, 12 controlled clinical trials were conducted worldwide-three for each indication (erosive or ulcerative GERD healing, long-term GERD healing maintenance, duodenal ulcer healing, and gastric ulcer healing)." | 4.81 | Efficacy of rabeprazole once daily for acid-related disorders. ( Bardhan, KD; Barth, J; Lanza, F; Niecestro, R; Perdomo, C, 2001) |
| "In uncontrolled clinical trials and case reports to date, omeprazole has been effective and well tolerated for the acute and chronic treatment of esophageal and peptic ulcer disease in children, particularly those who had failed to respond to previous treatment with histamine2-receptor antagonists." | 4.81 | A review of omeprazole use in the treatment of acid-related disorders in children. ( Katona, BG; Levine, D; Souney, PE; Walters, JK; Zimmermann, AE, 2001) |
| " When the two newest PPIs, rabeprazole and esomeprazole, are compared with the older drugs in this class (omeprazole, lansoprazole and pantoprazole), the newer PPIs offer several key advantages over older agents, particularly in terms of the management of gastro-oesophageal reflux disease." | 4.81 | New-generation proton pump inhibitors: overcoming the limitations of early-generation agents. ( Robinson, M, 2001) |
| " In 8-week studies, among patients with gastro-oesophageal reflux disease (GORD), rabeprazole 20 mg/day or 10mg twice daily was as effective as omeprazole and superior to ranitidine in the healing of GORD." | 4.81 | Rabeprazole: an update of its use in acid-related disorders. ( Carswell, CI; Goa, KL, 2001) |
| " Studies indicate that the omeprazole test is the most sensitive and cost effective test for diagnosing gastro-oesophageal reflux disease (GORD) in patients with extra-oesophageal or more "classic" symptoms suggestive of GORD." | 4.81 | Use of antisecretory agents as a trial of therapy. ( Fennerty, MB, 2002) |
| " Key search terms included gastroesophageal reflux, benzimidazoles; omeprazole; lansoprazole; pantoprazole; rabeprazole; receptor antagonists, histamine(2); therapy, combination drug; therapy, combined modality; and combinations, drug." | 4.81 | Combination drug therapy for gastroesophageal reflux disease. ( Cross, LB; Justice, LN, 2002) |
| " The newest PPI, esomeprazole, brings a statistically significant increase in healing of mucosal injury and symptom relief in patients with erosive esophagitis, compared with omeprazole and lansoprazole." | 4.81 | Pharmacologic management of gastroesophageal reflux disease. ( Katz, PO; Ramakrishnan, A, 2002) |
| " Although PPIs have been introduced into the therapy of acute peptic ulcer disease at different daily, oral doses of 20 mg (omeprazole and rabeprazole), 30 mg (lansoprazole) and 40 mg (pantoprazole), the data suggest that the optimal dose of lansoprazole, omeprazole and pantoprazole, with respect to the acute treatment of peptic ulcers and moderate to severe gastroesophageal reflux disease (GERD), is about 30-40 mg daily." | 4.80 | Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. ( Horbach, S; Kromer, W; Lühmann, R, 1999) |
| "Aim of this overview was to evaluate the main clinical trials with lansoprazole published from 1997 to 1999 in English-language journals, regarding gastroesophageal reflux disease, peptic ulcer, NSAID-induced ulcer, and ZES." | 4.80 | [Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999]. ( Capurso, L; Dobrilla, G, 2000) |
| " Healing rates for rabeprazole were equivalent to omeprazole in all indications, and superior (GORD healing and duodenal ulcer healing) or equivalent (gastric ulcer healing) to the histamine 2-receptor antagonist ranitidine." | 4.80 | The benefit/risk profile of rabeprazole, a new proton-pump inhibitor. ( Barth, J; Johnson, D; Jokubaitis, L; Perdomo, C, 2000) |
| "Pantoprazole is a new proton pump inhibitor indicated for the treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD) and is available in both oral and intravenous (IV) formulations." | 4.80 | Clinical experience with pantoprazole in gastroesophageal reflux disease. ( Avner, DL, 2000) |
| "The clinical efficacy of the proton pump inhibitor pantoprazole has been compared with ranitidine in a number of clinical studies in patients with either duodenal or gastric ulcer(s) or gastro-oesophageal reflux disease." | 4.79 | Clinical efficacy of pantoprazole compared with ranitidine. ( Bader, JP; Delchier, JC, 1994) |
| " In the treatment of gastric ulcer, analysis of all studies that have compared lansoprazole, a newly developed proton pump inhibitor, and H2-receptor antagonists has shown a statistically significant difference for a higher healing rate with lansoprazole." | 4.78 | Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer. ( Florent, C, 1993) |
| "Several studies have clearly demonstrated that omeprazole is highly efficacious in the management of patients with gastro-oesophageal reflux disease." | 4.77 | Management of gastro-oesophageal reflux disease. Are there alternatives to omeprazole? ( Klinkenberg-Knol, EC; Meuwissen, SG, 1989) |
| " In humans, omeprazole is a common drug used to mitigate Gastroesophageal Reflux Disease." | 4.31 | Intrauterine exposure to omeprazole increases the risk of teeth morphological anomalies in the offspring of a murine model. ( Ezequiel, BS; Frítola, M; Martins, CCN; Morimoto, J; Salles, MJS; Sestario, CS, 2023) |
| "In this prospective open-label comparative observational study, gastroesophageal reflux disease (GERD) patients were evaluated using 24-h dual-channel pH-impedance monitoring while on dexlansoprazole (60 mg, n = 39) and omeprazole (20 mg, n = 41) to study the degree of gastric acid suppression, esophageal acid exposure, and NAB (primary outcome measures)." | 4.12 | Nocturnal acid breakthrough and esophageal acidification during treatment with dexlansoprazole as compared to omeprazole in patients with gastroesophageal reflux disease. ( Blaachandran, A; Ghoshal, UC; Misra, A; Rai, S, 2022) |
| "The outcome of the airway stenosis was superior after laparoscopic fundoplication compared with medical treatment with omeprazole and was similar to the outcome of patients without gastroesophageal reflux." | 3.91 | Impact of fundoplication for gastroesophageal reflux in the outcome of benign tracheal stenosis. ( Bianchi, ET; Bibas, BJ; Guerreiro Cardoso, PF; Minamoto, H; Pego-Fernandes, PM; Salati, M, 2019) |
| "The efficacy of omeprazole in gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD), including those caused by non-steroidal antiinflammatory drugs (NSAIDs) is well documented." | 3.88 | Reliving 25 years of Experience with Omeprazole in Acid-peptic Diseases. ( Sharma, P, 2018) |
| "Clinical symptoms, cough symptom score, capsaicin cough sensitivity, gastroesophageal reflux diagnostic questionnaire (GerdQ) score, findings of multichannel intraluminal impedance-pH monitoring (MII-pH) and response to pharmacological anti-reflux therapy were retrospectively reviewed in 38 patients with non-acid GERC and compared with those of 49 patients with acid GERC." | 3.81 | Comparison of clinical characteristics of chronic cough due to non-acid and acid gastroesophageal reflux. ( Chen, Q; Liang, S; Lü, H; Qiu, Z; Xu, X; Yang, Z; Yu, L, 2015) |
| "Both omeprazole and its S enantiomer (esomeprazole) have been available and used to treat symptoms of gastroesophageal reflux disease (GERD) and conditions associated with excessive stomach acid secretion for more than a decade." | 3.81 | Comparative efficacy of esomeprazole and omeprazole: Racemate to single enantiomer switch. ( Asghar, W; Jamali, F; Pittman, E, 2015) |
| "To evaluate the efficacy and safety of baclofen for treatment of refractory gastroesophageal reflux-induced chronic cough (GERC) unresponsive to standard anti-reflux therapy." | 3.79 | Therapeutic efficacy of baclofen in refractory gastroesophageal reflux-induced chronic cough. ( Chen, Q; Liang, SW; Lv, HJ; Qiu, ZM; Xu, XH; Yang, ZM; Yu, L, 2013) |
| "To determine control of oesophageal reflux using Bravo pH monitoring in patients BE on omeprazole-sodium bicarbonate oral suspension powder (Ome-NaBic) 40 mg twice daily." | 3.78 | Control of intra-oesophageal pH in patients with Barrett's oesophagus on omeprazole-sodium bicarbonate therapy. ( Bleker, WF; Gerson, LB; Mitra, S; Yeung, P, 2012) |
| " We evaluated 34 patients with GERD (24 men and 10 women, aged 21-63) and extraesophageal respiratory symptoms (wheezing and/or cough) before therapy and after a 12-week treatment with double dose of omeprazole." | 3.77 | Patients with gastroesophageal reflux disease and respiratory manifestations do not present lung function disorders during cardiopulmonary exercise test. ( Giannikoulis, C; Karkoulias, K; Marangos, M; Nikolopoulou, V; Spiropoulos, K; Thomopoulos, K, 2011) |
| "Patients who had heartburn twice a week or more were treated with 20 mg omeprazole (OPZ) once daily for 8 wk as an initial therapy (study 1)." | 3.77 | Proton pump inhibitor step-down therapy for GERD: a multi-center study in Japan. ( Fujiwara, A; Ishioka, H; Kawahara, Y; Nasu, J; Okada, H; Takenaka, R; Tsuzuki, T; Yamamoto, K; Yoshinaga, F, 2011) |
| "We aimed to investigate effects of the proton pump inhibitors (PPIs) omeprazole, lansoprazole and pantoprazole, which are currently used for the treatment of hyperacidity and gastro-oesophageal reflux, on the reactivity of the isolated rat lower oesophageal sphincter." | 3.77 | Proton pump inhibitors omeprazole, lansoprazole and pantoprazole induce relaxation in the rat lower oesophageal sphincter. ( Buyukafsar, K; Erenmemisoglu, A; Ozkur, M; Pektas, M; Un, I; Yurtsever, AS, 2011) |
| "There are different clinical responses to omeprazole treatment in Iranian patients with gastroesophageal reflux disease." | 3.76 | Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis. ( Biramijamal, F; Doughaiemoghaddam, M; Hossein-Nezhad, A; Pourshams, A; Sarie, H; Zendehdel, N, 2010) |
| "Gastro-oesophageal reflux occurs when the pressure barrier of the lower oesophageal sphincter (LOS) fails due to a low basal pressure (less than or equal to 6 mm Hg), sphincteric relaxations or a noncompensated increase in intragastric pressure." | 3.76 | Pathophysiology and treatment of gastro-oesophageal reflux disease. ( Janssens, J; Vantrappen, G, 1989) |
| " Gastro-oesophageal reflux occurred more frequently in the control group compared with the omeprazole group (odds ratio 4." | 3.75 | The effect of omeprazole on oesophageal pH in dogs during anaesthesia. ( Bennett, RC; Brearley, J; Corletto, F; Jeffery, N; Jeffrey, N; Mellanby, RJ; Panti, A, 2009) |
| "To determine treatment satisfaction in patients with gastro-oesophageal reflux disease (GORD) when switched to esomeprazole." | 3.75 | Patient satisfaction with switching to esomeprazole from existing proton pump inhibitor therapy for gastro-oesophageal reflux disease: an observational, multicentre study. ( Groeneveld, L; Hoogendoorn, RJ; Kwee, JA, 2009) |
| "A 72-year-old lady who was prescribed Omeprazole for gastroesophageal reflux developed an allergic reaction within two days, which manifested initially as a generalised rash and marked eosinophilia." | 3.74 | Autoimmune haemolytic anaemia due to Omeprazole. ( Butt, MI; Sajid, S; Sobolewski, S, 2007) |
| "Episodes of respiratory distress with chest retraction and wheezing, sometimes associated with facial edema, were noted after administering the proton pump inhibitors omeprazole and esomeprazole in an infant with gastroesophageal reflux." | 3.74 | Severe systemic adverse reaction to proton pump inhibitors in an infant. ( Baldassarre, E; Bianchetti, MG; Ferrarini, A; Sagaon, MM, 2007) |
| "Two cases of severe hypomagnesaemia in adult long-term users of the PPI omeprazole, presenting with hypocalcaemic seizures." | 3.74 | Severe hypomagnesaemia in long-term users of proton-pump inhibitors. ( Cundy, T; Dissanayake, A, 2008) |
| "Gastric ulcer patients (n=88) were assigned either to the group receiving Helicobacter pylori eradication treatment (54 patients) or to the control group (34 patients; omeprazole treatment for 4 weeks) and were followed up for 1-year or until gastric ulcer relapsed." | 3.74 | Gastroesophageal reflux disease after Helicobacter pylori eradication in gastric ulcer patients: a one-year follow-up study. ( Jonaitis, L; Kiudelis, G; Kupcinskas, L, 2008) |
| "Resistance to proton pump inhibitors (PPI) in gastroesophageal reflux disease (GERD), which has been described in patients treated with omeprazole, could explain some exceptional cases of treatment failure and the need for surgery." | 3.73 | [Gastroesophageal reflux disease refractory to esomeprazole]. ( Ortiz, V; Ponce, J; Velasco, MJ, 2005) |
| "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease." | 3.73 | Lansoprazole-associated collagenous colitis: a case report. ( Höbling, W; Kirchgatterer, A; Knoflach, P; Rammer, M, 2005) |
| "Helicobacter pylori eradication was recommended for the prevention of atrophic gastritis in gastroesophageal reflux disease (GERD) patients on long-term omeprazole treatment." | 3.73 | Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients. ( Celikel, CA; Giral, A; Kalayci, C; Ozdogan, O; Tözün, N; Ulusoy, NB, 2005) |
| "To define the prevalence of gastroesophageal reflux disease (GERD) in mild persistent asthma and to value the effect of pantoprazole therapy on asthmatic symptoms." | 3.73 | Asthma and gastroesophageal reflux disease: effect of long-term pantoprazole therapy. ( Areni, A; Calabrese, C; Di Febo, G; Fabbri, A; Scialpi, C; Zahlane, D, 2005) |
| "Twenty-nine children with moderate to severe erosive oesophagitis and abnormal oesophageal bile reflux were studied before and after treatment with omeprazole 1 mg/kg per day." | 3.73 | Treatment of oesophageal bile reflux in children: the results of a prospective study with omeprazole. ( Brecelj, J; Heuschkel, R; Homan, M; Orel, R, 2006) |
| " Eight days before admission she had started and continued to take pantoprazole because of symptoms of gastroesophageal reflux." | 3.72 | [Pantoprazole-induced hepatitis]. ( Cordes, A; Maier, KP; Vogt, W, 2003) |
| "From a cohort of 114 consecutive patients with bronchial asthma, 53 patients agreed to participate in the study and were treated with rabeprazole 20mg daily for 8 weeks during an asymptomatic, stable period with no exacerbations of their asthma." | 3.72 | A proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal reflux. ( Ashida, S; Fujiki, S; Hosaki, Y; Mitsunobu, F; Mizuno, M; Okada, H; Okamoto, M; Shiratori, Y; Tanizaki, Y; Tsugeno, H, 2003) |
| "Our aims were to describe clinical characteristics of patients with chronic posterior laryngitis and to predict the response to omeprazole therapy." | 3.72 | Manifestations of gastroesophageal reflux and response to omeprazole therapy in patients with chronic posterior laryngitis: an evaluation based on clinical practice. ( Bastida, G; Bau, I; Garrigues, V; Gisbert, L; Nos, P; Ortiz, V; Ponce, J, 2003) |
| " The patient had initiated treatment with oral pantoprazole 40 mg/d for gastroesophageal reflux 2 months prior to admission." | 3.72 | Acute interstitial nephritis due to pantoprazole. ( Ra, A; Tobe, SW, 2004) |
| "The results of treatment of duodenal ulcers and gastroesophageal reflux disease with using of modern proton pump inhibitor controloc (pantoprazole) are presented in this article." | 3.72 | [Efficacy of controloc in the treatment of acid-dependent diseases]. ( Agibalov, AN; Chubenko, SS; Gaĭdukov, VO; Onishenko, AV, 2003) |
| " After 3-month treatment with Pantoprazole, a statistically significant improvement was noted for daytime sleepiness (P = ." | 3.72 | Pantoprazole for sleepiness associated with acid reflux and obstructive sleep disordered breathing. ( Steward, DL, 2004) |
| "In this randomized multicenter trial with a 5-year followup, we found antireflux surgery to be more effective than omeprazole in controlling gastroesophageal reflux disease as measured by the treatment failure rates." | 3.71 | Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. ( Carlsson, J; Hatlebakk, JG; Julkonen, R; Lamm, M; Levander, K; Liedman, B; Lundell, L; Miettinen, P; Myrvold, HE; Pedersen, SA; Wiklund, I, 2001) |
| "Omeprazole is an effective long-term drug for gastroesophageal reflux disease after failed fundoplication in children." | 3.71 | Omeprazole maintenance therapy for gastroesophageal reflux disease after failure of fundoplication. ( Blair, GK; Israel, DM; Pashankar, D, 2001) |
| "To compare the efficacy of laparoscopic fundoplication and lansoprazole in abolishing abnormal reflux in patients with gastro-oesophageal reflux disease." | 3.71 | Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison. ( De Micheli, E; Frazzoni, M; Grisendi, A; Lanzani, A; Melotti, G, 2002) |
| "To evaluate the cost effectiveness of on-demand treatment with esomeprazole 20mg compared with two alternative omeprazole treatment strategies for the long-term management of patients with gastro-oesophageal reflux disease (GORD) without oesophagitis." | 3.71 | Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies. ( Green, J; Higgins, A; Junghard, O; Wahlqvist, P, 2002) |
| "A 78-year-old nonvegetarian white woman with symptomatic gastroesophageal reflux (GER) was started on cimetidine 300 mg 4 times daily in February 1990 and took various other antisecretory medications over the course of the next 4 1/2 years." | 3.71 | Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor. ( Page, RL; Ruscin, JM; Valuck, RJ, 2002) |
| " Group 1 consisted of 17 patients with gastroesophageal reflux disease (GERD) taking omeprazole 20 mg b." | 3.70 | Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. ( Bracy, NA; Castell, DO; Katz, PO; Peghini, PL, 1998) |
| " A further evaluation was undertaken in patients with symptoms suggestive of GERD and in patients with non-ulcer dyspepsia, to identify factors that might predict symptom relief during treatment with omeprazole." | 3.70 | The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. ( Bolling-Sternevald, E; Carlsson, R; Dent, J; Johnsson, F; Junghard, O; Lauritsen, K; Lundell, L; Riley, S, 1998) |
| " pylori status of patients with gastroesophageal reflux disease (GERD) affects the severity of disease and the efficacy of omeprazole therapy to maintain disease remission, we conducted this study." | 3.70 | Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. ( Eskes, SA; Klinkenberg-Knol, EC; Kuipers, EJ; Meuwissen, SG; Schenk, BE, 1999) |
| "Recent evidence suggests that an empiric trial of omeprazole (the "omeprazole test") is sensitive and specific for diagnosing gastroesophageal reflux disease (GERD) as the cause of noncardiac chest pain." | 3.70 | The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. ( Fass, R; Fennerty, MB; Gralnek, IM; Ofman, JJ; Udani, J, 1999) |
| "Omeprazole maintenance therapy for gastro-oesophageal reflux disease (GERD) has been associated with an increased incidence of atrophic gastritis in H." | 3.70 | Atrophic gastritis during long-term omeprazole therapy affects serum vitamin B12 levels. ( Bloemena, EC; Festen, HP; Klinkenberg-Knol, EC; Kuipers, EJ; Meuwissen, SG; Nelis, GF; Sandell, M; Schenk, BE; Snel, P, 1999) |
| " We report data from patients with refractory reflux esophagitis who were undergoing maintenance therapy with >/=20 mg omeprazole daily for a mean period of 6." | 3.70 | Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. ( Dent, J; Frame, MH; Havu, N; Klinkenberg-Knol, EC; Lloyd, D; Mitchell, B; Nelis, F; Prichard, P; Romàn, J; Snel, P; Walan, A, 2000) |
| "To compare the omeprazole test to ambulatory 24-h oesophageal pH monitoring in diagnosing GERD in symptomatic patients using endoscopically proven erosive oesophagitis as a gold standard." | 3.70 | The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. ( Camargo, L; Fass, R; Fennerty, MB; Ofman, JJ; Sampliner, RE; Wendel, C, 2000) |
| "Lansoprazole intolerance requiring omeprazole conversion occurred in 5% of veterans on proton pump inhibitor therapy for chronic gastro-oesophageal reflux disease (GERD) symptoms and in 10% of patients with prior omeprazole success." | 3.70 | Clinical and fiscal impact of lansoprazole intolerance in veterans with gastro-oesophageal reflux disease. ( Fass, R; Gerson, LB; Hatton, BN; Jones, W; Pulliam, G; Ryono, R; Sampliner, RE; Triadafilopoulos, G, 2000) |
| "Omeprazole is a proton pump inhibitor widely used in the treatment of gastro-esophageal reflux disease and peptic ulcer disease." | 3.70 | Reversible renal failure after treatment with omeprazole. ( Post, AT; Voorhorst, G; Zanen, AL, 2000) |
| " Patients with symptoms suspected to be due to laryngopharyngeal reflux (based on a positive oesophageal pH test and/or changes on videolaryngoscopy consistent with posterior laryngitis) were treated with omeprazole for at least two to three months." | 3.70 | Presumed laryngo-pharyngeal reflux: investigate or treat? ( Fraser, AG; Gillibrand, J; Morton, RP, 2000) |
| "To evaluate the relationship between gastroesophageal reflux (GER) and obstructive sleep apnea (OSA) and the effect of combined therapy with cisapride and omeprazole." | 3.70 | [The relationship between obstructive sleep apnea and gastroesophageal reflux and the effect of antireflux therapy]. ( Huang, X; Ke, M; Wang, Z; Xiao, G, 1999) |
| "Successful omeprazole therapy in patients with symptomatic gastroesophageal reflux (GER) refractory to treatment with H2-receptor antagonists has often been reported." | 3.69 | Control of gastric acid with high dose H2-receptor antagonists after omeprazole failure: report of two cases. ( Castell, DO; Just, RJ; Lagerström, PO; Leite, LP, 1995) |
| "In patients undergoing long-term treatment with omeprazole, tiny gastric polyps, described histologically as glandular cysts, have occasionally been reported." | 3.69 | Observation of gastric glandular cysts in the corpus mucosa of the stomach under omeprazole treatment. ( Armbrecht, U; Bethke, B; Goldbrunner, P; Lütke, A; Rabast, U; Seifert, E; Stolte, M, 1995) |
| "Four of five patients showed persistent abnormal gastroesophageal reflux after treatment with omeprazole." | 3.69 | Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. ( Castell, DO; Katzka, DA, 1994) |
| " A decision-analytic strategy was performed to assess the economic impact of antacids alone (phase I therapy), and in combination with either omeprazole, 20 mg once daily, or ranitidine, 150 mg twice daily, for patients with persistent, symptomatic gastro-oesophageal reflux disease of grade II or more (Savary-Miller classification)." | 3.69 | Economic analysis of alternative treatments for persistent gastro-oesophageal reflux disease. ( Hillman, AL, 1994) |
| "To determine (1) the appropriate omeprazole (Prilosec) dose required for adequate acid suppression in asthmatics with gastroesophageal reflux, (2) whether aggressive acid suppressive therapy of gastroesophageal reflux improves asthma outcome in asthmatics with gastroesophageal reflux, (3) the time course of asthma improvement, and (4) demographic, esophageal, or pulmonary predictors of a positive asthma response to antireflux therapy." | 3.69 | Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. ( Alexander, RW; Bradley, LA; Guzzo, MR; Harding, SM; Richter, JE; Schan, CA, 1996) |
| "To test our standard dosing regimen in omeprazole treatment of gastro-oesophageal reflux disease (GORD) and to determine whether 'non-responders' could be pinpointed." | 3.69 | Monitoring of omeprazole treatment in gastro-oesophageal reflux disease. ( Aggestrup, S; Hage, E; Hendel, J; Hendel, L; Nielsen, OH, 1996) |
| "For a significant number of patients with severe or refractory gastroesophageal reflux disease, maintenance treatment with omeprazole and reflux surgery (Nissen fundoplication) are alternative treatment options." | 3.69 | Cost effectiveness of medical versus surgical treatment in patients with severe or refractory gastroesophageal reflux disease in the Netherlands. ( Ament, AJ; Dallemagne, B; Go, PM; Hameeteman, W; Van Den Boom, G, 1996) |
| "Patients were evaluated with a history, physical examination, esophageal manometry, upper endoscopy, and 24-hour pH-metry for determination of the presence of absence of underlying gastroesophageal reflux disease and then received an empiric trial of oral omeprazole therapy (20 mg twice daily for 1 month)." | 3.69 | Pilot study of the oral omeprazole test for reflux laryngitis. ( Childs, ML; Metz, DC; Ruiz, C; Weinstein, GS, 1997) |
| "Empiric omeprazole therapy is a reasonable, initial approach to patients with suspected gastroesophageal reflux-related posterior laryngitis." | 3.69 | Empiric trial of high-dose omeprazole in patients with posterior laryngitis: a prospective study. ( Delgaudio, JM; Grist, WJ; Gussack, G; Waring, JP; Wo, JM, 1997) |
| " To investigate the effect of omeprazole and higher-than-presently-recommended doses of H2-blockers, we evaluated gastric acidity and gastroesophageal reflux in 17 patients with severe-moderate esophagitis before and after treatment with 300 mg ranitidine twice daily or 20 mg omeprazole once daily." | 3.68 | Effect of omeprazole and high doses of ranitidine on gastric acidity and gastroesophageal reflux in patients with moderate-severe esophagitis. ( Fiorucci, S; Morelli, A; Santucci, L, 1990) |
| "The role of gastro-esophageal reflux disease (GERD) in poorly controlled asthma is often mentioned, but published studies have presented discordant results." | 3.11 | Does omeprazole improve asthma-control in poorly-controlled asthmatic children with gastro-esophageal reflux. ( Benhassine, F; Laid, Y; Nafissa Benhalla, K; Smati, L; Yagoubi, A, 2022) |
| "Gastro-oesophageal reflux (GOR) is characterised by the regurgitation of gastric contents into the oesophagus." | 3.01 | Pharmacological treatment of gastro-oesophageal reflux in children. ( Afzal, NA; Andrews, E; Beattie, RM; Hayen, A; Liddicoat, I; Tighe, MP, 2023) |
| "Omeprazole was found to be the most effective PPI in the management of APDs due to its rapid action, good antioxidant effects, and effectiveness against nocturnal acid breakthroughs." | 3.01 | Over 30 Years of Omeprazole. ( Sharma, P, 2023) |
| "The incidence of gastroesophageal reflux disease (GERD) is higher in patients with cystic fibrosis (CF) than in the general population." | 3.01 | Effect of omeprazole on symptoms of gastroesophageal reflux disease in children with cystic fibrosis. A randomized, double-blind, placebo-controlled trial. ( Banaszkiewicz, A; Dziekiewicz, M; Lisowska, A; Mielus, M; Radzikowski, A; Sands, D; Walkowiak, J, 2021) |
| "Proton pump inhibitor (PPI) twice daily dosing is a standard therapy for gastroesophageal reflux disease (GERD) in systemic sclerosis (SSc) but there is no data on its response rate or the predictors of PPI-partial response GERD." | 2.94 | Prevalence and predictors of proton pump inhibitor partial response in gastroesophageal reflux disease in systemic sclerosis: a prospective study. ( Chunlertrith, K; Foocharoen, C; Mahakkanukrauh, A; Mairiang, P; Namvijit, S; Nanagara, R; Suwannaroj, S; Wantha, O, 2020) |
| "Rabeprazole (20 mg) has proved similar Helicobacter pylori eradication rates compared with omeprazole (40 mg) when co-administered with of antibiotics (amoxicillin and clarithromycin) for two weeks." | 2.94 | Comparative Study on Effect of Rabeprazole Versus Omeprazole in Acid-peptic Disorder with Helicobacter pylori Infection. ( Amatya, GL; Gurung, SB; Gyawali, P; Kc, SR, 2020) |
| "Omeprazole is a proton pump inhibitor that is used in acid suppression therapy in infants." | 2.94 | Rectal Omeprazole in Infants With Gastroesophageal Reflux Disease: A Randomized Pilot Trial. ( Bestebreurtje, P; de Koning, BAE; de Wildt, SN; Knibbe, CAJ; Plötz, FB; Roeleveld, N; Tibboel, D; van de Ven, CP; van Groen, B, 2020) |
| "In infants with GERD, feeding modification with acid suppression is not superior to acid suppression alone in modifying aerodigestive reflexes (frequency, sensation, or magnitude)." | 2.94 | Impact of Feeding Strategies With Acid Suppression on Esophageal Reflexes in Human Neonates With Gastroesophageal Reflux Disease: A Single-Blinded Randomized Clinical Trial. ( Gulati, IK; Hasenstab, KA; Helmick, R; Ipek, H; Jadcherla, SR; Wei, L; Yildiz, V, 2020) |
| " Our aim was to compare effectiveness of increased PPI dosing with laparoscopic magnetic sphincter augmentation (MSA) in patients with moderate-to-severe regurgitation despite once-daily PPI therapy." | 2.90 | Laparoscopic magnetic sphincter augmentation versus double-dose proton pump inhibitors for management of moderate-to-severe regurgitation in GERD: a randomized controlled trial. ( Abbas, G; Bell, R; Buckley, FP; Dunst, C; Gould, J; Hill, M; Jacobsen, G; Katz, P; Khaitan, L; Kothari, S; Lipham, J; Lister, D; Louie, B; Luketich, J; McDowell-Jacobs, L; Park, A; Reardon, P; Richards, W; Smith, C; Smith, CD; Williams, V; Woods, K, 2019) |
| "The main symptoms of gastroesophageal reflux disease GERD are heartburn and acid regurgitation." | 2.90 | Effect of wu chu yu tang on gastroesophageal reflux disease: Randomized, double-blind, placebo-controlled trial. ( Chou, JW; Feng, CL; Hsieh, CL; Lai, HC; Li, TC; Shih, YS; Tsai, CH; Wang, KT; Yu, CJ, 2019) |
| "Pre-anesthetic administration of 2 PO doses of omeprazole at a dosage of 1." | 2.84 | Prevalence of Gastroesophageal Reflux in Cats During Anesthesia and Effect of Omeprazole on Gastric pH. ( Belafsky, PC; Della Maggiore, A; Fulton, A; Garcia, RS; Marks, SL; Osborn, JM; Pierce, T; Pypendop, BH; Walker, VJ, 2017) |
| "Twice-daily dosing of proton pump inhibitor (PPI), the standard therapy for gastro-oesophageal reflux disease (GERD), is an effective therapy for GERD in SSc." | 2.84 | Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial. ( Chunlertrith, K; Foocharoen, C; Mahakkanukrauh, A; Mairiang, P; Namvijit, S; Nanagara, R; Suwannaroj, S; Wantha, O, 2017) |
| "The current work assessed a pharmaceutical dosage form of Myrtus communis L." | 2.82 | Myrtus communis L. Freeze-Dried Aqueous Extract Versus Omeprazol in Gastrointestinal Reflux Disease: A Double-Blind Randomized Controlled Clinical Trial. ( Akrami, R; Hosseini-Asl, MK; Nimrouzi, M; Salehi, A; Zarshenas, MM; Zohalinezhad, ME, 2016) |
| " The daily dosage of GERD medications, measured as omeprazole equivalents (mean ± SD, mg), decreased from 66." | 2.82 | Long-term follow-up results of endoscopic treatment of gastroesophageal reflux disease with the MUSE™ endoscopic stapling device. ( Bapaye, A; Bonavina, L; Kessler, WR; Kim, HJ; Kwon, CI; Lehman, GA; McNulty, G; Selzer, DJ, 2016) |
| "Patients with GERD and hiatal hernias ≤2 cm were randomly assigned to groups that underwent TF and then received 6 months of placebo (n = 87), or sham surgery and 6 months of once- or twice-daily omeprazole (controls, n = 42)." | 2.80 | Efficacy of transoral fundoplication vs omeprazole for treatment of regurgitation in a randomized controlled trial. ( Bell, RC; Burch, MA; Diggs, BS; Dolan, JP; Hungness, ES; Hunter, JG; Kahrilas, PJ; Melvin, WS; Oelschlager, BK; Perry, KA; Reavis, KM; Snyder, BE; Soper, NJ; Trad, KS; Turgeon, DG; Wilson, EB, 2015) |
| "Sixty patients with GERD were divided into equal groups according to performed therapy: standard drug treatment or its combination with psychotherapeutic methods." | 2.79 | [Role of psychological correction in the combination treatment of patients with gastroesophageal reflux disease]. ( Bitkova, EN; Dicheva, DT; Iurenev, GL; Maev, IV; Sirota, NA, 2014) |
| "The burden of gastroesophageal reflux disease (GERD) is increasing in the Asia area and the majority of GERD patients have non-erosive reflux disease (NERD)." | 2.78 | Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease. ( Chang, JJ; Chen, LW; Chen, TH; Chiu, CT; Hsu, CM; Lin, CJ; Su, MY; Sung, CM; Wang, CC, 2013) |
| " The mean time to onset of the first 24-h heartburn-free period after initial dosing was 2." | 2.77 | Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial. ( Bigard, MA; Childs, M; Decaudin, A; Liard, F; McVey, D; Pouchain, D, 2012) |
| "Questionnaire screening for GERD in children with OSAS may be of benefit." | 2.77 | Respiratory response to proton pump inhibitor treatment in children with obstructive sleep apnea syndrome and gastroesophageal reflux disease. ( Cudowska, B; Dębkowska, K; Kaczmarski, M; Klukowski, M; Semeniuk, J; Wasilewska, J, 2012) |
| "Dysphonia is a significant problem in GER." | 2.75 | Effectiveness of voice therapy in reflux-related voice disorders. ( Bhatia, SJ; Gore, G; Hattiangadi, G; Keer, V; Murugesh, M; Ramesh, VS; Sandur, V; Vashani, K, 2010) |
| " lansoprazole 15 mg, dosed before breakfast." | 2.75 | Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: a comparison of over-the-counter doses of proton pump inhibitors. ( Erasala, GN; Gibb, RD; McKean, LA; McRorie, JW; Miner, PB; Ramsey, DL, 2010) |
| "In patients with GERD, disease-specific health-related quality of life instruments and symptom scores showed greater responsiveness than preference-based generic instruments." | 2.74 | Specific HRQL instruments and symptom scores were more responsive than preference-based generic instruments in patients with GERD. ( Akl, EA; Armstrong, D; Barkun, AN; Brozek, JL; Chiba, N; Degl'Innocenti, A; Fallone, CA; Guyatt, GH; Heels-Ansdell, D; Schünemann, HJ; van Zanten, SV; Wiklund, I, 2009) |
| "Gastroesophageal reflux disease (GERD) is a common disorder." | 2.73 | Dilated intercellular spaces in gastroesophageal reflux disease patients and the changes of intercellular spaces after omeprazole treatment. ( Lin, SR; Xue, Y; Zhou, LY, 2008) |
| "To compare repeated once daily bedtime dosing of IR-OME, lansoprazole and esomeprazole on nocturnal gastric acidity." | 2.73 | Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. ( Bagin, RG; Ballard, ED; Checani, GC; Gautille, TC; Hogan, DL; Katz, PO; Koch, FK; Pratha, VS, 2007) |
| "Relapse was defined as the recurrence of macroscopic esophageal lesions." | 2.73 | Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable? ( Boccia, G; Buonavolontà, R; Manguso, F; Miele, E; Staiano, A, 2007) |
| "Treatment with omeprazole significantly improved QL in both LPR subgroups patients." | 2.73 | Quality of life in laryngopharyngeal reflux patients. ( Adamonis, K; Siupsinskiene, N; Toohill, RJ, 2007) |
| "A new questionnaire for assessing gastroesophageal reflux disease (GERD), the Frequency Scale for Symptoms of GERD, covers the 12 most common symptoms of GERD patients." | 2.73 | Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients. ( Horikoshi, T; Kawamura, O; Kuribayashi, S; Kusano, M; Maeda, M; Moki, F; Mori, M; Nagoshi, A; Shimoyama, Y; Sugimoto, S; Toki, M; Zai, H, 2007) |
| "One hundred and sixteen patients of GERD were randomly assigned to two groups, group A treated with Western medicine and group B with integrated Chinese and Western medicine." | 2.73 | [Study on integrated Chinese and Western therapy and criterion for efficacy evaluation of gastroesophageal reflux disease--a clinical observation on 116 cases]. ( Bo, P; Xu, HR; Yuan, Y, 2007) |
| "Gastro-oesophageal reflux disease (GERD) is an important problem in systemic sclerosis due to impaired salivation and oesophageal function." | 2.73 | Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial. ( Brühlmann, P; Distler, O; Fox, M; Fried, M; Halim, S; Janiak, P; Menne, D; Schwizer, W; Thumshirn, M, 2007) |
| "Comparative studies of proton pump inhibitors (PPIs) have revealed that acid reflux is influenced by PPI treatment, formulations and dosing regimens." | 2.73 | Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients. ( Brugnera, R; Calabrese, C; Di Febo, G; Gabusi, V; Gionchetti, P; Liguori, G; Rizzello, F; Straforini, G, 2008) |
| "Omeprazole is a proton-pump inhibitor that acts to reduce acid secretion in the stomach and is used for treating various acid-related gastrointestinal disorders." | 2.73 | Bioavailability of two single-dose oral formulations of omeprazole 20 mg: an open-label, randomized sequence, two-period crossover comparison in healthy Mexican adult volunteers. ( Burke-Fraga, V; de Lago, A; Galán, JF; González-de la Parra, M; Jiménez, P; Namur, S; Oliva, I; Poo, JL; Rosete, A, 2008) |
| "The diagnosis of GERD was established on the presence of mucosal breaks at endoscopy and/or an abnormal esophageal 24-h pH test." | 2.72 | Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting. ( Aygalenq, P; Bonnot-Marlier, S; des Varannes, SB; Galmiche, JP; Le Rhun, M; Lequeux, Y; Masliah, C; Sacher-Huvelin, S; Vavasseur, F, 2006) |
| "The diagnosis of GERD was established by the method of Los Angeles classification including mucosal minimum change of Grade M and questionnaire for the diagnosis of reflux disease (QUEST) score." | 2.72 | A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease. ( Dobashi, K; Ishizuka, T; Kawamura, O; Kobayashi, S; Kusano, M; Mori, M; Ohki, I; Shimizu, Y; Shimoyama, Y; Sunaga, N; Tokushima, M; Utsugi, M, 2006) |
| "All omeprazole-treated patients showed improvement of laryngeal features and symptoms." | 2.72 | Silent reflux: ex juvantibus criteria for diagnosis and treatment of laryngeal disorders. ( Barbara, M; Di Stadio, A; Monini, S; Vestri, A, 2006) |
| "To evaluate the pharmacodynamic effect, efficacy, and safety of omeprazole 10 mg and 20 mg once daily in patients with nonerosive reflux disease (NERD) in Japan." | 2.72 | The pharmacodynamic effect of omeprazole 10 mg and 20 mg once daily in patients with nonerosive reflux disease in Japan. ( Aoshima, M; Asahina, K; Ashida, K; Haruma, K; Hirayama, M; Inoue, S; Kabemura, T; Kato, M; Kinoshita, Y; Kiyama, S; Kobayashi, T; Kurosawa, S; Kuwayama, H; Matsumoto, K; Shimatani, T; Suzuki, H; Suzuki, J; Yamamoto, M, 2006) |
| " Patients were randomized double-blindly to taper down or continue a constant dosage of omeprazole for three weeks." | 2.72 | Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. ( Abrahamsson, H; Agerforz, P; Björnsson, E; Jensen, C; Kilander, A; Mattsson, N; Simrén, M, 2006) |
| "The cause and effect between gastroesophageal reflux and laryngeal symptoms remain elusive." | 2.72 | Double-blind, placebo-controlled trial with single-dose pantoprazole for laryngopharyngeal reflux. ( Harrell, SP; Koopman, J; Lentsch, E; Parker, K; Winstead, W; Wo, JM, 2006) |
| "A total of 22 subjects (13 with gastroesophageal reflux disease and nine who served as control subjects) were prospectively evaluated by serial combined esophageal and gastric 24-h pH monitoring." | 2.71 | Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. ( Fackler, WK; Ours, TM; Richter, JE; Vaezi, MF, 2003) |
| "In subjects with gastro-oesophageal reflux disease, gastric secretion and integrated gastric acidity from 09." | 2.71 | Meal-stimulated gastric acid secretion and integrated gastric acidity in gastro-oesophageal reflux disease. ( Gardner, JD; Miner, PB; Robinson, M; Sloan, S, 2003) |
| "In subjects with gastro-oesophageal reflux disease treated with a gastric antisecretory agent, the extent to which gastric acidity needs to be reduced to prevent pathological oesophageal acid exposure is not known." | 2.71 | Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor. ( Gardner, JD; Miner, PB; Robinson, M; Sloan, S, 2003) |
| "Thirty asthmatic patients with GERD were randomly divided into two groups (group A and group B)." | 2.71 | Effects of antireflux treatment on bronchial hyper-responsiveness and lung function in asthmatic patients with gastroesophageal reflux disease. ( Jiang, SP; Li, JG; Liang, RY; Liang, YK; Liu, QL; Zeng, ZY, 2003) |
| " Furthermore, the data indicate that 1-week treatment with a once-daily dosage is sufficient to ensure adequate diagnosis." | 2.71 | One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease. ( Edin, R; Falk, A; Hatlebakk, JG; Johnsson, F; Klintenberg, AC; Román, J; Stubberöd, A; Toth, E, 2003) |
| "Gastroesophageal reflux disease (GERD) is characterized by heartburn and related symptoms that are distressing to patients and interfere with everyday functioning and well-being." | 2.71 | Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. ( Damiano, A; Johanson, J; Siddique, R; Sloan, S; Xu, X, 2003) |
| "Although the diagnosis of gastroesophageal reflux disease (GERD) is based primarily on symptoms experienced by a patient, relatively little attention has been paid to the development and validation of self-administered questionnaires specific to GERD symptoms." | 2.71 | Validation of the GSFQ, a self-administered symptom frequency questionnaire for patients with gastroesophageal reflux disease. ( Armstrong, D; Goeree, R; Meyer, F; Paré, P; Pericak, D; Pyzyk, M, 2003) |
| "Management costs for gastroesophageal reflux disease are high because of the expensive medications used for maintenance therapy." | 2.71 | Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. ( Bernard, L; Fendrick, AM; Inadomi, JM; McIntyre, L, 2003) |
| " These data suggest that administration of a PPI before the evening meal maximizes acid control and would be the preferred dosing schedule in GERD patients, particularly those with nocturnal symptoms." | 2.71 | Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. ( McCallum, RW; Olyaee, M; Pehlivanov, ND; Sarosiek, I, 2003) |
| "Ten patients with bruxism and 10 normal subjects were matched for height, weight, age, and sex." | 2.71 | Association between nocturnal bruxism and gastroesophageal reflux. ( Araki, Y; Fujii, A; Katayama, A; Miyawaki, S; Takano-Yamamoto, T; Tanimoto, Y, 2003) |
| "Omeprazole 20 mg daily was given for eight weeks for healing of oesophagitis and symptom relief." | 2.71 | Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial. ( Chan, FK; Ching, JY; Chung, SC; Hui, Y; Leong, R; Leung, WK; Sung, JJ; Wu, JC, 2004) |
| "Pantoprazole was also significantly more efficacious in controlling all gastrointestinal symptoms of GERD." | 2.71 | Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease. ( Fischer, R; van Rensburg, C; van Zyl, J; Vieweg, W, 2004) |
| "Fifty-five patients (17 with nonerosive GERD and 38 with low-grade esophagitis) were treated with rabeprazole, 20 mg/day." | 2.71 | On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. ( Argüello, L; Bastida, G; Garrigues, V; Ortiz, V; Ponce, J; Ponce, M, 2004) |
| "pylori) eradication on gastroesophageal reflux disease is controversial." | 2.71 | The effect of Helicobacter pylori eradication on gastroesophageal reflux disease. ( Güliter, S; Kandilci, U, 2004) |
| "In patients with nonerosive GERD there was no significant difference in symptomatic response to either regimen (17/20 in group A and 7/9 in group B responded; P = 0." | 2.71 | Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. ( Ahuja, V; Kashyap, PC; Madan, K; Sharma, MP, 2004) |
| "Rabeprazole treatment significantly improved subjective indices of sleep quality." | 2.71 | The effect of acid suppression on sleep patterns and sleep-related gastro-oesophageal reflux. ( Goodrich, S; Orr, WC; Robert, J, 2005) |
| "A cross-over study was made in 27 GERD patients (12 males and 15 females)." | 2.71 | [Esomeprasol and rabeprasol effects on esophageal acidification in patients with gastroesophageal reflux disease, intensively metabolizing inhibitors of proton pump]. ( Gushchin, AE; Isakov, VA; Morozov, SV; Shipulin, GA; Tereshchenko, SG; Tsodikova, OM, 2005) |
| "A total of 119 Japanese patients with recurrent reflux oesophagitis underwent cytochrome P450 2C19 genotyping prior to receiving daily omeprazole 10 mg or 20 mg for 6-12 months, during which adverse event frequency, serum gastrin levels and endoscopic findings were monitored." | 2.71 | Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis. ( Aoyama, N; Arakawa, T; Chida, N; Fujimoto, K; Hamada, S; Hoshino, E; Inoue, M; Kawahara, Y; Konda, Y; Maekawa, T; Mine, T; Mitachi, Y; Nagai, T; Nakajima, M; Ohkusa, T; Sato, N; Seno, H; Shimatani, T; Tadokoro, K; Yoshida, N, 2005) |
| "Both rabeprazole doses were significantly superior to placebo in preventing relapse of heartburn frequency and improving patient quality of life." | 2.71 | Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. ( Barth, J; Breiter, J; Caos, A; Perdomo, C, 2005) |
| "There were no recurrences of Schatzki's ring in the group of patients with documented GERD (follow-up [mean +/- SD]: 43." | 2.71 | Long-term acid suppressive therapy may prevent the relapse of lower esophageal (Schatzki's) rings: a prospective, randomized, placebo-controlled study. ( Avgerinos, A; Bergele, C; Karamanolis, G; Mantides, A; Papadopoulou, E; Sgouros, SN; Stefanidis, G; Vassiliadis, K; Vlachogiannakos, J, 2005) |
| " dosing of rabeprazole." | 2.71 | Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus. ( Hall, M; Higbee, A; Mathur, S; Sampliner, RE; Sharma, P; Wani, S; Weston, AP, 2005) |
| " This study was designed to investigate the dosing patterns of patients on on-demand treatment and to compare lansoprazole with omeprazole in this regard." | 2.70 | On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. ( Grove, O; Johnsson, F; Moum, B; Simren, M; Thoring, M; Vilien, M, 2002) |
| "Patients with moderately severe GERD completed the GSAS and SF-36 at baseline and four weeks following treatment." | 2.70 | Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS). ( Adler, E; Bhattacharyja, A; Damiano, A; Handley, K; Siddique, R, 2002) |
| "Esomeprazole 20 mg was superior to placebo for on-demand treatment of GORD; a higher dose did not confer additional clinical benefit." | 2.70 | Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. ( Armstrong, D; Bardhan, KD; Carlsson, RG; Chen, S; Giaffer, M; Green, JR; Hasselgren, GS; O'Kane, KP; Talley, NJ; Venables, TL, 2002) |
| "Pharyngoesophageal gastric acid reflux is thought to initiate chronic posterior laryngitis." | 2.70 | Short-term therapeutic trial of proton pump inhibitors in suspected extraesophageal reflux. ( Eherer, A; Friedrich, G; Habermann, W; Kiesler, K, 2002) |
| " Safety for all study participants was monitored by adverse event reports and laboratory evaluations." | 2.70 | Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. ( Fitzgerald, J; Hassall, E; Huang, B; Kane, R; Pilmer, B; Tolia, V, 2002) |
| "Most patients with gastro-oesophageal reflux disease (GERD), regardless of endoscopic status, suffer symptomatic relapse within 6 months of stopping acid suppressant therapy." | 2.70 | Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. ( Bang, C; Delle, M; Junghard, O; Lauritsen, K; Lind, T; Moum, B; Omland, TM; Schulz, T; Talley, NJ; Tunturi-Hihnala, H, 2001) |
| "Despite a high prevalence of mild gastroesophageal reflux disease (GERD), few studies investigated efficacy and safety of proton pump inhibitors in this indication." | 2.70 | Comparison of pantoprazole 20 mg to ranitidine 150 mg b.i.d. in the treatment of mild gastroesophageal reflux disease. ( Biedermann, A; Kaspari, S; Mey, J, 2001) |
| "pylori eradication, in preventing GERD, since no data exist so far." | 2.70 | Effectiveness of acid suppression in preventing gastroesophageal reflux disease (GERD) after successful treatment of Helicobacter pylori infection. ( Karameris, A; Ladas, SD; Liatsos, C; Panagou, E; Raptis, SA; Rokkas, T, 2001) |
| "A 24-h gastric pH recording and a pharmacokinetic study were performed after 7 days of lansoprazole, 17 mg/m2, in 23 patients with reflux oesophagitis (median age, 3." | 2.70 | Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. ( Faure, C; Hankard, R; Jacoz-Aigrain, E; Laurence, M; Michaud, L; Mougenot, JF; Navarro, J; Popon, M; Shaghaghi, EK, 2001) |
| "Omeprazole was discontinued at 8 weeks and patients were followed up for a further 10 months." | 2.70 | Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. ( Axon, AT; Bardhan, C; Brown, L; Dixon, MF; Moayyedi, P; Young, L, 2001) |
| "Pantoprazole once daily was superior to nizatidine b." | 2.70 | Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. ( Armstrong, D; Paré, P; Pericak, D; Pyzyk, M, 2001) |
| "When lansoprazole 30 mg was given once daily, the mean 24-hour intragastric pH values in the subjects who were homozygous extensive metabolizers, heterozygous extensive metabolizers, and poor metabolizers were 4." | 2.70 | Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. ( Furuta, T; Ishizaki, T; Ohashi, K; Shirai, N; Xiao, F, 2001) |
| "Twenty-three healthy volunteers and 20 gastroesophageal reflux disease (GERD) patients were studied." | 2.70 | Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. ( Fackler, WK; Ours, TM; Richter, JE; Vaezi, MF, 2002) |
| "Eleven patients with CRS and 19 GERD patients participated." | 2.70 | Role of GERD in chronic resistant sinusitis: a prospective, open label, pilot trial. ( DiBaise, JK; Huerter, JV; Olusola, BF; Quigley, EM, 2002) |
| "Esomeprazole was well tolerated." | 2.70 | Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. ( Hasselgren, G; Hedenström, H; Röhss, K, 2002) |
| "A urea breath test was performed 1 month after the end of therapy; patients and investigators were blind to the results." | 2.70 | Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. ( Dhir, V; Laine, L, 2002) |
| "Both rabeprazole doses were significantly superior to the placebo with respect to time to the first 24-h heartburn-free interval (2." | 2.70 | Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. ( Filippone, J; Jokubaitis, L; Miner, P; Orr, W; Sloan, S, 2002) |
| "Symptoms of gastro-oesophageal reflux are common, and currently available methods for diagnosing reflux disease are expensive and uncomfortable for the patient." | 2.69 | One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. ( Bengtsson, L; Hernqvist, H; Johnsson, F; Solhaug, JH; Weywadt, L, 1998) |
| "Acid gastro-oesophageal reflux may aggravate respiratory symptoms in patients with asthma and chronic obstructive pulmonary disease (COPD) by increasing airway hyperresponsiveness through vagally-mediated pathways." | 2.69 | No effects of high-dose omeprazole in patients with severe airway hyperresponsiveness and (a)symptomatic gastro-oesophageal reflux. ( Boeree, MJ; Kleibeuker, JH; Peters, FT; Postma, DS, 1998) |
| "Gastroesophageal reflux is frequently found in patients with chest pain despite normal coronary anatomy, but little data on the effect of specific medication exist." | 2.69 | Effect of omeprazole in patients with chest pain and normal coronary anatomy: initial experience. ( Anggiansah, A; Chambers, J; Cooke, R; Owen, W, 1998) |
| "To compare the effect of three different dosing regimens of omeprazole 40 mg daily with regard to suppressing nocturnal gastric acidity and avoiding NAB." | 2.69 | Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. ( Castell, DO; Hatlebakk, JG; Katz, PO; Kuo, B, 1998) |
| "Gastroesophageal reflux disease (GERD) accounts for up to 60% of patients with noncardiac chest pain (NCCP)." | 2.69 | Correlation of ambulatory 24-hour esophageal pH monitoring results with symptom improvement in patients with noncardiac chest pain due to gastroesophageal reflux disease. ( Camargo, L; Fass, R; Fennerty, MB; Johnson, C; Sampliner, RE, 1999) |
| "677 patients with gastro-oesophageal reflux disease." | 2.69 | Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. ( Bardhan, KD; Bianchi Porro, G; Bigard, MA; Fulton, C; Gillon, KR; Hosie, J; Müller-Lissner, S; Peacock, RA; Ponce, J; Scott, M; Weir, DG, 1999) |
| "Omeprazole was significantly more effective than ranitidine in resolving heartburn in this group of patients." | 2.69 | Efficacy of omeprazole versus ranitidine for symptomatic treatment of poorly responsive acid reflux disease-a prospective, controlled trial. ( Joelsson, B; Maton, PN; Orlando, R, 1999) |
| "Omeprazole treatment resulted in a decrease of acid reflux per 24 h from 23." | 2.69 | The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy. ( Ganesh, S; Kleibeuker, JH; Klinkenberg-Knol, EC; Kuipers, EJ; Lamers, CB; Peters, FT; Sluiter, WJ, 1999) |
| "Twenty-three patients were evaluated for gastroesophageal reflux disease; six (26%) were eventually determined to have an acid-related cough." | 2.69 | A prospective evaluation of esophageal testing and a double-blind, randomized study of omeprazole in a diagnostic and therapeutic algorithm for chronic cough. ( Kavuru, MS; Ours, TM; Richter, JE; Schilz, RJ, 1999) |
| "Lansoprazole was superior to famotidine in reducing the thickness of esophageal wall." | 2.69 | Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux. ( Aibe, T; Eto, S; Fujisaki, T; Iida, T; Matsuoka, H; Mine, S; Morimoto, I; Tabata, T; Tanaka, Y; Yamada, S, 2000) |
| " Few data exist to compare the ability of the most-often used proton pump inhibitors, omeprazole and lansoprazole, to control gastric acid at twice-daily dosage regimens." | 2.69 | Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. ( Castell, DO; Hatlebakk, JG; Katz, PO, 2000) |
| "Omeprazole was significantly (P< or =." | 2.69 | Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. ( Benjamin, SB; Joelsson, B; Peura, D; Richter, JE; Whipple, J, 2000) |
| "Omeprazole is a valuable therapeutic instrument to detect and treat patients with GERD in general practice." | 2.69 | High dose proton pump inhibitor response as an initial strategy for a clinical diagnosis of gastro-oesophageal reflux disease (GERD). Swedish multi-centre group in primary health care. ( Brun, J; Sörngård, H, 2000) |
| "Functional dyspepsia is a heterogeneous condition and a uniform response to drug treatment is not likely." | 2.69 | Identifying responders to acid suppression in dyspepsia using a random starting day trial. ( Bonnevie, O; Breinstrup, H; Bytzer, P; Funch-Jensen, P; Hansen, JM; Matzen, P; Meineche-Schmidt, V; Rune, S; Schaffalitzky De Muckadell, OB, 2000) |
| " Pharmacokinetic study was optional for subjects and was performed in 25 of the 57 enrolled." | 2.69 | Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group. ( Andersson, T; Becker, M; Behrens, R; Dalväg, A; Drouin, E; Göthberg, G; Hassall, E; Koletzko, S; Lundborg, P; Marcon, M; Martin, S; Radke, M; Shepherd, R, 2000) |
| "Twenty-one patients completed both treatment periods." | 2.69 | Chronic cough and gastro-oesophageal reflux: a double-blind placebo-controlled study with omeprazole. ( Hietanen, EK; Kiljander, TO; Salomaa, ER; Terho, EO, 2000) |
| "We present data on development of GERD from a controlled study of H." | 2.69 | Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease. ( Befrits, R; Lindberg, G; Odman, B; Sjöstedt, S; Sörngård, H, 2000) |
| "pylori-positive GERD patients randomly assigned to either an eradication or omeprazole-alone regime." | 2.69 | Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. ( Axon, AT; Bardhan, K; Dixon, MF; Moayyedi, P; Peacock, R; Walan, A; Wason, C, 2000) |
| "Rabeprazole 20 mg in two different dosing schedules is as effective as omeprazole 20 mg QD with regard to efficacy and tolerability in patients with erosive GERD." | 2.69 | Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease. ( Cohen, G; Delchier, JC; Humphries, TJ, 2000) |
| "To determine whether gastroesophageal reflux disease can be diagnosed empirically by acid suppression in patients with normal results of endoscopy." | 2.68 | Empiric therapy for gastroesophageal reflux disease. ( Klauser, AG; Müller-Lissner, SA; Schindlbeck, NE; Voderholzer, WA, 1995) |
| "Fifty-five patients with gastroesophageal reflux disease were prospectively evaluated using a symptom questionnaire, upper endoscopy, esophageal manometry, and 24-hour pH monitoring." | 2.68 | The role of a defective lower esophageal sphincter in the clinical outcome of treatment for gastroesophageal reflux disease. ( Ancona, E; Anselmino, M; Boccù, C; Costantini, M; Nicoletti, L; Zaninotto, G, 1996) |
| "All had had other symptoms of gastroesophageal reflux (GER); however, only 4 (33%) experienced symptoms of heartburn." | 2.68 | Paroxysmal laryngospasm secondary to gastroesophageal reflux. ( Koufman, JA; Loughlin, CJ, 1996) |
| "Gastro-oesophageal reflux disease (GORD) is a frequent cause for consultation in general practice and is a chronically relapsing disease." | 2.68 | Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice. ( Copeman, MB; Hole, J; Newland, RD; Patel, AC; Turbitt, ML; Venables, TL, 1997) |
| "Gastro-oesophageal reflux disease (GERD) can be effectively treated pharmacologically or surgically." | 2.68 | Lifetime costs of surgical versus medical treatment of severe gastro-oesophageal reflux disease in Finland. ( Isolauri, J; Nevalainen, J; Viljakka, M, 1997) |
| "Gastroesophageal reflux (GER) occurs in 22-66% of patients with noncardiac chest pain (NCCP)." | 2.68 | Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. ( Achem, SR; Burton, L; Castell, DO; Kolts, BE; MacMath, T; Mohr, D; Richter, J, 1997) |
| "Pantoprazole is a benzimidazole derivative which selectively inhibits the proton pump H+." | 2.68 | One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis. ( Koop, H; Maier, C; Mössner, J; Porst, H; Schneider, A; Wübbolding, H, 1997) |
| "Gastroesophageal reflux (GER) is common among patients with asthma, and it has been speculated that high GER may exacerbate asthma in some." | 2.67 | Does omeprazole (Prilosec) improve respiratory function in asthmatics with gastroesophageal reflux? A double-blind, placebo-controlled crossover study. ( Freeman, SR; McNally, PR; Meier, JH; Perry, M; Punja, M; Spaulding, HS; Stocker, N; Sudduth, RH, 1994) |
| "Gastroesophageal reflux was found in 13 of 20 patients (65%) who underwent pH studies, and endoscopy detected one patient with erosive esophagitis." | 2.67 | Chest pain associated with nutcracker esophagus: a preliminary study of the role of gastroesophageal reflux. ( Achem, SR; Burton, L; Kolts, BE; Richter, JE; Wears, R, 1993) |
| "Gastroesophageal reflux disease (GERD) is defined by recurrent and troublesome heartburn and regurgitation or GERD-specific complications and affects approximately 20% of the adult population in high-income countries." | 2.66 | Gastroesophageal Reflux Disease: A Review. ( Lagergren, J; Maret-Ouda, J; Markar, SR, 2020) |
| "Proton-pump inhibitors (PPIs) have been proved as safe and effective ways to treat patients with non-erosive reflux disease (NERD)." | 2.53 | The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis. ( Chen, L; Chen, Y; Li, B, 2016) |
| "This review provides an update on the following points: pharmacokinetic profile and metabolism of ilaprazole in relation to its pharmacodynamic properties; comparative data on the pharmacokinetics and pharmacodynamics of ilaprazole with currently available PPIs; and implications for studies on the therapeutic efficacy of ilaprazole in GERD." | 2.49 | The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment. ( Blandizzi, C; de Bortoli, N; Giacchino, M; Marchi, S; Martinucci, I; Savarino, E; Savarino, V, 2013) |
| "PPIs are not effective in reducing GERD symptoms in infants." | 2.47 | Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. ( Benninga, MA; Omari, TI; Smits, MJ; Tabbers, MM; van der Pol, RJ; van Wijk, MP, 2011) |
| "Unexplained chest pain is potentially attributable to gastro-oesophageal reflux disease (GORD) or oesophageal motility disorders." | 2.47 | Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. ( Howden, CW; Hughes, N; Kahrilas, PJ, 2011) |
| "Pediatric patients with gastroesophageal reflux disease and certain chronic comorbidities appear to have the greatest need of maintenance PPI treatment after healing of reflux esophagitis." | 2.46 | Maintenance treatment with proton pump inhibitors for reflux esophagitis in pediatric patients: a systematic literature analysis. ( Henderson, C; Illueca, M; Lundborg, P; Wernersson, B, 2010) |
| "We entered the MeSH terms "gastroesophageal reflux AND asthma AND children" in the PubMed tool Clinical Queries, selecting "therapy" and "broad, sensitive search." | 2.45 | Does treatment with proton pump inhibitors for gastroesophageal reflux disease (GERD) improve asthma symptoms in children with asthma and GERD? A systematic review. ( Calvani, M; Radzik, D; Sopo, SM, 2009) |
| "The consequences of nocturnal gastroesophageal reflux disease (GERD) may be greater than daytime GERD in terms of clinical complications such as increased risk of esophageal lesions and respiratory conditions, as well as issues of health-related quality of life, sleep, work productivity, and economics." | 2.44 | Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies. ( Johnson, DA; Katz, PO, 2008) |
| "Gastroesophageal reflux disease (GERD) often presents as typical symptoms such as heartburn or acid regurgitation." | 2.44 | [Extraesophageal manifestations of gastroesophageal reflux disease]. ( Kim, GH, 2008) |
| "Esomeprazole has been shown to be more effective than lansoprazole in relieving GORD symptoms, and esomeprazole and pantoprazole appear to be equally effective in resolving GORD symptoms in a comparative study." | 2.43 | Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management. ( Orr, WC, 2005) |
| "Pantoprazole has an excellent safety record and shows only minor interaction with other drugs." | 2.43 | Role of pantoprazole in the treatment of gastro-oesophageal reflux disease. ( Beglinger, C; Lehmann, FS, 2005) |
| "Gastric acid is pathogenic in many gastrointestinal disorders, such as gastroesophageal reflux disease and peptic ulcer disease." | 2.43 | Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. ( Robinson, M, 2005) |
| " For the better PPI-based treatment, doses and dosing schemes of PPIs should be optimized based on CYP2C19 genotype status." | 2.43 | Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. ( Furuta, T; Hishida, A; Ishizaki, T; Nakamura, A; Shirai, N; Sugimoto, M, 2005) |
| "However, the case that GERD is the cause of these symptoms is difficult to make because neither endoscopy nor prolonged reflux monitoring has shown consistent evidence of either esophageal injury or abnormal reflux frequency." | 2.43 | State of the art: extraesophageal manifestations of gastroesophageal reflux disease. ( Katz, PO, 2005) |
| "Gastroesophageal reflux disease (GERD) is a highly prevalent disorder which affects 10-30% of the population in Western countries." | 2.43 | Understanding GERD symptoms in the clinical setting. ( Holtmann, G, 2005) |
| "Extraesophageal manifestations of gastroesophageal reflux disease (GERD) can include upper airway disorders, asthma and chronic cough." | 2.43 | Extraesophageal manifestations of GERD: diagnosis and therapy. ( Halstead, LA, 2005) |
| "Lansoprazole is a proton pump inhibitor that inactivates the H(+)/K(+)-ATPase pump in parietal cells, thus inhibiting gastric acid secretion and increasing intragastric pH." | 2.43 | Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents. ( Croom, KF; Scott, LJ, 2005) |
| " Administration of immediate-release omeprazole at bedtime results in a rapid and sustained elevation of gastric pH, and seems to provide better night time control of gastric acidity than that observed with conventional morning dosing of delayed-release proton pump inhibitors." | 2.43 | Review of immediate-release omeprazole for the treatment of gastric acid-related disorders. ( Castell, D, 2005) |
| " Methods to optimize nocturnal acid control include careful attention to dosing schedule, using higher doses of PPIs, adding an histamine H2-receptor antagonist at bedtime to once or twice daily delayed-release PPI, or using immediate-release omeprazole (Zegerid powder for oral suspension; Santarus, Inc." | 2.43 | Review article: putting immediate-release proton-pump inhibitors into clinical practice--improving nocturnal acid control and avoiding the possible complications of excessive acid exposure. ( Katz, PO, 2005) |
| "Whether these patients are part of the GERD spectrum or have another diagnosis is not clear." | 2.43 | Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn. ( DeVault, KR, 2006) |
| "The presence of esophageal lesions and gastroesophageal reflux disease (GERD) symptoms do not coincide in some patients: some individuals suffer from the symptoms of GERD but have no evidence of GERD at endoscopy; while conversely, some with endoscopic evidence of GERD do not experience symptoms." | 2.43 | The complete remission concept. ( Mönnikes, H, 2006) |
| "To review the literature on the treatment of gastroesophageal reflux disease (GERD) with emphasis on pharmacological aspects." | 2.43 | Treatment of gastroesophageal reflux disease. ( Camargos, PA; Guimarães, EV; Marguet, C, 2006) |
| "Pantoprazole (Protonix) is an irreversible proton pump inhibitor (PPI) that reduces gastric acid secretion." | 2.42 | Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. ( Cheer, SM; Faulds, D; Lamb, HM; Prakash, A, 2003) |
| "The length of the Barrett's esophagus segment and the size of a hiatal hernia are associated with the risk of developing high-grade dysplasia and esophageal adenocarcinoma." | 2.42 | Reflux disease and Barrett's esophagus. ( Haag, S; Holtmann, G, 2003) |
| "Esomeprazole has an improved pharmacokinetic profile, resulting in increased systemic exposure and less interindividual variability compared with omeprazole, and more effective suppression of gastric acid production compared with other proton pump inhibitors." | 2.42 | Review of esomeprazole in the treatment of acid disorders. ( Johnson, DA, 2003) |
| "Gastroesophageal reflux disease (GERD) is associated with several symptoms, such as heartburn, belching, and regurgitation, which arise from esophageal exposure to gastric acid." | 2.42 | Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease. ( Sloan, S, 2003) |
| "It has been shown that GERD has a significant impact on patients' quality of life; therefore, improvement of quality of life is one of the major goals of GERD treatment." | 2.42 | The impact of gastroesophageal reflux disease on quality of life. ( Kamolz, T; Pointner, R; Velanovich, V, 2003) |
| "Gastro-oesophageal reflux disease (GORD) is common in the general population and is diagnosed based on patient-reported symptoms and clinical tests." | 2.42 | The impact of treatment for gastro-oesophageal reflux disease on health-related quality of life: a literature review. ( Prasad, M; Rentz, AM; Revicki, DA, 2003) |
| " Physiologic factors that may contribute to a poor response to these drugs include the considerable variation in the bioavailability of PPIs, the need to take PPIs with meals, the influence of Helicobacter pylori-associated gastritis, and genetic variation in enzyme capacity, resulting in rapid and slow metabolizers of PPIs." | 2.42 | Medical management of patients with esophageal or supraesophageal gastroesophageal reflux disease. ( Richter, JE, 2003) |
| "Gastro-oesophageal reflux disease (GORD) is a common, chronic disorder that can progress to erosive or ulcerative oesophagitis and other complications." | 2.42 | Improving health-related quality of life in gastro-oesophageal reflux disease. ( Crawley, JA; Shaw, MJ, 2003) |
| "Gastroesophageal reflux disease (GERD) is a wide spread disease characterized by distinct clinical polymorphism manifesting with various symptoms and/or inflammatory changes of a distal portion of the esophagus." | 2.42 | [Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease]. ( Balashova, NN; Busarova, GA; Maev, IV, 2003) |
| " Multicentre randomised controlled studies are needed to better define the efficacy profile, the optimal dosage with respect to the different indications and the safety profile for chronic therapy of proton pump inhibitors in children." | 2.42 | Proton pump inhibitors in children: a review. ( Gerarduzzi, T; Marchetti, F; Ventura, A, 2003) |
| " Therefore, a clear understanding of alternative dosing formulations and related efficacies is key in order for the clinician to select the most appropriate agent and strategy to optimize outcomes and cost-effectiveness for each patient." | 2.42 | Alternative dosing for PPI therapy: rationale and options. ( Johnson, DA, 2003) |
| "Gastro-oesophageal reflux disease (GERD) is an increasing health problem in developed countries and is associated with enormous costs in terms of reduced quality of life, loss of productivity, health expenses and mortality." | 2.42 | Review of rabeprazole in the treatment of gastro-oesophageal reflux disease. ( Thjodleifsson, B, 2004) |
| "Gastro-oesophageal reflux (GOR) and gastro-oesophageal reflux disease (GORD) have a higher prevalence among infants than among children or adults." | 2.42 | Managing gastro-oesophageal reflux disease in children. ( Cezard, JP, 2004) |
| "Esomeprazole has been studied clinically for a variety of acid-related conditions, showing that the compound is as well tolerated and more effective with regard to healing and symptom relief than the recommended treatment with omeprazole." | 2.42 | Single-isomer drugs: true therapeutic advances. ( Andersson, T, 2004) |
| "Rabeprazole is a second generation PPI with rapid onset of action that quickly relieves symptoms of GERD." | 2.42 | Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease. ( Goh, KL; Lim, PW, 2004) |
| "Gastroesophageal reflux disease (GERD) is defined as 'Chronic symptoms or mucosal damage produced by the abnormal reflux of gastric contents into the esophagus'." | 2.42 | [Significance of PPI-test in the diagnosis of GERD]. ( Ichimura, H; Kuwayama, H; Nishiki, R; Takada, H; Takahashi, M, 2004) |
| "Lansoprazole was superior to famotidine with regard to both efficacy and cost-effectiveness and therefore is the preferred therapeutic agent for the maintenance treatment of GERD." | 2.42 | [Evaluation of the efficacy and the cost-effectiveness of maintenance treatment of gastroesophageal reflux disease: proton pump inhibitor versus histamine-2-receptor antagonist]. ( Habu, Y; Hayakumo, T; Kawai, K; Shio, S; Yoshino, T, 2004) |
| "Initial therapy of GERD should be started with a full dose of PPI." | 2.42 | [PPI: new strategies for GERD]. ( Hoshino, E; Ishiyama, A; Tsuchida, T, 2004) |
| "Gastroesophageal reflux disease (GERD) is a common condition that effects about 10% of the adult population comprising a broad spectrum of symptoms and varying degrees of severity and frequency." | 2.42 | Extra-esophageal disorders in gastroesophageal reflux disease. ( Jaspersen, D, 2004) |
| "Gastroesophageal reflux disease (GERD) is among the most common disorders of the gastrointestinal tract, with symptoms affecting a substantial proportion of the US population on a daily basis." | 2.42 | Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor. ( Freston, JW, 2004) |
| " Novel dosage formulations of lansoprazole that may be appropriate for patients with dysphagia include the commercially manufactured lansoprazole strawberry-flavored enteric-coated granules for suspension and lansoprazole orally disintegrating tablets." | 2.42 | Management of acid-related disorders in patients with dysphagia. ( Howden, CW, 2004) |
| "Rabeprazole is a newer generation proton pump inhibitor that suppresses the gastric proton pump and acid secretion more rapidly than does omeprazole, lansoprazole or pantoprazole." | 2.42 | Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment. ( Miner, P, 2004) |
| "It is more effective in treating erosive esophagitis in patients with GERD than omeprazole." | 2.41 | Esomeprazole magnesium (Nexium). ( Baker, DE, 2001) |
| "Proton pump inhibitors are used to treat gastroesophageal reflux, a symptom common in pregnancy." | 2.41 | Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. ( Abdollahi, M; Koren, G; Magee, LA; Moretti, ME; Nikfar, S, 2002) |
| "Both GERD(gastroesophageal reflux disease) and chronic respiratory disease are common disease in old and the association between GERD and chronic respiratory disease are recently proved in many reports." | 2.41 | [Chronic respiratory disease and gastroesophageal reflux]. ( Dobashi, K, 2002) |
| "Studies that appeared to show that GERD could be provoked by antimicrobial therapy of duodenal ulcers also have methodological weaknesses." | 2.41 | Motion--Helicobacter pylori worsens GERD: arguments for the motion. ( O'Morain, CA; Qasim, A, 2002) |
| " Here, we identify factors in specific disease therapy and proton pump inhibitor (PPI) pharmacokinetic and pharmacodynamic characteristics that help us achieve this goal." | 2.41 | The clinical importance of proton pump inhibitor pharmacokinetics. ( Thomson, AB; Yacyshyn, BR, 2002) |
| "Gastroesophageal reflux disease is a complex, multifaceted disorder affecting a large proportion of the US population." | 2.41 | The pharmacology and clinical relevance of proton pump inhibitors. ( Frissora, C; Katz, PO, 2002) |
| "Esomeprazole is an effective agent in the treatment of gastroesophageal reflux disease (GERD) and erosive esophagitis." | 2.41 | Esomeprazole: update and clinical review. ( Baker, DE, 2002) |
| "Gastroesophageal reflux disease (GERD) causes chronic cough and triggers asthma." | 2.41 | Chronic cough, asthma, and gastroesophageal reflux. ( Harding, SM; Lazenby, JP, 2000) |
| "Pantoprazole has similar efficacy to other PPIs in the healing of gastric and duodenal ulcers, as well as erosive esophagitis, and as part of triple-drug regimens for the eradication of Helicobacter pylori from the gastric mucosa." | 2.41 | Pantoprazole: a new proton pump inhibitor. ( Jungnickel, PW, 2000) |
| " Intravenous pantoprazole has been shown to maintain acid suppression in patients switched from oral PPIs, so no change in dosage is required when switching from one formulation to the other." | 2.41 | Switching between intravenous and oral pantoprazole. ( Pisegna, JR, 2001) |
| " Instances in which laparoscopic Nissen fundoplication should be considered include: 1) Individuals who are intolerant of proton pump inhibitor therapy because of side effects, 2) When patients are inadequately responsive to proton pump inhibitor therapy even after dosage and dose interval have been optimized, and 3) When a patient desires a permanent solution to their reflux problem that frees them of the need to chronically consume pharmaceuticals." | 2.41 | Management of GERD: medical versus surgical. ( Kahrilas, PJ, 2001) |
| "Gastroesophageal reflux disease (GERD) can present with both typical symptoms such as heartburn and regurgitation as well as atypical symptoms." | 2.41 | Gastroesophageal reflux disease: extraesophageal manifestations and therapy. ( DeVault, KR, 2001) |
| "Gastroesophageal reflux disease is the most common esophageal abnormality associated with unexplained chest pain and may be identified by an aggressive trial of anti-reflux therapy or an abnormal prolonged ambulatory pH monitoring study." | 2.41 | Approach to the patient with unexplained chest pain. ( Katz, PO, 2001) |
| "Short-segment Barrett's esophagus is now clearly associated with an increased risk of dysplasia or cancer compared to intestinal metaplasia of the cardia, and the cancer risk in this condition is similar to that with long-segment Barrett's esophagus." | 2.41 | Gastroesophageal reflux disease and Barrett's esophagus. ( Falk, GW, 2001) |
| "Pantoprazole is a gastric hydrogen-potassium adenosine triphosphatase (H+/K(+)-ATPase) inhibitor." | 2.41 | Pantoprazole. ( Poole, P, 2001) |
| " The time of dosing and ingestion of meals may also influence the pharmacokinetics of these agents as well as their ability to suppress gastric acid secretion." | 2.41 | Shortcomings of the first-generation proton pump inhibitors. ( Tytgat, GN, 2001) |
| "Gastroesophageal reflux disease (GERD) is one of the most common diagnoses in a gastroenterologist's practice." | 2.41 | Pharmacoeconomic issues of the treatment of gastroesophageal reflux disease. ( Allescher, HD; Meining, A; Storr, M, 2001) |
| "Both GERD (gastroesophageal reflux disease) and asthma are common disease and the association between GERD and asthma are recently proved in many reports." | 2.41 | [GERD (gastroesophageal reflux disease)]. ( Dobashi, K, 2001) |
| "Gastroesophageal reflux is a normal phenomenon recognized in infants as "spitting up." | 2.41 | Gastroesophageal reflux in infants and children. When to reassure and when to go further. ( Jones, AB, 2001) |
| "Occult gastroesophageal reflux disease (GERD) is more common than motor disorders and is found in 30% to 40% of these patients; a subset has hypersensitivity, with a normal pH profile." | 2.41 | Noncardiac chest pain. ( Botoman, VA, 2002) |
| "Gastro-oesophageal reflux disease (GERD) is a common disorder in the primary care setting." | 2.41 | The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease. ( Dorn, GH; Fass, R; Fennerty, MB; Ofman, JJ, 2002) |
| "Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion in a dose-dependent manner via inhibition of H+/K+-adenosine triphosphatase in gastric parietal cells." | 2.41 | An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. ( Bown, RL, 2002) |
| "Esomeprazole is an effective, well tolerated treatment for managing GORD and for eradicating H." | 2.41 | Esomeprazole: a review of its use in the management of acid-related disorders. ( Dunn, CJ; Mallarkey, G; Scott, LJ; Sharpe, M, 2002) |
| "Although gastroesophageal reflux disease (GERD) is believed to be primarily a motor disorder, current medical therapy is based on the inhibition of acid secretion, since it is the deleterious effects of the acidic refluxate that lead to the symptoms and complications of GERD." | 2.40 | Long-term management of gastroesophageal reflux disease and its complications. ( Richter, JE, 1997) |
| "Gastroesophageal reflux disease (GERD) is a common problem in medical practice." | 2.40 | Current medical treatment and indications for surgical referral for gastroesophageal reflux disease (GERD). ( Castell, DO; Katz, PO, 1997) |
| "Omeprazole has the potential to mask other disorders such as peptic ulcer disease, thereby delaying appropriate testing for and eradication of Helicobacter pylori." | 2.40 | Value of a therapeutic trial to diagnose gastroesophageal reflux disease: step up versus step down therapy. ( Da Costa, LR, 1997) |
| " Conversely, several studies have shown that long-term use of proton pump inhibitors is associated with progression and worsening of body gastritis exclusively in Helicobacter pylori-positives." | 2.40 | Should Helicobacter pylori be eradicated before starting long-term proton pump inhibitors? ( Rauws, EA, 1997) |
| "Gastroesophageal reflux disease results from excessive exposure of the oesophagus to acidic contents." | 2.40 | Acid pump inhibitors. The treatment of gastroesophageal reflux. ( Hetzel, D, 1998) |
| "Omeprazole is a well studied proton pump inhibitor that reduces gastric acid secretion." | 2.40 | Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. ( Langtry, HD; Wilde, MI, 1998) |
| "Gastro-oesophageal reflux disease is the most common cause of indigestion in the community, and is usually chronic." | 2.40 | Gastro-oesophageal reflux disease. ( de Carle, DJ, 1998) |
| "pylori and GERD and its potential implications for the management of GERD." | 2.40 | Review article: Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management. ( O'Connor, HJ, 1999) |
| "Gastroesophageal reflux (GER) is common in those with asthma, with 77% of asthmatics complaining of heartburn, with 41% experiencing reflux-associated respiratory symptoms." | 2.40 | Nocturnal asthma: role of nocturnal gastroesophageal reflux. ( Harding, SM, 1999) |
| "Rabeprazole is an inhibitor of the gastric proton pump." | 2.40 | Rabeprazole: a review of its use in acid-related gastrointestinal disorders. ( Langtry, HD; Markham, A, 1999) |
| "Heartburn and other symptoms of gastroesophageal reflux disease can be a lifelong problem, affecting millions of Americans each year." | 2.40 | A practical approach to heartburn. ( Castell, DO, 1999) |
| "Gastroesophageal reflux (GER) occurs in 2 distinct forms that differ in pathophysiology, clinical presentation, natural history, and therapy: mild GER (with no or minimal esophagitis) and classic, severe reflux (at risk for erosive esophagitis)." | 2.40 | Gastroesophageal reflux: practical management of a common, challenging disorder. ( Fass, R; Soll, AH, 1999) |
| "Although relatively rare, GERD patients refractory to medical therapy remain a challenge for the clinician." | 2.40 | Medical therapy. Management of the refractory patient. ( Castell, DO; Hatlebakk, JG; Katz, PO, 1999) |
| "Noncardiac chest pain is a common but important clinical challenge with respect to diagnostic strategy as well as therapeutic intervention." | 2.39 | Pathophysiology and management of noncardiac chest pain. ( Joseph, AS; Minocha, A, 1995) |
| "Severe gastroesophageal reflux disease is usually a chronic problem with periods of relapse, but effective medical and surgical therapies are available." | 2.39 | Severe gastroesophageal reflux disease. Medical and surgical options for long-term care. ( Marshall, JB, 1995) |
| "In gastroesophageal reflux disease in particular, although the optimal degree of acid suppression is not yet defined, the consistently superior performance of proton pump inhibitors demonstrates that increased suppression of acidity is clinically beneficial." | 2.39 | Optimizing acid suppression for treatment of acid-related diseases. ( Cederberg, C; Dent, J; Halter, F; Howden, C; Hunt, RH; Marks, IN; Rune, S; Walt, RP, 1995) |
| "Gastroesophageal reflux disease (GERD) is a common disorder which may result in esophageal ulcers, erosions, strictures and motility disorders if it is not treated promptly." | 2.39 | The treatment of gastroesophageal reflux disease. ( Kaplan, B; Koppelo, KL, 1994) |
| "Omeprazole has been shown to have a good long-term safety profile, as evaluated in these trials." | 2.39 | Long-term treatment of gastro-oesophageal reflux disease with omeprazole. ( Lundell, L, 1994) |
| "Gastroesophageal reflux disease (GERD) is recognized to be present in 10-20% of cases of chronic cough." | 2.39 | Excluding gastroesophageal reflux disease as the cause of chronic cough. ( Castell, DO; Gideon, RM; Johnston, BT, 1996) |
| "Pantoprazole is an irreversible proton pump inhibitor which, at the therapeutic dose of 40mg, effectively reduces gastric acid secretion." | 2.39 | Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. ( Fitton, A; Wiseman, L, 1996) |
| "The vast majority of patients with GERD have mild symptoms, no gross endoscopic evidence of esophagitis, and little risk of developing complications." | 2.39 | Influence of pathophysiology, severity, and cost on the medical management of gastroesophageal reflux disease. ( Reynolds, JC, 1996) |
| " The ideal therapy for GORD will have linear pharmacokinetics, a relatively long plasma half-life (t1/2), a duration of action allowing once daily administration, and a stable effect independent of interactions with food, antacids and other drugs." | 2.39 | Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. ( Berstad, A; Hatlebakk, JG, 1996) |
| "Reflux esophagitis is a chronic condition and after stopping antisecretory treatment, including lansoprazole, most patients relapse in terms of symptoms and endoscopical lesions, which suggests the need for long-term treatment." | 2.38 | Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview. ( Di Fede, F; Dobrilla, G, 1993) |
| " The H2 antagonists differ in potency, pharmacodynamic effect, pharmacokinetics in certain patient groups, drug interactions, and adverse effects." | 2.38 | Efficacy, safety, and cost issues in managing patients with gastroesophageal reflux disease. ( Garnett, WR, 1993) |
| "Key pharmacokinetic and pharmacodynamic aspects of gastric acid-suppressive agents in patients with gastroesophageal reflux disease (GERD) are discussed." | 2.38 | Pharmacokinetics and pharmacodynamics of acid-suppressive agents in patients with gastroesophageal reflux disease. ( Goss, TF; Schentag, JJ, 1993) |
| " Tests of gastric acidity, in particular 24-h acidity studies, have provided considerable insight into normal and abnormal gastric physiology, and have largely determined the dosing regimens for the management of acid-peptic diseases." | 2.38 | Gastric acid secretion and intragastric acidity: measurement in health and disease. ( Fraser, AG; Pounder, RE, 1993) |
| "Gastro-oesophageal reflux disease is a common condition with a complex pathophysiology." | 2.38 | Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. ( Bell, NJ; Hunt, RH, 1992) |
| " Conventional dosing with H2-receptor antagonists has been successful in only about 50% of the patients with reflux esophagitis." | 2.38 | The role of omeprazole in healing and prevention of reflux disease. ( Klinkenberg-Knol, EC, 1992) |
| "Omeprazole is a potent and effective antisecretory drug." | 2.38 | Omeprazole. ( Langman, MJ, 1991) |
| "Omeprazole is a powerful inhibitor of gastric acid secretion." | 2.38 | Omeprazole. Overview and opinion. ( Holt, S; Howden, CW, 1991) |
| "Treatment with omeprazole resulted not only in improvement of gastro-oesophageal reflux but also in alleviation of asthmatic symptoms and increases in expiratory peak flow values." | 2.38 | Gastro-oesophageal reflux in patients with bronchial asthma. ( Depla, AC, 1989) |
| "There is no curative treatment for gastroesophageal reflux disease." | 1.91 | The Role of Endoplasmic Reticulum Stress in Gastroesophageal Reflux Disease Symptoms and Treatment. ( Aktan, Ç; Balcan, E; Buran, T; Kasap, E; Korkmaz, M; Solmaz Hasdemir, P; Toraman Avcu, A, 2023) |
| "Omeprazole was healthcare professional (HCP)-preferred first-line treatment (60." | 1.72 | Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients. ( Atkinson, C; Brunton, S; Howden, CW; Jacob, R; Mark Fendrick, A; Pelletier, C; Spechler, SJ; Vaezi, MF, 2022) |
| "To treat symptoms of gastroesophageal reflux disease, omeprazole was replaced with famotidine, and the visual hallucinations did not recur after the omeprazole had been discontinued." | 1.62 | Omeprazole-induced Visual Hallucinations: A Case Report. ( Kim, GS; Nunez, T; Vargas, E, 2021) |
| "We assessed the relationship between gastroesophageal reflux disease (GERD) and hypertension and whether antiacid therapy could be used to control blood pressure (BP) on hypertension in patients with GERD." | 1.48 | The Role of Gastroesophageal Reflux in Provoking High Blood Pressure Episodes in Patients With Hypertension. ( Han, XW; Ji, F; Li, ZT; Wang, L; Wang, ZG; Yue, YQ, 2018) |
| "A 56-year-old man with gastroesophageal reflux disease (GERD) was referred to our hospital." | 1.46 | Gastric Hyperplastic Polyps Associated with Proton Pump Inhibitor Use in a Case without a History of Helicobacter pylori Infection. ( Abiko, S; Hatanaka, KC; Kato, M; Kudo, T; Matsuda, K; Miyamoto, S; Mizushima, T; Ono, S; Sakamoto, N; Shimizu, Y; Tsuda, M; Tsunematsu, I; Yamamoto, K, 2017) |
| "Gastroesophageal reflux disease (GERD) is frequently seen during pregnancy." | 1.46 | Treatment of reflux disease during pregnancy and lactation. ( Dağlı, Ü; Kalkan, İH, 2017) |
| "The 3-year incidence of gastro-oesophageal reflux disease was 0·9% of our referral dog population." | 1.46 | Gastro-oesophageal reflux disease in 20 dogs (2012 to 2014). ( Hoerauf, A; Muenster, M; Vieth, M, 2017) |
| "However, effect of BILs in refractory GERD (RGERD) has not been well investigated." | 1.43 | Role of altered esophageal intraluminal baseline impedance levels in patients with gatroesophageal reflux disease refractory to proton pump inhibitors. ( Jiang, L; Lin, L; Wang, M; Wang, Y; Ye, B, 2016) |
| " Clinical trials validating omeprazole dosage in neonates are limited." | 1.43 | Dose-Finding Study of Omeprazole on Gastric pH in Neonates with Gastro-Esophageal Acid Reflux Using a Bayesian Sequential Approach. ( Alberti, C; Biran, V; Bourdon, O; Farnoux, C; Jacqz-Aigrain, E; Kaguelidou, F; Zohar, S, 2016) |
| "Because of gastroesophageal reflux disease prevalence, this retrospective analysis was undertaken to determine if coadministering erlotinib with AS therapy affected NSCLC outcomes." | 1.42 | Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer. ( Basappa, N; Butts, CA; Chambers, CR; Chu, MP; Chu, Q; Fenton, D; Ghosh, S; Joy, AA; Sangha, R; Sawyer, MB; Smylie, M, 2015) |
| " Reported serious adverse events (SAEs) and changes in laboratory variables were analysed." | 1.42 | Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. ( Attwood, SE; Eklund, S; Ell, C; Fiocca, R; Galmiche, JP; Hasselgren, B; Hatlebakk, JG; Jahreskog, M; Långström, G; Lind, T; Lundell, L, 2015) |
| "The treatment of gastro-esophageal reflux disease (GERD) shows several issues among paediatric patients." | 1.42 | Alginate beads as a carrier for omeprazole/SBA-15 inclusion compound: A step towards the development of personalized paediatric dosage forms. ( Adami, R; Aquino, RP; De Cicco, F; Del Gaudio, P; Giovagnoli, S; Ricci, M; Sansone, F, 2015) |
| "Chest pain is a common cause for referral to emergency departments." | 1.42 | A jackhammer in the gullet: high amplitude oesophageal contractions as a cause of atypical chest pain. ( Anggiansah, A; Goel, R; Wilkinson, M; Wong, T, 2015) |
| "Acid reflux esophagitis was induced by ligating the transitional region between the forestomach and the glandular portion and then wrapping the duodenum near the pylorus." | 1.40 | Acid reflux directly causes sleep disturbances in rat with chronic esophagitis. ( Arakawa, T; Fujiwara, Y; Nakahara, K; Shiba, M; Tanigawa, T; Tominaga, K; Tsukahara, T; Urade, Y; Watanabe, T; Yamagami, H, 2014) |
| "Gastroesophageal reflux disease was assessed by 24-hour pH monitoring with a Bravo catheter-free radio pH capsule." | 1.39 | Gastroesophageal reflux disease and its association with bronchiolitis obliterans syndrome in allogeneic hematopoietic stem cell transplant recipients. ( Ahmed, S; Al Mohareb, F; Aljurf, M; Chaudhri, N; Ibrahim, Kel T; Khalid, M; Khan, B; Khan, MQ; Mobeireek, A; Saleemi, S, 2013) |
| "Despite GERD being a chronic disease in most patients, there was a high degree of alteration seen in the utilization patterns of PPIs." | 1.39 | Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study. ( Hatlebakk, JG; Jonasson, C; Tvete, IF, 2013) |
| "The combination of bronchial asthma with pathology of the digestive tract--one of the most frequent, clinically diverse and difficult, which complicates its course." | 1.39 | [Comparison of the effectiveness of omeprazole and pantoprazole treatment of gastroesophageal reflux disease in patients with asthma]. ( Popadynets', IR, 2013) |
| "Patients were ranked as ne-GERD (162: 67." | 1.38 | Low levels of adherence with proton pump inhibitor therapy contribute to therapeutic failure in gastroesophageal reflux disease. ( Barbuti, R; Dal-Paz, K; Eisig, JN; Moraes-Filho, JP; Navarro-Rodriguez, T; Quigley, EM, 2012) |
| " Rates of congenital malformations in PPIs exposed and unexposed pregnancies, as well as other adverse fetal effects were compared." | 1.38 | The safety of fetal exposure to proton-pump inhibitors during pregnancy. ( Gorodischer, R; Koren, G; Levy, A; Matok, I; Uziel, E; Wiznitzer, A, 2012) |
| "In our study of 154 GERD patients, 50 received omeprazole, 51 - lansoprazole and 53 - pantoprazole in a standard daily dose." | 1.38 | [Factors affecting efficacy of gastroesophageal reflux disease treatment with proton pump inhibitors]. ( , 2012) |
| "Although most patients with gastro-oesophageal reflux disease (GERD) benefit from proton pump inhibitor (PPI) therapy, some experience only partial symptom relief." | 1.38 | Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients. ( Bytzer, P; Mattsson, H; van Zanten, SV; Wernersson, B, 2012) |
| " Adverse events were rare (2." | 1.38 | [Efficacy and safety of OTC omeprazole]. ( Labenz, J; Willmer, C, 2012) |
| "TREATMEN The contribution of eosinophilic esophagitis (EoE) to refractory gastroesophageal reflux disease (GERD) remains unknown." | 1.37 | Eosinophilic esophagitis in patients with typical gastroesophageal reflux disease symptoms refractory to proton pump inhibitor. ( Barbuti, RC; Eisig, JN; Hashimoto, CL; Kishi, HS; Moraes-Filho, JP; Navarro-Rodriguez, T; Sá, CC; Silva-Werneck, AL, 2011) |
| "nonwhite patients with gastro-oesophageal reflux disease (GERD)." | 1.37 | Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors. ( Illueca, M; Johnson, DA; Monyak, JT; Sharma, P, 2011) |
| "Gastroesophageal reflux disease (GERD) constitutes a significant health problem in societies of high socioeconomic status." | 1.37 | The usefulness of the original questionnaire in the evaluation of quality of life in patients with gastroesophageal reflux disease. ( Huk, J; Masiak, W; Pedowski, T; Wallner, G; Wiktor, W, 2011) |
| "Many patients with asthma also have gastroesophageal reflux disease (GERD), and GERD can cause symptoms that mimic those of poorly controlled asthma." | 1.36 | Treating silent reflux disease does not improve poorly controlled asthma. ( Mastronarde, JG; Parsons, JP; Riscili, BP, 2010) |
| " However, as with all drugs, PPIs should be dosed appropriately, and should be reserved for patients with conditions for which there is clear evidence of benefit from therapy." | 1.36 | Editorial: just how "difficult" is it to withdraw PPI treatment? ( Howden, CW; Kahrilas, PJ, 2010) |
| "Pre-existing nonerosive gastroesophageal reflux disease, smoking, and older age are important predictors of de novo development of erosive esophagitis." | 1.36 | De novo erosive esophagitis in duodenal ulcer patients related to pre-existing reflux symptoms, smoking, and patient age, but not to Helicobacter pylori eradication: a one-year follow-up study. ( Jonaitis, L; Kiudelis, G; Kupčinskas, J; Kupčinskas, L, 2010) |
| "Thirty adult subjects with gastroesophageal reflux disease requiring endoscopy underwent enteroscopy." | 1.36 | Endoscopic jejunal biopsy culture: a simple and effective method to study jejunal microflora. ( Chandra, S; Dutta, U; Kochhar, R; Noor, MT; Sharma, M; Singh, K; Taneja, N, 2010) |
| "Was performed an assessment of GERD symptom severity, the establishment of periodontal status of patients and analysis of the effects of GERD therapy on the course parodontopaty inflammatory genesis (chronic catarrhal gingivitis and chronic periodontitis mild)." | 1.36 | [Dynamics of inflammatory periodontal diseases under the influence of gastroesophageal reflux disease therapy]. ( Dzhamaldinova, TD, 2010) |
| "The correlation between gastroesophageal reflux and several related variables was evaluated." | 1.35 | Gastroesophageal scintigraphy in the evaluation of adult patients with chronic cough due to gastroesophageal reflux disease. ( Cerci, SS; Oztürk, O; Sahin, U; Senol, A; Songür, N; Songür, Y; Yarktaş, MH, 2008) |
| "Gastroesophageal reflux disease patients who continued to report symptoms 3 times a week for 3 months while on PPI once a day were assigned to the PPI failure group." | 1.35 | Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily. ( Fass, R; Gasiorowska, A; Koenig, K; Krupinski, E; Moty, B; Navarro-Rodriguez, T; Perry, ZH; Powers, J; Wendel, C, 2009) |
| "Esophageal squamous cell carcinoma developed in INK4a/Arf+/- mice (7." | 1.35 | Gastroesophageal reflux leads to esophageal cancer in a surgical model with mice. ( Chen, X; Hao, J; Liu, B; Yang, CS, 2009) |
| "Gastroesophageal reflux is a well-recognized complication of obesity." | 1.35 | Case reports--resolution of Barrett's disease and esophageal epithelial atypia after gastric bypass and LAP-BAND. ( Chang, CG; Perez, E, 2009) |
| " The literature suggests three possibilities to explain the inadequacy of the substitution: (a) biphasic metabolism where the raised pH in the stomach may prematurely inactivate the PPI, with an unpredictable effect, (b) differences in acid-resistant coating of the generic products, and (c) influence of multiple dosing of PPIs after several days' use." | 1.35 | [Why some proton pump inhibitors are more equal than others]. ( Lekkerkerker, JF; Mulder, CJ; Otten, MH, 2009) |
| "In 20 GERD patients with normal esophageal peristalsis an NF was performed, in 20 patients with impaired esophageal peristalsis a PPF was chosen, and 20 patients received proton-pump inhibitor (PPI) treatment." | 1.35 | Laparoscopic partial posterior (Toupet) fundoplication improves esophageal bolus propagation on scintigraphy. ( Bodner, J; Bonatti, H; Gadenstaetter, M; Hugl, B; Wetscher, GJ; Wykypiel, H, 2008) |
| "Symptoms of gastroesophageal reflux disease (GERD) are common in the general population." | 1.35 | Symptom-focused results after laparoscopic fundoplication for refractory gastroesophageal reflux disease--a prospective study. ( Antoniou, GA; Antoniou, SA; Dalenbäck, J; Delivorias, P; Kalambakas, A; Makridis, C; Natsiopoulos, I, 2008) |
| "There is controversial evidence that gastroesophageal reflux disease (GERD) is an etiologic factor for idiopathic laryngotracheal stenosis." | 1.35 | Idiopathic tracheal stenosis: successful outcome with antigastroesophageal reflux disease therapy. ( de Medeiros, IL; Jatene, FB; Minamoto, H; Nasi, A; Pego-Fernandes, PM; Terra, RM, 2008) |
| "The prevalence of pathologic 24-hour esophageal reflux in both studies was significantly higher when measured as time pH < 4 than when measured as integrated acidity." | 1.35 | Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors. ( Gardner, JD; Gerson, LB; Miner, PB; Robinson, M; Sahbaie, P; Sloan, S; Triadafilopoulos, G; Young, W, 2008) |
| "Children with symptoms suggesting GERD underwent prolonged 24h intraesophageal pH monitoring and/or upper GI endoscopy with biopsies before and after a 6 months of pharmaceutical (omeprazole) and nutritional (20% increment of daily caloric intake) treatments." | 1.34 | Impact of malnutrition on gastrointestinal disorders and gross motor abilities in children with cerebral palsy. ( Campanozzi, A; Capano, G; Del Giudice, E; Miele, E; Militerni, R; Romano, A; Scuccimarra, G; Staiano, A; Strisciuglio, C, 2007) |
| "Omeprazole was used in 90% of the patients; lansoprazole, in 7%." | 1.34 | Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. ( El-Serag, HB; Hassall, E; Kerr, W, 2007) |
| "Using GERD as an example, the authors were able to determine differences in patient satisfaction between proton pump inhibitors (PPIs), H(2) antagonists, and antacids, and even within the PPI category, down to individual products." | 1.34 | Comparative drug effects: the case of GERD therapies. ( Wertheimer, AI; Wilson, JM, 2007) |
| "It was shown that gastroesophageal reflux disease was one of the possible causes of eosinophilia." | 1.34 | [A case of gastroesophageal reflux disease with marked eosinophilia]. ( Inoue, T; Inui, Y; Katata, T; Kizu, T; Kohro, T; Matsumoto, Y; Miyoshi, R; Nishikawa, M; Watanabe, C; Yasunaga, Y, 2007) |
| "Omeprazole is a commonly prescribed inhibitor of the gastric proton pump and has numerous indications in the treatment of gastrointestinal diseases." | 1.34 | Omeprazole-associated digoxin toxicity. ( Cragin, DJ; Kiley, CA; Roth, BJ, 2007) |
| "Duodenal ulcer (DU) and gastroesophageal reflux disease (GERD) are often combined." | 1.34 | [Characteristics of a combined course of duodenal ulcer and gastroesophageal reflux disease]. ( Tsimmerman, IaS; Vologzhanina, LG, 2007) |
| "To determine the role of duodenogastro-esophageal reflux (DGER) in the pathogenesis of refractory gastro-esophageal reflux disease (GERD) in children." | 1.34 | Duodenogastro-esophageal reflux in children with refractory gastro-esophageal reflux disease. ( De Greef, T; Ectors, N; Haesendonck, N; Hoffman, I; Tack, J; Tertychnyy, A, 2007) |
| "Gastroesophageal reflux disease is a common and chronic disorder but long term, prospective studies of the fate of patients seeking medical advice are scarce." | 1.34 | Prospective Acid Reflux Study of Iran (PARSI): methodology and study design. ( Abedi, B; Alimohamadi, SM; Ghotbi, MH; Malekzadeh, R; Mamarabadi, M; Mofid, A; Mostajabi, P; Nasseri-Moghaddam, S; Nouraie, M; Razjouyan, H; Sohrabpour, AA; Sotoudeh, M; Tofangchiha, S, 2007) |
| " Medical charts were reviewed in a subset of patients to gather dosing information." | 1.34 | Proton pump inhibitor utilization patterns in infants. ( Bakst, AW; Barron, JJ; Singer, J; Spalding, J; Tan, H, 2007) |
| "Gastro-oesophageal reflux disease is one of the most common diseases in primary care and has a significant negative impact on patients' quality of life." | 1.33 | Validation of the Reflux Disease Questionnaire for a German population. ( Kulig, M; Leodolter, A; Malfertheiner, P; Nocon, M; Willich, SN, 2005) |
| "pylori-infected gastro-oesophageal reflux disease patients does not increase or accelerate gastric autoimmunity." | 1.33 | Long-term acid suppression by omeprazole in gastro-oesophageal reflux disease patients does not lead to anti-gastric autoantibody production. ( Aar, A; Appelmelk, BJ; Bergman, MP; Faller, G; Klinkenberg-Knol, EC; Kuipers, EJ; Lakhai, W; Vandenbroucke-Grauls, CM, 2005) |
| "Laryngopharyngeal reflux (LPR) is frequently treated with empiric proton-pump inhibitors (PPI), but the optimal dosing and duration is unknown." | 1.33 | Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response. ( Abelson, TI; Hicks, DM; Khandwala, F; Milstein, C; Park, W; Richter, JE; Vaezi, MF, 2005) |
| "The article covers the modem concept of gastroesophageal reflux disease (GERD) pharmacogenomics." | 1.33 | [Pharmacogenomical aspects of gastroesophageal reflux disease]. ( Isaev, VA, 2005) |
| "The effect of gastro-oesophageal reflux on sleep and sleep quality is highly controversial." | 1.33 | The effect of gastro-oesophageal reflux and omeprazole on key sleep parameters. ( Banwait, KS; Cohen, S; Dimarino, AJ; Dimarino, M; Doghramji, K; Eschinger, E; Greenberg, A, 2005) |
| "Gastroesophageal reflux disease (GERD) is commonly associated with asthma; however, frequency in nonatopic children with asthmatic symptoms is unknown." | 1.33 | Frequency of gastroesophageal reflux disease in nonatopic children with asthma-like airway disease. ( Aydoğdu, S; Kasirga, E; Kirmaz, C; Yilmaz, O; Yüksel, H, 2006) |
| "Gastro-esophageal reflux disease (GERD) may cause chest pain." | 1.33 | Does gastro-esophageal reflux provoke the myocardial ischemia in patients with CAD? ( Bachórzewska-Gajewska, H; Baniukiewicz, A; Dabrowski, A; Dobrzycki, S; Kamiński, KA; Korecki, J; Musial, WJ; Prokopczuk, P, 2005) |
| " Long-term dosing schedule (high dose or step-down dose) was based on current market data." | 1.33 | Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK. ( Brown, RE; Remák, E; Robinson, A; Yuen, C, 2005) |
| "The Gastroesophageal Reflux Disease (GERD) Treatment Satisfaction Questionnaire (GTSQ) was developed to assess satisfaction with GERD medication." | 1.33 | Development and validation of the Gastroesophageal Reflux Disease Treatment Satisfaction Questionnaire. ( Dodd, SL; Flood, E; Howell, J; Shikiar, R; Siddique, R, 2005) |
| "Rabeprazole was administered on days 2-4 of the study (20 mg orally twice a day)." | 1.33 | Four-day Bravo pH capsule monitoring with and without proton pump inhibitor therapy. ( Hirano, I; Kahrilas, PJ; Pandolfino, JE; Zhang, Q, 2005) |
| "Gastroesophageal reflux (GER) can cause serious voice problems and laryngopharyngeal disorders influencing the patient's quality of life." | 1.33 | Voice disorders and gastroesophageal reflux. ( Hocevar-Boltezar, I; Jansa, R; Sereg-Bahar, M, 2005) |
| "The scale of GERD-HRQL decreased significantly in RE patients than in NERD patients." | 1.33 | [The impact of rabeprazole treatment on the quality of life in patients with reflux esophagitis and non-erosive reflux disease]. ( Hou, XH; Ke, MY; Liu, XH; Luo, JY; Song, ZQ; Sun, J; Yuan, YZ; Zha, H; Zhu, YL, 2005) |
| "The subjects were 88 patients with gastroesophageal reflux disease (GERD), who had changes in the oral cavity typical of this disease." | 1.33 | [Oral cavity manifestations of gastroesophageal reflux disease]. ( Barer, GM; Burkov, SG; Busarova, GA; Gurenev, GL; Maev, IV; Polikanova, EN; Pustovoĭt, EV, 2005) |
| "Gastroesophageal reflux disease (GERD) is present in up to 75% of patients with chronic refractory ear, nose, and throat (ENT) symptoms, and proton pump inhibitor (PPI) therapy induces symptom relief in the majority of these patients." | 1.33 | Determinants of long-term outcome of patients with reflux-related ear, nose, and throat symptoms. ( Feenstra, L; Poelmans, J; Tack, J, 2006) |
| "The causal association between gastro-oesophageal reflux disease (GERD) and difficult-to-control asthma is unclear." | 1.33 | Gastro-oesophageal reflux disease in 'difficult-to-control' asthma: prevalence and response to treatment with acid suppressive therapy. ( Chua, CJ; Goh, KL; Liam, CK; Wong, CH, 2006) |
| "A prolonged GA inhibitor-induced hypochlorhydria has been suggested as a risk factor for severe gastrointestinal infections." | 1.33 | Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. ( Canani, RB; Cirillo, P; Guarino, A; Malamisura, B; Manguso, F; Morelli, L; Passariello, A; Roggero, P; Romano, C; Terrin, G, 2006) |
| " Pre-meal dosing maximizes efficacy while sub-optimal dose timing may limit efficacy." | 1.33 | Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. ( Gunaratnam, NT; Inadomi, J; Jessup, TP; Lascewski, DP, 2006) |
| "Cough was significantly less severe in NEE adolescents than in younger children." | 1.33 | Presenting symptoms of nonerosive and erosive esophagitis in pediatric patients. ( Amer, F; Chiu, YL; Gupta, SK; Hassall, E; Heyman, MB, 2006) |
| "In most patients with GERD esophagitis is not detected by endoscopy, which represents GERD with a negative endoscopy or non-erosive reflux disease (NERD)." | 1.33 | Efficacy of low-dose lansoprazole in the treatment of non-erosive gastrooesophageal reflux disease. Influence of infection by Helicobacter pylori. ( Castro Fernández, M; García Díaz, E; Lamas Rojas, E; Larraona, JL; Núñez Hospital, D; Pallarés Querol, M; Rodríguez Hornillo, MC, 2006) |
| "Rabeprazole is a PPI whose metabolism shows fewer interactions compared to other PPIs." | 1.33 | Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastresophageal reflux disease. ( Giannini, EG; Savarino, V; Testa, R, 2006) |
| "Thirty one patients with gastroesophageal reflux disease were treated with a daily oral dose of 20 mg OMP for 28 days." | 1.33 | [Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease]. ( Choi, SK; Joo, YE; Kim, HS; Kim, SJ; Lee, WS; Park, CH; Rew, JS; Sohn, YH, 2006) |
| "The cough was eliminated or markedly improved in 38 patients (86%) after 4 weeks and by 8 weeks in the remaining 6 patients." | 1.32 | Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment. ( Kallay, MC; Poe, RH, 2003) |
| "Omeprazole treatment success occurred more frequently in patients with a total diagnostic score of > 7 and oesophagitis II-IV in patients with a total diagnostic score of > 9." | 1.32 | Reflux symptoms in general practice: diagnostic evaluation of the Carlsson-Dent gastro-oesophageal reflux disease questionnaire. ( de Wit, NJ; Numans, ME, 2003) |
| "Recent studies suggest that gastroesophageal reflux disease (GERD) may be a major cause of globus sensation." | 1.32 | Globus sensation and gastroesophageal reflux. ( Brossard, E; Chevalier, JM; Monnier, P, 2003) |
| "Sixty-eight gastroesophageal reflux disease patients (age range 18-61 years) were studied by upper endoscopy." | 1.32 | Acid exposure and altered acid clearance in GERD patients treated for Helicobacter pylori infection. ( Bottiglieri, ME; Budillon, G; Cuomo, R; Grasso, R; Ierardi, E; Nardone, G; Sarnelli, G; Verde, C, 2003) |
| "Presence of gastro-oesophageal reflux symptoms and medication of proton pump inhibitors, H2-blockers or prokinetics were investigated at final endoscopy." | 1.32 | Long-term observation of reflux oesophagitis developing after Helicobacter pylori eradication therapy. ( Chayama, K; Haruma, K; Manabe, N; Sasaki, A; Tanaka, S; Yoshihara, M, 2003) |
| "Severity and frequency of gastroesophageal reflux disease (GERD) related symptoms are associated with impaired health-related quality of life (HRQL)." | 1.32 | Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity. ( Crawley, JA; Joshua-Gotlib, S; Levine, D; Revicki, DA; Zodet, MW, 2003) |
| "Radical treatment of GERD allows the pulmonologist to perform correct respiratory treatment and to prevent the development chronic and life-threatening complications." | 1.32 | Outcome of laparoscopic Nissen-Rossetti fundoplication in children with gastroesophageal reflux disease and supraesophageal symptoms. ( Castagnetti, M; Gentilino, V; Jasonni, V; Martino, F; Mattioli, G; Montobbio, G; Pini Prato, A; Sacco, O, 2004) |
| "Gastroesophageal reflux disease (GERD), is a common disorder." | 1.32 | Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions. ( Kivioja, A; Linnosmaa, I; Vehviläinen, A; Vohlonen, I, 2004) |
| "In refractory cases of GERD, eosinophilic esophagitis must be considered before any surgical measure." | 1.32 | Eosinophilic infiltration of the esophagus: gastroesophageal reflux versus eosinophilic esophagitis in children--discussion on daily practice. ( Cury, EK; Faintuch, S; Schraibman, V, 2004) |
| "Thirty-two patients with long-segment Barrett esophagus who were asymptomatic with PPIs." | 1.32 | Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy. ( Casey, JF; Clark, GW; Guillou, PJ; Hick, DG; Sarela, AI; Verbeke, CS, 2004) |
| "Gastroesophageal reflux disease (GERD) has evolved from a scarcely reported, little understood disease process just a century ago to a now highly prevalent disease with up to 25% of the population complaining of symptoms of reflux." | 1.32 | GERD 2003: issues from the past and a consensus for the future. ( Kidd, M; Modlin, I, 2004) |
| "Effective therapy for gastro-oesophageal reflux disease (GERD) is associated with improvement in health-related quality of life." | 1.32 | Evaluation of treatment for gastro-oesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and Helicobacter pylori infection in Japan. ( Azuma, T; Dojo, M; Kuriyama, M; Muramatsu, A; Ohtani, M; Okajima, T; Yamazaki, Y, 2004) |
| "Mechanisms of chest pain in gastroesophageal reflux disease (GERD) are poorly understood." | 1.32 | Patients with chest pain and occult gastroesophageal reflux demonstrate visceral pain hypersensitivity which may be partially responsive to acid suppression. ( Aziz, Q; Hobson, AR; Millane, T; Sarkar, S; Thompson, DG; Woolf, CJ, 2004) |
| "Reflux-cough is a diagnosis based on demonstrating both gastro-oesophageal reflux and a positive response to anti-reflux therapy." | 1.32 | Oesophageal pH monitoring is of limited value in the diagnosis of "reflux-cough". ( Heaney, LG; Johnston, BT; MacMahon, J; McGarvey, LP; Patterson, RN, 2004) |
| "Gastroesophageal reflux (GER) is a common episode in pediatric patients with severe motor and intellectual disabilities (SMID) and occasionally leads to a severe clinical state accompanied with nausea, hematemesis, melena, wheezing, pneumonia, anemia and/or failure to thrive." | 1.32 | Treatment of gastric hemorrhage by pulverized omeprazole and antacid--concomitant administration via a nasogastric tube. ( Kinoshita, E; Mukai, S; Ohtani, H; Sawada, Y; Yamaguchi, T, 2004) |
| "Some patients with gastro-oesophageal reflux disease continue to experience symptoms despite therapy with proton pump inhibitors." | 1.31 | An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. ( Murray, JA; Nzeako, UC, 2002) |
| "Seven GERD patients (4 males and 3 females, mean age 39 +/- 8 years) were studied." | 1.31 | Assessment of the afferent vagal nerve in patients with gastroesophageal reflux. ( Anvari, M; Hong, D; Kamath, M; Tabet, J; Tougas, G; Wang, S, 2002) |
| "Rabeprazole subjects had lower GERD-related costs, less escalation, and lower DACON (measured as number of tablets consumed per day), compared to lansoprazole and omeprazole subjects." | 1.31 | Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs. ( Dodd, S; Durkin, M; Hall, J; Sloan, S, 2002) |
| "A total of 65 patients with GERD (grades A-D) completed treatment with lansoprazole, by taking 30 mg orally once a day for 8 weeks." | 1.31 | Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. ( Furuta, T; Futami, H; Hanai, H; Honda, S; Iida, T; Ishizaki, T; Kajimura, M; Ohashi, K; Sato, Y; Shirai, N; Takayanagi, S; Takeuchi, K; Watanabe, F; Yamada, M, 2002) |
| "To assess both acid gastro-oesophageal reflux (GOR) suppression in patients with Barrett's oesophagus on proton-pump inhibitors (PPI) and the predictive value of symptoms." | 1.31 | Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy. ( Bale, R; Basu, KK; de Caestecker, JS; West, KP, 2002) |
| "Patients with erosive gastroesophageal reflux disease participating in an open-label, 8-week study completed the SF-36 Health Survey before and after treatment with rabeprazole." | 1.31 | Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease. ( Bhattacharjya, A; Damiano, AM; Johanson, JF; Jokubaitis, L; Murthy, A; Siddique, R, 2002) |
| "Idiopathic hoarseness as a single symptom increases the odds ratio for laryngopharyngeal reflux disease 85 times." | 1.31 | [Typical and atypical symptoms of laryngopharyngeal reflux disease]. ( Jonaitis, L; Pribuisiene, R; Uloza, V, 2002) |
| "Eight patients with refractory GERD symptoms were controlled over a mean of 15." | 1.31 | Persistent gastroesophageal reflux disease symptoms on standard proton-pump inhibitor therapy. ( Sontag, SJ, 2002) |
| "pylori induces de novo GERD symptoms in ulcer patients." | 1.31 | Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. ( Dickson, A; El-Nujumi, A; El-Omar, E; Kelman, A; McColl, KE, 2000) |
| "In gastro-oesophageal reflux disease (GORD), the majority of patients are endoscopy negative." | 1.31 | How do we offer clinical relief to patients with gastro-oesophageal reflux disease? ( Galmiche, JP, 2000) |
| "pylori and oesophagitis is mediated by the effect of H." | 1.31 | Should we eradicate Helicobacter pylori in patients with recurrent gastro-oesophageal reflux disease? ( Bianchi Porro, G; Pace, F, 2000) |
| "In the dysphagia group, 48 of 54 patients (89%) had edema of the posterior larynx, and 42 of 54 (78%) had laryngopharyngeal sensory deficits." | 1.31 | Laryngopharyngeal sensory deficits in patients with laryngopharyngeal reflux and dysphagia. ( Aviv, JE; Close, LG; Kaplan, ST; Liu, H; Parides, M, 2000) |
| "A total of 300 patients with GERD completed questionnaires before and 6 months after laparoscopic Nissen fundoplication." | 1.31 | Reproducibility, validity, and responsiveness of a disease-specific symptom questionnaire for gastroesophageal reflux disease. ( Allen, CJ; Anvari, M; Belda, J; Parameswaran, K, 2000) |
| "Gastroesophageal reflux disease (GERD) is a condition where acid contents of the stomach are regurgitated into the oral cavity, which results in continual exposure of the teeth to these acids." | 1.31 | Restoration of enamel and dentin erosion due to gastroesophageal reflux disease: a case report. ( Cobb, D; Denehy, G; Ibarra, G; Senna, G, 2001) |
| "Duodenoesophageal reflux was induced in 60 rats by performing a duodenesophagostomy." | 1.31 | Adenocarcinoma of the rat esophagus in the presence of a proton pump inhibitor: a pilot study. ( Barry, P; Burn, J; Falk, G; Moore, KH, 2001) |
| "Patients with chronic ear problems and GERD were thoroughly analyzed by the otorhinolaryngologist and the gastroenterologist." | 1.31 | Chronic middle ear disease and gastroesophageal reflux disease: a causal relation? ( Feenstra, L; Poelmans, J; Tack, J, 2001) |
| "Patients with gastro-oesophageal reflux disease (GORD) frequently report that meals high in fat worsen heartburn." | 1.31 | Duodenal fat intensifies the perception of heartburn. ( Elashoff, JD; Fass, R; Lembo, A; Mayer, EA; Meyer, JH, 2001) |
| "Gastroesophageal reflux disease has a multifactorial etiology." | 1.31 | Efficacy of medical therapy and antireflux surgery to prevent Barrett's metaplasia in patients with gastroesophageal reflux disease. ( Gadenstaetter, M; Klaus, A; Klingler, PJ; Obrist, P; Profanter, C; Weiss, H; Wetscher, GJ; Wykypiel, H, 2001) |
| "Gastroesophageal reflux, common in infants, usually resolves spontaneously by 12 to 18 months." | 1.31 | [Laryngeal manifestations of gastroesophageal reflux disease (GERD) in pediatric patients: the usefulness of therapeutic (proton pump inhibitor (PPI)) trials]. ( Niimi, S; Saigusa, H; Saigusa, U; Yagi, T, 2001) |
| "Gastroesophageal reflux (GER) is associated with a variety of laryngopharyngeal signs and symptoms." | 1.31 | Effect of aggressive therapy on laryngeal symptoms and voice characteristics in patients with gastroesophageal reflux. ( Fuleihan, N; Hamdan, AL; Sharara, AI; Younes, A, 2001) |
| "Rabeprazole has also been shown to have a more consistent suppression of acid, including at night." | 1.31 | Optimizing acid-suppression therapy. ( Barnett, JL; Robinson, M, 2001) |
| " Dosage of omeprazole used was 1." | 1.31 | Clinical efficacy of proton pump inhibitor therapy in neurologically impaired children with gastroesophageal reflux: prospective study. ( Chan, KH; Chan, YC; Cheung, KM; Ko, CH; Leung, CY; Tse, PW, 2001) |
| "All 8 patients had initial control of laryngospasm." | 1.31 | Laryngospasm: an atypical manifestation of severe gastroesophageal reflux disease (GERD). ( Maceri, DR; Zim, S, 2001) |
| "To determine the extent to which gastroesophageal reflux (GER)-initiated laryngeal chemoreflexes contribute to obstructive sleep apnea (OSA)." | 1.31 | Gastroesophageal reflux and obstructive sleep apnea. ( Benninger, M; Khan, M; Rosenthal, L; Schwimmer, C; Senior, BA, 2001) |
| "Rabeprazole has a favourable profile with rapid action and good safety." | 1.31 | [Pharma-clinics medication of the month. Rabeprazole (Pariet)]. ( Louis, E, 2002) |
| "Esomeprazole is an effective and well tolerated treatment for managing GORD and for eradicating H." | 1.31 | Esomeprazole: a review of its use in the management of acid-related disorders in the US. ( Dunn, CJ; Mallarkey, G; Scott, LJ; Sharpe, M, 2002) |
| "Although the association between gastroesophageal reflux disease (GERD) and laryngeal disorders in adults is well established there is still a lack of information concerning the true extent of the laryngeal complications of GERD in children." | 1.31 | Laryngeal manifestations of gastroesophageal reflux disease in children. ( Blitek, A; Horobiowska, M; Iwanczak, B; Krecicki, T; Zalesska-Krecicka, M, 2002) |
| "The therapeutic approach to gastroesophageal reflux disease (GERD) in intellectually disabled individuals has not been studied extensively." | 1.30 | Gastroesophageal reflux disease in intellectually disabled individuals: leads for diagnosis and the effect of omeprazole therapy. ( Bohmer, CJ; Devillé, WL; Klinkenberg-Knol, EC; Meuwissen, SG; Niezen-de Boer, MC; Tuynman, HA; Voskuil, JH, 1997) |
| "Lansoprazole was mostly prescribed in patients with reflux oesophagitis (55." | 1.30 | A prospective follow-up study of 5669 users of lansoprazole in daily practice. ( Claessens, A; Heerdink, E; Lamers, CB; Leufkens, H; van Eijk, J, 1997) |
| "Laryngeal manifestations of gastroesophageal reflux disease are thought to be prevalent in our society." | 1.30 | Laryngeal manifestations of gastroesophageal reflux before and after treatment with omeprazole. ( Searl, JP; Shaw, GY, 1997) |
| "In 21 GERD patients with RS, reflux was assessed by endoscopy, manometry, and pH monitoring." | 1.30 | Respiratory symptoms in patients with gastroesophageal reflux disease following medical therapy and following antireflux surgery. ( Bammer, T; Glaser, K; Hinder, RA; Klingler, A; Klingler, P; Perdikis, G; Pointner, R; Schwab, G; Wetscher, GJ; Wieschemeyer, T, 1997) |
| " A major part of this sum was spent for patients who needed to increase the initial 20 mg dosage of Omeprazol within 5 years." | 1.30 | [Laparoscopic interventions in gastroesophageal reflux--a cost-benefit analysis]. ( Freys, SM; Fuchs, KH; Heimbucher, J; Thiede, A; Tigges, H, 1997) |
| "Symptomatic gastroesophageal reflux is a common complication of pregnancy and lactation." | 1.30 | Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation. ( Armstrong, D; Marshall, JK; Thompson, AB, 1998) |
| " The two groups were not different in regard to their symptom frequency and severity before therapy, amount of lansoprazole dosage required to eliminate symptoms, length of Barrett's metaplasia, presence of hiatal hernia, lower esophageal sphincter resting tone and length, or esophageal peristaltic function." | 1.30 | Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. ( Ouatu-Lascar, R; Triadafilopoulos, G, 1998) |
| " Long-term use of proton pump inhibitors may be associated with the presence of small gastric fundic gland polyps and hyperplastic polyps." | 1.30 | Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. ( Boyce, HW; Choudhry, U; Coppola, D, 1998) |
| "Both omeprazole and endoscopy were compared to pH monitoring as the 'gold standard' for the diagnosis of GERD and the cost per correct diagnosis with omeprazole was pound47 (95% CI: pound40- pound59) compared to pound480 (95% CI: pound396- pound608) with endoscopy." | 1.30 | Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease. ( Bate, CM; Chapman, RW; Durnin, AT; Riley, SA; Taylor, MD, 1999) |
| "Only surgery improved regurgitation." | 1.30 | The effect of medical therapy and antireflux surgery on dysphagia in patients with gastroesophageal reflux disease without esophageal stricture. ( Gadenstaetter, M; Glaser, K; Hinder, RA; Profanter, C; Wetscher, GJ, 1999) |
| "Gastroesophageal reflux (GER) plays a causative role in the development of subglottic stenosis (SGS) in children." | 1.30 | Gastroesophageal reflux: A critical factor in pediatric subglottic stenosis. ( Halstead, LA, 1999) |
| "Treatment of gastroesophageal reflux disease (GERD) with modern acid-suppressive agents is supposed to be effective and safe." | 1.30 | Gastroesophageal reflux disease as a cause of death: analysis of fatal cases under conservative treatment. ( Rantanen, TK; Salo, JA, 1999) |
| "The association between GERD and these supraesophageal symptoms may be elusive." | 1.30 | Supraesophageal manifestations of gastroesophageal reflux disease. ( Al-Sabbagh, G; Wo, JM, 1999) |
| "58 patients with gastroesophageal reflux (GER) and 18 patients with chronic gastroduodenitis (CGD) were examined using 24-h monitoring of intraesophageal pH." | 1.30 | [Role of 24 hour intraesophageal pH monitoring in diagnosis of gastroesophageal reflux and assessment of drug effectiveness]. ( Abidin, ZU; Ivashkin, VT; Okhlobystin, AV; Sheptulin, AA; Trukhmanov, AS, 1999) |
| "A total of 172 symptomatic GERD patients completed a 57-item questionnaire (containing the SF-12; symptom frequency/bothersomeness; problems related to activities, sleep, work disability; overall HRQoL; and treatment satisfaction) at baseline, week 1 [retest (N = 25)], and week 4 [follow-up (N = 100)]." | 1.30 | Development of a health-related quality-of-life questionnaire for individuals with gastroesophageal reflux disease: a validation study. ( Colwell, HH; Henning, JM; Hunt, RH; Mathias, SD; Pasta, DJ, 1999) |
| "Those ascribed to gastroesophageal reflux and vocal abuse have a high resolution rate, although some cases need rescue procedures." | 1.30 | Clinical evolution of laryngeal granulomas: treatment and prognosis. ( De Biase, NG; de Lima Pontes, PA; Gadelha, EC, 1999) |
| "The relationship between gastroesophageal reflux disease and these symptoms has been studied but remains unclear." | 1.29 | Role of gastroesophageal reflux disease in patients with cervical symptoms. ( Freeman, J; Goldberg, M; Mendelsohn, M; Rival, R; Rosgen, S; Wong, R, 1995) |
| "Histamine content was significantly greater both in the subjects with higher gastrinemic levels (omeprazole-treated subjects) and those with more abundant enterogastric reflux (Billroth II subjects) than in controls." | 1.29 | Gastric mucosal histamine storing cells. Evidence for different roles of mast cells and enterochromaffin-like cells in humans. ( Amorosi, A; Bacci, S; Bechi, P; Dei, R; Masini, E; Panula, P; Romagnoli, P, 1995) |
| "Although gastro-esophageal reflux (GER) is one of the major causes of chronic persistent cough (CPC) in the USA and in Europe, it is a rare cause of CPC in Japan." | 1.29 | [A case of chronic persistent cough caused by gastro-esophageal reflux]. ( Amemiya, T; Fujimura, M; Matsuda, T; Mizuguchi, M; Nishi, K; Ooka, T, 1995) |
| "Gastroesophageal reflux may be responsible for atypical symptoms such as chronic cough and hoarseness." | 1.29 | Chronic cough and hoarseness in patients with severe gastroesophageal reflux disease. Diagnosis and response to therapy. ( Hunter, J; Katz, E; Lacayo, L; Suwak, B; Waring, JP, 1995) |
| "Baclofen was used as a first treatment in patients without evidence of any gastro-oesophageal disease (n = 17), and was undertaken only after full treatment of such disease (n = 55) had failed to solve the hiccup problem (n = 20)." | 1.29 | Baclofen therapy for chronic hiccup. ( Bizec, JL; Cabane, J; Derenne, JP; Guelaud, C; Similowski, T; Whitelaw, WA, 1995) |
| "The cervical site of dysphagia demonstrated acid-induced hypersensitivity to esophageal distension with water or air." | 1.29 | Unusual presentation of mucosal hypersensitivity secondary to gastroesophageal reflux disease. ( Andres, JM; Baron, TH; Richter, JE; Singh, S; Tennyson, GS, 1993) |
| "Respiratory complications of gastroesophageal reflux disease that have been reported include hoarseness, wheezing, bronchospasm, stridor, laryngitis, and chronic cough." | 1.29 | Gastroesophageal reflux-induced cough syncope. ( Puetz, TR; Vakil, N, 1995) |
| "Documenting abnormal gastroesophageal reflux helps direct appropriate therapy, and proximal pH monitoring may identify patients with pulmonary symptoms who respond to anti-reflux therapy." | 1.29 | Pulmonary symptoms associated with gastroesophageal reflux: use of ambulatory pH monitoring to diagnose and to direct therapy. ( Castell, DO; Castell, JA; Schnatz, PF, 1996) |
| "Patients with gastroesophageal reflux disease (GERD) who remain symptomatic despite receiving a moderate dose of a proton pump inhibitor need accurate assessment to determine who will respond to high doses of the drug or even need surgery." | 1.29 | Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms: testing while on therapy identifies the need for more aggressive anti-reflux therapy. ( Castell, DO; Katzka, DA; Leite, L; Paoletti, V, 1996) |
| "Laryngeal manifestation of gastroesophageal reflux is felt to be prevalent in our society." | 1.29 | Subjective, laryngoscopic, and acoustic measurements of laryngeal reflux before and after treatment with omeprazole. ( Miner, PB; Searl, JP; Shaw, GY; Young, JL, 1996) |
| "Presentation of 7 cases of Gastro-oesophageal Reflux (GOR) detected through the respiratory symptomatology which they manifested." | 1.28 | [Respiratory manifestations and gastroesophageal reflux]. ( Cabratosa, J; Cordón, F; Gómez, F; Jaumá, R; Payola, N, 1992) |
| "Omeprazole was well tolerated, and the incidence of clinical and laboratory adverse experiences was similar in patients receiving omeprazole, placebo, cimetidine, or ranitidine." | 1.28 | Comparative tolerability profile of omeprazole in clinical trials. ( Bradstreet, DC; Simon, TJ, 1991) |
| "As a consequence, pathological gastro-oesophageal reflux occurred, particularly in the supine period." | 1.28 | Combined gastric and oesophageal 24-hour pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole. ( Klinkenberg-Knol, EC; Meuwissen, SG, 1990) |
| "In patients with Barrett's esophagus, LES pressure was considerably lower and percentage exposure to acid was considerably higher than in either patients with esophagitis or controls (p less than 0." | 1.28 | Effect of omeprazole on gastroesophageal reflux in Barrett's esophagus. ( Farroni, F; Fiorucci, S; Morelli, A; Pelli, MA; Santucci, L, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (0.92) | 18.7374 |
| 1990's | 282 (25.99) | 18.2507 |
| 2000's | 637 (58.71) | 29.6817 |
| 2010's | 127 (11.71) | 24.3611 |
| 2020's | 29 (2.67) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, KS | 1 |
| Shah, AK | 1 |
| Bariwal, J | 1 |
| Shelke, SM | 1 |
| Kale, AP | 1 |
| Jagtap, JR | 1 |
| Bhosale, AV | 1 |
| Kim, GS | 1 |
| Nunez, T | 1 |
| Vargas, E | 1 |
| Jayasekara, R | 1 |
| Smith, I | 1 |
| Ghoshal, UC | 1 |
| Blaachandran, A | 1 |
| Rai, S | 1 |
| Misra, A | 1 |
| Vaezi, MF | 5 |
| Brunton, S | 1 |
| Mark Fendrick, A | 1 |
| Howden, CW | 9 |
| Atkinson, C | 1 |
| Pelletier, C | 1 |
| Jacob, R | 1 |
| Spechler, SJ | 5 |
| Barberio, B | 1 |
| Visaggi, P | 1 |
| Savarino, E | 3 |
| de Bortoli, N | 2 |
| Black, CJ | 1 |
| Ford, AC | 1 |
| Frítola, M | 1 |
| Sestario, CS | 1 |
| Martins, CCN | 1 |
| Ezequiel, BS | 1 |
| Morimoto, J | 1 |
| Salles, MJS | 1 |
| Mitchell, TK | 1 |
| Hall, NJ | 1 |
| Yardley, I | 1 |
| Cole, C | 1 |
| Hardy, P | 1 |
| King, A | 1 |
| Murray, D | 1 |
| Nuthall, E | 1 |
| Roehr, C | 1 |
| Stanbury, K | 1 |
| Williams, R | 1 |
| Pearce, J | 1 |
| Woolfall, K | 1 |
| Kasap, E | 1 |
| Buran, T | 1 |
| Toraman Avcu, A | 1 |
| Solmaz Hasdemir, P | 1 |
| Balcan, E | 1 |
| Aktan, Ç | 1 |
| Korkmaz, M | 1 |
| Tighe, MP | 1 |
| Andrews, E | 1 |
| Liddicoat, I | 1 |
| Afzal, NA | 1 |
| Hayen, A | 1 |
| Beattie, RM | 2 |
| Sharma, P | 8 |
| López-Suárez, CM | 1 |
| Abdo-Francis, JM | 1 |
| Okazaki, Y | 1 |
| Kotani, K | 1 |
| Higashi, Y | 1 |
| Bianchi, ET | 1 |
| Guerreiro Cardoso, PF | 1 |
| Minamoto, H | 2 |
| Bibas, BJ | 1 |
| Salati, M | 1 |
| Pego-Fernandes, PM | 2 |
| Hunter, JG | 2 |
| Jones, KM | 1 |
| Lee, R | 1 |
| Smith, BR | 1 |
| Mashimo, H | 1 |
| Sanchez, VM | 1 |
| Dunbar, KB | 2 |
| Pham, TH | 2 |
| Murthy, UK | 1 |
| Kim, T | 1 |
| Jackson, CS | 1 |
| Wallen, JM | 1 |
| von Rosenvinge, EC | 1 |
| Pearl, JP | 1 |
| Laine, L | 2 |
| Kim, AW | 1 |
| Kaz, AM | 1 |
| Tatum, RP | 1 |
| Gellad, ZF | 1 |
| Lagoo-Deenadayalan, S | 1 |
| Rubenstein, JH | 1 |
| Ghaferi, AA | 1 |
| Lo, WK | 1 |
| Fernando, RS | 1 |
| Chan, BS | 1 |
| Paski, SC | 1 |
| Provenzale, D | 1 |
| Castell, DO | 28 |
| Lieberman, D | 1 |
| Souza, RF | 3 |
| Chey, WD | 1 |
| Warren, SR | 1 |
| Davis-Karim, A | 1 |
| Melton, SD | 1 |
| Genta, RM | 2 |
| Serpi, T | 1 |
| Biswas, K | 1 |
| Huang, GD | 1 |
| Shifera, AS | 1 |
| Thélin, CS | 1 |
| Richter, JE | 20 |
| Foocharoen, C | 2 |
| Chunlertrith, K | 2 |
| Mairiang, P | 2 |
| Mahakkanukrauh, A | 2 |
| Suwannaroj, S | 2 |
| Namvijit, S | 2 |
| Wantha, O | 2 |
| Nanagara, R | 2 |
| Gurung, SB | 1 |
| Kc, SR | 1 |
| Gyawali, P | 1 |
| Amatya, GL | 1 |
| Bestebreurtje, P | 1 |
| de Koning, BAE | 1 |
| Roeleveld, N | 1 |
| Knibbe, CAJ | 1 |
| Tibboel, D | 1 |
| van Groen, B | 1 |
| van de Ven, CP | 1 |
| Plötz, FB | 1 |
| de Wildt, SN | 1 |
| Scarpignato, C | 4 |
| Hongo, M | 1 |
| Wu, JCY | 1 |
| Lottrup, C | 1 |
| Lazarescu, A | 1 |
| Stein, E | 1 |
| Hunt, RH | 7 |
| Jadcherla, SR | 1 |
| Hasenstab, KA | 1 |
| Gulati, IK | 1 |
| Helmick, R | 1 |
| Ipek, H | 1 |
| Yildiz, V | 1 |
| Wei, L | 1 |
| Berdnikov, A | 1 |
| McPhee, S | 1 |
| LaBine, L | 1 |
| Fatoye, T | 1 |
| Maret-Ouda, J | 1 |
| Markar, SR | 1 |
| Lagergren, J | 1 |
| Lattey, K | 1 |
| Quinn, S | 1 |
| O'Brien, K | 1 |
| Dziekiewicz, M | 1 |
| Mielus, M | 1 |
| Lisowska, A | 1 |
| Walkowiak, J | 1 |
| Sands, D | 1 |
| Radzikowski, A | 1 |
| Banaszkiewicz, A | 1 |
| Adel Mehraban, MS | 1 |
| Shirzad, M | 1 |
| Ahmadian-Attari, MM | 1 |
| Shakeri, R | 1 |
| Taghizadeh Kashani, LM | 1 |
| Tabarrai, M | 1 |
| Shirbeigi, L | 1 |
| Lotti, F | 1 |
| Twedt, D | 1 |
| Warrit, K | 1 |
| Bryan, S | 1 |
| Vaca, C | 1 |
| Krause, L | 1 |
| Fukushima, K | 1 |
| Boscan, P | 1 |
| Yagoubi, A | 1 |
| Laid, Y | 1 |
| Smati, L | 1 |
| Nafissa Benhalla, K | 1 |
| Benhassine, F | 1 |
| Rehmani, A | 1 |
| Mehta, I | 1 |
| Siu, NY | 1 |
| Smith, E | 1 |
| Zhang, J | 1 |
| Che, H | 1 |
| Zhang, B | 2 |
| Zhang, C | 1 |
| Zhou, B | 1 |
| Ji, H | 1 |
| Xie, J | 1 |
| Shi, X | 1 |
| Li, X | 1 |
| Wang, F | 1 |
| Tang, X | 1 |
| Kim, YD | 1 |
| Wang, J | 2 |
| Shibli, F | 1 |
| Poels, KE | 1 |
| Ganocy, SJ | 1 |
| Fass, R | 17 |
| Garcia, RS | 1 |
| Belafsky, PC | 2 |
| Della Maggiore, A | 1 |
| Osborn, JM | 1 |
| Pypendop, BH | 1 |
| Pierce, T | 1 |
| Walker, VJ | 1 |
| Fulton, A | 1 |
| Marks, SL | 1 |
| Koh, ZY | 1 |
| Lim, SWM | 1 |
| Lim, WS | 1 |
| Miyamoto, S | 1 |
| Kato, M | 2 |
| Matsuda, K | 1 |
| Abiko, S | 1 |
| Tsuda, M | 1 |
| Mizushima, T | 1 |
| Yamamoto, K | 2 |
| Ono, S | 1 |
| Kudo, T | 1 |
| Shimizu, Y | 2 |
| Hatanaka, KC | 1 |
| Tsunematsu, I | 1 |
| Sakamoto, N | 1 |
| Li, ZT | 1 |
| Ji, F | 1 |
| Han, XW | 1 |
| Wang, L | 1 |
| Yue, YQ | 1 |
| Wang, ZG | 1 |
| Semb, S | 1 |
| Helgstrand, F | 1 |
| Hjørne, F | 1 |
| Bytzer, P | 8 |
| Dağlı, Ü | 1 |
| Kalkan, İH | 1 |
| Higuera-de-la-Tijera, F | 1 |
| Lu, B | 1 |
| Zhang, L | 1 |
| Wang, B | 1 |
| Zou, X | 1 |
| Fei, G | 1 |
| Chen, D | 1 |
| Wang, X | 1 |
| Wu, B | 1 |
| Zou, D | 1 |
| Bell, R | 1 |
| Lipham, J | 1 |
| Louie, B | 1 |
| Williams, V | 1 |
| Luketich, J | 1 |
| Hill, M | 1 |
| Richards, W | 1 |
| Dunst, C | 1 |
| Lister, D | 1 |
| McDowell-Jacobs, L | 1 |
| Reardon, P | 1 |
| Woods, K | 1 |
| Gould, J | 1 |
| Buckley, FP | 1 |
| Kothari, S | 1 |
| Khaitan, L | 1 |
| Smith, CD | 1 |
| Park, A | 1 |
| Smith, C | 1 |
| Jacobsen, G | 1 |
| Abbas, G | 1 |
| Katz, P | 3 |
| Waghray, A | 1 |
| Waghray, N | 1 |
| Perzynski, AT | 1 |
| Votruba, M | 1 |
| Wolfe, MM | 1 |
| Graham, DY | 1 |
| Saifullah, AM | 1 |
| Ahmed, F | 1 |
| Shil, BC | 1 |
| Banik, RK | 1 |
| Saha, SK | 1 |
| Chowdhury, M | 1 |
| Haque, A | 1 |
| Alam, MS | 1 |
| Akhter, A | 1 |
| Dutta, P | 1 |
| Funston, W | 1 |
| Mossop, H | 1 |
| Ryan, V | 1 |
| Jones, R | 1 |
| Forbes, R | 1 |
| Sen, S | 1 |
| Pearson, J | 1 |
| Griffin, SM | 1 |
| Smith, JA | 1 |
| Ward, C | 1 |
| Forrest, IA | 1 |
| Simpson, AJ | 1 |
| Shih, YS | 1 |
| Tsai, CH | 1 |
| Li, TC | 1 |
| Yu, CJ | 1 |
| Chou, JW | 1 |
| Feng, CL | 1 |
| Wang, KT | 1 |
| Lai, HC | 1 |
| Hsieh, CL | 1 |
| Kim, JH | 1 |
| Lee, YC | 1 |
| Kim, EH | 1 |
| Park, JC | 1 |
| Shin, SK | 1 |
| Lee, SK | 1 |
| Jung, DH | 1 |
| Park, JJ | 1 |
| Youn, YH | 1 |
| Park, H | 1 |
| Jia, BY | 1 |
| Xie, CE | 1 |
| Wang, ZB | 1 |
| Pei, WJ | 1 |
| Li, XH | 1 |
| Shi, L | 1 |
| Liu, JL | 1 |
| Han, YF | 1 |
| Tan, X | 1 |
| Ding, PH | 1 |
| Sun, ZM | 1 |
| Yuan, WJ | 1 |
| Li, JX | 1 |
| Osadchuk, AM | 1 |
| Davydkin, IL | 1 |
| Khalid, M | 1 |
| Aljurf, M | 1 |
| Saleemi, S | 1 |
| Khan, MQ | 1 |
| Khan, B | 1 |
| Ahmed, S | 1 |
| Ibrahim, Kel T | 1 |
| Mobeireek, A | 1 |
| Al Mohareb, F | 1 |
| Chaudhri, N | 1 |
| Martinucci, I | 1 |
| Giacchino, M | 1 |
| Blandizzi, C | 1 |
| Marchi, S | 1 |
| Savarino, V | 10 |
| Jonasson, C | 1 |
| Tvete, IF | 1 |
| Hatlebakk, JG | 15 |
| Xu, XH | 1 |
| Yang, ZM | 1 |
| Chen, Q | 2 |
| Yu, L | 2 |
| Liang, SW | 1 |
| Lv, HJ | 1 |
| Qiu, ZM | 1 |
| Chiu, CT | 1 |
| Hsu, CM | 1 |
| Wang, CC | 1 |
| Chang, JJ | 1 |
| Sung, CM | 1 |
| Lin, CJ | 1 |
| Chen, LW | 1 |
| Su, MY | 1 |
| Chen, TH | 1 |
| Nagahara, A | 3 |
| Hojo, M | 1 |
| Asaoka, D | 2 |
| Sasaki, H | 1 |
| Watanabe, S | 1 |
| Nannapaneni, S | 1 |
| Olson, E | 1 |
| Ramar, K | 1 |
| Zamora, Z | 1 |
| Molina, V | 1 |
| Mas, R | 1 |
| Ravelo, Y | 1 |
| Perez, Y | 1 |
| Oyarzabal, A | 1 |
| Sachs, G | 4 |
| Shin, JM | 4 |
| Munson, K | 1 |
| Scott, DR | 1 |
| Xu, X | 2 |
| Yang, Z | 1 |
| Liang, S | 1 |
| Lü, H | 1 |
| Qiu, Z | 1 |
| Yamaji, Y | 1 |
| Isomura, Y | 1 |
| Yoshida, S | 2 |
| Yamada, A | 1 |
| Hirata, Y | 1 |
| Koike, K | 1 |
| Nakahara, K | 1 |
| Fujiwara, Y | 2 |
| Tsukahara, T | 1 |
| Yamagami, H | 1 |
| Tanigawa, T | 1 |
| Shiba, M | 1 |
| Tominaga, K | 2 |
| Watanabe, T | 2 |
| Urade, Y | 1 |
| Arakawa, T | 3 |
| Chu, MP | 1 |
| Ghosh, S | 1 |
| Chambers, CR | 1 |
| Basappa, N | 1 |
| Butts, CA | 1 |
| Chu, Q | 1 |
| Fenton, D | 1 |
| Joy, AA | 1 |
| Sangha, R | 1 |
| Smylie, M | 1 |
| Sawyer, MB | 1 |
| Iurenev, GL | 2 |
| Sirota, NA | 1 |
| Dicheva, DT | 2 |
| Bitkova, EN | 1 |
| Maev, IV | 8 |
| Alwan, W | 1 |
| Banerjee, P | 1 |
| White, IR | 1 |
| Kahrilas, PJ | 12 |
| Bell, RC | 1 |
| Wilson, EB | 1 |
| Trad, KS | 1 |
| Dolan, JP | 1 |
| Perry, KA | 1 |
| Oelschlager, BK | 1 |
| Soper, NJ | 1 |
| Snyder, BE | 1 |
| Burch, MA | 1 |
| Melvin, WS | 1 |
| Reavis, KM | 1 |
| Turgeon, DG | 1 |
| Hungness, ES | 1 |
| Diggs, BS | 1 |
| Popadynets', IR | 1 |
| Zeng, W | 1 |
| Finlayson, AE | 1 |
| Shankar, S | 1 |
| de Bruyn, W | 1 |
| Godman, B | 1 |
| Walker, D | 1 |
| Ng Kwet Shing, R | 1 |
| Jones, D | 1 |
| Gruss, HJ | 1 |
| Reguła, J | 1 |
| Takeuchi, T | 1 |
| Oota, K | 1 |
| Harada, S | 1 |
| Edogawa, S | 1 |
| Kojima, Y | 1 |
| Sanomura, M | 1 |
| Sakaguchi, M | 1 |
| Hayashi, K | 1 |
| Hongoh, Y | 1 |
| Itabashi, T | 1 |
| Kitae, H | 1 |
| Hoshimoto, M | 1 |
| Takeuchi, N | 1 |
| Higuchi, K | 2 |
| Attwood, SE | 2 |
| Ell, C | 2 |
| Galmiche, JP | 10 |
| Fiocca, R | 4 |
| Hasselgren, B | 1 |
| Långström, G | 1 |
| Jahreskog, M | 1 |
| Eklund, S | 2 |
| Lind, T | 11 |
| Lundell, L | 17 |
| Teng, M | 1 |
| Khoo, AL | 1 |
| Zhao, YJ | 1 |
| Lin, L | 2 |
| Lim, BP | 1 |
| Wu, TS | 1 |
| Dan, YY | 1 |
| Toseef, MU | 1 |
| Saeed, A | 1 |
| Mohi-Ud-Din, E | 1 |
| Usmanghani, K | 1 |
| Nazar, H | 1 |
| Nawaz, A | 1 |
| Ahmad, I | 1 |
| Siddiqui, FA | 1 |
| Zohalinezhad, ME | 2 |
| Hosseini-Asl, MK | 1 |
| Akrami, R | 1 |
| Nimrouzi, M | 1 |
| Salehi, A | 2 |
| Zarshenas, MM | 1 |
| Waldum, HL | 3 |
| Hauso, Ø | 1 |
| Fossmark, R | 2 |
| Qi, Q | 1 |
| Wang, R | 1 |
| Liu, L | 1 |
| Zhao, F | 1 |
| Wang, S | 2 |
| Del Gaudio, P | 1 |
| De Cicco, F | 1 |
| Sansone, F | 1 |
| Aquino, RP | 1 |
| Adami, R | 1 |
| Ricci, M | 1 |
| Giovagnoli, S | 1 |
| Goel, R | 1 |
| Anggiansah, A | 4 |
| Wong, T | 1 |
| Wilkinson, M | 1 |
| Kim, HJ | 1 |
| Kwon, CI | 1 |
| Kessler, WR | 1 |
| Selzer, DJ | 1 |
| McNulty, G | 1 |
| Bapaye, A | 1 |
| Bonavina, L | 1 |
| Lehman, GA | 1 |
| Asghar, W | 1 |
| Pittman, E | 1 |
| Jamali, F | 1 |
| Imanieh, MH | 1 |
| Samani, SM | 1 |
| Mohagheghzadeh, A | 1 |
| Dehghani, SM | 1 |
| Haghighat, M | 1 |
| Faridi, P | 1 |
| Akbarzadeh, AR | 1 |
| Abdul-Hussein, M | 1 |
| Freeman, J | 2 |
| Castell, D | 3 |
| Treudler, R | 1 |
| Reuter, A | 1 |
| Engin, AM | 1 |
| Simon, JC | 1 |
| Tobin, E | 1 |
| Pokharel, S | 1 |
| Haqqie, S | 1 |
| Asif, A | 1 |
| Agoston, AT | 1 |
| Odze, RD | 1 |
| Huo, X | 2 |
| Cipher, DJ | 1 |
| Jiang, L | 1 |
| Ye, B | 1 |
| Wang, Y | 1 |
| Wang, M | 1 |
| Sun, S | 1 |
| Cui, Z | 1 |
| Zhou, M | 1 |
| Li, R | 1 |
| Li, H | 2 |
| Zhang, S | 1 |
| Ba, Y | 1 |
| Cheng, G | 1 |
| Chen, L | 1 |
| Chen, Y | 3 |
| Li, B | 1 |
| Emken, BG | 1 |
| Lundell, LR | 1 |
| Wallin, L | 5 |
| Myrvold, HE | 9 |
| Engström, C | 2 |
| Montgomery, M | 2 |
| Malm, AR | 1 |
| Modak, AS | 1 |
| Klyarytska, I | 1 |
| Kriviy, V | 1 |
| Tsapyak, T | 1 |
| Rabotyagova, Y | 1 |
| Kaguelidou, F | 1 |
| Alberti, C | 1 |
| Biran, V | 1 |
| Bourdon, O | 1 |
| Farnoux, C | 1 |
| Zohar, S | 1 |
| Jacqz-Aigrain, E | 1 |
| Muenster, M | 1 |
| Hoerauf, A | 1 |
| Vieth, M | 2 |
| Koak, Y | 1 |
| Davies, SE | 1 |
| Winslet, M | 1 |
| Garrean, CP | 1 |
| Zhang, Q | 3 |
| Gonsalves, N | 1 |
| Hirano, I | 2 |
| Brozek, JL | 1 |
| Guyatt, GH | 1 |
| Heels-Ansdell, D | 1 |
| Degl'Innocenti, A | 1 |
| Armstrong, D | 12 |
| Fallone, CA | 1 |
| Wiklund, I | 6 |
| van Zanten, SV | 2 |
| Chiba, N | 1 |
| Barkun, AN | 1 |
| Akl, EA | 1 |
| Schünemann, HJ | 1 |
| McKeage, K | 1 |
| Blick, SK | 1 |
| Croxtall, JD | 1 |
| Lyseng-Williamson, KA | 1 |
| Keating, GM | 1 |
| Johnson, DA | 5 |
| Katz, PO | 22 |
| Xue, Y | 1 |
| Zhou, LY | 1 |
| Lin, SR | 1 |
| Achem, SR | 3 |
| Ballard, ED | 3 |
| Koch, FK | 2 |
| Gautille, TC | 2 |
| Bagin, RG | 2 |
| Tafuri, G | 1 |
| Trotta, F | 1 |
| Leufkens, HG | 1 |
| Martini, N | 1 |
| Sagliocca, L | 1 |
| Traversa, G | 1 |
| Uemura, N | 1 |
| Inokuchi, H | 1 |
| Serizawa, H | 1 |
| Chikama, T | 1 |
| Yamauchi, M | 1 |
| Tsuru, T | 1 |
| Umezu, T | 1 |
| Urata, T | 1 |
| Yurino, N | 1 |
| Tanabe, S | 1 |
| Yoshida, T | 1 |
| Kawamura, S | 1 |
| Murakami, A | 1 |
| Yamamoto, M | 2 |
| Chiba, T | 1 |
| Klotz, U | 3 |
| Mori, H | 1 |
| Tonai-Kachi, H | 1 |
| Ochi, Y | 1 |
| Taniguchi, Y | 1 |
| Ohshiro, H | 1 |
| Takahashi, N | 2 |
| Aihara, T | 1 |
| Hirao, A | 1 |
| Kato, T | 1 |
| Sakakibara, M | 1 |
| Kurebayashi, Y | 1 |
| Songür, N | 1 |
| Songür, Y | 1 |
| Cerci, SS | 1 |
| Oztürk, O | 1 |
| Sahin, U | 1 |
| Senol, A | 1 |
| Yarktaş, MH | 1 |
| Hao, J | 2 |
| Liu, B | 2 |
| Lee, M | 1 |
| Hao, X | 1 |
| Reuhl, KR | 1 |
| Chen, X | 2 |
| Yang, CS | 2 |
| Kim, GH | 1 |
| Beck, J | 1 |
| Zheng, RN | 1 |
| Sopo, SM | 1 |
| Radzik, D | 1 |
| Calvani, M | 1 |
| Pellicano, R | 1 |
| Ntaios, G | 1 |
| Chatzinikolaou, A | 1 |
| Kaiafa, G | 1 |
| Savopoulos, C | 1 |
| Hatzitolios, A | 1 |
| Karamitsos, D | 1 |
| Asano, K | 1 |
| Suzuki, H | 2 |
| Gwee, KA | 1 |
| Teng, L | 1 |
| Wong, RK | 1 |
| Ho, KY | 1 |
| Sutedja, DS | 1 |
| Yeoh, KG | 1 |
| Moretzsohn, LD | 1 |
| Carvalho, EB | 1 |
| Franco, JD | 1 |
| Soares, MP | 1 |
| Brito, EM | 1 |
| Belarmino, K | 1 |
| Coelho, LG | 1 |
| McColl, KE | 3 |
| Gillen, D | 1 |
| Miettinen, P | 8 |
| Julkunen, R | 3 |
| Malm, A | 3 |
| Walan, A | 6 |
| Gasiorowska, A | 1 |
| Navarro-Rodriguez, T | 3 |
| Wendel, C | 3 |
| Krupinski, E | 1 |
| Perry, ZH | 1 |
| Koenig, K | 1 |
| Moty, B | 1 |
| Powers, J | 1 |
| Vashani, K | 1 |
| Murugesh, M | 1 |
| Hattiangadi, G | 1 |
| Gore, G | 1 |
| Keer, V | 1 |
| Ramesh, VS | 1 |
| Sandur, V | 1 |
| Bhatia, SJ | 1 |
| Cohen, H | 1 |
| Tomasso, G | 1 |
| Luisa Cafferata, M | 1 |
| Zapata, C | 1 |
| Moraes-Filho, JP | 3 |
| Blasco, C | 1 |
| Corti, R | 1 |
| Estape, G | 1 |
| Leite Luna, L | 1 |
| Ortuño, R | 1 |
| Sakai, P | 1 |
| Salis, G | 1 |
| Taullard, D | 1 |
| Trakal, E | 1 |
| Valdovinos, M | 1 |
| Vergara, M | 1 |
| Gónzalez, O | 1 |
| Broeders, JA | 1 |
| Draaisma, WA | 1 |
| Bredenoord, AJ | 1 |
| de Vries, DR | 1 |
| Rijnhart-de Jong, HG | 1 |
| Smout, AJ | 4 |
| Gooszen, HG | 1 |
| Krishnamurthy, M | 1 |
| Snyder, R | 1 |
| Bachurina, M | 1 |
| Wong, H | 1 |
| Yau, T | 1 |
| Chan, P | 1 |
| Ng, IO | 1 |
| Chan, G | 1 |
| Hui, P | 1 |
| Law, WL | 1 |
| Lo, CM | 1 |
| Hedley, AJ | 1 |
| Epstein, RJ | 1 |
| Chang, CG | 1 |
| Perez, E | 1 |
| Molloy, D | 1 |
| Molloy, A | 1 |
| O'Loughlin, C | 1 |
| Falconer, M | 1 |
| Hennessy, M | 1 |
| Otten, MH | 2 |
| Lekkerkerker, JF | 1 |
| Mulder, CJ | 2 |
| Panti, A | 1 |
| Bennett, RC | 1 |
| Corletto, F | 1 |
| Brearley, J | 1 |
| Jeffery, N | 1 |
| Jeffrey, N | 1 |
| Mellanby, RJ | 1 |
| Reiche, I | 1 |
| Tröger, U | 1 |
| Martens-Lobenhoffer, J | 1 |
| Kandulski, A | 2 |
| Neumann, H | 1 |
| Malfertheiner, P | 6 |
| Bode-Böger, SM | 1 |
| Hoogendoorn, RJ | 1 |
| Groeneveld, L | 1 |
| Kwee, JA | 1 |
| Wo, JM | 4 |
| Eversmann, J | 1 |
| Mann, S | 1 |
| Futagami, S | 1 |
| Iwakiri, K | 1 |
| Shindo, T | 1 |
| Kawagoe, T | 1 |
| Horie, A | 1 |
| Shimpuku, M | 1 |
| Tanaka, Y | 3 |
| Kawami, N | 1 |
| Gudis, K | 1 |
| Sakamoto, C | 1 |
| Kandil, TS | 1 |
| Mousa, AA | 1 |
| El-Gendy, AA | 1 |
| Abbas, AM | 1 |
| Miner, PB | 11 |
| McKean, LA | 1 |
| Gibb, RD | 1 |
| Erasala, GN | 1 |
| Ramsey, DL | 1 |
| McRorie, JW | 1 |
| Riscili, BP | 1 |
| Parsons, JP | 1 |
| Mastronarde, JG | 1 |
| de Leone, A | 2 |
| Tonini, M | 2 |
| Dominici, P | 2 |
| Grossi, E | 2 |
| Pace, F | 7 |
| Onuchina, EV | 1 |
| Brikova, SI | 1 |
| Rozhanskiĭ, AA | 1 |
| Kazakova, RV | 1 |
| Poshkaĭte, IA | 1 |
| Peshkov, DV | 1 |
| Bushkova, EV | 1 |
| Tsukanov, VV | 1 |
| Mankia, SK | 1 |
| Rytina, E | 1 |
| Burrows, NP | 1 |
| Ebell, MH | 1 |
| Velez, LI | 1 |
| Feng, SY | 1 |
| Neerman, MF | 1 |
| Blokpoel, RG | 1 |
| Broos, N | 1 |
| de Jong-van den Berg, LT | 1 |
| de Vries, TW | 1 |
| Zendehdel, N | 2 |
| Biramijamal, F | 1 |
| Hossein-Nezhad, A | 1 |
| Sarie, H | 1 |
| Doughaiemoghaddam, M | 1 |
| Pourshams, A | 1 |
| Illueca, M | 2 |
| Wernersson, B | 2 |
| Henderson, C | 1 |
| Lundborg, P | 4 |
| Hunt, R | 1 |
| Jonaitis, L | 3 |
| Kupčinskas, J | 1 |
| Kiudelis, G | 2 |
| Kupčinskas, L | 4 |
| Giannikoulis, C | 1 |
| Karkoulias, K | 1 |
| Thomopoulos, K | 1 |
| Marangos, M | 1 |
| Spiropoulos, K | 1 |
| Nikolopoulou, V | 2 |
| Spiegel, BM | 1 |
| Soifer, L | 1 |
| Pedrana, R | 1 |
| Parrota, M | 1 |
| Gadea, O | 1 |
| Naisberg, G | 2 |
| Caruso, N | 2 |
| Miwa, H | 2 |
| Inoue, K | 2 |
| Ashida, K | 2 |
| Kogawa, T | 1 |
| Tano, N | 2 |
| Yamazaki, Y | 2 |
| Wada, T | 2 |
| Fujita, T | 1 |
| Tanaka, J | 1 |
| Shimatani, T | 3 |
| Manabe, N | 3 |
| Oshima, T | 2 |
| Haruma, K | 5 |
| Azuma, T | 2 |
| Yokoyama, T | 1 |
| Triadafilopoulos, G | 5 |
| Lombard, CM | 1 |
| Jobe, BA | 1 |
| Miehlke, S | 1 |
| Löbe, S | 1 |
| Madisch, A | 1 |
| Kuhlisch, E | 1 |
| Laass, M | 1 |
| Grossmann, D | 1 |
| Knoth, H | 1 |
| Morgner, A | 1 |
| Labenz, J | 4 |
| Chandra, S | 1 |
| Dutta, U | 1 |
| Noor, MT | 1 |
| Taneja, N | 1 |
| Kochhar, R | 1 |
| Sharma, M | 2 |
| Singh, K | 1 |
| Dzhamaldinova, TD | 1 |
| Bjornsson, E | 2 |
| Lord, RV | 1 |
| Riegler, G | 1 |
| van der Pol, RJ | 1 |
| Smits, MJ | 1 |
| van Wijk, MP | 1 |
| Omari, TI | 2 |
| Tabbers, MM | 1 |
| Benninga, MA | 1 |
| Tsuzuki, T | 1 |
| Okada, H | 2 |
| Kawahara, Y | 2 |
| Takenaka, R | 1 |
| Nasu, J | 1 |
| Ishioka, H | 1 |
| Fujiwara, A | 1 |
| Yoshinaga, F | 1 |
| Hughes, N | 1 |
| Sá, CC | 1 |
| Kishi, HS | 1 |
| Silva-Werneck, AL | 1 |
| Eisig, JN | 2 |
| Barbuti, RC | 1 |
| Hashimoto, CL | 1 |
| Monyak, JT | 1 |
| Zentilin, P | 2 |
| Dal-Paz, K | 1 |
| Barbuti, R | 1 |
| Quigley, EM | 3 |
| Orsi, M | 1 |
| Donato, G | 1 |
| Busoni, V | 1 |
| Yurtsever, AS | 1 |
| Pektas, M | 1 |
| Ozkur, M | 1 |
| Un, I | 1 |
| Erenmemisoglu, A | 1 |
| Buyukafsar, K | 1 |
| Coudsy, B | 1 |
| DeLemos, B | 1 |
| Sun, Y | 1 |
| Xiang, J | 1 |
| LoCoco, J | 1 |
| Casalini, S | 2 |
| Pelosini, I | 1 |
| Koivusalo, AI | 1 |
| Pakarinen, MP | 1 |
| Wikström, A | 1 |
| Rintala, RJ | 1 |
| Matok, I | 1 |
| Levy, A | 1 |
| Wiznitzer, A | 1 |
| Uziel, E | 1 |
| Koren, G | 3 |
| Gorodischer, R | 1 |
| Ito, M | 1 |
| Takasugi, H | 1 |
| Wada, Y | 1 |
| Nakata, H | 1 |
| Katoh, T | 1 |
| Miyamoto, M | 1 |
| Tanaka, S | 2 |
| Ndraha, S | 1 |
| Huk, J | 1 |
| Wiktor, W | 1 |
| Pedowski, T | 1 |
| Masiak, W | 1 |
| Wallner, G | 1 |
| Aro, P | 1 |
| Ronkainen, J | 1 |
| Gladu, RH | 1 |
| Hawkins, CA | 1 |
| Gerson, LB | 4 |
| Mitra, S | 1 |
| Bleker, WF | 1 |
| Yeung, P | 1 |
| Pouchain, D | 1 |
| Bigard, MA | 8 |
| Liard, F | 1 |
| Childs, M | 1 |
| Decaudin, A | 1 |
| McVey, D | 1 |
| Sakurai, K | 1 |
| Akiyama, J | 1 |
| Mabe, K | 1 |
| Suzuki, J | 3 |
| Habu, Y | 2 |
| Araki, A | 1 |
| Suzuki, T | 1 |
| Satoh, K | 1 |
| Nagami, H | 1 |
| Harada, R | 1 |
| Kusaka, M | 1 |
| Fujioka, Y | 1 |
| Fujimura, T | 2 |
| Shigeto, N | 1 |
| Oumi, T | 1 |
| Miwa, J | 1 |
| Fujimoto, K | 3 |
| Kinoshita, Y | 3 |
| Cheng, E | 1 |
| Zhang, X | 1 |
| Yu, C | 1 |
| Wang, DH | 1 |
| Adamko, DJ | 1 |
| Majaesic, CM | 1 |
| Skappak, C | 1 |
| Jones, AB | 2 |
| Joshaghani, H | 1 |
| Amiriani, T | 1 |
| Vaghari, G | 1 |
| Besharat, S | 1 |
| Molana, A | 1 |
| Badeleh, M | 1 |
| Roshandel, G | 1 |
| Wasilewska, J | 1 |
| Semeniuk, J | 1 |
| Cudowska, B | 1 |
| Klukowski, M | 1 |
| Dębkowska, K | 1 |
| Kaczmarski, M | 1 |
| Mattsson, H | 1 |
| Reimer, C | 1 |
| Miyashita, T | 1 |
| Shah, FA | 1 |
| Harmon, JW | 1 |
| Marti, GP | 1 |
| Matsui, D | 1 |
| Okamoto, K | 1 |
| Makino, I | 1 |
| Hayashi, H | 1 |
| Oyama, K | 1 |
| Nakagawara, H | 1 |
| Tajima, H | 1 |
| Fujita, H | 1 |
| Takamura, H | 1 |
| Murakami, M | 1 |
| Ninomiya, I | 1 |
| Kitagawa, H | 1 |
| Fushida, S | 1 |
| Ohta, T | 1 |
| Hudson, B | 1 |
| Alderton, A | 1 |
| Doocey, C | 1 |
| Nicholson, D | 1 |
| Toop, L | 1 |
| Day, AS | 1 |
| Willmer, C | 1 |
| Baker, DE | 2 |
| Johnsson, F | 4 |
| Moum, B | 3 |
| Vilien, M | 1 |
| Grove, O | 1 |
| Simren, M | 2 |
| Thoring, M | 1 |
| Scholte, GH | 1 |
| van Doorn, LJ | 1 |
| Cats, A | 1 |
| Bloemena, E | 5 |
| Lindeman, J | 4 |
| Quint, WG | 1 |
| Meuwissen, SG | 15 |
| Kuipers, EJ | 17 |
| Nikfar, S | 1 |
| Abdollahi, M | 1 |
| Moretti, ME | 1 |
| Magee, LA | 1 |
| Damiano, A | 2 |
| Handley, K | 1 |
| Adler, E | 1 |
| Siddique, R | 4 |
| Bhattacharyja, A | 1 |
| Nzeako, UC | 1 |
| Murray, JA | 1 |
| Vanderhoff, BT | 1 |
| Tahboub, RM | 1 |
| Hong, D | 1 |
| Kamath, M | 1 |
| Tabet, J | 1 |
| Tougas, G | 2 |
| Anvari, M | 3 |
| Kawano, S | 1 |
| Murata, H | 1 |
| Tsuji, S | 1 |
| Kubo, M | 1 |
| Tatsuta, M | 1 |
| Iishi, H | 1 |
| Kanda, T | 1 |
| Sato, T | 1 |
| Yoshihara, H | 1 |
| Masuda, E | 1 |
| Noguchi, M | 2 |
| Kashio, S | 1 |
| Ikeda, M | 1 |
| Kaneko, A | 1 |
| Talley, NJ | 4 |
| Venables, TL | 3 |
| Green, JR | 3 |
| O'Kane, KP | 1 |
| Giaffer, M | 1 |
| Bardhan, KD | 9 |
| Carlsson, RG | 1 |
| Chen, S | 1 |
| Hasselgren, GS | 1 |
| Kazim, F | 1 |
| Gervais, M | 1 |
| Pyzyk, M | 4 |
| Hall, J | 1 |
| Dodd, S | 1 |
| Durkin, M | 1 |
| Sloan, S | 13 |
| Rodríguez-Téllez, M | 1 |
| Galera-Ruiz, H | 1 |
| Argüelles-Arias, F | 1 |
| Carmona, I | 1 |
| Muñoz-Borje, F | 1 |
| Herrerías, JM | 1 |
| Dobashi, K | 3 |
| Kocsis, I | 1 |
| Arató, A | 1 |
| Bodánszky, H | 1 |
| Szönyi, L | 1 |
| Szabó, A | 1 |
| Tulassay, T | 1 |
| Vásárhelyi, B | 1 |
| Nyrén, O | 1 |
| Johnson, M | 1 |
| Guilford, S | 1 |
| Libretto, SE | 1 |
| Vasil'ev, IuV | 1 |
| Noskova, KK | 1 |
| Zelenikin, SA | 1 |
| Pandak, WM | 1 |
| Arezo, S | 1 |
| Everett, S | 1 |
| Jesse, R | 1 |
| DeCosta, G | 1 |
| Crofts, T | 1 |
| Gennings, C | 1 |
| Siuta, M | 1 |
| Zfass, A | 1 |
| Busarova, GA | 3 |
| Samsonov, AA | 1 |
| Agapova, NR | 1 |
| O'Morain, CA | 2 |
| Qasim, A | 1 |
| Moore, MG | 1 |
| Sprogis, A | 1 |
| Katelaris, P | 1 |
| Furuta, T | 4 |
| Shirai, N | 4 |
| Watanabe, F | 1 |
| Honda, S | 1 |
| Takeuchi, K | 1 |
| Iida, T | 3 |
| Sato, Y | 1 |
| Kajimura, M | 1 |
| Futami, H | 1 |
| Takayanagi, S | 1 |
| Yamada, M | 1 |
| Ohashi, K | 2 |
| Ishizaki, T | 4 |
| Hanai, H | 1 |
| Poelmans, J | 3 |
| Tack, J | 5 |
| Feenstra, L | 3 |
| Habermann, W | 3 |
| Kiesler, K | 2 |
| Eherer, A | 2 |
| Friedrich, G | 3 |
| Yacyshyn, BR | 1 |
| Thomson, AB | 3 |
| Basu, KK | 2 |
| Bale, R | 1 |
| West, KP | 1 |
| de Caestecker, JS | 3 |
| Louis, E | 2 |
| Frissora, C | 1 |
| Johanson, JF | 1 |
| Damiano, AM | 1 |
| Jokubaitis, L | 5 |
| Murthy, A | 2 |
| Bhattacharjya, A | 1 |
| Kovacs, TO | 2 |
| Wilcox, CM | 1 |
| DeVault, K | 2 |
| Miska, D | 1 |
| Bochenek, W | 3 |
| Pribuisiene, R | 2 |
| Uloza, V | 2 |
| Cheer, SM | 1 |
| Prakash, A | 1 |
| Faulds, D | 2 |
| Lamb, HM | 1 |
| Dabney-Smith, K | 1 |
| Nam, J | 1 |
| Ghazale, A | 1 |
| Cai, Q | 1 |
| Sontag, SJ | 2 |
| Patel, AS | 1 |
| Pohl, JF | 1 |
| Easley, DJ | 1 |
| Scott, LJ | 4 |
| Pérez Prim, FJ | 1 |
| Vila, I | 1 |
| Wepner, U | 1 |
| Frazzoni, M | 4 |
| De Micheli, E | 4 |
| Grisendi, A | 4 |
| Haag, S | 1 |
| Holtmann, G | 3 |
| Thjodleifsson, B | 4 |
| Rindi, G | 2 |
| Humphries, TJ | 8 |
| Morocutti, A | 3 |
| Miller, N | 3 |
| Xia, HH | 2 |
| Lai, KC | 2 |
| Lam, SK | 2 |
| Hu, WH | 2 |
| Wong, NY | 2 |
| Hui, WM | 2 |
| Lau, CP | 1 |
| Chen, WH | 1 |
| Chan, CK | 1 |
| Wong, WM | 2 |
| Wong, BC | 3 |
| Siupsinskiene, N | 3 |
| Adamonis, K | 2 |
| Delve, P | 1 |
| Lau, M | 1 |
| Yun, K | 1 |
| Walker, R | 1 |
| Tolia, V | 5 |
| Fitzgerald, J | 2 |
| Hassall, E | 9 |
| Huang, B | 6 |
| Pilmer, B | 2 |
| Kane, R | 1 |
| Ferry, G | 1 |
| Gunasekaran, T | 3 |
| Keith, R | 2 |
| Book, L | 2 |
| Gupta, S | 1 |
| Gremse, D | 4 |
| Karol, M | 2 |
| Pan, WJ | 2 |
| Chiu, YL | 3 |
| Winter, H | 1 |
| Dent, J | 9 |
| Poe, RH | 1 |
| Kallay, MC | 1 |
| O'Leary, C | 1 |
| McCarthy, J | 1 |
| Humphries, M | 1 |
| Shanahan, F | 1 |
| Quigley, E | 1 |
| Pallotta, S | 1 |
| Bianchi Porro, G | 6 |
| Cordes, A | 1 |
| Vogt, W | 1 |
| Maier, KP | 1 |
| Ours, TM | 3 |
| Fackler, WK | 2 |
| Gardner, JD | 9 |
| Robinson, M | 16 |
| Kawamura, M | 1 |
| Ohara, S | 1 |
| Koike, T | 1 |
| Iijima, K | 1 |
| Kayaba, S | 1 |
| Noguchi, K | 1 |
| Hamada, S | 2 |
| Shimosegawa, T | 1 |
| Numans, ME | 1 |
| de Wit, NJ | 1 |
| Moazzez, R | 1 |
| Bartlett, D | 1 |
| Jiang, SP | 1 |
| Liang, RY | 1 |
| Zeng, ZY | 1 |
| Liu, QL | 1 |
| Liang, YK | 1 |
| Li, JG | 1 |
| Scheid, SC | 1 |
| Anderson, TD | 1 |
| Sataloff, RT | 2 |
| Klintenberg, AC | 1 |
| Román, J | 2 |
| Toth, E | 1 |
| Stubberöd, A | 3 |
| Falk, A | 1 |
| Edin, R | 1 |
| Johanson, J | 3 |
| Körner, T | 2 |
| Schütze, K | 2 |
| van Leendert, RJ | 1 |
| Fumagalli, I | 2 |
| Costa Neves, B | 1 |
| Bohuschke, M | 2 |
| Gatz, G | 2 |
| Pohland, CJ | 1 |
| Scavnicky, SA | 1 |
| Lasky, SS | 1 |
| Good, CB | 1 |
| van Hout, BA | 1 |
| Klok, RM | 1 |
| Brouwers, JR | 1 |
| Postma, MJ | 1 |
| Chevalier, JM | 1 |
| Brossard, E | 1 |
| Monnier, P | 1 |
| Paré, P | 3 |
| Meyer, F | 1 |
| Pericak, D | 3 |
| Goeree, R | 1 |
| Nayyar, AK | 1 |
| Royston, C | 1 |
| Sarnelli, G | 1 |
| Ierardi, E | 1 |
| Grasso, R | 1 |
| Verde, C | 1 |
| Bottiglieri, ME | 1 |
| Nardone, G | 1 |
| Budillon, G | 1 |
| Cuomo, R | 2 |
| Vakil, N | 3 |
| Tsugeno, H | 1 |
| Mizuno, M | 1 |
| Fujiki, S | 1 |
| Okamoto, M | 1 |
| Hosaki, Y | 1 |
| Ashida, S | 1 |
| Mitsunobu, F | 1 |
| Tanizaki, Y | 1 |
| Shiratori, Y | 1 |
| Eherer, AJ | 1 |
| Hammer, HF | 1 |
| Krejs, GJ | 1 |
| Kamolz, T | 1 |
| Pointner, R | 2 |
| Velanovich, V | 2 |
| Bilgen, C | 1 |
| Ogüt, F | 1 |
| Kesimli-Dinç, H | 1 |
| Kirazli, T | 1 |
| Bor, S | 1 |
| Galli, J | 1 |
| Scarano, S | 1 |
| Agostino, S | 1 |
| Quaranta, N | 1 |
| Cammarota, G | 2 |
| Ottaviani, F | 1 |
| Sasaki, A | 1 |
| Yoshihara, M | 1 |
| Chayama, K | 1 |
| Orr, WC | 5 |
| Harnish, MJ | 1 |
| Laheij, RJ | 2 |
| Van Rossum, LG | 1 |
| Jansen, JB | 2 |
| Verheugt, FW | 1 |
| Prasad, M | 1 |
| Rentz, AM | 1 |
| Revicki, DA | 3 |
| Hellström, PM | 1 |
| Vitols, S | 1 |
| Ricciardi, L | 1 |
| Fedele, R | 1 |
| Mazzeo, L | 1 |
| Saitta, S | 1 |
| Mancuso, V | 1 |
| Isola, S | 1 |
| Koek, GH | 1 |
| Sifrim, D | 2 |
| Lerut, T | 1 |
| Janssens, J | 2 |
| Moore, DJ | 1 |
| Tao, BS | 1 |
| Lines, DR | 1 |
| Hirte, C | 1 |
| Heddle, ML | 1 |
| Davidson, GP | 2 |
| Inadomi, JM | 2 |
| McIntyre, L | 1 |
| Bernard, L | 1 |
| Fendrick, AM | 2 |
| Shaw, MJ | 1 |
| Crawley, JA | 2 |
| Viuchnova, ES | 1 |
| Balashova, NN | 2 |
| Shchekina, MI | 2 |
| Wang, YR | 1 |
| Pauly, MV | 1 |
| Lin, YA | 1 |
| Pehlivanov, ND | 1 |
| Olyaee, M | 1 |
| Sarosiek, I | 1 |
| McCallum, RW | 1 |
| Gallo-Torres, H | 1 |
| Marchetti, F | 1 |
| Gerarduzzi, T | 1 |
| Ventura, A | 1 |
| Kucheriavyĭ, IuA | 1 |
| Danilin, MS | 1 |
| Starostin, BD | 1 |
| Starostina, GA | 1 |
| Barbato, A | 1 |
| Panizzolo, C | 1 |
| Landi, L | 1 |
| Semenzato, R | 1 |
| Rugge, M | 2 |
| Zodet, MW | 2 |
| Joshua-Gotlib, S | 1 |
| Levine, D | 2 |
| Füessl, HS | 3 |
| Borjesson, M | 1 |
| Rolny, P | 1 |
| Mannheimer, C | 1 |
| Pilhall, M | 1 |
| Miyawaki, S | 1 |
| Tanimoto, Y | 1 |
| Araki, Y | 1 |
| Katayama, A | 1 |
| Fujii, A | 1 |
| Takano-Yamamoto, T | 1 |
| Ivashkin, VT | 2 |
| Trukhmanov, AS | 2 |
| Chang, FY | 2 |
| Lu, CL | 2 |
| Chen, CY | 2 |
| Luo, JC | 1 |
| Jiun, KL | 1 |
| Lee, SD | 2 |
| Wu, HC | 1 |
| Nelis, GF | 4 |
| Klinkenberg-Knol, EC | 19 |
| Snel, P | 5 |
| Goldfain, D | 1 |
| Kolkman, JJ | 1 |
| Festen, HP | 7 |
| Zeitoun, P | 1 |
| Havu, N | 4 |
| Lamm, M | 5 |
| Miner, P | 4 |
| Sostek, M | 1 |
| Garrigues, V | 2 |
| Gisbert, L | 1 |
| Bastida, G | 2 |
| Ortiz, V | 3 |
| Bau, I | 1 |
| Nos, P | 2 |
| Ponce, J | 7 |
| Weusten, BL | 1 |
| Exalto, N | 1 |
| Wu, JC | 2 |
| Chan, FK | 2 |
| Ching, JY | 1 |
| Leung, WK | 2 |
| Hui, Y | 1 |
| Leong, R | 1 |
| Chung, SC | 1 |
| Sung, JJ | 2 |
| Urbach, DR | 1 |
| Ungar, WJ | 1 |
| Rabeneck, L | 1 |
| Ra, A | 1 |
| Tobe, SW | 1 |
| Marier, JF | 1 |
| Dubuc, MC | 1 |
| Drouin, E | 2 |
| Alvarez, F | 1 |
| Ducharme, MP | 1 |
| Brazier, JL | 1 |
| Junghard, O | 13 |
| Carlsson, R | 7 |
| Juul-Hansen, P | 3 |
| Rydning, A | 4 |
| Mattioli, G | 1 |
| Sacco, O | 1 |
| Gentilino, V | 1 |
| Martino, F | 1 |
| Pini Prato, A | 1 |
| Castagnetti, M | 1 |
| Montobbio, G | 1 |
| Jasonni, V | 1 |
| van Grieken, NC | 2 |
| Meijer, GA | 2 |
| Kale, I | 1 |
| Offerhaus, GJ | 1 |
| Baak, JP | 2 |
| Kivioja, A | 1 |
| Linnosmaa, I | 1 |
| Vehviläinen, A | 1 |
| Vohlonen, I | 1 |
| Rifas, DC | 1 |
| Lam, KF | 1 |
| Huang, JQ | 1 |
| Lam, CL | 1 |
| Chan, AO | 1 |
| Chubenko, SS | 1 |
| Gaĭdukov, VO | 1 |
| Agibalov, AN | 1 |
| Onishenko, AV | 1 |
| Cury, EK | 1 |
| Schraibman, V | 1 |
| Faintuch, S | 1 |
| Cezard, JP | 1 |
| Peitz, U | 1 |
| Raps, S | 1 |
| Plein, K | 2 |
| Leodolter, A | 3 |
| Hotz Dagger, J | 1 |
| Pehl, C | 1 |
| Boccali, I | 1 |
| Hennig, M | 1 |
| Schepp, W | 1 |
| Shaikh, MG | 1 |
| Anderson, JM | 1 |
| Neafsey, P | 1 |
| Zimmerman, J | 1 |
| Andersson, T | 3 |
| Alfonzo, CA | 1 |
| Bobo, WV | 1 |
| Almond, MD | 1 |
| Weber, R | 4 |
| Williams, RB | 1 |
| Szczesniak, MM | 1 |
| Maclean, JC | 1 |
| Brake, HM | 1 |
| Cole, IE | 1 |
| Cook, IJ | 1 |
| Sarela, AI | 1 |
| Hick, DG | 1 |
| Verbeke, CS | 1 |
| Casey, JF | 1 |
| Guillou, PJ | 1 |
| Clark, GW | 1 |
| Kountouras, J | 1 |
| Zavos, C | 1 |
| Chatzopoulos, D | 1 |
| Bautista, J | 1 |
| Fullerton, H | 1 |
| Briseno, M | 1 |
| Cui, H | 2 |
| Gillessen, A | 2 |
| Di Mario, F | 1 |
| Ingegnoli, A | 1 |
| Dal Bò, N | 1 |
| Cavestro, GM | 1 |
| Moussa, AM | 1 |
| Cavallaro, LG | 1 |
| Aragona, G | 1 |
| Iori, V | 1 |
| Pilotto, A | 1 |
| Franzè, A | 1 |
| Modlin, I | 1 |
| Kidd, M | 1 |
| Singh, G | 1 |
| Czerwionka-Szaflarska, M | 2 |
| Mierzwa, G | 1 |
| Kuczyńska, R | 1 |
| Torregrosa, E | 1 |
| Rovira, RE | 1 |
| Calvo, C | 1 |
| Hernández-Jaras, J | 1 |
| Maduell, F | 1 |
| García, H | 1 |
| Blum, A | 1 |
| De Herdt, D | 1 |
| Dubois, D | 2 |
| van Zyl, J | 1 |
| van Rensburg, C | 1 |
| Vieweg, W | 1 |
| Fischer, R | 2 |
| Muramatsu, A | 1 |
| Okajima, T | 1 |
| Ohtani, M | 1 |
| Dojo, M | 1 |
| Kuriyama, M | 1 |
| Lauritsen, K | 7 |
| Tunturi-Hihnala, H | 2 |
| Venables, T | 1 |
| Green, J | 2 |
| Mössner, J | 2 |
| Madsen, LG | 1 |
| Wit, NJ | 1 |
| Boer, WA | 1 |
| Geldof, H | 1 |
| Hazelhoff, B | 1 |
| Bergmans, P | 1 |
| Tytgat, GN | 5 |
| Argüello, L | 1 |
| Ponce, M | 1 |
| Lim, PW | 2 |
| Goh, KL | 4 |
| Swiatkowski, M | 2 |
| Budzyński, J | 2 |
| Kłopocka, M | 2 |
| Pulkowski, G | 2 |
| Suppan, K | 2 |
| Fabisiak, J | 2 |
| Morawski, W | 1 |
| Majer, M | 2 |
| Fraga, P | 1 |
| Mack, M | 1 |
| Sabesin, SM | 1 |
| Shimoyama, Y | 3 |
| Kuribayashi, S | 2 |
| Maeda, M | 2 |
| Kusano, M | 3 |
| Takahashi, M | 1 |
| Nishiki, R | 1 |
| Ichimura, H | 1 |
| Takada, H | 1 |
| Kuwayama, H | 2 |
| Takeda, H | 1 |
| Yoshino, T | 1 |
| Shio, S | 1 |
| Hayakumo, T | 1 |
| Kawai, K | 1 |
| Hoshino, E | 2 |
| Ishiyama, A | 1 |
| Tsuchida, T | 1 |
| Röhss, K | 3 |
| Wilder-Smith, C | 1 |
| Güliter, S | 1 |
| Kandilci, U | 1 |
| Hong, SP | 1 |
| Park, PW | 1 |
| Hwang, SG | 1 |
| Ko, KH | 1 |
| Kwak, SY | 1 |
| Kim, SH | 1 |
| Kwon, KS | 1 |
| Shin, YW | 1 |
| Ryu, JK | 1 |
| Ryu, KH | 1 |
| Park, SJ | 1 |
| Won, WH | 1 |
| Yoo, HM | 1 |
| Bae, HM | 1 |
| Park, MJ | 1 |
| Woo, YK | 1 |
| Kim, KC | 1 |
| Kim, KH | 1 |
| Na, SH | 1 |
| Kim, JW | 1 |
| Jaspersen, D | 7 |
| Sarkar, S | 1 |
| Thompson, DG | 1 |
| Woolf, CJ | 1 |
| Hobson, AR | 1 |
| Millane, T | 1 |
| Aziz, Q | 1 |
| Khavkin, AI | 1 |
| Zhikhareva, NS | 1 |
| Rachkova, NS | 1 |
| Babaian, ML | 1 |
| Volynets, GV | 1 |
| Khanakaeva, ZK | 1 |
| Steward, DL | 2 |
| Wilson, KM | 1 |
| Kelly, DH | 1 |
| Patil, MS | 1 |
| Schwartzbauer, HR | 1 |
| Long, JD | 1 |
| Welge, JA | 1 |
| Hill, RK | 1 |
| Simpson, CB | 1 |
| Velazquez, R | 1 |
| Larson, N | 1 |
| Freston, JW | 2 |
| Kollmeier, AP | 1 |
| Eddleston, J | 1 |
| Zuraw, BL | 1 |
| Christiansen, SC | 1 |
| Horn, J | 1 |
| Patterson, RN | 1 |
| Johnston, BT | 6 |
| MacMahon, J | 1 |
| Heaney, LG | 1 |
| McGarvey, LP | 1 |
| Tamhankar, AP | 1 |
| Peters, JH | 1 |
| Portale, G | 1 |
| Hsieh, CC | 1 |
| Hagen, JA | 1 |
| Bremner, CG | 1 |
| DeMeester, TR | 1 |
| Lussi, A | 1 |
| Jaeggi, T | 1 |
| Minushkin, ON | 2 |
| Maslovskiĭ, LV | 2 |
| Anikina, NIu | 2 |
| Ivanov, AN | 1 |
| Iakovenko, EP | 1 |
| Iakovenko, AV | 1 |
| Livzan, MA | 1 |
| Kononov, AV | 1 |
| Bochenek, WJ | 1 |
| Mack, ME | 1 |
| Fraga, PD | 1 |
| Metz, DC | 4 |
| Madan, K | 1 |
| Ahuja, V | 1 |
| Kashyap, PC | 1 |
| Sharma, MP | 1 |
| Yamaguchi, T | 1 |
| Mukai, S | 1 |
| Kinoshita, E | 1 |
| Ohtani, H | 1 |
| Sawada, Y | 1 |
| Sawabata, N | 1 |
| Maeda, H | 1 |
| Takeda, S | 1 |
| Inoue, M | 2 |
| Koma, M | 1 |
| Tokunaga, T | 1 |
| Matsuda, H | 1 |
| Nocon, M | 1 |
| Kulig, M | 1 |
| Willich, SN | 1 |
| Goodrich, S | 1 |
| Robert, J | 1 |
| Johnsen, G | 1 |
| Johanessen, E | 1 |
| Diav-Citrin, O | 1 |
| Arnon, J | 1 |
| Shechtman, S | 1 |
| Schaefer, C | 1 |
| van Tonningen, MR | 1 |
| Clementi, M | 1 |
| De Santis, M | 1 |
| Robert-Gnansia, E | 1 |
| Valti, E | 1 |
| Malm, H | 1 |
| Ornoy, A | 1 |
| Lehmann, FS | 1 |
| Beglinger, C | 1 |
| Velasco, MJ | 1 |
| Fiedorek, S | 1 |
| Gold, BD | 1 |
| Stolle, J | 1 |
| Lee, C | 1 |
| Calabrese, C | 3 |
| Bortolotti, M | 2 |
| Fabbri, A | 2 |
| Areni, A | 2 |
| Cenacchi, G | 1 |
| Scialpi, C | 2 |
| Miglioli, M | 1 |
| Di Febo, G | 3 |
| Paleev, NR | 1 |
| Isakov, VA | 2 |
| Ivanova, OV | 1 |
| Chung, KF | 1 |
| Kosel, BW | 1 |
| Storey, SS | 1 |
| Collier, AC | 1 |
| Morozov, SV | 1 |
| Tsodikova, OM | 1 |
| Tereshchenko, SG | 1 |
| Gushchin, AE | 1 |
| Shipulin, GA | 1 |
| Calleja, JL | 1 |
| Suarez, M | 1 |
| De Tejada, AH | 1 |
| Navarro, A | 1 |
| Todd, JA | 1 |
| Bergman, MP | 1 |
| Faller, G | 1 |
| Aar, A | 1 |
| Lakhai, W | 1 |
| Vandenbroucke-Grauls, CM | 1 |
| Appelmelk, BJ | 1 |
| Jacobs, A | 1 |
| Taghavi, SA | 1 |
| Ghasedi, M | 1 |
| Saberi-Firoozi, M | 1 |
| Alizadeh-Naeeni, M | 1 |
| Bagheri-Lankarani, K | 1 |
| Kaviani, MJ | 1 |
| Hamidpour, L | 1 |
| Featherstone, EA | 1 |
| Archimandritis, AJ | 1 |
| Kouklakis, G | 1 |
| Paraskevas, E | 1 |
| Avgerinos, A | 2 |
| Tsianos, E | 1 |
| Triantafillidis, JK | 1 |
| Oh, DS | 1 |
| Ohning, GV | 1 |
| Pisegna, JR | 3 |
| Shuleshova, AG | 1 |
| Ohkusa, T | 1 |
| Maekawa, T | 1 |
| Nakajima, M | 1 |
| Mitachi, Y | 1 |
| Mine, T | 1 |
| Nagai, T | 1 |
| Aoyama, N | 1 |
| Yoshida, N | 1 |
| Tadokoro, K | 1 |
| Chida, N | 1 |
| Konda, Y | 1 |
| Seno, H | 1 |
| Sato, N | 1 |
| Sasaki, M | 1 |
| Kataoka, H | 1 |
| Tanida, S | 1 |
| Itoh, K | 1 |
| Ogasawara, N | 1 |
| Togawa, S | 1 |
| Kubota, E | 1 |
| Yamada, T | 1 |
| Mori, Y | 1 |
| Fujita, F | 1 |
| Ohara, H | 1 |
| Nakao, H | 1 |
| Sobue, S | 1 |
| Joh, T | 1 |
| Itoh, M | 1 |
| Nebiki, H | 1 |
| Chono, S | 1 |
| Uno, H | 1 |
| Kitada, K | 1 |
| Satoh, H | 1 |
| Nakagawa, K | 1 |
| Kobayashi, K | 1 |
| Oshitani, N | 1 |
| Bagin, R | 1 |
| Goldlust, B | 1 |
| Major, J | 1 |
| Hepburn, B | 1 |
| Adachi, K | 1 |
| Hashimoto, T | 1 |
| Komazawa, Y | 1 |
| Mihara, T | 1 |
| Furuta, K | 1 |
| Fujishiro, H | 1 |
| Ishihara, S | 1 |
| Amano, Y | 1 |
| Hattori, S | 1 |
| Gawrońska-Szklarz, B | 1 |
| Wrześniewska, J | 1 |
| Starzyńska, T | 1 |
| Pawlik, A | 1 |
| Safranow, K | 1 |
| Ferenc, K | 1 |
| Droździk, M | 1 |
| Sugimoto, M | 2 |
| Nakamura, A | 1 |
| Hishida, A | 1 |
| Park, W | 1 |
| Hicks, DM | 2 |
| Khandwala, F | 1 |
| Abelson, TI | 1 |
| Milstein, C | 1 |
| Gopal, B | 1 |
| Singhal, P | 1 |
| Gaur, SN | 1 |
| Rammer, M | 1 |
| Kirchgatterer, A | 1 |
| Höbling, W | 1 |
| Knoflach, P | 1 |
| Isaev, VA | 1 |
| Annese, V | 1 |
| Prada, A | 4 |
| Zambelli, A | 1 |
| Nardini, P | 1 |
| Raghunath, AS | 1 |
| O'Morain, C | 1 |
| McLoughlin, RC | 1 |
| Caos, A | 2 |
| Breiter, J | 2 |
| Perdomo, C | 6 |
| Barth, J | 4 |
| Kaspari, S | 2 |
| Heinze, H | 1 |
| Berghöfer, P | 1 |
| Hritz, I | 1 |
| Herszenyi, L | 2 |
| Molnar, B | 1 |
| Tulassay, Z | 2 |
| Pronai, L | 1 |
| Dimarino, AJ | 1 |
| Banwait, KS | 1 |
| Eschinger, E | 1 |
| Greenberg, A | 1 |
| Dimarino, M | 1 |
| Doghramji, K | 1 |
| Cohen, S | 1 |
| Yüksel, H | 1 |
| Yilmaz, O | 1 |
| Kirmaz, C | 1 |
| Aydoğdu, S | 1 |
| Kasirga, E | 1 |
| Mine, S | 2 |
| Tabata, T | 2 |
| Kishikawa, H | 1 |
| Størdal, K | 1 |
| Johannesdottir, GB | 1 |
| Bentsen, BS | 1 |
| Knudsen, PK | 1 |
| Carlsen, KC | 1 |
| Closs, O | 1 |
| Handeland, M | 1 |
| Holm, HK | 1 |
| Sandvik, L | 1 |
| Scholten, T | 1 |
| Dekkers, CP | 2 |
| Sgouros, SN | 3 |
| Vlachogiannakos, J | 2 |
| Karamanolis, G | 1 |
| Vassiliadis, K | 2 |
| Stefanidis, G | 2 |
| Bergele, C | 2 |
| Papadopoulou, E | 1 |
| Mantides, A | 3 |
| Dobrzycki, S | 1 |
| Baniukiewicz, A | 1 |
| Korecki, J | 1 |
| Bachórzewska-Gajewska, H | 1 |
| Prokopczuk, P | 1 |
| Musial, WJ | 1 |
| Kamiński, KA | 1 |
| Dabrowski, A | 1 |
| Mantani, N | 1 |
| Ito, K | 1 |
| Kogure, T | 1 |
| Hoshino, A | 1 |
| Kawada, E | 1 |
| Sakamoto, H | 1 |
| Fujita, K | 1 |
| Tamura, J | 1 |
| Littner, MR | 1 |
| Leung, FW | 1 |
| Samra, NK | 1 |
| Dickman, R | 1 |
| Emmons, S | 1 |
| Sewell, J | 1 |
| Hernández, D | 1 |
| Esquivel, RF | 1 |
| Wani, S | 1 |
| Sampliner, RE | 10 |
| Weston, AP | 1 |
| Mathur, S | 1 |
| Hall, M | 1 |
| Higbee, A | 1 |
| Genestin, E | 1 |
| Oda, K | 1 |
| Iwakiri, R | 1 |
| Hara, M | 1 |
| Watanabe, K | 1 |
| Danjo, A | 1 |
| Shimoda, R | 1 |
| Kikkawa, A | 1 |
| Ootani, A | 1 |
| Sakata, H | 1 |
| Tsunada, S | 1 |
| Ulualp, S | 1 |
| Brodsky, L | 1 |
| Halstead, LA | 2 |
| Croom, KF | 1 |
| Remák, E | 1 |
| Brown, RE | 1 |
| Yuen, C | 1 |
| Robinson, A | 1 |
| Mao, L | 1 |
| Shikiar, R | 1 |
| Flood, E | 1 |
| Howell, J | 1 |
| Dodd, SL | 1 |
| Gentilini, L | 1 |
| Morselli, C | 1 |
| Giovannini, M | 1 |
| Pandolfino, JE | 1 |
| Sereg-Bahar, M | 1 |
| Jansa, R | 1 |
| Hocevar-Boltezar, I | 1 |
| Hansen, RA | 1 |
| Shaheen, NJ | 1 |
| Schommer, JC | 1 |
| Peura, DA | 1 |
| Liu, XH | 1 |
| Ke, MY | 1 |
| Song, ZQ | 1 |
| Luo, JY | 1 |
| Yuan, YZ | 1 |
| Hou, XH | 1 |
| Zhu, YL | 1 |
| Sun, J | 1 |
| Zha, H | 1 |
| Giral, A | 1 |
| Celikel, CA | 1 |
| Ozdogan, O | 1 |
| Tözün, N | 1 |
| Ulusoy, NB | 1 |
| Kalayci, C | 1 |
| Hofmann, U | 2 |
| Schwab, M | 2 |
| Treiber, G | 2 |
| Schaeffeler, E | 1 |
| Esteller, E | 1 |
| Modolell, I | 1 |
| Segarra, F | 1 |
| Matiño, E | 1 |
| Enrique, A | 1 |
| Ademà, JM | 1 |
| Estivill, E | 1 |
| Park, SH | 1 |
| Stavroulaki, P | 1 |
| Talwar, V | 1 |
| Barer, GM | 1 |
| Pustovoĭt, EV | 1 |
| Polikanova, EN | 1 |
| Burkov, SG | 2 |
| Gurenev, GL | 1 |
| Zahlane, D | 1 |
| Hata, M | 1 |
| Shiono, M | 1 |
| Sekino, H | 1 |
| Furukawa, H | 1 |
| Sezai, A | 1 |
| Iida, M | 1 |
| Yoshitake, I | 1 |
| Hattori, T | 1 |
| Wakui, S | 1 |
| Taoka, M | 1 |
| Negishi, N | 1 |
| Sezai, Y | 1 |
| Baldi, F | 1 |
| Cappiello, R | 1 |
| Cavoli, C | 1 |
| Ghersi, S | 1 |
| Torresan, F | 1 |
| Roda, E | 1 |
| Ludwig, C | 1 |
| Young, W | 2 |
| Levander, K | 6 |
| Liedman, B | 4 |
| Karkos, PD | 1 |
| Wilson, JA | 1 |
| DeVault, KR | 4 |
| Dettmar, PW | 2 |
| Sykes, J | 1 |
| Little, SL | 2 |
| Bryan, J | 1 |
| Wong, CH | 2 |
| Chua, CJ | 1 |
| Liam, CK | 1 |
| Geevasinga, N | 1 |
| Coleman, PL | 1 |
| Webster, AC | 1 |
| Roger, SD | 1 |
| Orel, R | 1 |
| Brecelj, J | 1 |
| Homan, M | 1 |
| Heuschkel, R | 1 |
| Bishop, PR | 1 |
| Tsou, VM | 1 |
| Soffer, EF | 1 |
| Comer, GM | 1 |
| Schmitt, C | 2 |
| Lightdale, CJ | 2 |
| Hwang, C | 3 |
| Hamelin, B | 5 |
| Canani, RB | 1 |
| Cirillo, P | 1 |
| Roggero, P | 1 |
| Romano, C | 2 |
| Malamisura, B | 1 |
| Terrin, G | 2 |
| Passariello, A | 1 |
| Manguso, F | 2 |
| Morelli, L | 1 |
| Guarino, A | 1 |
| Gunaratnam, NT | 1 |
| Jessup, TP | 1 |
| Inadomi, J | 1 |
| Lascewski, DP | 1 |
| des Varannes, SB | 2 |
| Sacher-Huvelin, S | 1 |
| Vavasseur, F | 1 |
| Masliah, C | 1 |
| Le Rhun, M | 2 |
| Aygalenq, P | 1 |
| Bonnot-Marlier, S | 1 |
| Lequeux, Y | 1 |
| Gupta, SK | 1 |
| Amer, F | 1 |
| Heyman, MB | 1 |
| Castro Fernández, M | 1 |
| García Díaz, E | 1 |
| Larraona, JL | 1 |
| Rodríguez Hornillo, MC | 1 |
| Lamas Rojas, E | 1 |
| Núñez Hospital, D | 1 |
| Pallarés Querol, M | 1 |
| Menon, MS | 1 |
| Al-Hajji, M | 1 |
| Morice, A | 1 |
| Kobayashi, S | 1 |
| Ohki, I | 1 |
| Tokushima, M | 1 |
| Kawamura, O | 2 |
| Utsugi, M | 1 |
| Sunaga, N | 1 |
| Ishizuka, T | 1 |
| Mori, M | 2 |
| Davis, S | 1 |
| Kshirsagar, NA | 1 |
| Hampson, FC | 1 |
| Jain, A | 1 |
| Choubey, S | 1 |
| Baxter, T | 1 |
| Demirkan, K | 1 |
| Bozkurt, B | 1 |
| Karakaya, G | 1 |
| Kalyoncu, AF | 1 |
| Campanozzi, A | 2 |
| Capano, G | 1 |
| Miele, E | 2 |
| Romano, A | 1 |
| Scuccimarra, G | 1 |
| Del Giudice, E | 1 |
| Strisciuglio, C | 1 |
| Militerni, R | 1 |
| Staiano, A | 2 |
| Monini, S | 1 |
| Di Stadio, A | 1 |
| Vestri, A | 1 |
| Barbara, M | 1 |
| Zerbib, F | 2 |
| Roman, S | 1 |
| Ropert, A | 1 |
| Pouderoux, P | 1 |
| Chaput, U | 1 |
| Mion, F | 1 |
| Vérin, E | 1 |
| Kobayashi, T | 1 |
| Asahina, K | 1 |
| Inoue, S | 1 |
| Kabemura, T | 1 |
| Kurosawa, S | 1 |
| Hirayama, M | 1 |
| Kiyama, S | 1 |
| Matsumoto, K | 1 |
| Aoshima, M | 1 |
| Robb-Nicholson, C | 1 |
| Sato, A | 1 |
| Tanifuji, Y | 1 |
| Kobayashi, H | 1 |
| Inoue, H | 1 |
| Garcia, I | 1 |
| Krishna, P | 1 |
| Rosen, CA | 1 |
| Pratha, V | 2 |
| Hogan, DL | 2 |
| Lynn, RB | 1 |
| Field, B | 1 |
| Giannini, EG | 1 |
| Testa, R | 1 |
| Teraishi, F | 1 |
| Fujiwara, T | 1 |
| Jikuhara, A | 1 |
| Kamitani, S | 1 |
| Morino, Y | 1 |
| Sato, K | 1 |
| Tanaka, N | 1 |
| Eryuksel, E | 1 |
| Dogan, M | 1 |
| Golabi, P | 1 |
| Sehitoglu, MA | 1 |
| Celikel, T | 1 |
| Anandasabapathy, S | 1 |
| Jaffin, BW | 1 |
| Pereira, Rde S | 1 |
| Abrahamsson, H | 1 |
| Mattsson, N | 1 |
| Jensen, C | 1 |
| Agerforz, P | 1 |
| Kilander, A | 1 |
| Koopman, J | 1 |
| Harrell, SP | 1 |
| Parker, K | 1 |
| Winstead, W | 1 |
| Lentsch, E | 1 |
| Mönnikes, H | 1 |
| Kennerly, P | 1 |
| Ravic, M | 1 |
| Brørs, O | 1 |
| Gerson, L | 1 |
| Friday, K | 1 |
| Kolos, P | 1 |
| Babb, RR | 1 |
| Sohn, YH | 1 |
| Lee, WS | 2 |
| Park, CH | 1 |
| Joo, YE | 1 |
| Kim, HS | 1 |
| Choi, SK | 1 |
| Rew, JS | 1 |
| Kim, SJ | 1 |
| Burns, RB | 1 |
| Mehta, S | 1 |
| Bennett, J | 1 |
| Mahon, D | 1 |
| Rhodes, M | 1 |
| Guimarães, EV | 1 |
| Marguet, C | 1 |
| Camargos, PA | 1 |
| Haslam, RR | 1 |
| Samoliński, B | 1 |
| Allgood, LD | 1 |
| Grender, JM | 1 |
| Checani, GC | 1 |
| Pratha, VS | 1 |
| Sutherland, I | 1 |
| Kuipers, E | 1 |
| Poe, DS | 1 |
| Grimmer, JF | 1 |
| Metson, R | 1 |
| Kerr, W | 1 |
| El-Serag, HB | 3 |
| Wertheimer, AI | 1 |
| Wilson, JM | 1 |
| Duggan, AE | 1 |
| Boccia, G | 1 |
| Buonavolontà, R | 1 |
| Toohill, RJ | 1 |
| De Giorgi, F | 1 |
| Savarese, MF | 1 |
| Atteo, E | 1 |
| Leone, CA | 1 |
| Lassen, AT | 2 |
| Ferrari, M | 1 |
| Benini, L | 1 |
| Brotto, E | 1 |
| Locatelli, F | 1 |
| De Iorio, F | 1 |
| Bonella, F | 1 |
| Tacchella, N | 1 |
| Corradini, G | 1 |
| Lo Cascio, V | 1 |
| Vantini, I | 1 |
| Butt, MI | 2 |
| Sajid, S | 2 |
| Sobolewski, S | 2 |
| Nagoshi, A | 1 |
| Zai, H | 1 |
| Moki, F | 1 |
| Horikoshi, T | 1 |
| Toki, M | 1 |
| Sugimoto, S | 1 |
| Miyoshi, R | 1 |
| Yasunaga, Y | 1 |
| Kizu, T | 1 |
| Inoue, T | 1 |
| Watanabe, C | 1 |
| Matsumoto, Y | 1 |
| Katata, T | 1 |
| Inui, Y | 1 |
| Kohro, T | 1 |
| Nishikawa, M | 1 |
| Xu, HR | 1 |
| Bo, P | 1 |
| Yuan, Y | 1 |
| Okuyama, K | 1 |
| Saito, N | 1 |
| Kume, E | 1 |
| Noto, T | 1 |
| Nagasaki, M | 1 |
| Haas, SJ | 1 |
| Kiley, CA | 1 |
| Cragin, DJ | 1 |
| Roth, BJ | 1 |
| Sharma, B | 1 |
| Daga, MK | 1 |
| Sachdev, GK | 1 |
| Bondi, E | 1 |
| Baldassarre, E | 1 |
| Sagaon, MM | 1 |
| Ferrarini, A | 1 |
| Bianchetti, MG | 1 |
| Beckerling, A | 1 |
| Braun, W | 1 |
| Sommer, M | 1 |
| V'iuchnova, ES | 2 |
| Tsimmerman, IaS | 1 |
| Vologzhanina, LG | 1 |
| Wiklund, IK | 1 |
| Halling, K | 1 |
| Bishop, J | 1 |
| Furman, M | 1 |
| Thomson, M | 1 |
| Brazowski, J | 1 |
| Tuleu, C | 1 |
| Arenas-Lopez, S | 1 |
| Robinson, C | 1 |
| McCarthy, D | 1 |
| Paget, RI | 1 |
| Tibby, S | 1 |
| Taylor, KM | 1 |
| Lombardi, G | 1 |
| de' Angelis, G | 1 |
| Rutigliano, V | 1 |
| Guariso, G | 1 |
| Falchetti, D | 1 |
| Pittschieler, K | 1 |
| Brunero, M | 1 |
| Lerro, P | 1 |
| Sabbi, T | 1 |
| Pepe, G | 1 |
| De Venuto, D | 1 |
| Torroni, F | 1 |
| Bizzarri, B | 1 |
| Di Nicola, M | 1 |
| Di Mascio, R | 1 |
| Dall'Oglio, L | 1 |
| Hoffman, I | 1 |
| Tertychnyy, A | 1 |
| Ectors, N | 1 |
| De Greef, T | 1 |
| Haesendonck, N | 1 |
| Young, P | 2 |
| Finn, BC | 1 |
| Bruetman, JE | 1 |
| Trimarchi, H | 1 |
| Janiak, P | 1 |
| Thumshirn, M | 2 |
| Menne, D | 2 |
| Fox, M | 1 |
| Halim, S | 1 |
| Fried, M | 2 |
| Brühlmann, P | 1 |
| Distler, O | 1 |
| Schwizer, W | 2 |
| Butkus, E | 1 |
| Nasseri-Moghaddam, S | 1 |
| Razjouyan, H | 1 |
| Alimohamadi, SM | 1 |
| Mamarabadi, M | 1 |
| Ghotbi, MH | 1 |
| Mostajabi, P | 1 |
| Sohrabpour, AA | 1 |
| Sotoudeh, M | 1 |
| Abedi, B | 1 |
| Mofid, A | 1 |
| Nouraie, M | 1 |
| Tofangchiha, S | 1 |
| Malekzadeh, R | 1 |
| Barron, JJ | 1 |
| Tan, H | 1 |
| Spalding, J | 1 |
| Bakst, AW | 1 |
| Singer, J | 1 |
| García Rodríguez, LA | 1 |
| Ruigómez, A | 1 |
| Panés, J | 1 |
| Wykypiel, H | 2 |
| Hugl, B | 1 |
| Gadenstaetter, M | 3 |
| Bonatti, H | 1 |
| Bodner, J | 1 |
| Wetscher, GJ | 5 |
| Cundy, T | 1 |
| Dissanayake, A | 1 |
| Hatlebakk, J | 3 |
| Pai, V | 1 |
| Pai, N | 1 |
| Pérez-Manauta, J | 1 |
| Antoniou, SA | 1 |
| Delivorias, P | 1 |
| Antoniou, GA | 1 |
| Natsiopoulos, I | 1 |
| Kalambakas, A | 1 |
| Dalenbäck, J | 2 |
| Makridis, C | 1 |
| Terra, RM | 1 |
| de Medeiros, IL | 1 |
| Nasi, A | 1 |
| Jatene, FB | 1 |
| Sabharwal, T | 1 |
| Gulati, MS | 1 |
| Fotiadis, N | 1 |
| Dourado, R | 1 |
| Botha, A | 1 |
| Mason, R | 1 |
| Adam, A | 1 |
| Wiles, MB | 1 |
| Yaghoobi, M | 1 |
| James, C | 1 |
| Leonard, J | 1 |
| Lee, E | 2 |
| Tang-Liu, D | 1 |
| Liguori, G | 1 |
| Gabusi, V | 1 |
| Gionchetti, P | 1 |
| Rizzello, F | 1 |
| Straforini, G | 1 |
| Brugnera, R | 1 |
| Sahbaie, P | 1 |
| Poo, JL | 1 |
| Galán, JF | 1 |
| Rosete, A | 1 |
| de Lago, A | 1 |
| Oliva, I | 1 |
| González-de la Parra, M | 1 |
| Jiménez, P | 1 |
| Burke-Fraga, V | 1 |
| Namur, S | 1 |
| Mouly, S | 1 |
| Charlemagne, A | 1 |
| Le Jeunne, P | 1 |
| Fagnani, F | 1 |
| Hammar, CH | 3 |
| Draf, W | 3 |
| Leite, LP | 3 |
| Rival, R | 1 |
| Wong, R | 1 |
| Mendelsohn, M | 1 |
| Rosgen, S | 1 |
| Goldberg, M | 1 |
| Just, RJ | 2 |
| Lagerström, PO | 1 |
| Bechi, P | 1 |
| Romagnoli, P | 1 |
| Panula, P | 1 |
| Dei, R | 1 |
| Bacci, S | 1 |
| Amorosi, A | 1 |
| Masini, E | 1 |
| Bardou, M | 2 |
| Mallet, L | 1 |
| Terris, G | 1 |
| Hanson, DG | 1 |
| Kamel, PL | 2 |
| Minocha, A | 1 |
| Joseph, AS | 1 |
| Bough, ID | 1 |
| Hills, JR | 1 |
| Gideon, RM | 3 |
| Spiegel, JR | 1 |
| Allen, C | 1 |
| Borm, A | 1 |
| Schindlbeck, NE | 1 |
| Klauser, AG | 1 |
| Voderholzer, WA | 1 |
| Müller-Lissner, SA | 1 |
| Nishi, K | 1 |
| Amemiya, T | 1 |
| Mizuguchi, M | 1 |
| Ooka, T | 1 |
| Fujimura, M | 1 |
| Matsuda, T | 1 |
| Collen, MJ | 2 |
| Strong, RM | 2 |
| Waring, JP | 3 |
| Lacayo, L | 1 |
| Hunter, J | 1 |
| Katz, E | 1 |
| Suwak, B | 1 |
| Schulman, MI | 1 |
| Orlando, RC | 2 |
| Marshall, JB | 1 |
| Stolte, M | 4 |
| Bethke, B | 1 |
| Seifert, E | 4 |
| Armbrecht, U | 2 |
| Lütke, A | 1 |
| Goldbrunner, P | 1 |
| Rabast, U | 1 |
| Guelaud, C | 1 |
| Similowski, T | 1 |
| Bizec, JL | 1 |
| Cabane, J | 1 |
| Whitelaw, WA | 1 |
| Derenne, JP | 1 |
| Teare, JP | 1 |
| Spedding, C | 1 |
| Whitehead, MW | 1 |
| Greenfield, SM | 1 |
| Challacombe, SJ | 1 |
| Thompson, RP | 1 |
| Paoletti, V | 2 |
| Timmer, R | 1 |
| Breumelhof, R | 1 |
| Nadorp, JH | 1 |
| Cederberg, C | 1 |
| Halter, F | 2 |
| Howden, C | 1 |
| Marks, IN | 1 |
| Rune, S | 2 |
| Walt, RP | 1 |
| Jayanthi, V | 1 |
| Shankar, VR | 1 |
| Kaplan, B | 2 |
| Koppelo, KL | 2 |
| Fuchs, KH | 2 |
| Engemann, R | 1 |
| Thiede, A | 2 |
| Florent, C | 1 |
| Dobrilla, G | 2 |
| Di Fede, F | 1 |
| Lee, MG | 1 |
| Meier, JH | 1 |
| McNally, PR | 1 |
| Punja, M | 1 |
| Freeman, SR | 1 |
| Sudduth, RH | 1 |
| Stocker, N | 1 |
| Perry, M | 1 |
| Spaulding, HS | 1 |
| Mackel, C | 1 |
| Just, R | 1 |
| Katzka, DA | 3 |
| Ford, GA | 1 |
| Oliver, PS | 1 |
| Prior, JS | 1 |
| Butland, RJ | 1 |
| Wilkinson, SP | 1 |
| Stahl, WG | 1 |
| Beton, RR | 1 |
| Johnson, CS | 1 |
| Brown, CL | 1 |
| Havelund, T | 5 |
| Laursen, LS | 2 |
| Burget, DW | 1 |
| Hillman, AL | 2 |
| Garnett, WR | 1 |
| Schentag, JJ | 1 |
| Goss, TF | 1 |
| Pounder, RE | 1 |
| Fraser, AG | 2 |
| Arens, MJ | 1 |
| Hanson, D | 1 |
| Ducrotté, P | 2 |
| Guillemot, F | 1 |
| Elouaer-Blanc, L | 1 |
| Hirschauer, C | 1 |
| Thorel, JM | 1 |
| Petit, A | 1 |
| Hochain, P | 1 |
| Michel, P | 1 |
| Cortot, A | 1 |
| Colin, R | 1 |
| Bader, JP | 1 |
| Delchier, JC | 2 |
| Shoenut, JP | 1 |
| Wieler, JA | 1 |
| Micflikier, AB | 1 |
| Alliët, P | 1 |
| Raes, M | 1 |
| Gillis, P | 1 |
| Zimmermann, A | 1 |
| Gunasekaran, TS | 1 |
| Hassall, EG | 1 |
| Loizeau, E | 1 |
| Kolts, BE | 2 |
| Wears, R | 1 |
| Burton, L | 2 |
| Baron, TH | 1 |
| Singh, S | 2 |
| Tennyson, GS | 1 |
| Andres, JM | 1 |
| Decktor, DL | 1 |
| Maton, PN | 4 |
| Sabesin, S | 1 |
| Roufail, W | 1 |
| Kogut, D | 1 |
| Roberts, W | 1 |
| McCullough, A | 1 |
| Pardoll, P | 1 |
| Saco, L | 1 |
| Watson, A | 1 |
| Tibbling, L | 1 |
| Lahaie, R | 1 |
| Laroche, C | 1 |
| Boivin, M | 1 |
| Le Lorier, J | 1 |
| Caussignac, Y | 1 |
| Martin, S | 2 |
| Jobin, G | 1 |
| Beauchamp, G | 1 |
| Puetz, TR | 1 |
| Weiner, GM | 1 |
| Batch, AJ | 1 |
| Radford, K | 1 |
| Cadiot, G | 1 |
| Vissuzaine, C | 1 |
| Pospai, D | 1 |
| Ruszniewski, P | 1 |
| Potet, F | 1 |
| Mignon, M | 2 |
| Adamek, RJ | 1 |
| Wegener, M | 1 |
| Wienbeck, M | 1 |
| Pulte, T | 1 |
| Bondesen, S | 1 |
| Hansen, J | 1 |
| Sanchez, G | 1 |
| Sebelin, E | 1 |
| Fenger, C | 1 |
| Mellow, MH | 1 |
| Grossman, MR | 1 |
| Harding, SM | 3 |
| Guzzo, MR | 1 |
| Schan, CA | 1 |
| Alexander, RW | 1 |
| Bradley, LA | 1 |
| Costantini, M | 1 |
| Zaninotto, G | 1 |
| Anselmino, M | 1 |
| Boccù, C | 1 |
| Nicoletti, L | 1 |
| Ancona, E | 1 |
| Skoutakis, VA | 1 |
| Joe, RH | 1 |
| Hara, DS | 1 |
| Pollmann, H | 1 |
| Zillessen, E | 1 |
| Pohl, J | 1 |
| Rosemeyer, D | 1 |
| Abucar, A | 1 |
| Bornhofen, B | 1 |
| Herz, R | 1 |
| Mela, GS | 3 |
| Vigneri, S | 2 |
| Schnatz, PF | 1 |
| Castell, JA | 1 |
| Hendel, J | 4 |
| Hendel, L | 3 |
| Hage, E | 2 |
| Aggestrup, S | 2 |
| Nielsen, OH | 1 |
| Weber, L | 1 |
| Leite, L | 1 |
| Rademaker, AW | 1 |
| Bellou, A | 1 |
| Aimone-Gastin, I | 1 |
| De Korwin, JD | 1 |
| Bronowicki, JP | 1 |
| Moneret-Vautrin, A | 1 |
| Nicolas, JP | 1 |
| Guéant, JL | 1 |
| Fitton, A | 1 |
| Wiseman, L | 1 |
| Mee, AS | 1 |
| Rowley, JL | 1 |
| Van Den Boom, G | 1 |
| Go, PM | 1 |
| Hameeteman, W | 1 |
| Dallemagne, B | 1 |
| Ament, AJ | 1 |
| Reynolds, JC | 1 |
| Fennerty, MB | 11 |
| Shaw, GY | 2 |
| Searl, JP | 2 |
| Young, JL | 1 |
| Loughlin, CJ | 1 |
| Koufman, JA | 2 |
| Teichtahl, H | 1 |
| Kronborg, IJ | 1 |
| Yeomans, ND | 1 |
| Robinson, P | 1 |
| Childs, ML | 1 |
| Ruiz, C | 1 |
| Weinstein, GS | 1 |
| Cucchiara, S | 2 |
| Minella, R | 1 |
| Salvia, G | 2 |
| Borrelli, O | 1 |
| Ciccimarra, E | 1 |
| Emiliano, M | 1 |
| Berstad, A | 3 |
| Camargo, E | 3 |
| Profanter, C | 3 |
| Gadenstätter, M | 1 |
| Perdikis, G | 2 |
| Glaser, K | 3 |
| Hinder, RA | 4 |
| Viljakka, M | 2 |
| Luostarinen, M | 1 |
| Isolauri, J | 2 |
| Aalykke, C | 1 |
| Rasmussen, L | 1 |
| Keerl, R | 1 |
| Huppmann, A | 1 |
| Watson, RG | 1 |
| Tham, TC | 1 |
| McDougall, NI | 1 |
| Newland, RD | 2 |
| Patel, AC | 2 |
| Hole, J | 2 |
| Copeman, MB | 1 |
| Turbitt, ML | 2 |
| Nevalainen, J | 1 |
| Bate, CM | 4 |
| Axon, AT | 4 |
| Murray, FE | 1 |
| Tildesley, G | 2 |
| Emmas, CE | 1 |
| Taylor, MD | 3 |
| Barthelemy, P | 1 |
| Bohmer, CJ | 2 |
| Niezen-de Boer, MC | 1 |
| Tuynman, HA | 2 |
| Voskuil, JH | 1 |
| Devillé, WL | 1 |
| Da Costa, LR | 1 |
| Leufkens, H | 1 |
| Claessens, A | 1 |
| Heerdink, E | 1 |
| van Eijk, J | 1 |
| Lamers, CB | 6 |
| Wilcock, C | 1 |
| Schenk, BE | 6 |
| Jansen, EH | 2 |
| Schrijver, M | 1 |
| Dieleman, LA | 1 |
| MacMath, T | 1 |
| Richter, J | 1 |
| Mohr, D | 1 |
| Parks, SM | 1 |
| Lalkin, A | 1 |
| Magee, L | 1 |
| Addis, A | 1 |
| Loebstein, R | 1 |
| Grist, WJ | 1 |
| Gussack, G | 1 |
| Delgaudio, JM | 1 |
| Klingler, P | 1 |
| Bammer, T | 1 |
| Wieschemeyer, T | 1 |
| Schwab, G | 1 |
| Klingler, A | 1 |
| Chiocca, JC | 1 |
| Salis, GB | 1 |
| de Caestecker, J | 1 |
| Hotz, J | 2 |
| Weywadt, L | 1 |
| Solhaug, JH | 1 |
| Hernqvist, H | 2 |
| Bengtsson, L | 1 |
| Tigges, H | 1 |
| Heimbucher, J | 1 |
| Freys, SM | 1 |
| Eggleston, A | 1 |
| Wigerinck, A | 1 |
| Huijghebaert, S | 1 |
| Haycox, A | 1 |
| Rauws, EA | 1 |
| Zylicz, Z | 1 |
| van Sorge, AA | 1 |
| Yska, JP | 1 |
| Meining, A | 3 |
| Schmitz, JM | 2 |
| Alexandridis, T | 3 |
| Watts, R | 1 |
| Riley, S | 2 |
| Sheikh, R | 1 |
| Haug, K | 1 |
| de Groot, G | 1 |
| van Oudvorst, A | 1 |
| Dalväg, A | 3 |
| Marshall, JK | 1 |
| Thompson, AB | 1 |
| Cloud, ML | 1 |
| Enas, N | 1 |
| Bassion, S | 1 |
| Sonnenberg, A | 1 |
| Delcò, F | 1 |
| West, BC | 1 |
| Agastya, G | 1 |
| Sodeman, W | 1 |
| Callahan, J | 1 |
| Wittmann, T | 1 |
| Rosztóczy, A | 1 |
| Fehér, A | 1 |
| Jármay, K | 1 |
| Oláh, T | 1 |
| Szendrényi, V | 1 |
| Kiss, I | 1 |
| Müller-Lissner, S | 3 |
| Hosie, J | 3 |
| Scott, M | 3 |
| Weir, D | 1 |
| Fulton, C | 3 |
| Gillon, K | 2 |
| Peacock, R | 3 |
| Rothstein, SG | 1 |
| Ouatu-Lascar, R | 1 |
| Peghini, PL | 1 |
| Bracy, NA | 1 |
| Hetzel, D | 1 |
| Boeree, MJ | 1 |
| Peters, FT | 4 |
| Postma, DS | 1 |
| Kleibeuker, JH | 4 |
| Ofman, JJ | 7 |
| Gralnek, IM | 3 |
| Johnson, C | 3 |
| So, JB | 1 |
| Zeitels, SM | 1 |
| Rattner, DW | 1 |
| Koop, H | 1 |
| Porst, H | 1 |
| Wübbolding, H | 1 |
| Schneider, A | 2 |
| Maier, C | 1 |
| Levin, TR | 1 |
| Sperling, RM | 1 |
| McQuaid, KR | 1 |
| Field, SK | 3 |
| Sutherland, LR | 2 |
| Blum, RA | 1 |
| Kidd, SL | 1 |
| Shi, H | 1 |
| Jennings, DE | 1 |
| Greski-Rose, PA | 1 |
| Murrays, FE | 1 |
| Owen, SM | 1 |
| Emmas, C | 1 |
| Diehl, KL | 3 |
| Schoeppner, H | 1 |
| Geyer, P | 3 |
| Martens, E | 3 |
| Chambers, J | 1 |
| Cooke, R | 1 |
| Owen, W | 1 |
| Biemond, I | 1 |
| Katelaris, PH | 1 |
| Hansen, JM | 2 |
| Schaffalitzky de Muckadell, OB | 2 |
| Lee, JM | 1 |
| Langtry, HD | 2 |
| Wilde, MI | 1 |
| Choudhry, U | 1 |
| Boyce, HW | 1 |
| Coppola, D | 1 |
| Niezen-de Boer, RC | 1 |
| Marshall, RE | 1 |
| Manifold, DK | 1 |
| Owen, WA | 1 |
| Owen, WJ | 1 |
| Bolling-Sternevald, E | 1 |
| Sagar, M | 3 |
| Seensalu, R | 3 |
| Tybring, G | 1 |
| Dahl, ML | 1 |
| Bertilsson, L | 2 |
| Newton, M | 1 |
| Burnham, WR | 1 |
| Kamm, MA | 1 |
| Hattlebakk, J | 2 |
| Janatuinen, E | 3 |
| Pedersen, SA | 7 |
| Thor, K | 3 |
| Andersson, A | 2 |
| Blustein, PK | 1 |
| Beck, PL | 1 |
| Meddings, JB | 1 |
| Van Rosendaal, GM | 1 |
| Bailey, RJ | 1 |
| Lalor, E | 1 |
| Verhoef, MJ | 1 |
| de Carle, DJ | 1 |
| Friedel, D | 1 |
| Ozick, LA | 1 |
| Anderson, C | 1 |
| Khoury, R | 1 |
| Kuo, B | 1 |
| Beker, JA | 1 |
| Gabryelewicz, A | 1 |
| Bell, NE | 1 |
| Riley, SA | 1 |
| Chapman, RW | 1 |
| Durnin, AT | 1 |
| Camargo, L | 2 |
| Severens, JL | 1 |
| Verbeek, AL | 1 |
| Qvigstad, G | 1 |
| Arnestad, JS | 1 |
| Brenna, E | 1 |
| Janczewska, I | 1 |
| Sjöstedt, S | 2 |
| Hammarlund, B | 1 |
| Iwarzon, M | 1 |
| Weir, DG | 2 |
| Gillon, KR | 1 |
| Peacock, RA | 1 |
| Devière, H | 1 |
| Bouilliez, D | 1 |
| Melot, C | 1 |
| Urbain, D | 1 |
| Ahmad, M | 1 |
| Arps, H | 1 |
| O'Connor, HJ | 1 |
| Richardson, PD | 1 |
| Eskes, SA | 1 |
| Schenk, E | 1 |
| Tan, G | 1 |
| Nelis, F | 2 |
| Rantanen, TK | 1 |
| Salo, JA | 1 |
| Salzberg, SA | 1 |
| Newton, WP | 1 |
| O'Connor, JF | 1 |
| Singer, ME | 1 |
| Bieszk, N | 1 |
| Kale-Pradhan, PB | 1 |
| Orlando, R | 1 |
| Joelsson, B | 2 |
| Glise, H | 2 |
| Anker-Hansen, O | 2 |
| Eriksson, G | 1 |
| Ganesh, S | 3 |
| Sluiter, WJ | 3 |
| Kepekci, Y | 1 |
| Kadayifci, A | 1 |
| Nyström, P | 2 |
| Fändriks, L | 1 |
| Jönsson, C | 1 |
| Al-Sabbagh, G | 1 |
| Farup, PG | 2 |
| Hovde, O | 1 |
| Torp, R | 1 |
| Wetterhus, S | 1 |
| Kromer, W | 1 |
| Horbach, S | 1 |
| Lühmann, R | 2 |
| Peters, HP | 1 |
| De Kort, AF | 1 |
| Van Krevelen, H | 1 |
| Akkermans, LM | 1 |
| Van Berge Henegouwen, GP | 1 |
| Bol, E | 1 |
| Mosterd, WL | 1 |
| De Vries, WR | 1 |
| Barbezat, GO | 1 |
| Schlup, M | 1 |
| Lubcke, R | 1 |
| Khoury, RM | 1 |
| Abidin, ZU | 1 |
| Sheptulin, AA | 1 |
| Okhlobystin, AV | 1 |
| Colwell, HH | 2 |
| Mathias, SD | 2 |
| Pasta, DJ | 2 |
| Henning, JM | 3 |
| Udani, J | 1 |
| Declich, P | 3 |
| Ambrosiani, L | 1 |
| Bellone, S | 3 |
| Tavani, E | 3 |
| Bortoli, A | 3 |
| Gozzini, C | 3 |
| Condra, LJ | 1 |
| Morreale, AP | 1 |
| Stolley, SN | 1 |
| Marcus, D | 1 |
| Bloemena, EC | 1 |
| Sandell, M | 1 |
| Markham, A | 1 |
| Miller, JL | 1 |
| Kiljander, TO | 2 |
| Salomaa, ER | 3 |
| Hietanen, EK | 2 |
| Terho, EO | 3 |
| Irwin, RS | 1 |
| Zawacki, JK | 1 |
| Kavuru, MS | 1 |
| Schilz, RJ | 1 |
| Ortiz, A | 1 |
| Martínez de Haro, LF | 1 |
| Parrilla, P | 1 |
| Molina, J | 1 |
| Bermejo, J | 1 |
| Munitiz, V | 1 |
| Feldman, M | 1 |
| Cryer, B | 1 |
| Sammer, D | 1 |
| Meadows, N | 1 |
| Walker-Smith, JA | 1 |
| Martín de Argila, C | 1 |
| Boixeda de Miquel, D | 1 |
| Moreira Vicente, V | 1 |
| García Plaza, A | 1 |
| Dickson, A | 1 |
| El-Nujumi, A | 1 |
| El-Omar, E | 1 |
| Kelman, A | 1 |
| Stålhammar, NO | 1 |
| Carlsson, J | 3 |
| Porro, GB | 1 |
| de Mestier, P | 1 |
| Pillans, PI | 1 |
| Kubler, PA | 1 |
| Radford, JM | 1 |
| Overland, V | 1 |
| Soll, AH | 1 |
| Fujisaki, T | 1 |
| Matsuoka, H | 1 |
| Yamada, S | 1 |
| Morimoto, I | 1 |
| Eto, S | 1 |
| Aibe, T | 1 |
| Martin, P | 1 |
| Paul, J | 1 |
| Lew, E | 1 |
| Mitchell, B | 1 |
| Prichard, P | 1 |
| Lloyd, D | 1 |
| Frame, MH | 1 |
| Backe, KW | 1 |
| van Zyl, JH | 1 |
| de K Grundling, H | 1 |
| van Rensburg, CJ | 2 |
| Retief, FJ | 1 |
| O'Keefe, SJ | 1 |
| Theron, I | 1 |
| Bethke, T | 1 |
| McCaffrey, E | 1 |
| Lindbichler, F | 1 |
| Raith, J | 1 |
| Hatton, BN | 1 |
| Ryono, R | 1 |
| Jones, W | 1 |
| Pulliam, G | 3 |
| Thijs, JC | 1 |
| Luckers, AE | 1 |
| Viergever, PP | 1 |
| Wurzer, H | 1 |
| Capurso, L | 1 |
| Peura, D | 1 |
| Benjamin, SB | 2 |
| Whipple, J | 2 |
| Campbell, DR | 1 |
| Fludas, C | 1 |
| Rydberg, L | 1 |
| Kylebäck, A | 1 |
| Jonsson, A | 1 |
| Hasselgren, G | 2 |
| Holmberg, J | 1 |
| de Lima Pontes, PA | 1 |
| De Biase, NG | 1 |
| Gadelha, EC | 1 |
| Vakil, NB | 2 |
| Hernandez, LV | 1 |
| Grøntved, AM | 1 |
| West, F | 1 |
| Grahn, LT | 1 |
| Kaplan-Machlis, B | 1 |
| Spiegler, GE | 1 |
| Post, AT | 1 |
| Voorhorst, G | 1 |
| Zanen, AL | 1 |
| Sauer, J | 1 |
| Junginger, T | 1 |
| Johnson, D | 1 |
| Farley, A | 1 |
| Wruble, LD | 1 |
| Pahn, J | 1 |
| Schlottmann, A | 1 |
| Witt, G | 1 |
| Wilke, W | 1 |
| Lazenby, JP | 1 |
| Blomqvist, A | 1 |
| Birbara, C | 1 |
| Hahne, W | 1 |
| Morton, RP | 1 |
| Gillibrand, J | 1 |
| Nelson, WW | 1 |
| Vermeulen, LC | 1 |
| Geurkink, EA | 1 |
| Ehlert, DA | 1 |
| Reichelderfer, M | 1 |
| Spencer, CM | 1 |
| Menes, T | 1 |
| Lelcuk, S | 1 |
| Spivak, H | 1 |
| Holloway, RH | 1 |
| Periclou, AP | 1 |
| Goldwater, R | 1 |
| Lee, SM | 1 |
| Park, DW | 1 |
| Kim, DY | 1 |
| Cho, KD | 1 |
| Boileau, F | 1 |
| Jung, WT | 1 |
| Rapoport, SI | 1 |
| Lapteva, ON | 1 |
| Raĭkhlin, NT | 1 |
| Smirnova, EA | 1 |
| Khutsishvili, MB | 1 |
| Rasulov, MI | 1 |
| Brun, J | 1 |
| Sörngård, H | 2 |
| Bonnevie, O | 1 |
| Breinstrup, H | 1 |
| Funch-Jensen, P | 1 |
| Matzen, P | 1 |
| Meineche-Schmidt, V | 1 |
| Stridsberg, M | 1 |
| Kjellin, A | 1 |
| Mârdh, S | 1 |
| Aviv, JE | 1 |
| Liu, H | 1 |
| Parides, M | 1 |
| Kaplan, ST | 1 |
| Close, LG | 1 |
| Dawson, R | 1 |
| Manson, JM | 1 |
| Moskovitz, M | 1 |
| Dayal, Y | 1 |
| Niecestro, R | 2 |
| Shepherd, R | 2 |
| Radke, M | 2 |
| Marcon, M | 1 |
| Behrens, R | 1 |
| Koletzko, S | 1 |
| Becker, M | 1 |
| Göthberg, G | 1 |
| Avner, DL | 1 |
| Israel, D | 1 |
| Sköld, B | 1 |
| Jungnickel, PW | 1 |
| Murthy, U | 1 |
| Hayden, CW | 1 |
| Malagon, IB | 1 |
| Franco, MT | 1 |
| Spadaro, R | 1 |
| De Rosa, I | 1 |
| Iula, VD | 1 |
| Porcellati, M | 2 |
| Mukherjee, S | 1 |
| Befrits, R | 1 |
| Odman, B | 1 |
| Lindberg, G | 1 |
| Moayyedi, P | 2 |
| Wason, C | 1 |
| Bardhan, K | 1 |
| Dixon, MF | 2 |
| Yamashita, BD | 1 |
| Siddique, RM | 1 |
| Larson, LR | 1 |
| Willian, MK | 1 |
| Gregor, JC | 1 |
| Goldstein, JL | 1 |
| Lamet, M | 1 |
| Damico, D | 1 |
| Cohen, G | 1 |
| Karrenbeld, A | 1 |
| de Jager-Krikken, A | 1 |
| Driman, DK | 1 |
| Riddell, R | 1 |
| Cianci, R | 1 |
| Gasbarrini, G | 1 |
| Pashankar, DS | 1 |
| Bang, C | 1 |
| Schulz, T | 1 |
| Omland, TM | 1 |
| Delle, M | 1 |
| Julkonen, R | 1 |
| Falk, GW | 1 |
| Schwetz, BA | 1 |
| Maton, P | 1 |
| Breiter, JR | 1 |
| Marino, V | 1 |
| Levine, JG | 1 |
| Allen, CJ | 1 |
| Parameswaran, K | 1 |
| Belda, J | 1 |
| Reichart, M | 1 |
| Busch, OR | 1 |
| Bruno, MJ | 1 |
| Van Lanschot, JJ | 1 |
| Buderus, S | 1 |
| Keller, KM | 1 |
| Lentze, MJ | 1 |
| Singh, A | 1 |
| Newton, W | 1 |
| Tefera, S | 1 |
| Lee, P | 1 |
| Buchner, A | 1 |
| Gavin, M | 1 |
| McCarthy, DM | 1 |
| Lanza, F | 1 |
| Pashankar, D | 1 |
| Blair, GK | 1 |
| Israel, DM | 1 |
| Xue, S | 1 |
| Biedermann, A | 1 |
| Mey, J | 1 |
| Vela, MF | 1 |
| Camacho-Lobato, L | 1 |
| Srinivasan, R | 1 |
| Tutuian, R | 1 |
| Kiljander, T | 1 |
| Hietanen, E | 1 |
| Helenius, H | 1 |
| Liippo, K | 1 |
| Zimmermann, AE | 1 |
| Walters, JK | 1 |
| Katona, BG | 1 |
| Souney, PE | 1 |
| Poole, P | 1 |
| Ibarra, G | 1 |
| Senna, G | 1 |
| Cobb, D | 1 |
| Denehy, G | 1 |
| Guldenschuh, I | 1 |
| Cathomas, G | 1 |
| Postma, GN | 1 |
| Corless, CL | 1 |
| Sheppard, B | 1 |
| Faigel, DO | 1 |
| Lieberman, DA | 1 |
| McGuigan, JE | 1 |
| Lukasik, N | 1 |
| Neal, K | 1 |
| Logan, R | 1 |
| Moore, KH | 1 |
| Barry, P | 1 |
| Burn, J | 1 |
| Falk, G | 1 |
| O'Boyle, CJ | 1 |
| Watson, DI | 1 |
| Raisch, DW | 1 |
| Klaurens, LM | 1 |
| Hayden, C | 1 |
| Malagon, I | 1 |
| Rokkas, T | 1 |
| Ladas, SD | 1 |
| Liatsos, C | 1 |
| Panagou, E | 1 |
| Karameris, A | 1 |
| Raptis, SA | 1 |
| Jacobsen, CD | 1 |
| Hansen, T | 1 |
| Juul-Hansen, PH | 1 |
| Ferrara, A | 1 |
| Caruso, S | 1 |
| Caro, JJ | 1 |
| Salas, M | 1 |
| Ward, A | 1 |
| Lebedev, EG | 1 |
| Ovsiannikova, EV | 1 |
| Antonenko, OM | 1 |
| Fournet, J | 1 |
| Rampal, P | 1 |
| Avasthy, N | 1 |
| Netzer, P | 1 |
| Gut, A | 1 |
| Brundler, R | 1 |
| Gaia, C | 1 |
| Inauen, W | 1 |
| Faure, C | 1 |
| Michaud, L | 1 |
| Shaghaghi, EK | 1 |
| Popon, M | 1 |
| Laurence, M | 1 |
| Mougenot, JF | 1 |
| Hankard, R | 1 |
| Navarro, J | 1 |
| Jacoz-Aigrain, E | 1 |
| Mattson, C | 1 |
| Ståhlhammar, NO | 1 |
| Morreale, A | 1 |
| Storr, M | 1 |
| Allescher, HD | 1 |
| Meyer, JH | 1 |
| Lembo, A | 1 |
| Elashoff, JD | 1 |
| Mayer, EA | 1 |
| Bardhan, C | 1 |
| Young, L | 1 |
| Brown, L | 1 |
| Geboes, K | 1 |
| Dekker, W | 1 |
| Nusteling, K | 1 |
| Klingler, PJ | 1 |
| Weiss, H | 1 |
| Obrist, P | 1 |
| Klaus, A | 1 |
| Weiss, MM | 1 |
| Saigusa, H | 1 |
| Niimi, S | 1 |
| Saigusa, U | 1 |
| Yagi, T | 1 |
| Miller, DP | 1 |
| Hamdan, AL | 1 |
| Sharara, AI | 1 |
| Younes, A | 1 |
| Fuleihan, N | 1 |
| Xiao, F | 1 |
| Barnett, JL | 1 |
| Botoman, VA | 1 |
| Schönfeld, J | 1 |
| Erhard, J | 1 |
| Carswell, CI | 1 |
| Goa, KL | 1 |
| Cheung, KM | 1 |
| Tse, PW | 1 |
| Ko, CH | 1 |
| Chan, YC | 1 |
| Leung, CY | 1 |
| Chan, KH | 1 |
| Chen, TS | 1 |
| Kang, LJ | 1 |
| Xiao, G | 1 |
| Wang, Z | 1 |
| Ke, M | 1 |
| Huang, X | 1 |
| Maceri, DR | 1 |
| Zim, S | 1 |
| Senior, BA | 1 |
| Khan, M | 1 |
| Schwimmer, C | 1 |
| Rosenthal, L | 1 |
| Benninger, M | 1 |
| Macaigne, G | 1 |
| Boivin, JF | 1 |
| Simon, P | 1 |
| Chayette, C | 1 |
| Cheaib, S | 1 |
| Deplus, R | 1 |
| Chattopadhyay, A | 1 |
| Sood, A | 1 |
| Wanchu, A | 1 |
| Bambery, P | 1 |
| Rodriguez-Stanley, S | 2 |
| Ciociola, AA | 1 |
| Filinto, J | 1 |
| Zubaidi, S | 1 |
| Dorn, GH | 1 |
| Beck, IT | 1 |
| Fitzgerald, S | 1 |
| Hegedus, R | 1 |
| Hahne, WF | 1 |
| Barth, JA | 1 |
| Metz, M | 1 |
| Loeffler, V | 1 |
| Blum, AL | 1 |
| Wong, SK | 1 |
| Lee, YT | 1 |
| Kazantsev, GB | 1 |
| Schwesinger, WH | 1 |
| Heim-Hall, J | 1 |
| Lanzani, A | 1 |
| Melotti, G | 1 |
| Bown, RL | 1 |
| Wahlqvist, P | 1 |
| Higgins, A | 1 |
| Ruscin, JM | 1 |
| Page, RL | 1 |
| Valuck, RJ | 1 |
| Cross, LB | 1 |
| Justice, LN | 1 |
| Kim, JD | 1 |
| Booth, M | 1 |
| Dunn, CJ | 2 |
| Mallarkey, G | 2 |
| Sharpe, M | 2 |
| DiBaise, JK | 1 |
| Olusola, BF | 1 |
| Huerter, JV | 1 |
| Ramakrishnan, A | 1 |
| Hedenström, H | 1 |
| Zalesska-Krecicka, M | 1 |
| Krecicki, T | 1 |
| Iwanczak, B | 1 |
| Blitek, A | 1 |
| Horobiowska, M | 1 |
| Dhir, V | 1 |
| Sheth, NP | 1 |
| de Silva, KK | 1 |
| Schade, G | 1 |
| Hess, M | 1 |
| Varughese, LA | 1 |
| Mazur, LJ | 1 |
| Orr, W | 1 |
| Filippone, J | 1 |
| Bell, NJ | 1 |
| Stentoft, P | 1 |
| Cappell, MS | 1 |
| Goldberg, J | 1 |
| Jaumá, R | 1 |
| Payola, N | 1 |
| Gómez, F | 1 |
| Cordón, F | 1 |
| Cabratosa, J | 1 |
| Bloom, BS | 1 |
| Schwartz, JS | 1 |
| Langman, MJ | 2 |
| Vallot, T | 1 |
| Gouilloud-Celle, S | 1 |
| Allen, ML | 1 |
| McIntosh, D | 1 |
| Cagliola, AJ | 1 |
| Bradstreet, TE | 1 |
| Secher, E | 1 |
| Encinas Sotillos, A | 1 |
| Romero Ganuza, FJ | 1 |
| Hernández Navarrete, C | 1 |
| Cabrerizo Puente, A | 1 |
| Simon, TJ | 1 |
| Bradstreet, DC | 1 |
| Marinos, Y | 1 |
| Honson, K | 1 |
| Holt, S | 2 |
| Taylor, TV | 1 |
| Celle, G | 1 |
| Fiorucci, S | 2 |
| Santucci, L | 2 |
| Morelli, A | 2 |
| Buhl, K | 1 |
| Clearfield, HR | 1 |
| Cheung, G | 1 |
| Vantrappen, G | 1 |
| Depla, AC | 2 |
| Farroni, F | 1 |
| Pelli, MA | 1 |
| Stern, WR | 1 |
| Nio, CY | 1 |
| Ruth, M | 1 |
| Enbom, H | 1 |
| Lönroth, H | 1 |
| Sandberg, N | 1 |
| Sandmark, S | 1 |
| Bartelsman, JF | 1 |
| Roos, CM | 1 |
| Jansen, HM | 1 |
| Lee, FI | 1 |
| Isaacs, PE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CSP #573 - A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors[NCT01265550] | Phase 3 | 366 participants (Actual) | Interventional | 2012-08-13 | Completed | ||
| Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program[NCT03719170] | 208,266 participants (Actual) | Interventional | 2019-09-16 | Completed | |||
| Rectal and Oral Omeprazole Treatment of Gastroesophageal Reflux in Infants With Esophageal Atresia or Congenital Diaphragmatic Hernia; A Pharmacodynamic and Pharmacokinetic Study.[NCT00226044] | Phase 3 | 17 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Pathophysiology of the Aerodigestive Reflex in Infants: GERD Management Trial[NCT02486263] | 76 participants (Actual) | Interventional | 2012-12-31 | Completed | |||
| Evaluating Efficacy and Safety of Combined Thread Embedding and Auricular Acupuncture in Gastroesophageal Reflux Disease With Liver Qi Invading Stomach Pattern: A Randomized Controlled Trial[NCT06157424] | 66 participants (Anticipated) | Interventional | 2023-12-06 | Recruiting | |||
| Efficacy of Traditional Chinese Medicine Jianpi Qinghua Granule Combined With Low Dose Omeprazole in Patients With Non-erosive Reflux Disease (NERD)[NCT02892357] | Phase 1/Phase 2 | 204 participants (Anticipated) | Interventional | 2017-01-31 | Recruiting | ||
| The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease[NCT02505945] | Phase 4 | 152 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| Prospective Study Assessing Patient Satisfaction of Symptom Control With Proton Pump Inhibitor Dosing Regimen[NCT02623816] | Phase 4 | 64 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| A Multi-center, Double-blind, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Sodium Alginate Oral Suspension (50 mg/ml) in Comparison to Omeprazole (20 mg/Cap) to Treat Non-erosive Gastro-esophageal Reflux Disease (NERD)[NCT01338077] | Phase 3 | 195 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| A Randomized Controlled Trial Comparing Transoral Incisionless Fundoplication (TIF) Using EsophyX With Sham Procedure for the Treatment of PPI Dependent GERD Compared With Sham and Placebo Controls[NCT01136980] | 129 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| A Phase III, Multi-centre, Double-blind, Double-dummy, Randomised, Study to Assess the Superiority of Zegerid® 20 mg vs. Losec® 20 mg in the Rapid Relief of Heartburn Associated With GERD as on Demand Therapy[NCT01493089] | Phase 3 | 239 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| An Open, Randomized, Multicenter, Phase IIIB Study During 5 Years to Assess Long-term Efficacy and Tolerability of Esomeprazole Compared to Laparoscopic Anti-reflux Surgery in Adult Subjects With Gastroesophageal Reflux Disease - LOTUS.[NCT00251927] | Phase 3 | 626 participants (Actual) | Interventional | 2001-10-31 | Completed | ||
| Omeprazole Versus Anti-reflux Surgery in the Long-term Management of Peptic Esophagitis - a 10 Year Follow up Study of Patients Previously Studied for 5 Years - A Nordic Multicentre Study[NCT00256737] | Phase 3 | 219 participants | Interventional | 1998-01-31 | Completed | ||
| A Worldwide Post-Market Surveillance Registry to Assess the Medigus Ultrasonic Surgical Endostapler (MUSE™) System for the Treatment of GERD[NCT02366169] | 200 participants (Anticipated) | Observational [Patient Registry] | 2015-03-31 | Recruiting | |||
| Evaluation of the Medigus SRS Endoscopic Stapling System for the Treatment of Gastro-Esophageal Reflux Disease (GERD)[NCT00734747] | Phase 3 | 72 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| The Effectiveness of Domperidone Versus Alginic Acid Add on Omeprazole Therapy in Omeprazole Resistance Gastroesophageal Reflux in Systemic Sclerosis[NCT01878526] | Phase 3 | 80 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis[NCT01733810] | 12 participants (Actual) | Interventional | 2013-02-01 | Completed | |||
| Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features in a Primary Care Setting: A Pragmatic, Randomized, Single Blind Study[NCT04028466] | Phase 4 | 82 participants (Actual) | Interventional | 2019-05-26 | Terminated (stopped due to Budget for the study was withdrawn and discontinued) | ||
| Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Patients With Heartburn Associated With Gastroparesis[NCT00492622] | Phase 4 | 12 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Evaluation of MicroRNA Expression in Blood and Cytology Specimens as a Novel Method for Detecting Barrett's Esophagus[NCT02464930] | 220 participants (Anticipated) | Observational | 2015-04-30 | Recruiting | |||
| Endoscopic Resection or Ablation for Patients With Dysplasia or Intramucosal Cancer in Barrett's Esophagus[NCT01572987] | 12 participants (Actual) | Interventional | 2011-09-30 | Terminated (stopped due to Recruitment goals not being met) | |||
| Evaluation of Performance Characteristics of Capsule Endoscopy With PillCam UGI Capsule Compared to Standard Endoscopy for Screening of Barrett's Esophagus: A Prospective Tandem Study[NCT03167970] | 21 participants (Actual) | Observational | 2017-05-03 | Completed | |||
| The Potential Therapeutic Effect of Melatonin in Gastro-Esophageal Reflux Disease[NCT00915616] | Phase 3 | 0 participants | Interventional | Withdrawn | |||
| Clinical Study on the Effects of the Product Mucosave® on Gastrointestinal Discomfort and the Quality of Life in Healthy Volunteers[NCT04119817] | 100 participants (Actual) | Interventional | 2019-02-09 | Completed | |||
| Evaluation of the Effects of Lansoprazole Usage on Bone Turnover Markers in Children With Gastroesophageal Reflux or Gastroesophageal Reflux Disease[NCT04814316] | 60 participants (Actual) | Observational | 2019-12-02 | Completed | |||
| A Randomized, Placebo-Controlled Assessment of Lansoprazole 30 mg Bid in the Treatment of Gastroesophageal Reflux Associated With Laryngitis[NCT00369265] | Phase 4 | 18 participants (Actual) | Interventional | 2006-08-31 | Terminated (stopped due to Pharmaceutical company purchased by another company and funding was terminated.) | ||
| Economic Impact of Guidelines for Gastroesophageal Reflux Disease[NCT00057174] | 484 participants (Anticipated) | Interventional | Completed | ||||
| A Multicenter, Randomized, Double-blinded, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Rebamipide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (REPAIR)[NCT02755753] | Phase 4 | 143 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309] | 30 participants (Anticipated) | Interventional | 2006-04-30 | Completed | |||
| A Prospective Evaluation of the Utility, Optimal Cutoff and Positive Predictive Value of a Pharyngeal pH Probe for Predicting Proton Pump Inhibitor Response in Treatment Naive Laryngopharyngeal Reflux[NCT01755221] | 80 participants (Anticipated) | Interventional | 2012-08-31 | Active, not recruiting | |||
| "Double-Blind Placebo-Controlled Randomized Withdrawal Trial Assessing the Efficacy and Tolerability of On-Demand Maintenance Therapy With 10mg o.d. Rabeprazole for 6 Months in Non-Erosive Reflux Disease Patients With Complete Symptom Relief After 4 Week [NCT00236392] | Phase 3 | 422 participants (Actual) | Interventional | 2001-10-31 | Completed | ||
| Clinical Application of Vagus Nerve Preservation in Minimally Invasive Surgery for Early Lung Cancer[NCT04125979] | 120 participants (Anticipated) | Interventional | 2019-01-01 | Recruiting | |||
| Prospective Randomized Controlled Study on the Effects of Vagus Nerve Pulmonary Branch Preservation During Video-assisted Thoracic Surgery Lobectomy in Non-small Cell Lung Cancer: Can it Decrease Postoperative Cough and Pulmonary Complications[NCT04923412] | 214 participants (Anticipated) | Interventional | 2021-07-01 | Recruiting | |||
| The Effect Of Pantoprazole 40 mg Once Daily Versus Placebo On The Power Spectral Analysis Of The Sleep Electroencephalogram (EEG) Of Patients With Gastroesophageal Reflux Disease (GERD)[NCT00674245] | Phase 2/Phase 3 | 40 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin[NCT00281047] | Phase 2/Phase 3 | 138 participants | Interventional | 2006-01-31 | Recruiting | ||
| Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori[NCT00149084] | Phase 3 | 296 participants | Interventional | 2003-04-30 | Recruiting | ||
| Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication[NCT03650543] | Phase 4 | 133 participants (Actual) | Interventional | 2012-09-10 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled Study of Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy[NCT01328652] | Phase 4 | 80 participants (Anticipated) | Interventional | 2011-06-30 | Not yet recruiting | ||
| Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial[NCT01269788] | Phase 2/Phase 3 | 144 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Improving Care For Infants With Laryngomalacia: A Pilot Randomized Controlled Trial of Omeprazole Versus Placebo[NCT01782560] | Phase 1 | 0 participants (Actual) | Interventional | 2013-02-28 | Withdrawn (stopped due to Unable to recruit a sufficient amount of subjects) | ||
| Comparison of Voice Therapy and Antireflex Therapy in the Treatment of Laryngopharyngeal Reflux-related Hoarseness: A Prospective Randomized Control Trial[NCT02530879] | Phase 4 | 0 participants (Actual) | Interventional | 2016-05-31 | Withdrawn (stopped due to Inability to recruit patients) | ||
| Open Label, Randomized, Single Site Clinical Trial To Compare The Safety Of Herbal Melanin Extracted From Nigella Sativa Seeds Vs Standard Of Care Treatment In Treating Gastritis Patients[NCT03428568] | Phase 2 | 132 participants (Anticipated) | Interventional | 2018-03-31 | Not yet recruiting | ||
| The Effects of Melatonin on GERD Symptoms and Esophageal Acid Exposure[NCT00564590] | Phase 1/Phase 2 | 150 participants (Anticipated) | Interventional | 2008-10-31 | Not yet recruiting | ||
| Study of the Effect of PROGRESSive Withdrawal Esomeprazole of on Acid-related Symptoms, PROGRESS Study A Randomized, Placebo-controlled, Double Blinded Study[NCT02476097] | Phase 4 | 58 participants (Anticipated) | Interventional | 2015-06-30 | Active, not recruiting | ||
| Evaluating Gastro-oesophageal Reflux After Palliative Stenting for Malignant Distal Oesophageal Obstruction Using Anti-Reflux Stents: a Randomised Controlled Trial[NCT05303298] | 72 participants (Anticipated) | Interventional | 2022-10-01 | Recruiting | |||
| Impact of Head of Bed Elevation in Symptoms of Patients With Gastroesophageal Reflux Disease: a Randomized Single-blind Study[NCT02706938] | 65 participants (Actual) | Interventional | 2016-04-08 | Completed | |||
| Pulmonary Function Test, Bronchial Hyperresponsiveness and Quality of Life in Patients With Vocal Cord Dysfunction (VCD)[NCT00906867] | 25 participants (Actual) | Observational | 2009-04-30 | Completed | |||
| Barrett's Esophagus Study (BEST) Trial - a Multi-Center and Endoscopic Outcomes Project[NCT00586404] | 1,250 participants (Actual) | Observational | 2007-11-30 | Terminated (stopped due to lack of enrollment) | |||
| Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study[NCT02081404] | 98 participants (Actual) | Interventional | 2009-03-01 | Completed | |||
| Pharmacodynamic Dose-Response of S-Tenatoprazole-Na (STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers[NCT00284908] | Phase 1 | 32 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Assessment of the Healing Rate of Erosive or Ulcerative Esophagitis After Two and Four Weeks of Treatment With S-Tenatoprazole-Na (STU-Na) 15 mg, 30 mg, 60 mg, 90 mg and Esomeprazole 40 mg. A Multicenter, Randomized, Double-Blind, Parallel Group Study.[NCT00282555] | Phase 2 | 450 participants | Interventional | 2006-02-28 | Suspended | ||
| Role of Empiric Anti-reflux Therapy in Pediatric Otitis Media With Effusion - a Pilot Study[NCT01082029] | Phase 4 | 65 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis[NCT01524757] | 48 participants (Anticipated) | Interventional | 2012-03-31 | Not yet recruiting | |||
| Study of a Dietary Supplement for Reflux During Sleep[NCT02274636] | 50 participants (Anticipated) | Interventional | 2014-10-31 | Not yet recruiting | |||
| A Randomized Controlled Trial Comparing Proton Pump Inhibitor Therapy With and Without Interarytenoid Botulinum Toxin Injection for Vocal Fold Granuloma[NCT01678053] | Phase 2 | 0 participants (Actual) | Interventional | 2012-09-30 | Withdrawn (stopped due to Was not able to recruit patients for randomization.) | ||
| A Phase I, Randomized, Double-blind, Placebo- and Positive-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of H008 (Carenoprazan Hydrochloride Tablets) in Healthy Volunteers[NCT05050188] | Phase 1 | 24 participants (Actual) | Interventional | 2021-06-24 | Completed | ||
| Assessing the Impacts of an Upper Esophageal Sphincter Assist Device on Laryngeal Symptoms and Salivary Pepsin: A Pilot Study[NCT02552966] | 20 participants (Actual) | Interventional | 2015-09-01 | Completed | |||
| Post-nasal Drainage as an Extraesophageal Manifestation of Reflux[NCT00199953] | Phase 2 | 50 participants | Interventional | 2002-06-30 | Completed | ||
| Physiology of GERD and Treatment Response[NCT04292470] | 7 participants (Actual) | Interventional | 2020-11-05 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 2 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 3 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 125 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 0 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 130 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 3 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 51 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 86 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 3 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 16 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 0 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 8 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 13 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 4 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 7 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 1 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 221 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 32 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 0 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 0 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 3 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 1 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 152 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 8 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 0 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 2 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 2 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 4 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 56 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 10 |
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 9 |
"Success; ≥50% improvement in the baseline GERD-HRQL score at 12 months.~Failure; <50% improvement in the baseline GERD-HRQL score at 12 months or:~For patients randomized to Surgical Treatment: a.<50% improvement in the baseline GERD-HRQL score and/or persistent heartburn of sufficient severity to warrant treatment with any antisecretory medication, antireflux medication or neurotropic medication at any quarterly clinic visit.~For patients randomized to Active Medical or Placebo Medical Treatment:~a.inability to tolerate both study medications or b.For patients treated with desipramine, i.<50% improvement in baseline GERD-HRQL score symptom after at least 10 weeks of treatment with the second drug at any quarterly clinic visit. c.For patients in whom desipramine is contraindicated,i.<50% improvement in baseline GERD-HRQL score symptom after at least 10 weeks of treatment with baclofen or its corresponding placebo at any quarterly clinic visit." (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 7 |
| Surgical Treatment Group | 18 |
| Placebo Medical Treatment Group | 3 |
Association between anxiety and/or depression (GAD-7 and PHQ-9) and the outcome of medical and surgical treatments (success or failure) will be evaluated. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 2 |
| Surgical Treatment Group | 5 |
| Placebo Medical Treatment Group | 0 |
Presence of belching disorders as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 3 |
| Surgical Treatment Group | 12 |
| Placebo Medical Treatment Group | 2 |
Presence of chronic idiopathic nausea as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 0 |
| Surgical Treatment Group | 3 |
| Placebo Medical Treatment Group | 0 |
Presence of cyclic vomiting syndrome as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 1 |
| Surgical Treatment Group | 7 |
| Placebo Medical Treatment Group | 1 |
Presence of functional bloating as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 1 |
| Surgical Treatment Group | 1 |
| Placebo Medical Treatment Group | 0 |
Presence of functional chest pain of presumed esophageal origin as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 0 |
| Surgical Treatment Group | 0 |
| Placebo Medical Treatment Group | 0 |
Presence of functional diarrhea as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 0 |
| Surgical Treatment Group | 0 |
| Placebo Medical Treatment Group | 0 |
Presence of functional dysphagia as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 0 |
| Surgical Treatment Group | 0 |
| Placebo Medical Treatment Group | 0 |
Presence of functional gallbladder disorder as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 0 |
| Surgical Treatment Group | 0 |
| Placebo Medical Treatment Group | 0 |
Presence of functional heartburn as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 7 |
| Surgical Treatment Group | 14 |
| Placebo Medical Treatment Group | 3 |
Presence of functional vomiting as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 1 |
| Surgical Treatment Group | 1 |
| Placebo Medical Treatment Group | 1 |
Presence of globus as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 0 |
| Surgical Treatment Group | 0 |
| Placebo Medical Treatment Group | 0 |
Presence of irritable bowel syndrome as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 3 |
| Surgical Treatment Group | 10 |
| Placebo Medical Treatment Group | 3 |
Presence of unspecified functional bowel disorder as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 2 |
| Surgical Treatment Group | 5 |
| Placebo Medical Treatment Group | 0 |
(NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgical Treatment Group | 14 |
(NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgical Treatment Group | 18 |
(NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgical Treatment Group | 18 |
(NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgical Treatment Group | 18 |
(NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgical Treatment Group | 15 |
(NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgical Treatment Group | 18 |
(NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgical Treatment Group | 18 |
(NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgical Treatment Group | 14 |
The primary endpoint is the feeding success defined as achieving full oral feeds (defined as no need for tube feeds to maintain hydration and nutrition) and/or a >/= 6 point decrease from baseline symptom score as described by the Infant-Gastro-Esophageal Reflux Questionnaire-Revised. The minimum score is 0 (no symptoms) and the maximum score is 42 (maximum symptoms). Any total score greater than or equal to 16 is considered abnormal. (NCT02486263)
Timeframe: Up to 5 weeks after enrollment
| Intervention | percentage of participants (Number) |
|---|---|
| Study | 33 |
| Conventional | 44 |
Supplemental oxygen requirement at discharge was recorded for both groups (NCT02486263)
Timeframe: at discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Study | 7 |
| Conventional | 9 |
Growth: The investigators will measure and track weight growth velocity during the study period (NCT02486263)
Timeframe: at 5 weeks
| Intervention | grams/day (Mean) |
|---|---|
| Study | 27.6 |
| Conventional | 26.5 |
This is part of Aim 2 of this RCT, which is a mechanistic outcome designed to understand the reasons for the clinical outcome. Presence of peristaltic reflex mechanisms elicited upon esophageal provocation during esophageal manometry were compared within the groups, week-5 vs. week-0. Odds ratios (ORs) with 95% confidence interval (CI) are reported from Generalized Estimation Equation models. (NCT02486263)
Timeframe: 5 weeks
| Intervention | odds ratio, week-5 vs. week-0 (Number) |
|---|---|
| Study | 0.5 |
| Conventional | 0.7 |
The primary endpoint was the percent of patients in both treatment arms who achieved elimination of moderate-severe regurgitation at 6 months, as reported on the foregut symptom questionnaire. (NCT02505945)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Arm | 10 |
| Treatment Arm | 42 |
Successful Reduction at 6 months (≥50% reduction in total) Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) scores from Baseline PPI On medication GERD HRQL scores. (NCT02505945)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Arm | 7 |
| Treatment Arm | 38 |
"The 15-symptom GSAS questionnaire includes measures of: Gastrointestinal distress, Regurgitation/heartburn and Upper respiratory manifestations. The outcome measures were the number, frequency, and severity of GSAS symptoms reported at 6 weeks. Measures were based on aggregate GSAS scores. Symptom numbers range from 0 to 15. Frequency is based on the total number of reported days of symptomatic episodes in the past week divided by the number of potential symptoms (number reported divided by 15 for GSAS score. The range for frequency score:0 to 7 with higher scores indicative of greater frequency of symptoms. Severity is the average distress score reported by individuals (zero if no symptoms). Symptom distress is based on a 4 point Likert scale (0= not at all, 1=somewhat, 2=quite a bit and 3=very much). The higher the score the worse outcome.~." (NCT02623816)
Timeframe: 6 weeks
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| GSAS Symptoms Score | GSAS Frequency Score | GSAS Severity Score | |
| Optimal Dosing | 5.2 | 1.0 | 0.6 |
| Sub-optimal Dosing | 8.5 | 2.2 | 1.0 |
"Primary efficacy Hypothesis 1: At 6-month follow-up, the proportion of Transesophageal Incisionless Fundoplication (TIF)2+Placebo pts who are free of troublesome symptoms will be statistically significantly larger than those randomized to the Sham+PPI (Proton Pump Inhibitor) treatment group." (NCT01136980)
Timeframe: 6 month follow up
| Intervention | Participants (Count of Participants) |
|---|---|
| Sham Placebo Procedure | 17 |
| TIF Transoral Fundoplication | 54 |
"DeMeester Score is a composite score taking into consideration reflux episodes, percentage of time pH is < 4 and others. DMS was first reported in 1974 by Johnson and DeMeester. It is a composite score that measures acid exposure during prolonged ambulatory pH monitoring. The parameters that constitute the score are:~total number of episodes of reflux, - reflux is undesirable, therefore lower numbers are better, higher numbers are worse. Ideally there would be zero reflux episodes.~% total time esophageal pH < 4, upright position and supine position, respectively - pH < 4 is undesirable, therefor lower percentages are better~number of episodes longer than 5 minutes, - lower is better~maximal reflux duration, (reflux is undesirable - lower is better~total percentage of time with pH below 4 - below 4 is undesirable - lower is better~The composite score can be obtained by adding the scores calculated for each of the six components." (NCT01136980)
Timeframe: 6 months post procedure
| Intervention | Composite DeMeester Score (Mean) | |
|---|---|---|
| Pre-Procedure DeMeester Score | 6 month post-procedure DeMeester Score | |
| Sham Placebo Procedure | 30.9 | 32.7 |
| TIF Transoral Fundoplication | 33.6 | 23.9 |
Reduction in severity of heartburn by 2 points or more on a 9-point Likert severity scale, which is sustained for 45 minutes or more (NCT01493089)
Timeframe: up to 14 days following treatment
| Intervention | Minutes (Median) |
|---|---|
| Zegerid Group | 37.5 |
| Losec Group | 37.5 |
Reduction in severity of heartburn by 2 points or more on a 9-point Likert severity scale, which is sustained for 45 minutes or more (NCT01493089)
Timeframe: up to 14 days
| Intervention | Minutes (Median) |
|---|---|
| Zegerid Group | 37.5 |
| Losec Group | 37.5 |
Time to sustained total relief, defined as zero severity (no heartburn) on a 9-point Likert severity scale, which is sustained for 45 minutes or more (NCT01493089)
Timeframe: 14 days
| Intervention | Minutes (Median) |
|---|---|
| Zegerid Group | 105.0 |
| Losec Group | 105.0 |
percentage of patients who have achieved sustained partial response, sustained response, or sustained total relief, by 45 minutes (NCT01493089)
Timeframe: up to 14 days
| Intervention | percentage of patients (Number) |
|---|---|
| Zegerid Group | 65 |
| Losec Group | 62.2 |
Proportion of patients who have achieved sustained response, sustained partial response or sustained total relief by 60 minutes (NCT01493089)
Timeframe: 14 days
| Intervention | Percentage of patients (Number) |
|---|---|
| Zegerid Group | 74.4 |
| Losec Group | 78.4 |
Proportion of patients who have achieved sustained response, sustained partial response or sustained total relief by 90 minutes (NCT01493089)
Timeframe: 14 days
| Intervention | Percentage of patients (Number) |
|---|---|
| Zegerid Group | 88.0 |
| Losec Group | 85.6 |
Presence of heartburn assessed retrospectively by the investigator. Classified by severity (none, mild, moderate, severe). Participants with mild heartburn (NCT00251927)
Timeframe: At 5 year visit
| Intervention | participants (Number) |
|---|---|
| Esomeprazole Surgical Arm | 11 |
| Esomeprazole Medical Arm | 25 |
Presence of heartburn assessed retrospectively by the investigator. Classified by severity (none, mild, moderate, severe). Participants with moderate heartburn (NCT00251927)
Timeframe: At 5 year visit
| Intervention | participants (Number) |
|---|---|
| Esomeprazole Surgical Arm | 3 |
| Esomeprazole Medical Arm | 3 |
Presence of heartburn assessed retrospectively by the investigator. Classified by severity (none, mild, moderate, severe) Participants with no heartburn (NCT00251927)
Timeframe: At 5 year visit
| Intervention | participants (Number) |
|---|---|
| Esomeprazole Surgical Arm | 163 |
| Esomeprazole Medical Arm | 161 |
Presence of heartburn assessed retrospectively by the investigator. Classified by severity (none, mild, moderate, severe). Participants with severe heartburn (NCT00251927)
Timeframe: At 5 year visit
| Intervention | participants (Number) |
|---|---|
| Esomeprazole Surgical Arm | 0 |
| Esomeprazole Medical Arm | 2 |
"Endoscopic findings classified according to the Los Angeles classification:~Grade Normal - endoscopy reveals no mucosal break Grade A- one or more mucosal breaks <5 mm in maximal length Grade B - one or more mucosal breaks >5 mm, but without continuity across mucosal folds Grade C - Mucosal breaks continuous between >2 mucosal folds, but involving less than 75% of the esophageal circumference Grade D - Mucosal breaks involving more than 75% of the esophageal circumference" (NCT00251927)
Timeframe: At 5 year visit
| Intervention | participants (Number) |
|---|---|
| Esomeprazole Surgical Arm | 12 |
| Esomeprazole Medical Arm | 16 |
"Endoscopic findings classified according to the Los Angeles classification:~Grade Normal - endoscopy reveals no mucosal break Grade A- one or more mucosal breaks <5 mm in maximal length Grade B - one or more mucosal breaks >5 mm, but without continuity across mucosal folds Grade C - Mucosal breaks continuous between >2 mucosal folds, but involving less than 75% of the esophageal circumference Grade D - Mucosal breaks involving more than 75% of the esophageal circumference" (NCT00251927)
Timeframe: At 5 year visit
| Intervention | participants (Number) |
|---|---|
| Esomeprazole Surgical Arm | 5 |
| Esomeprazole Medical Arm | 7 |
"Endoscopic findings classified according to the Los Angeles classification:~Grade Normal - endoscopy reveals no mucosal break Grade A- one or more mucosal breaks <5 mm in maximal length Grade B - one or more mucosal breaks >5 mm, but without continuity across mucosal folds Grade C - Mucosal breaks continuous between >2 mucosal folds, but involving less than 75% of the esophageal circumference Grade D - Mucosal breaks involving more than 75% of the esophageal circumference" (NCT00251927)
Timeframe: At 5 year visit
| Intervention | participants (Number) |
|---|---|
| Esomeprazole Surgical Arm | 144 |
| Esomeprazole Medical Arm | 158 |
"Endoscopic findings classified according to the Los Angeles classification:~Grade Normal - endoscopy reveals no mucosal break Grade A- one or more mucosal breaks <5 mm in maximal length Grade B - one or more mucosal breaks >5 mm, but without continuity across mucosal folds Grade C - Mucosal breaks continuous between >2 mucosal folds, but involving less than 75% of the esophageal circumference Grade D - Mucosal breaks involving more than 75% of the esophageal circumference" (NCT00251927)
Timeframe: At 5 year visit
| Intervention | participants (Number) |
|---|---|
| Esomeprazole Surgical Arm | 1 |
| Esomeprazole Medical Arm | 2 |
Treatment failure in the surgical arm defined when need for medical treatment for control of symptoms from reflux disease. Treatment failure in the medical arm defined when need for treatment other than esomeprazole for control of symptoms of reflux disease. (NCT00251927)
Timeframe: During 5 years
| Intervention | participants (Number) |
|---|---|
| Esomeprazole Surgical Arm | 33 |
| Esomeprazole Medical Arm | 19 |
Intra-gastric acid exposures assessed by 24-h pH-metry. Only participants with pH-emtry performed at 5 year visit included (NCT00251927)
Timeframe: At 5 year visit
| Intervention | percentage of time recorded (Mean) |
|---|---|
| Esomeprazole Surgical Arm | 2.9 |
| Esomeprazole Medical Arm | 4.7 |
The total score expressed as a mean of all the scores/number of lesions assessed; scored 2 when erosion/necrosis is found. The score could range from 0 to 2 (maximum severity). Only participants with biopsy at 5 years visit included (NCT00251927)
Timeframe: At 5 year visit
| Intervention | units on a scale (Mean) |
|---|---|
| Esomeprazole Surgical Arm | 0.23 |
| Esomeprazole Medical Arm | 0.25 |
Gastroesophageal Reflux Disease Health Related Quality of Life (GERD-HRQL) questionnaire, also known as Velanovich score. The questionnaire consists of 10 questions with responses of 0-5. The responses of the 10 questions are totaled (range of 0-50) where a higher total indicates more severe disease than a lower total. This questionnaire was administered while the subjects were not taking proton pump inhibitor (PPI) medication (i.e. off-PPI). Criterion for success was an improvement >= 50% compared to baseline, at six months post procedure in at least 53% of the subjects (53% is the lower boundary of the 95% confidence interval) (NCT00734747)
Timeframe: Six months
| Intervention | percentage of total participants (Number) |
|---|---|
| Medigus SRS Endoscopic Stapling System | 73 |
Esophageal pH (off PPI therapy) was measured in 66 patients pre-procedure and 64 patients at 6 months post-procedure (NCT00734747)
Timeframe: 6 months
| Intervention | percentage of time pH <4.0 (Mean) |
|---|---|
| Medigus SRS Endoscopic Stapling System | 7.3 |
(NCT00734747)
Timeframe: 6 months
| Intervention | percentage of subjects (Number) | |
|---|---|---|
| % patients who eliminated PPI use | % patients who reduced PPI use by >50% | |
| Medigus SRS Endoscopic Stapling System | 65 | 85 |
"The primary safety endpoint consisted of all treatment-related adverse events, during and after the SRS procedure. The primary safety endpoint consisted of all treatment-related adverse events, during and after the SRS procedure. Treatment-related events were conventionally defined as those which occurred in the first 30 days post-procedure. The SAEs presented here include all SAEs from the study, including one that occurred 35 days post-procedure (suicidal behavior). There was an interim review of early Serious Adverse Events (SAEs) after the first 24 patients. Protocol and device changes were then implemented, prior to the final 48 patients. Therefore, the SAEs are presented in two categories consisting of the first 24 patients and the final 48 patients." (NCT00734747)
Timeframe: 6 months
| Intervention | participants (Number) | |
|---|---|---|
| Serious Adverse Event - First 24 patients | Serious Adverse Events - final 48 participants | |
| Medigus SRS Endoscopic Stapling System | 8 | 2 |
Unit scale 0-48 was applied for an outcome measurement of the frequency of symptoms. The unit scale 0 was no symptom and scale 48 was usual symptom of GERD. The changing of the frequency of symptoms was the changing of the unit scale before and after treatment. (NCT01878526)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Omeprazole Plus Alginic Acid and Placebo of Domperidone | 4.6 |
| Omeprazole Plus Domperidone and Placebo of Alginic Acid | 4.7 |
VAS scale 0-100 was applied for an outcome measurement of the quality of life. The VAS scale 0 was the worst quality of life and scale 100 was the best quality of life. The changing of the quality of life was the changing of VAS of quality of life before and after treatment. (NCT01878526)
Timeframe: 8 weeks
| Intervention | VAS (100) (Mean) |
|---|---|
| Omeprazole Plus Alginic Acid and Placebo of Domperidone | 75.7 |
| Omeprazole Plus Domperidone and Placebo of Alginic Acid | 76.1 |
VAS scale 0-100 was applied for an outcome measurement of the severity of regurgitation. The VAS scale 0 was no symptoms of regurgitation and scale 100 was a maximum symptom of regurgitation. The changing of the severity of regurgitation was the changing of VAS before and after treatment. (NCT01878526)
Timeframe: 8 weeks
| Intervention | VAS (100) (Mean) |
|---|---|
| Omeprazole Plus Alginic Acid and Placebo of Domperidone | 24.9 |
| Omeprazole Plus Domperidone and Placebo of Alginic Acid | 23.1 |
VAS scale 0-100 was applied for an outcome measurement of the severity of heart burn. The VAS scale 0 was no symptoms of heart burn and scale 100 was a maximum symptom of heart burn. The changing of the severity of heart burn was the changing of VAS before and after treatment. (NCT01878526)
Timeframe: 8 weeks
| Intervention | VAS (100) (Mean) |
|---|---|
| Omeprazole Plus Alginic Acid and Placebo of Domperidone | 17.9 |
| Omeprazole Plus Domperidone and Placebo of Alginic Acid | 17.2 |
(NCT01878526)
Timeframe: 4 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Overall Systemic Sclerosis With GERD (Before Randomization) | 59 |
The area under the curve for omeprazole concentration-time curve for immediate release and delayed release omeprazole. (NCT00492622)
Timeframe: 0 to 5 hrs after the study drug was ingested on treatment day 7
| Intervention | mg*h/mL (Mean) |
|---|---|
| All Study Participants Immediate Release Arm | 3842 |
| All Study Subjects Delayed Release Arm | 3745 |
Maximal concentration of immediate-release vs. delayed-release omeprazole (NCT00492622)
Timeframe: 10, 20, 30, 45, 60, 90, 120, 150, 180, 210, 240 and 300 min after the study drug was ingested on day 7 of treatment
| Intervention | ng/mL plasma (Mean) |
|---|---|
| All Study Participants Immediate Release Arm | 1979 |
| All Study Subjects Delayed Release Arm | 1625 |
Time to max concentration for Immediate release vs. Delayed release omeprazole (NCT00492622)
Timeframe: 10, 20, 30, 45, 60, 90, 120, 150, 180, 210, 240 and 300 min after the study drug was ingested on day 7 of treatment
| Intervention | minutes (Mean) |
|---|---|
| All Study Participants Immediate Release Arm | 32 |
| All Study Subjects Delayed Release Arm | 97 |
Change in Short Form 36 Scores administered at baseline and 6 weeks after each intervention. Range from 0 to 100, with a higher punctuation meaning a better outcome. Quality of life change of ≥ 10 points from baseline was considered clinically relevant. (NCT02706938)
Timeframe: Secondary outcome will be assessed at baseline and 6 weeks after starting each period
| Intervention | scores on a scale (Mean) |
|---|---|
| Head of Bed Elevation | 6.5992 |
| Control | -0.3139 |
Change in Reflux Disease Questionnaire Scores administered at baseline and 6 weeks after each intervention. Range from 0 to 6, with a higher punctuation meaning a worse outcome. Symptom change of ≥ 0,6 points from baseline was considered clinically relevant. (NCT02706938)
Timeframe: Primary outcome will be assessed at baseline and 6 weeks after starting each period
| Intervention | scores on a scale (Mean) |
|---|---|
| Head of Bed Elevation | -1.2397 |
| Control | 0.0869 |
Percentage of patients who preferred head of bed elevation after trial ending (NCT02706938)
Timeframe: Secondary outcome will be assessed 14 weeks after starting the trial
| Intervention | percent of participants (Number) |
|---|---|
| All Participants | 63.158 |
GERDQ score. Scale of 0-12, higher score indicates increased symptom severity. (NCT02552966)
Timeframe: 2 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| UESAD | 8.6 |
NGSSI questionnaire score (NCT02552966)
Timeframe: 2 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| UESAD | 26.8 |
Respiratory symptom index (RSI) score. Values between 0 and 45. Higher value is associated with increased symptom severity. (NCT02552966)
Timeframe: 2 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| UESAD | 19.4 |
Average salivary pepsin concentration (NCT02552966)
Timeframe: 2 weeks
| Intervention | ng/mL (Mean) |
|---|---|
| UESAD | 158.4 |
Change in the average daily GERD symptom severity score over a 7-day period from baseline to the last week of the study in the expanded vs. standard group. GERD symptom severity is based on the sum of scores assessing the severity of daytime heartburn, nighttime heartburn, and acid reflux each on a 0-4 point scale (none, mild, moderate, severe, very severe; higher scores signify worse symptoms). Possible score range = 0 - 12. Change score calculated as average score at 8 weeks minus average score at baseline. For statistical testing, we used a general linear model of post-GERD symptoms adjusted for baseline GERD symptoms and randomization assignment. (NCT04292470)
Timeframe: Time 0 (baseline) to 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Standard Visit | 0.6 |
| Expanded Visit | -1.7 |
Concordance in skin conductance response (SCR) between patient and physician was calculated using an established approach to create a single index value for the visit (baseline). Average slopes of the SCR were calculated in moving 5 second windows, offset by 1 second. Pearson correlations between time-locked patient and physician SCR slopes were calculated over successive 15 second windows. A single session index was calculated from the ratio of the sum of the positive correlations across the entire visit divided by the sum of the absolute value of the negative correlations across the entire visit. To reduce skew, the natural logarithm of the index was calculated. An index value of zero reflects equal positive and negative correlations, a value greater than zero reflects more concordance in SCR than not, while a value less than zero reflects less than 50% concordance. In the statistical analysis, we included change in GERD symptoms from baseline to 8 weeks. (NCT04292470)
Timeframe: Time 0 (baseline) to 8 weeks.
| Intervention | natural log of the index value (Mean) |
|---|---|
| Standard Visit | 0.02 |
| Expanded Visit | -2.2 |
236 reviews available for omeprazole and Gastroesophageal Reflux
| Article | Year |
|---|---|
Recent advances in proton pump inhibitors and management of acid-peptic disorders.
Topics: Animals; Anti-Ulcer Agents; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Humans; | 2007 |
Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis.
Topics: Adult; Alginates; Dexlansoprazole; Endoscopy, Gastrointestinal; Gastroesophageal Reflux; Gastrointes | 2023 |
Pharmacological treatment of gastro-oesophageal reflux in children.
Topics: Adolescent; Child; Esomeprazole; Gastroesophageal Reflux; Humans; Infant; Infant, Newborn; Omeprazol | 2023 |
Over 30 Years of Omeprazole.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Child; Gastroesophageal Reflux; Humans; Omeprazole; P | 2023 |
Review article: the management of heartburn during pregnancy and lactation.
Topics: Alginates; Antacids; Breast Feeding; Contraindications, Drug; Female; Gastroesophageal Reflux; Gastr | 2020 |
Pharmacologic treatment of GERD: Where we are now, and where are we going?
Topics: Cimetidine; Esomeprazole; Esophageal Mucosa; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazo | 2020 |
Gastroesophageal Reflux Disease: A Review.
Topics: Adenocarcinoma; Barrett Esophagus; Diagnosis, Differential; Esophageal Neoplasms; Fundoplication; Ga | 2020 |
Efficacy of omeprazole/sodium bicarbonate treatment in gastroesophageal reflux disease: a systematic review.
Topics: Drug Administration Schedule; Drug Combinations; Gastroesophageal Reflux; Humans; Omeprazole; Proton | 2018 |
The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Aryl Hydrocarbon H | 2013 |
Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection.
Topics: Esomeprazole; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Omepraz | 2015 |
Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis.
Topics: Esomeprazole; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors; Publication Bias | 2015 |
Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro-esophageal reflux disease: a meta-analysis.
Topics: Cardiovascular Diseases; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Omeprazole; Proto | 2017 |
The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis.
Topics: Anti-Ulcer Agents; Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inh | 2016 |
Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults.
Topics: Adult; Anti-Ulcer Agents; Duodenal Ulcer; Esomeprazole; Gastroesophageal Reflux; Helicobacter Infect | 2008 |
Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; O | 2008 |
Treatment of non-cardiac chest pain.
Topics: Anti-Ulcer Agents; Botulinum Toxins, Type A; Calcium Channel Blockers; Chest Pain; Diltiazem; Enzyme | 2008 |
[Extraesophageal manifestations of gastroesophageal reflux disease].
Topics: Anti-Ulcer Agents; Asthma; Cough; Esophageal pH Monitoring; Gastric Acidity Determination; Gastroeso | 2008 |
Treatment for patients with gastroesophageal reflux disease.
Topics: Aged; Anti-Ulcer Agents; Drug Monitoring; Endoscopy, Digestive System; Gastroesophageal Reflux; Huma | 2004 |
Does treatment with proton pump inhibitors for gastroesophageal reflux disease (GERD) improve asthma symptoms in children with asthma and GERD? A systematic review.
Topics: Asthma; Child; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors; Randomized Contr | 2009 |
[Proton pump inhibitors, a family of drugs in continuous expansion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett E | 2000 |
Latin american consensus on gastroesophageal reflux disease: an update on therapy.
Topics: Alginates; Antacids; Anti-Ulcer Agents; Cohort Studies; Consensus; Dose-Response Relationship, Drug; | 2010 |
Clinical practice. Barrett's esophagus.
Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E | 2009 |
Clinical practice. Barrett's esophagus.
Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E | 2009 |
Clinical practice. Barrett's esophagus.
Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E | 2009 |
Clinical practice. Barrett's esophagus.
Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E | 2009 |
Clinical practice. Barrett's esophagus.
Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E | 2009 |
Clinical practice. Barrett's esophagus.
Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E | 2009 |
Clinical practice. Barrett's esophagus.
Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E | 2009 |
Clinical practice. Barrett's esophagus.
Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E | 2009 |
Clinical practice. Barrett's esophagus.
Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E | 2009 |
[Omeprazole of limited value in crying babies].
Topics: Anti-Ulcer Agents; Body Weight; Crying; Dose-Response Relationship, Drug; Female; Gastroesophageal R | 2010 |
Maintenance treatment with proton pump inhibitors for reflux esophagitis in pediatric patients: a systematic literature analysis.
Topics: Anti-Ulcer Agents; Child; Esophagitis; Gastroesophageal Reflux; Humans; Omeprazole; Outcome Assessme | 2010 |
GERD in 2010: diagnosis, novel mechanisms of disease and promising agents.
Topics: Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Esophagus; Gastroesophageal Reflux; Humans; Hydrogen | 2011 |
Does antireflux surgery prevent progression of Barrett's esophagus?
Topics: Adenocarcinoma; Barrett Esophagus; Cohort Studies; Combined Modality Therapy; Disease Progression; E | 2011 |
Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Age Factors; Child; Child, Preschool; Cross-Ove | 2011 |
Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chest Pain; Esophagus; Gastroesophageal Reflux; Heartburn; | 2011 |
Do proton pump inhibitors protect against cancer progression in GERD?
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Barrett Esop | 2013 |
Crying and spilling--time to stop the overmedicalisation of normal infant behaviour.
Topics: Anti-Ulcer Agents; Child Development; Crying; Gastroesophageal Reflux; Humans; Infant; Infant Behavi | 2012 |
Esomeprazole magnesium (Nexium).
Topics: Anti-Ulcer Agents; Esomeprazole; Esophagitis; Gastroesophageal Reflux; Helicobacter Infections; Huma | 2001 |
Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis.
Topics: Abnormalities, Drug-Induced; Female; Fetus; Gastroesophageal Reflux; Humans; Maternal-Fetal Exchange | 2002 |
[Chronic respiratory disease and gastroesophageal reflux].
Topics: Asthma; Chronic Disease; Cough; Diet Therapy; Gastroesophageal Reflux; Histamine H2 Antagonists; Hum | 2002 |
Motion--Helicobacter pylori worsens GERD: arguments for the motion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clinical Trials a | 2002 |
Motion--Helicobacter pylori causes or worsens GERD: arguments against the motion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Enzyme Inhibit | 2002 |
The clinical importance of proton pump inhibitor pharmacokinetics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cost Savings; Duodenal U | 2002 |
The pharmacology and clinical relevance of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Administration Schedule; Drug Therapy, | 2002 |
Esomeprazole: update and clinical review.
Topics: Anti-Ulcer Agents; Clinical Trials as Topic; Drug Labeling; Enzyme Inhibitors; Esomeprazole; Esophag | 2002 |
Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2003 |
What's new: proton pump inhibitors and pediatrics.
Topics: Child; Dyspepsia; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Ome | 2003 |
Lansoprazole: in the management of gastroesophageal reflux disease in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Child; Child, Pres | 2003 |
Reflux disease and Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Anti-Ulcer Agents; Barrett Esophagus; Endos | 2003 |
Review of esomeprazole in the treatment of acid disorders.
Topics: Anti-Ulcer Agents; Dose-Response Relationship, Drug; Esomeprazole; Esophagitis, Peptic; Gastric Acid | 2003 |
Review article: pharmacology of esomeprazole and comparisons with omeprazole.
Topics: Anti-Ulcer Agents; Esomeprazole; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concent | 2003 |
Review article: initial therapy of reflux disease with esomeprazole.
Topics: Anti-Ulcer Agents; Double-Blind Method; Esomeprazole; Gastroesophageal Reflux; Gastroscopy; Humans; | 2003 |
On-demand proton pump inhibitor therapy in patients with gastro-oesophageal reflux disease.
Topics: Esomeprazole; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors; Ranitidine | 2002 |
Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Gastr | 2003 |
A pharmacoeconomic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in The Netherlands.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cost-Benefit Analysis; E | 2003 |
Review article: test and treat or treat and test in reflux disease?
Topics: Adenocarcinoma; Ambulatory Care; Anti-Ulcer Agents; Barrett Esophagus; Esophageal Neoplasms; Gastroe | 2003 |
The impact of gastroesophageal reflux disease on quality of life.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Combined Modality Therapy; Cross-Over St | 2003 |
The impact of treatment for gastro-oesophageal reflux disease on health-related quality of life: a literature review.
Topics: Drug Evaluation; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Omeprazole; Proton Pumps | 2003 |
[All proton pump inhibitors are equally efficacious in standard dosages].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 2003 |
Medical management of patients with esophageal or supraesophageal gastroesophageal reflux disease.
Topics: Age Factors; Barrett Esophagus; Female; Gastric Acid; Gastritis; Gastroesophageal Reflux; Gastrointe | 2003 |
Improving health-related quality of life in gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Lansopr | 2003 |
[Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Gastroesophageal Reflux; | 2003 |
Proton pump inhibitors in children: a review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child; Drug Interactions; Esophagitis, P | 2003 |
Alternative dosing for PPI therapy: rationale and options.
Topics: Antacids; Capsules; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Gastroesophageal Reflux | 2003 |
Epigastric pain in dyspepsia and reflux disease.
Topics: Abdominal Pain; Anti-Ulcer Agents; Drug Therapy, Combination; Dyspepsia; Gastroesophageal Reflux; He | 2003 |
Sleep issues in gastroesophageal reflux disease: beyond simple heartburn control.
Topics: Antacids; Esophagitis; Gastroesophageal Reflux; Heartburn; Humans; Omeprazole; Proton Pump Inhibitor | 2003 |
[Modern approach to the therapy of gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2003 |
Review of rabeprazole in the treatment of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2004 |
[Drug treatment of gastro-esophageal reflux disease in pregnant women: consensus guidelines of gastroenterologists and gynaecologists].
Topics: Adult; Anti-Ulcer Agents; Female; Gastroenterology; Gastroesophageal Reflux; Gynecology; Humans; Ome | 2003 |
Whither surgery in the treatment of gastroesophageal reflux disease (GERD)?
Topics: Anti-Ulcer Agents; Female; Fundoplication; Gastroesophageal Reflux; Humans; Male; Omeprazole; Ontari | 2004 |
Managing gastro-oesophageal reflux disease in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child; Gastroesophageal Reflux; Humans; | 2004 |
Protein pump inhibitors go over the counter.
Topics: Administration, Intravaginal; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Aryl Hydro | 2004 |
Single-isomer drugs: true therapeutic advances.
Topics: Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors | 2004 |
[Treatment of reflux disease. An international consensus conference put things in its place].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal Reflux; | 2003 |
The basis of differentiation of PPIs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Cysteine; Dose- | 2004 |
Understanding NSAID-PPI-COX-2 interrelationships.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benzimida | 2004 |
[Acute interstitial nephritis associated with omeprazole therapy].
Topics: Acute Disease; Aged; Combined Modality Therapy; Enzyme Inhibitors; Female; Gastroesophageal Reflux; | 2004 |
Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cytochrome P-450 Enzyme | 2004 |
[Test of refractory gastroesophageal reflux disease].
Topics: Aryl Hydrocarbon Hydroxylases; Bile; Bilirubin; Biomarkers; Circadian Rhythm; Cytochrome P-450 CYP2C | 2004 |
[Significance of PPI-test in the diagnosis of GERD].
Topics: Enzyme Inhibitors; Gastroesophageal Reflux; Heartburn; Humans; Omeprazole; Proton Pump Inhibitors | 2004 |
[Primary care for GEDR].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Circadian Rhythm; Drug Therapy, Combination | 2004 |
[Evaluation of the efficacy and the cost-effectiveness of maintenance treatment of gastroesophageal reflux disease: proton pump inhibitor versus histamine-2-receptor antagonist].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Drug Therapy, Combin | 2004 |
[PPI: new strategies for GERD].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Ci | 2004 |
Extra-esophageal disorders in gastroesophageal reflux disease.
Topics: Asthma; Cough; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Laryngitis; Omeprazole; Proton Pu | 2004 |
Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Biological Availability; Dose-Response Relatio | 2004 |
Management of acid-related disorders in patients with dysphagia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Age Factors; Aged; Aged, 80 an | 2004 |
Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida | 2004 |
Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis; Gastric Aci | 2004 |
Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esomeprazole; Gastric Ac | 2004 |
Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Benzimidazoles; D | 2004 |
Effectiveness of proton pump inhibitors: beyond cost.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esophagitis; Gastroesoph | 2004 |
Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Circadian Rhythm; Esomep | 2005 |
Role of pantoprazole in the treatment of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Gastric Acid; Gastroesophageal Reflux; H(+) | 2005 |
[Bronchial asthma and gastroesophageal reflux disease: are they interrelated by chance?].
Topics: Adult; Algorithms; Anti-Ulcer Agents; Asthma; Bronchodilator Agents; Cimetidine; Controlled Clinical | 2005 |
Severe GERD: effective treatment prevents potentially serious complications.
Topics: Diagnosis, Differential; Digestive System Surgical Procedures; Education, Medical, Continuing; Gastr | 2005 |
Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: still an unexplored triangle.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esophagitis, Peptic; Famotidine; Gastroesophageal Reflux; H | 2005 |
Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastric Acid; Gastroesop | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Review article: the long-term use of proton-pump inhibitors.
Topics: Age Factors; Enzyme Inhibitors; Gastritis, Atrophic; Gastroesophageal Reflux; Helicobacter Infection | 2005 |
State of the art: extraesophageal manifestations of gastroesophageal reflux disease.
Topics: Clinical Trials as Topic; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Lung Diseases; Omepraz | 2005 |
Understanding GERD symptoms in the clinical setting.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2005 |
Extraesophageal manifestations of GERD: diagnosis and therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Chronic Disease; | 2005 |
Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Ulcer Agents; Child; Child, Preschool; Gas | 2005 |
Review of immediate-release omeprazole for the treatment of gastric acid-related disorders.
Topics: Administration, Oral; Anti-Ulcer Agents; Circadian Rhythm; Dosage Forms; Drug Administration Schedul | 2005 |
Review article: immediate-release proton-pump inhibitor therapy--potential advantages.
Topics: Delayed-Action Preparations; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Omeprazole; Proton | 2005 |
Review article: putting immediate-release proton-pump inhibitors into clinical practice--improving nocturnal acid control and avoiding the possible complications of excessive acid exposure.
Topics: Adenocarcinoma; Barrett Esophagus; Chronotherapy; Delayed-Action Preparations; Disease Progression; | 2005 |
Rabeprazole experience in Korea; focus on CYP2C19 polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Aryl Hydrocar | 2005 |
CYP2C19 genotype and the PPIs--focus on rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Aryl Hydrocar | 2005 |
Diagnostic and management problems of laryngopharyngeal reflux disease in children.
Topics: Child; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Infant; Laryngeal Diseases; L | 2006 |
Intravenous proton pump inhibitor therapy: a rationale for use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal Reflux; | 2005 |
Gastroesophageal reflux disease and extraesophageal disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Benzimidazoles; Esophageal pH Mo | 2005 |
Empiric treatment of laryngopharyngeal reflux with proton pump inhibitors: a systematic review.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow | 2006 |
Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Endoscopy, Digestive Sys | 2006 |
Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anaphylaxis; Anti-Ulcer Agents; Benzimidazoles; Famotidine; | 2006 |
Gastroesophageal reflux disease symptoms on antisecretory therapy: acid, non-acid, or no GERD.
Topics: Aged; Anti-Ulcer Agents; Barrett Esophagus; Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Ma | 2006 |
The complete remission concept.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagoscopy; Gastroesophageal Reflux; | 2006 |
[Dosaging of proton pumps inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; | 2006 |
Treatment of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Adult; Anti-Ulcer Agents; Barre | 2006 |
[Safety of proton pump inhibitors for long-term application].
Topics: Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors | 2006 |
Medical treatment of gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Omeprazole; Proton Pum | 2006 |
Acid-related disorders and use of antisecretory medication.
Topics: Anti-Ulcer Agents; Denmark; Drug Utilization; Enzyme Inhibitors; Esophagitis; Esophagoscopy; Female; | 2007 |
Process of measuring in clinical medicine--implications of different definitions in clinical therapeutic studies.
Topics: Anti-Ulcer Agents; Clinical Medicine; Dose-Response Relationship, Drug; Evidence-Based Medicine; Fem | 2007 |
[Therapeutic innovations in gastroesophageal reflux].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Catheter Ablation; Cisapride; End | 2007 |
[Proton pump inhibitors in developmental period medicine].
Topics: Adult; Age Factors; Anti-Ulcer Agents; Child; Drug Interactions; Duodenitis; Enzyme Inhibitors; Esom | 2007 |
[Gastroesophageal reflux as a cause of night sweating].
Topics: Adult; Aged; Anti-Ulcer Agents; Cholestyramine Resin; Diagnosis, Differential; Domperidone; Female; | 2007 |
CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Biotransf | 2007 |
[Modern attitude towards management of laryngopharyngeal form of gastroesophageal reflux disease. Lithuanian clinical practice guidelines for adults].
Topics: Adult; Algorithms; Antacids; Anti-Ulcer Agents; Domperidone; Dopamine Antagonists; Gastroesophageal | 2007 |
Recent advances in chirally pure proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esomeprazole; Gastroesophageal Reflux; Humans; Isomerism; O | 2007 |
Pathophysiology and management of noncardiac chest pain.
Topics: Arousal; Chest Pain; Diagnosis, Differential; Esophageal Motility Disorders; Esophagogastric Junctio | 1995 |
[Lansoprazol].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Controlled Clinical Trials as Topic; Duo | 1995 |
Wrap session: is the Nissen slipping? Can medical treatment replace surgery for severe gastroesophageal reflux disease in children?
Topics: Adult; Child; Costs and Cost Analysis; Fundoplication; Gastroesophageal Reflux; Histamine H2 Antagon | 1995 |
Treatment of gastroesophageal reflux: the role of proton pump inhibitors.
Topics: Adult; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Male; | 1995 |
Severe gastroesophageal reflux disease. Medical and surgical options for long-term care.
Topics: Antacids; Anti-Ulcer Agents; Cisapride; Drug Therapy, Combination; Esophageal Diseases; Esophagogast | 1995 |
Optimizing acid suppression for treatment of acid-related diseases.
Topics: Duodenal Ulcer; Gastric Acid; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Omeprazole; | 1995 |
Gastro-oesophageal reflux disease pathophysiology, diagnosis and management.
Topics: Clinical Trials as Topic; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Omeprazole | 1994 |
The treatment of gastroesophageal reflux disease.
Topics: Antacids; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Omeprazole; Recurrence; Sucralf | 1994 |
[Surgical or conservative therapy of Barrett esophagus?].
Topics: Antacids; Barrett Esophagus; Esophageal Neoplasms; Esophagus; Follow-Up Studies; Gastroesophageal Re | 1994 |
Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Gastritis; Gastroesophag | 1993 |
Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Esophagitis; Gastric Acid; Gastr | 1993 |
Gastro-oesophageal reflux.
Topics: Combined Modality Therapy; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Omeprazole; Re | 1994 |
[Is remission of Barrett esophagus possible?].
Topics: Antacids; Barrett Esophagus; Bethanechol Compounds; Cimetidine; Drug Therapy, Combination; Gastroeso | 1994 |
Efficacy of omeprazole in lower grades of gastro-oesophageal reflux disease.
Topics: Cimetidine; Clinical Trials as Topic; Double-Blind Method; Gastroesophageal Reflux; Humans; Omeprazo | 1994 |
Long-term treatment of gastro-oesophageal reflux disease with omeprazole.
Topics: Chronic Disease; Clinical Trials as Topic; Gastroesophageal Reflux; Humans; Omeprazole | 1994 |
Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease.
Topics: Costs and Cost Analysis; Depression, Chemical; Duodenal Ulcer; Gastric Acid; Gastroesophageal Reflux | 1994 |
Efficacy, safety, and cost issues in managing patients with gastroesophageal reflux disease.
Topics: Alginates; Antacids; Drug Costs; Gastric Acid; Gastroesophageal Reflux; Glucuronic Acid; Hexuronic A | 1993 |
Pharmacokinetics and pharmacodynamics of acid-suppressive agents in patients with gastroesophageal reflux disease.
Topics: Gastric Acid; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Omeprazole | 1993 |
Gastric acid secretion and intragastric acidity: measurement in health and disease.
Topics: Duodenal Ulcer; Female; Gastric Acid; Gastric Acidity Determination; Gastroesophageal Reflux; Helico | 1993 |
Acid pump blockers: what are their current therapeutic roles?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duodenal Ulcer; Gastroesophageal Reflux; | 1993 |
Clinical efficacy of pantoprazole compared with ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 1994 |
Barrett's esophagus: new definitions and approaches in children.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Barrett Esophagus; Child; Child, Preschool; Cimetidine; End | 1993 |
Is there any acid peptic disease that is refractory to proton pump inhibitors?
Topics: Clinical Trials as Topic; Drug Resistance; Duodenal Ulcer; Gastric Acid; Gastroesophageal Reflux; Hu | 1993 |
Comparative role of omeprazole in the treatment of gastroesophageal reflux disease.
Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Double-Blind Method; Enzyme Inhibitors; Gastroesoph | 1995 |
Excluding gastroesophageal reflux disease as the cause of chronic cough.
Topics: Anti-Ulcer Agents; Chronic Disease; Cough; Female; Gastroesophageal Reflux; Humans; Middle Aged; Ome | 1996 |
The medical management of gastro-oesophageal reflux.
Topics: Anti-Ulcer Agents; Dopamine Antagonists; Esophagitis; Gastroesophageal Reflux; Histamine H2 Antagoni | 1996 |
Management of gastroesophageal reflux disease.
Topics: Antacids; Gastroesophageal Reflux; Gastrointestinal Agents; Histamine Antagonists; Humans; Omeprazol | 1996 |
Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroes | 1996 |
Influence of pathophysiology, severity, and cost on the medical management of gastroesophageal reflux disease.
Topics: Aged; Anti-Ulcer Agents; Cisapride; Drug Interactions; Drug Therapy, Combination; Esophagitis, Pepti | 1996 |
Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Benzimidazoles; Cimetidine; Cisapride; Domperidon | 1996 |
Long-term management of gastroesophageal reflux disease and its complications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Gastroesophageal Reflux; Hista | 1997 |
Current medical treatment and indications for surgical referral for gastroesophageal reflux disease (GERD).
Topics: Enzyme Inhibitors; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Omeprazole; Patient Ed | 1997 |
Value of a therapeutic trial to diagnose gastroesophageal reflux disease: step up versus step down therapy.
Topics: Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Omeprazole; Proton Pump Inhibitors | 1997 |
[Gastroesophageal reflux disease refractory to medical treatment. Which approach: the pill or the scalpel?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Fundoplication; Gastroesophageal Reflux; Hu | 1997 |
Medical therapy for supraesophageal complications of gastroesophageal reflux.
Topics: Clinical Trials as Topic; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Laryngeal Disea | 1997 |
Should Helicobacter pylori be eradicated before starting long-term proton pump inhibitors?
Topics: Anti-Ulcer Agents; Atrophy; Gastric Acid; Gastric Mucosa; Gastritis; Gastroesophageal Reflux; Helico | 1997 |
[Drug therapy of gastroesophageal reflux (a prospective controlled clinical trial)].
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Domperidone; Dose-Response Relationship, Drug; Fe | 1998 |
Acid pump inhibitors. The treatment of gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cisapride; Gastroesophag | 1998 |
Does medical antireflux therapy improve asthma in asthmatics with gastroesophageal reflux?: a critical review of the literature.
Topics: Antacids; Anti-Asthmatic Agents; Anti-Ulcer Agents; Asthma; Cimetidine; Circadian Rhythm; Cisapride; | 1998 |
Proton pump inhibitors.
Topics: Anti-Ulcer Agents; Drug Therapy, Combination; Enzyme Inhibitors; Gastroesophageal Reflux; H(+)-K(+)- | 1998 |
Different management for Helicobacter pylori positive and negative patients with gastro-oesophageal reflux disease?
Topics: Anti-Ulcer Agents; Barrett Esophagus; Duodenal Ulcer; Gastroesophageal Reflux; Helicobacter Infectio | 1998 |
Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Gastroesophageal Reflux; Helico | 1998 |
Gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Diagnosis, Differential; Gastroesophageal Reflux; Histamine H2 Antagonists; Human | 1998 |
Helicobacter pylori, acid, and omeprazole revisited: bacterial eradication and rebound hypersecretion.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Gastric Acid; Gastroesophagea | 1999 |
Gastro-oesophageal reflux and Helicobacter pylori.
Topics: Adenocarcinoma; Anti-Ulcer Agents; Barrett Esophagus; Diagnosis, Differential; Esophageal Neoplasms; | 1998 |
Review article: Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management.
Topics: Barrett Esophagus; Gastritis, Atrophic; Gastroesophageal Reflux; Helicobacter Infections; Helicobact | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Nocturnal asthma: role of nocturnal gastroesophageal reflux.
Topics: Acids; Adult; Asthma; Bronchoconstriction; Child; Circadian Rhythm; Gastroesophageal Reflux; Humans; | 1999 |
Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 1999 |
Asthma and gastroesophageal reflux disease: the truth is difficult to define.
Topics: Animals; Anti-Ulcer Agents; Asthma; Gastroesophageal Reflux; Humans; Omeprazole; Prevalence | 1999 |
A practical approach to heartburn.
Topics: Anti-Ulcer Agents; Circadian Rhythm; Drug Administration Schedule; Drug Therapy, Combination; Female | 1999 |
[25 years of gastric acid blockers].
Topics: Anti-Ulcer Agents; Cimetidine; Dyspepsia; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; | 1999 |
[Indications and use of omeprazole in esophago-gastro-duodenal diseases].
Topics: Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Esophageal Diseases; Esophagitis; Gastritis; | 1999 |
Gastroesophageal reflux: practical management of a common, challenging disorder.
Topics: Anti-Ulcer Agents; Barrett Esophagus; Cisapride; Endoscopy, Gastrointestinal; Gastrins; Gastroesopha | 1999 |
Medical therapy. Management of the refractory patient.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Therapy, Combination; Enzyme Inhibitors; Gastroesophag | 1999 |
Empirical trials in treatment of gastroesophageal reflux disease.
Topics: Chest Pain; Clinical Trials as Topic; Cost-Benefit Analysis; Diagnosis, Differential; Enzyme Inhibit | 2000 |
The efficacy and safety of long-term omeprazole treatment for gastroesophageal reflux disease.
Topics: Animals; Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Omeprazole; Time Factors | 2000 |
[Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2000 |
[Conservative and surgical antireflux therapy as prevention of carcinoma].
Topics: Adenocarcinoma; Anti-Ulcer Agents; Barrett Esophagus; Biopsy; Clinical Trials as Topic; Esophageal N | 2000 |
The benefit/risk profile of rabeprazole, a new proton-pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Controlled Clinical Trials as Topic; Duoden | 2000 |
Acid suppression therapy in Barrett's esophagus: the importance of pH monitoring.
Topics: Anti-Ulcer Agents; Barrett Esophagus; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Co | 2000 |
Chronic cough, asthma, and gastroesophageal reflux.
Topics: Anti-Ulcer Agents; Asthma; Chronic Disease; Cough; Gastroesophageal Reflux; Humans; Hydrogen-Ion Con | 2000 |
Quality of life and severity of symptoms in gastro-oesophageal reflux disease: a clinical review.
Topics: Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Laparoscopy; Omeprazole; Patient Satisfaction; Q | 2000 |
Esomeprazole.
Topics: Animals; Anti-Ulcer Agents; Clinical Trials as Topic; Duodenal Ulcer; Enzyme Inhibitors; Esomeprazol | 2000 |
Pathogenesis and current management of gastrooesophageal-reflux-related asthma.
Topics: Asthma; Enzyme Inhibitors; Fundoplication; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans | 2000 |
Endoscopy-negative reflux disease.
Topics: Anti-Ulcer Agents; Esophagitis; Esophagoscopy; Female; Gastroesophageal Reflux; Humans; Male; Omepra | 2000 |
[Gastroesophageal reflux disease: new data on the mechanisms of esophageal ulcer lesion healing].
Topics: Anti-Ulcer Agents; Esophagus; Gastroesophageal Reflux; Humans; Laser Therapy; Mucous Membrane; Omepr | 2000 |
Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Duode | 2000 |
Clinical experience with pantoprazole in gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Ulcer Agents; Benzi | 2000 |
Pantoprazole: a new proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2000 |
Switching between intravenous and oral pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Benzimidazoles; Cl | 2001 |
Managed care issues in the treatment of gastroesophageal reflux disease.
Topics: Cost of Illness; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Life Style; Managed Care Progra | 2000 |
Management of GERD: medical versus surgical.
Topics: Adenocarcinoma; Anti-Ulcer Agents; Costs and Cost Analysis; Esophageal Neoplasms; Esophagitis, Pepti | 2001 |
Gastroesophageal reflux disease: extraesophageal manifestations and therapy.
Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Asthma; Cough; Female; Fundoplication; Gastroesophageal | 2001 |
Approach to the patient with unexplained chest pain.
Topics: Adult; Algorithms; Anti-Ulcer Agents; Chest Pain; Diagnosis, Differential; Esophagus; Gastroesophage | 2001 |
Aggressive acid control: minimizing progression of Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Barrett Esophagus; Enzyme Inhibitors; Gastroesophageal Refl | 2001 |
Gastroesophageal reflux disease and Barrett's esophagus.
Topics: Adenocarcinoma; Barrett Esophagus; Endoscopy, Gastrointestinal; Esophageal Neoplasms; Esophagus; Gas | 2001 |
Efficacy of rabeprazole once daily for acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Benzimidazole | 2001 |
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child | 2001 |
A review of omeprazole use in the treatment of acid-related disorders in children.
Topics: Administration, Oral; Adolescent; Adult; Anti-Ulcer Agents; Biological Availability; Child; Child, P | 2001 |
Pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Esoph | 2001 |
Shortcomings of the first-generation proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Biological Availability; Cytochrome P-450 E | 2001 |
New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P | 2001 |
Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal Reflux; | 2001 |
[Experience in the use of losek (omeprazole) in gastroenterology].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Double | 2001 |
Review article: long-term use of proton pump inhibitors in GORD--help or hindrance?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Lansopr | 2001 |
Pharmacoeconomic issues of the treatment of gastroesophageal reflux disease.
Topics: Antacids; Anti-Ulcer Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Dopamine Antagonists; | 2001 |
[GERD (gastroesophageal reflux disease)].
Topics: Asthma; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Omeprazole; Prevalence; Proton Pump Inhi | 2001 |
[Comparative study of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 2001 |
Gastroesophageal reflux in infants and children. When to reassure and when to go further.
Topics: Child; Child, Preschool; Enzyme Inhibitors; Esophagitis; Gastroesophageal Reflux; Humans; Infant; Om | 2001 |
Noncardiac chest pain.
Topics: Algorithms; Anti-Anxiety Agents; Anti-Ulcer Agents; Chest Pain; Diagnosis, Differential; Esophagus; | 2002 |
[Long-term therapy of gastrooesophageal reflux disease: Medical treatment or anti-reflux surgery?].
Topics: Esophagitis, Peptic; Follow-Up Studies; Fundoplication; Gastroesophageal Reflux; Humans; Multicenter | 2001 |
Rabeprazole: an update of its use in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida | 2001 |
Improving opportunities for effective management of gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Biological Availability; Esomeprazole; Esophagitis; Gastric Mucosa; Gastroesophag | 2001 |
The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Decision Support Techniques; Gastroesophageal Reflux; Humans; Office Visits; Omep | 2002 |
An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Digestive System Diseases; Duodenal Ulcer; Dyspepsia; Enzym | 2002 |
Use of antisecretory agents as a trial of therapy.
Topics: Anti-Ulcer Agents; Dyspepsia; Gastroesophageal Reflux; Humans; Omeprazole | 2002 |
Combination drug therapy for gastroesophageal reflux disease.
Topics: Anti-Ulcer Agents; Clinical Trials as Topic; Drug Therapy, Combination; Gastroesophageal Reflux; H(+ | 2002 |
Pharmacologic management of gastroesophageal reflux disease.
Topics: Barrett Esophagus; Esomeprazole; Esophagitis; Female; Gastroesophageal Reflux; Humans; Omeprazole; P | 2002 |
Is omeprazole helpful in the management of children with reflux oesophagitis?
Topics: Esophagitis; Gastroesophageal Reflux; Humans; Infant; Male; Omeprazole; Proton Pump Inhibitors | 2002 |
Esomeprazole: a review of its use in the management of acid-related disorders.
Topics: Databases, Bibliographic; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Humans; Omeprazo | 2002 |
Gastroesophageal reflux: diagnosis and management.
Topics: Alginates; Antacids; Barium; Bethanechol Compounds; Cisapride; Endoscopy, Gastrointestinal; Gastric | 1992 |
Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.
Topics: Gastric Acid; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Omeprazole | 1992 |
Acid suppression in the long-term treatment of peptic stricture and Barrett's oesophagus.
Topics: Barrett Esophagus; Dilatation; Esophageal Stenosis; Gastric Acid; Gastric Acidity Determination; Gas | 1992 |
Omeprazole in the treatment of peptic ulcers and gastroesophageal reflux disease.
Topics: Gastroesophageal Reflux; Humans; Omeprazole; Peptic Ulcer | 1992 |
The role of omeprazole in healing and prevention of reflux disease.
Topics: Esophagitis, Peptic; Gastric Acid; Gastroesophageal Reflux; Humans; Omeprazole; Recurrence; Time Fac | 1992 |
[Intragastric pH modifications induced by antisecretory treatments].
Topics: Duodenal Ulcer; Esophagitis; Gastric Acidity Determination; Gastroesophageal Reflux; Histamine H2 An | 1991 |
Omeprazole.
Topics: Animals; Gastroesophageal Reflux; Humans; Omeprazole; Peptic Ulcer | 1991 |
The medical management of reflux esophagitis. Role of antacids and acid inhibition.
Topics: Antacids; Esophagitis, Peptic; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Omeprazole | 1990 |
Omeprazole. Overview and opinion.
Topics: Duodenal Ulcer; Gastroesophageal Reflux; Gastrointestinal Diseases; Humans; Omeprazole; Stomach Ulce | 1991 |
Antireflux surgery.
Topics: Gastroesophageal Reflux; Humans; Methods; Omeprazole; Postoperative Complications | 1990 |
Pathophysiology and treatment of gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Cisapride; Clinical Trials as Topic; Esophagitis, Peptic; Esophagogastric Junctio | 1989 |
Management of gastro-oesophageal reflux disease. Are there alternatives to omeprazole?
Topics: Cisapride; Drug Administration Schedule; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; | 1989 |
Gastro-oesophageal reflux in patients with bronchial asthma.
Topics: Asthma; Drug Administration Schedule; Follow-Up Studies; Gastroesophageal Reflux; Humans; Omeprazole | 1989 |
The medical therapy of reflux oesophagitis.
Topics: Antacids; Bethanechol; Bethanechol Compounds; Cimetidine; Cisapride; Domperidone; Esophagitis, Pepti | 1987 |
347 trials available for omeprazole and Gastroesophageal Reflux
| Article | Year |
|---|---|
Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn.
Topics: Adult; Baclofen; Desipramine; Drug Resistance; Drug Therapy, Combination; Female; Fundoplication; Ga | 2019 |
Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn.
Topics: Adult; Baclofen; Desipramine; Drug Resistance; Drug Therapy, Combination; Female; Fundoplication; Ga | 2019 |
Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn.
Topics: Adult; Baclofen; Desipramine; Drug Resistance; Drug Therapy, Combination; Female; Fundoplication; Ga | 2019 |
Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn.
Topics: Adult; Baclofen; Desipramine; Drug Resistance; Drug Therapy, Combination; Female; Fundoplication; Ga | 2019 |
Prevalence and predictors of proton pump inhibitor partial response in gastroesophageal reflux disease in systemic sclerosis: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Gastroesophageal Reflux; Human | 2020 |
Comparative Study on Effect of Rabeprazole Versus Omeprazole in Acid-peptic Disorder with Helicobacter pylori Infection.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Cross-Sectional Studies; Drug Therapy, Combin | 2020 |
Rectal Omeprazole in Infants With Gastroesophageal Reflux Disease: A Randomized Pilot Trial.
Topics: Administration, Oral; Administration, Rectal; Esophageal Atresia; Esophageal pH Monitoring; Female; | 2020 |
Impact of Feeding Strategies With Acid Suppression on Esophageal Reflexes in Human Neonates With Gastroesophageal Reflux Disease: A Single-Blinded Randomized Clinical Trial.
Topics: Esophagus; Feeding Behavior; Female; Follow-Up Studies; Gastroesophageal Reflux; Humans; Infant; Inf | 2020 |
Effect of omeprazole on symptoms of gastroesophageal reflux disease in children with cystic fibrosis. A randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Child; Child, Preschool; Cystic Fibrosis; Double-Blind Method; Gastroesophageal Reflux; | 2021 |
Effect of rose oil on Gastroesophageal Reflux Disease in comparison with omeprazole: A double-blind controlled trial.
Topics: Double-Blind Method; Gastroesophageal Reflux; Humans; Iran; Omeprazole; Quality of Life; Rosa; Treat | 2021 |
Effect of two different pre-anaesthetic omeprazole protocols on gastroesophageal reflux incidence and pH in dogs.
Topics: Anesthetics; Animals; Dog Diseases; Dogs; Female; Gastroesophageal Reflux; Hydrogen-Ion Concentratio | 2021 |
Does omeprazole improve asthma-control in poorly-controlled asthmatic children with gastro-esophageal reflux.
Topics: Adolescent; Asthma; Child; Child, Preschool; Gastroesophageal Reflux; Humans; Male; Omeprazole; Prev | 2022 |
JianpiQinghua granule reduced PPI dosage in patients with nonerosive reflux disease: A multicenter, randomized, double-blind, double-dummy, noninferiority study.
Topics: Adult; Complementary Therapies; Double-Blind Method; Drugs, Chinese Herbal; Female; Gastroesophageal | 2021 |
Prevalence of Gastroesophageal Reflux in Cats During Anesthesia and Effect of Omeprazole on Gastric pH.
Topics: Administration, Oral; Anesthesia; Animals; Anti-Ulcer Agents; Cat Diseases; Cats; Esophagus; Female; | 2017 |
Laparoscopic magnetic sphincter augmentation versus double-dose proton pump inhibitors for management of moderate-to-severe regurgitation in GERD: a randomized controlled trial.
Topics: Adult; Aged; Cross-Over Studies; Esophageal pH Monitoring; Esophageal Sphincter, Lower; Female; Gast | 2019 |
Optimal Omeprazole Dosing and Symptom Control: A Randomized Controlled Trial (OSCAR Trial).
Topics: Adult; Aged; Drug Administration Schedule; Female; Gastroesophageal Reflux; Heartburn; Humans; Male; | 2019 |
Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis.
Topics: Adult; Aged; Aged, 80 and over; Cough; Double-Blind Method; Feasibility Studies; Female; Forced Expi | 2019 |
Effect of wu chu yu tang on gastroesophageal reflux disease: Randomized, double-blind, placebo-controlled trial.
Topics: Administration, Oral; Adult; Aged; Alkaloids; Double-Blind Method; Evodia; Female; Gastroesophageal | 2019 |
The Clinical Efficacy of a Pure Alginate Formulation (Lamina G) for Controlling Symptoms in Individuals with Reflux Symptoms: A Randomized Clinical Study.
Topics: Adult; Aged; Aged, 80 and over; Alginates; Double-Blind Method; Drug Therapy, Combination; Female; G | 2019 |
[Using ursodez in the treatment of refractory form of gastroesophageal reflux disease].
Topics: Adult; Aged; Cholagogues and Choleretics; Drug Administration Schedule; Drug Therapy, Combination; E | 2012 |
Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease.
Topics: Administration, Oral; Adult; Alginates; Double-Blind Method; Female; Gastroesophageal Reflux; Gastro | 2013 |
A randomized prospective study comparing the efficacy of on-demand therapy versus continuous therapy for 6 months for long-term maintenance with omeprazole 20 mg in patients with gastroesophageal reflux disease in Japan.
Topics: Anti-Ulcer Agents; Drug Administration Schedule; Female; Gastroesophageal Reflux; Humans; Japan; Mai | 2014 |
Randomized controlled trial comparing the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in gastroesophageal reflux disease.
Topics: Aged; Benzamides; Drug Therapy, Combination; Female; Gastroesophageal Reflux; Gastrointestinal Agent | 2014 |
[Role of psychological correction in the combination treatment of patients with gastroesophageal reflux disease].
Topics: Adult; Aged; Antacids; Combined Modality Therapy; Domperidone; Drug Therapy, Combination; Endoscopy, | 2014 |
Efficacy of transoral fundoplication vs omeprazole for treatment of regurgitation in a randomized controlled trial.
Topics: Adult; Aged; Female; Fundoplication; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Ma | 2015 |
Challenges of correlating pH change with relief of clinical symptoms in gastro esophageal reflux disease: a phase III, randomized study of Zegerid versus Losec.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Drug Combinations; Female; Gastric Mucosa; Gastroesoph | 2015 |
Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Anxiety; Cytochrome P-450 CYP2C19; Depression; Dos | 2015 |
Comparative clinical evaluation on herbal formulation Pepsil, Safoof-e-Katira and Omeprazole in gastro esophageal reflux disease.
Topics: Astragalus gummifer; Coriandrum; Deglutition Disorders; Female; Gastroesophageal Reflux; Heartburn; | 2015 |
Myrtus communis L. Freeze-Dried Aqueous Extract Versus Omeprazol in Gastrointestinal Reflux Disease: A Double-Blind Randomized Controlled Clinical Trial.
Topics: Adult; Double-Blind Method; Female; Gastroesophageal Reflux; Humans; Male; Myrtus; Omeprazole; Plant | 2016 |
Long-term follow-up results of endoscopic treatment of gastroesophageal reflux disease with the MUSE™ endoscopic stapling device.
Topics: Adult; Drug Utilization; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Gastroesophageal Re | 2016 |
Long-term follow-up results of endoscopic treatment of gastroesophageal reflux disease with the MUSE™ endoscopic stapling device.
Topics: Adult; Drug Utilization; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Gastroesophageal Re | 2016 |
Long-term follow-up results of endoscopic treatment of gastroesophageal reflux disease with the MUSE™ endoscopic stapling device.
Topics: Adult; Drug Utilization; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Gastroesophageal Re | 2016 |
Long-term follow-up results of endoscopic treatment of gastroesophageal reflux disease with the MUSE™ endoscopic stapling device.
Topics: Adult; Drug Utilization; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Gastroesophageal Re | 2016 |
Effects of Quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: A double-blind randomized controlled clinical trial.
Topics: Adolescent; Anti-Ulcer Agents; Child; Child, Preschool; Gastroesophageal Reflux; Humans; Infant; Inf | 2015 |
Concomitant Administration of a Histamine2 Receptor Antagonist and Proton Pump Inhibitor Enhances Gastric Acid Suppression.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Gastric Acid; Gas | 2015 |
Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial.
Topics: Adult; Aged; Alginates; Antiemetics; Domperidone; Drug Therapy, Combination; Female; Gastroesophagea | 2017 |
Effects of omeprazole or anti-reflux surgery on lower oesophageal sphincter characteristics and oesophageal acid exposure over 10 years.
Topics: Aged; Barrett Esophagus; Esophageal Sphincter, Lower; Europe; Female; Follow-Up Studies; Gastroesoph | 2017 |
The effect of proton pump inhibitors on the CYP2C19 enzyme activity evaluated by the pantoprazole-
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Biomarkers; Breath Tests; Carbon R | 2016 |
Specific HRQL instruments and symptom scores were more responsive than preference-based generic instruments in patients with GERD.
Topics: Activities of Daily Living; Adult; Anti-Ulcer Agents; Canada; Female; Gastroesophageal Reflux; Healt | 2009 |
Dilated intercellular spaces in gastroesophageal reflux disease patients and the changes of intercellular spaces after omeprazole treatment.
Topics: Adult; Anti-Ulcer Agents; Esophageal pH Monitoring; Esophagitis, Peptic; Extracellular Space; Female | 2008 |
Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Cross-Over Studies | 2009 |
Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 C | 2008 |
Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; Female; Gastr | 2009 |
The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Asian People; Clarithromycin; Double-Blind Method; | 2009 |
Control of esophageal and intragastric pH with compounded and manufactured omeprazole in patients with reflux esophagitis: a pilot study.
Topics: Adult; Aged; Brazil; Chemistry, Pharmaceutical; Drug Compounding; Esophageal pH Monitoring; Esophagi | 2009 |
Effectiveness of voice therapy in reflux-related voice disorders.
Topics: Adult; Anti-Ulcer Agents; Dysphonia; Esophagitis; Female; Gastroesophageal Reflux; Hoarseness; Human | 2010 |
Pharmacokinetic profile of immediate-release omeprazole in patients with gastro-oesophageal reflux associated with gastroparesis.
Topics: Anti-Ulcer Agents; Area Under Curve; Cross-Over Studies; Delayed-Action Preparations; Female; Gastri | 2010 |
The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying.
Topics: Adult; Anti-Ulcer Agents; Benzamides; Case-Control Studies; Double-Blind Method; Drug Resistance; Dr | 2010 |
The potential therapeutic effect of melatonin in Gastro-Esophageal Reflux Disease.
Topics: Drug Therapy, Combination; Gastrins; Gastroesophageal Reflux; Humans; Melatonin; Omeprazole; Treatme | 2010 |
Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: a comparison of over-the-counter doses of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Cross-Over Studies; Dos | 2010 |
The proton pump inhibitor test for gastroesophageal reflux disease: optimal cut-off value and duration.
Topics: Adult; Drug Administration Schedule; Esophageal pH Monitoring; Esophagitis; Esophagoscopy; Female; G | 2010 |
[On-demand treatment of nonerosive reflux disease: omeprazole plus bicarbonate powder versus omeprazole capsules].
Topics: Adult; Aged; Anti-Ulcer Agents; Bicarbonates; Capsules; Cross-Over Studies; Female; Gastroesophageal | 2010 |
Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease - a double-blind, placebo-controlled study.
Topics: Adult; Aged; Anti-Ulcer Agents; Benzamides; Double-Blind Method; Drug Therapy, Combination; Female; | 2011 |
Intragastric acidity during administration of generic omeprazole or esomeprazole - a randomised, two-way crossover study including CYP2C19 genotyping.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome | 2011 |
Gastroesophageal reflux disease management according to contemporary international guidelines: a translational study.
Topics: Adult; Esophagitis; Female; Gastroesophageal Reflux; Guidelines as Topic; Heartburn; Humans; Male; M | 2011 |
Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Body Mass Index; Double-Blind Method; Esophagitis, P | 2011 |
Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial.
Topics: Adult; Aged; Alginates; Deglutition Disorders; Drug Therapy, Combination; Female; Gastroesophageal R | 2012 |
Combination of PPI with a prokinetic drug in gastroesophageal reflux disease.
Topics: Administration, Oral; Adult; Antiemetics; Domperidone; Double-Blind Method; Drug Synergism; Drug The | 2011 |
Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial.
Topics: Adolescent; Adult; Alginates; Aluminum Hydroxide; Double-Blind Method; Drug Combinations; Female; Ga | 2012 |
Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS).
Topics: Algorithms; Benzamides; Diterpenes; Dose-Response Relationship, Drug; Dyspepsia; Famotidine; Gastroe | 2012 |
[A pilot trial on the treatment of gastroesophageal reflux-related cough in infants].
Topics: Bethanechol; Cough; Double-Blind Method; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Conce | 2012 |
Effects of omeprazole consumption on serum levels of trace elements.
Topics: Adult; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Trace Elements; Young | 2012 |
Respiratory response to proton pump inhibitor treatment in children with obstructive sleep apnea syndrome and gastroesophageal reflux disease.
Topics: Adolescent; Child; Child, Preschool; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentra | 2012 |
On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and | 2002 |
Genotyping of Helicobacter pylori in paraffin-embedded gastric biopsy specimens: relation to histological parameters and effects on therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Outer Membrane Proteins; Bacteria | 2002 |
Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Double-Blind Method; Female; Gastroe | 2002 |
Randomized comparative study of omeprazole and famotidine in reflux esophagitis.
Topics: Aged; Drug Evaluation; Enzyme Inhibitors; Esophagitis, Peptic; Esophagoscopy; Famotidine; Female; Ga | 2002 |
Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; | 2002 |
Posterior laryngitis: effects of treatment with omeprazole alone.
Topics: Adult; Aged; Anti-Ulcer Agents; Female; Gastroesophageal Reflux; Humans; Laryngitis; Laryngoscopy; M | 2002 |
Short-term omeprazole treatment does not influence biochemical parameters of bone turnover in children.
Topics: Adolescent; Alkaline Phosphatase; Anti-Ulcer Agents; Bone Resorption; Calcium; Child; Collagen; Coll | 2002 |
Patients have treatment preferences: a multicentre, double-blind, crossover study comparing rabeprazole and omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Chi-Square | 2002 |
Short course of omeprazole: a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour esophageal pH monitoring.
Topics: Adult; Aged; Anti-Ulcer Agents; Chest Pain; Cross-Over Studies; Diagnosis, Differential; Dose-Respon | 2002 |
[Clinico-functional evaluation of the efficacy of treating gastroesophageal reflux disease combined with bronchial asthma with omeprazole].
Topics: Adult; Asthma; Gastroesophageal Reflux; Humans; Middle Aged; Omeprazole; Placebos; Treatment Outcome | 2002 |
Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2002 |
Short-term therapeutic trial of proton pump inhibitors in suspected extraesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Female; Fol | 2002 |
Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Dose-Respon | 2002 |
Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 2003 |
A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Dose-Respon | 2003 |
Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Chest Pain; Female; Gastroe | 2003 |
Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child; Child, Preschool; Dose-Response R | 2002 |
Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child; Child, Preschool; Endoscopy, Gast | 2002 |
Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Ulcer Agents; Area Under Curve; Child; Dos | 2002 |
Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Area Under Curve; Body Weight; Child; Ch | 2002 |
The prophylactic use of a proton pump inhibitor before food and alcohol.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alcohol Drinking; Anti-Ulcer Agents; Double-Blind Me | 2003 |
Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure.
Topics: Adult; Aged; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Esophagus; | 2003 |
Meal-stimulated gastric acid secretion and integrated gastric acidity in gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Eating; Female; G | 2003 |
Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Gast | 2003 |
The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cytochrome P-450 Enzyme System; Esophagi | 2003 |
Effects of antireflux treatment on bronchial hyper-responsiveness and lung function in asthmatic patients with gastroesophageal reflux disease.
Topics: Adult; Aged; Asthma; Bronchial Hyperreactivity; Domperidone; Female; Gastric Emptying; Gastroesophag | 2003 |
One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Endoscopy, Gastrointestinal; Esomeprazole; Fema | 2003 |
Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Double-Blind Method; Esophagitis, Pe | 2003 |
Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Confidence Intervals; Do | 2003 |
Validation of the GSFQ, a self-administered symptom frequency questionnaire for patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Canada; Dou | 2003 |
Effect of pantoprazole on the course of reflux-associated laryngitis: a placebo-controlled double-blind crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cross-Over | 2003 |
The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity.
Topics: Adult; Anti-Ulcer Agents; Circadian Rhythm; Drug Therapy, Combination; Esophagus; Female; Gastric Ac | 2003 |
Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2003 |
Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux disease patients treated with a proton-pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2003 |
Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2003 |
Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors.
Topics: Adult; Baclofen; Chi-Square Distribution; Drug Resistance; Drug Therapy, Combination; Duodenogastric | 2003 |
Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux.
Topics: Anti-Ulcer Agents; Cross-Over Studies; Double-Blind Method; Esophagitis, Peptic; Female; Gastroesoph | 2003 |
Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Cohort Studies; Dose-Respon | 2003 |
[Use of omeprazole and esomeprazole in patients suffering from bronchial asthma with associated gastroesophageal reflux disease].
Topics: Adult; Anti-Ulcer Agents; Asthma; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male; Middl | 2003 |
Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Circadian Rhythm; Cross- | 2003 |
The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2003 |
[Evaluation of the efficacy of pariet in patients with gastroesophageal reflux disease with thoracic pain not connected with cardiac disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Chest Pain; Enzyme Inhibitors; Femal | 2003 |
[Comparative clinical and economic efficiency of new generation proton pump inhibitors in the treatment of gastroesophageal reflux].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Benzimidazoles; Drug Adm | 2003 |
Nutcracker oesophagus: a double-blind, placebo-controlled, cross-over study of the effects of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Antacids; Anti-Ulcer Agents | 2003 |
Association between nocturnal bruxism and gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Bruxism; Electrom | 2003 |
Stomach myoelectrical response of patients with gastroesophageal reflux disease receiving omeprazole treatment.
Topics: Adult; Aged; Anti-Ulcer Agents; China; Fasting; Female; Gastroesophageal Reflux; Humans; Male; Middl | 2003 |
Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Disease Progression; Double- | 2004 |
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Chi-S | 2003 |
Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial.
Topics: Aged; Amoxicillin; Anti-Ulcer Agents; Chi-Square Distribution; Clarithromycin; Double-Blind Method; | 2004 |
Pharmacokinetics of omeprazole in healthy adults and in children with gastroesophageal reflux disease.
Topics: Adult; Child; Child, Preschool; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Female; Gas | 2004 |
Sufficient control of heartburn in endoscopy-negative gastro-oesophageal reflux disease trials.
Topics: Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Esophagitis, Peptic; Female; Gastroesophageal Reflux | 2003 |
Endoscopy-negative reflux disease: what is the value of a proton-pump inhibitor test in everyday clinical practice?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Endoscopy, Gastrointestinal | 2003 |
Quantitative assessment of gastric antrum atrophy shows restitution to normal histology after Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Atrophy; Biopsy; Endoscopy, Gastrointestinal; Gastric Muco | 2004 |
Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; China; Cross-Over Studies; Double-Blind | 2004 |
Validation of a brief inventory for diagnosis and monitoring of symptomatic gastro-oesophageal reflux.
Topics: Adult; Anti-Ulcer Agents; Female; Gastroesophageal Reflux; Humans; Male; Omeprazole; Predictive Valu | 2004 |
Predictors of outcome in an open label, therapeutic trial of high-dose omeprazole in laryngitis.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Dose-Response Relationship, Drug; Drug Admi | 2004 |
The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Chest Pa | 2004 |
Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Double-Blin | 2004 |
Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Ulcer Agents; Benzi | 2004 |
The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole.
Topics: Adult; Aged; Anti-Ulcer Agents; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Gastros | 2004 |
Identifying response to acid suppressive therapy in functional dyspepsia using a random starting day trial--is gastro-oesophageal reflux important?
Topics: Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Female; Gastric Acid; Gastroesophageal Reflux; Hu | 2004 |
Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Female; Gas | 2004 |
On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Esophagitis; Fema | 2004 |
Suppression of gastric acid production may improve the course of angina pectoris and the results of treadmill stress test in patients with coronary artery disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Angina Pectoris; Anti-Ulcer Agents; Benzimidazoles; Comorbi | 2004 |
Prevention of erosive oesophagitis relapse with pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Eso | 2004 |
Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazo | 2004 |
On-demand PPI requirements in patients with endoscopy-negative GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Capsules; Drug Administrati | 2004 |
The effect of Helicobacter pylori eradication on gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2004 |
Significance of non-erosive minimal esophageal lesions in gastro-esophageal reflux disorder.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2004 |
[Particular features of application of proton pump inhibitors (Rabeprazole) in children with the gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Benzimidazoles; Child; Enzyme Inhibitors; Femal | 2004 |
Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Chronic Disease; Double-Blind Method; Enzym | 2004 |
[Some comparative aspects of treating the gastroesophageal reflux disease eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 2004 |
[Effect of H2-blockers and proton pump inhibitors on intragastric acidity and intraesophageal pH in patients with gastroesophageal reflux disease].
Topics: Drug Administration Schedule; Endoscopy, Digestive System; Famotidine; Gastric Acid; Gastric Acidity | 2004 |
[Clinical and pharmacoeconomic aspects of the antisecretory therapy of gastroesophageal refluxed disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Esophagoscopy; Gastr | 2004 |
Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2004 |
The effect of acid suppression on sleep patterns and sleep-related gastro-oesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Benzimidazoles; Female; | 2005 |
The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abnormalities, Drug-Induced; Adult; Anti-Ulcer Agents; Benz | 2005 |
Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Ulcer Agents; Child; Dose-Response Relatio | 2005 |
[Esomeprasol and rabeprasol effects on esophageal acidification in patients with gastroesophageal reflux disease, intensively metabolizing inhibitors of proton pump].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenoscopy; Esophagosc | 2005 |
Normalization of oesophageal pH does not guarantee control of duodenogastro-oesophageal reflux in Barrett's oesophagus.
Topics: Aged; Anti-Ulcer Agents; Barrett Esophagus; Duodenal Diseases; Esophagoscopy; Esophagus; Female; Gas | 2005 |
Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Biopsy; Dis | 2005 |
Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Ulcer Agents; Benzi | 2005 |
[Assessment of efficacy and safety of two modes of maintenance therapy with rabeprazole in patients with gastroesophageal reflux disease (GERD) of degrees 0 and 1].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Enzyme Inhibitors; Female; Gas | 2005 |
Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis.
Topics: Adult; Aged; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Esophagitis | 2005 |
Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
Topics: Analysis of Variance; Anti-Ulcer Agents; Drug Therapy, Combination; Famotidine; Female; Gastroesopha | 2005 |
Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Famotidine; Female; Gastroesophageal Reflux; Helicobacter Infections; Helicobacte | 2005 |
Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Anti-Ulcer A | 2005 |
Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Comorbidity; Cross-Over Studies; D | 2005 |
Gastroesophageal reflux disease in bronchial asthma and the response to omeprazole.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Asthma; Child; Female; Gastroesophageal Reflux; Humans; Incide | 2005 |
Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance o
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Benzimidazoles; Dose-Re | 2005 |
Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2005 |
Pantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anthropometry; Anti-Ulcer Agents; | 2005 |
Management of symptoms in step-down therapy of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Deglutition Disorders; Endosonography; Enzyme Inhibit | 2005 |
Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease.
Topics: Adolescent; Anti-Ulcer Agents; Asthma; Child; Esophagus; Female; Gastroesophageal Reflux; Humans; Hy | 2005 |
On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Benzimidazoles; Female; Gastro | 2005 |
Long-term acid suppressive therapy may prevent the relapse of lower esophageal (Schatzki's) rings: a prospective, randomized, placebo-controlled study.
Topics: Anti-Ulcer Agents; Dilatation; Esophageal Diseases; Female; Gastroesophageal Reflux; Humans; Hydroge | 2005 |
Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Inhalation; Adrenal Cortex Hormones; Adult; | 2005 |
The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Chest Pain; | 2005 |
Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Barrett | 2005 |
Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Female | 2005 |
Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Benzimidazoles; Deglutition Disord | 2005 |
Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Benzimidazoles; Dose-Response Relationship | 2005 |
Obstructive sleep apnoea is improved by a prolonged treatment of gastrooesophageal reflux with omeprazole.
Topics: Aged; Anti-Ulcer Agents; Comorbidity; Double-Blind Method; Female; Gastroesophageal Reflux; Humans; | 2006 |
Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Area Under Curve; Aryl H | 2005 |
Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough: a comparison between two different daily doses of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Chronic Disease; Cough; Enz | 2006 |
Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial.
Topics: Aged; Anti-Ulcer Agents; Atrophy; Enteroendocrine Cells; Female; Gastric Acid; Gastric Mucosa; Gastr | 2006 |
Rapid onset of effect of sodium alginate on gastro-oesophageal reflux compared with ranitidine and omeprazole, and relationship between symptoms and reflux episodes.
Topics: Adolescent; Adult; Aged; Alginates; Antacids; Cross-Over Studies; Female; Gastroesophageal Reflux; G | 2006 |
Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Child; Child, Preschool; | 2006 |
A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double-Blind Method; E | 2006 |
Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2006 |
A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double-Blind Method; E | 2006 |
A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Asthma; Drug Evaluation; | 2006 |
Administration of an alginate based gastric reflux suppressant on the bioavailability of omeprazole.
Topics: Adolescent; Adult; Alginates; Antacids; Biological Availability; Cross-Over Studies; Drug Interactio | 2006 |
Silent reflux: ex juvantibus criteria for diagnosis and treatment of laryngeal disorders.
Topics: Adjuvants, Immunologic; Administration, Oral; Administration, Sublingual; Adult; Aged; Aged, 80 and | 2006 |
The pharmacodynamic effect of omeprazole 10 mg and 20 mg once daily in patients with nonerosive reflux disease in Japan.
Topics: Adult; Aged; Double-Blind Method; Drug Administration Schedule; Female; Gastroesophageal Reflux; Hum | 2006 |
Intravenous pantoprazole as initial treatment in patients with gastroesophageal reflux disease and a history of erosive esophagitis: a randomized clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aluminum Hydroxide; Analysis o | 2006 |
Regression of gastroesophageal reflux disease symptoms using dietary supplementation with melatonin, vitamins and aminoacids: comparison with omeprazole.
Topics: Adult; Amino Acids; Anti-Ulcer Agents; Dietary Supplements; Female; Gastroesophageal Reflux; Humans; | 2006 |
Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial.
Topics: Aged; Double-Blind Method; Drug Administration Schedule; Dyspepsia; Enzyme Inhibitors; Female; Gastr | 2006 |
Double-blind, placebo-controlled trial with single-dose pantoprazole for laryngopharyngeal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Rel | 2006 |
Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Double-Blind Method; Enzyme Inhibitors; Esophagitis; Female | 2006 |
Prospective trial of laparoscopic nissen fundoplication versus proton pump inhibitor therapy for gastroesophageal reflux disease: Seven-year follow-up.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Female; Follow-Up Studies; | 2006 |
Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux.
Topics: Anti-Ulcer Agents; Cross-Over Studies; Double-Blind Method; Esophageal pH Monitoring; Gastric Acid; | 2007 |
Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Antacids; Anti-Ulcer Age | 2007 |
Seven-year follow-up of a randomized clinical trial comparing proton-pump inhibition with surgical therapy for reflux oesophagitis.
Topics: Aged; Anti-Ulcer Agents; Esophagitis; Female; Follow-Up Studies; Fundoplication; Gastroesophageal Re | 2007 |
Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable?
Topics: Adolescent; Anti-Ulcer Agents; Child; Child, Preschool; Esophagitis, Peptic; Female; Gastroesophagea | 2007 |
Quality of life in laryngopharyngeal reflux patients.
Topics: Adult; Enzyme Inhibitors; Female; Follow-Up Studies; Gastroesophageal Reflux; Humans; Laryngeal Dise | 2007 |
Omeprazole reduces the response to capsaicin but not to methacholine in asthmatic patients with proximal reflux.
Topics: Adult; Airway Resistance; Analgesics, Non-Narcotic; Anti-Ulcer Agents; Asthma; Bronchial Hyperreacti | 2007 |
Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Dyspepsia; Female; Gastroesophageal Reflux; Hu | 2007 |
[Study on integrated Chinese and Western therapy and criterion for efficacy evaluation of gastroesophageal reflux disease--a clinical observation on 116 cases].
Topics: Adult; Aged; Anti-Ulcer Agents; Combined Modality Therapy; Diagnosis, Differential; Drug Therapy, Co | 2007 |
Single-session, graded esophageal dilation without fluoroscopy in outpatients with lower esophageal (Schatzki's) rings: a prospective, long-term follow-up study.
Topics: Aged; Ambulatory Care; Deglutition Disorders; Dilatation; Enzyme Inhibitors; Esophageal Stenosis; Es | 2007 |
Effect of omeprazole and domperidone on adult asthmatics with gastroesophageal reflux.
Topics: Adult; Anti-Asthmatic Agents; Asthma; Domperidone; Dose-Response Relationship, Drug; Double-Blind Me | 2007 |
[Rabeprazole test and comparison of the effectiveness of course treatment with rabeprazole in patients with gastroesophageal reflux disease and non-coronary chest pain].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Chest Pain; Female; Gastroe | 2007 |
Effect of baseline symptom severity on patient-reported outcomes in gastroesophageal reflux disease.
Topics: Adult; Aged; Anti-Ulcer Agents; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male; Middle | 2007 |
Omeprazole for gastroesophageal reflux disease in the first 2 years of life: a dose-finding study with dual-channel pH monitoring.
Topics: Anti-Ulcer Agents; Dose-Response Relationship, Drug; Esophagus; Female; Gastroesophageal Reflux; Hum | 2007 |
Reflux oesophagitis in children; the role of endoscopy. A multicentric Italian survey.
Topics: Adolescent; Anti-Ulcer Agents; Biopsy; Child; Child, Preschool; Cohort Studies; Endoscopy, Gastroint | 2007 |
The effect of double dose of omeprazole on the course of angina pectoris and treadmill stress test in patients with coronary artery disease--a randomised, double-blind, placebo controlled, crossover trial.
Topics: Analysis of Variance; Angina Pectoris; Anti-Ulcer Agents; Chest Pain; Coronary Disease; Cross-Over S | 2008 |
Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial.
Topics: Aged; Anti-Ulcer Agents; Cross-Over Studies; Drug Therapy, Combination; Female; Gastroesophageal Ref | 2007 |
Use of acid-suppressing drugs and the risk of bacterial gastroenteritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Bacterial Infections; Enzyme Inhibitors; Femal | 2007 |
Standardization of surgical technique in antireflux surgery: the LOTUS Trial experience.
Topics: Adult; Anti-Ulcer Agents; Female; Fundoplication; Gastroesophageal Reflux; Humans; Laparoscopy; Male | 2008 |
Randomised comparison of the FerX Ella antireflux stent and the ultraflex stent: proton pump inhibitor combination for prevention of post-stent reflux in patients with esophageal carcinoma involving the esophago-gastric junction.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Drug-Eluting Stents; Esophageal Neoplasms | 2008 |
Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z.
Topics: Adult; Anti-Ulcer Agents; Esomeprazole; Gastric Acidity Determination; Gastroesophageal Reflux; Huma | 2008 |
Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Esophageal pH Monitoring; Female; | 2008 |
Bioavailability of two single-dose oral formulations of omeprazole 20 mg: an open-label, randomized sequence, two-period crossover comparison in healthy Mexican adult volunteers.
Topics: Administration, Oral; Adult; Biological Availability; Chromatography, High Pressure Liquid; Cross-Ov | 2008 |
Laparoscopic Nissen fundoplication is a satisfactory alternative to long-term omeprazole therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Follow-Up Studies; Fundopli | 1995 |
Empiric therapy for gastroesophageal reflux disease.
Topics: Adult; Aged; Endoscopy, Digestive System; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Conc | 1995 |
Does omeprazole (Prilosec) improve respiratory function in asthmatics with gastroesophageal reflux? A double-blind, placebo-controlled crossover study.
Topics: Adult; Asthma; Cross-Over Studies; Double-Blind Method; Esophagus; Female; Gastroesophageal Reflux; | 1994 |
Omeprazole in the treatment of asthmatics with nocturnal symptoms and gastro-oesophageal reflux: a placebo-controlled cross-over study.
Topics: Aged; Aged, 80 and over; Asthma; Circadian Rhythm; Double-Blind Method; Female; Gastroesophageal Ref | 1994 |
Omeprazole for the treatment of posterior laryngitis.
Topics: Adult; Aged; Esophagitis; Female; Gastroesophageal Reflux; Humans; Laryngitis; Laryngoscopy; Male; M | 1994 |
Efficacy and safety of omeprazole for severe gastroesophageal reflux in children.
Topics: Acute Disease; Adolescent; Biopsy; Capsules; Child; Child, Preschool; Endoscopy, Gastrointestinal; E | 1993 |
Chest pain associated with nutcracker esophagus: a preliminary study of the role of gastroesophageal reflux.
Topics: Adult; Aged; Chest Pain; Esophageal Motility Disorders; Esophagoscopy; Esophagus; Female; Gastric Ac | 1993 |
Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive oesophagitis.
Topics: Adult; Antacids; Circadian Rhythm; Drug Therapy, Combination; Esophagitis, Peptic; Female; Gastroeso | 1993 |
Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Confidence Intervals; Dose-Response Relationship, | 1995 |
Patterns of 24-hour oesophageal acid exposure after acute withdrawal of acid suppression.
Topics: Adult; Aged; Anti-Ulcer Agents; Esophagus; Female; Gastric Acid; Gastroesophageal Reflux; Histamine | 1995 |
The role of a defective lower esophageal sphincter in the clinical outcome of treatment for gastroesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Data Interpretation, Statistical; Eso | 1996 |
Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy.
Topics: Anti-Ulcer Agents; Case-Control Studies; Dose-Response Relationship, Drug; Drug Administration Sched | 1996 |
[Effect of elevated head position in bed in therapy of gastroesophageal reflux].
Topics: Adult; Antacids; Anti-Ulcer Agents; Cisapride; Combined Modality Therapy; Esophagitis, Peptic; Femal | 1996 |
Morning or evening dosage of omeprazole for gastro-oesophageal reflux disease?
Topics: Adult; Aged; Anti-Ulcer Agents; Cross-Over Studies; Drug Administration Schedule; Female; Gastric Ac | 1995 |
Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and | 1996 |
Paroxysmal laryngospasm secondary to gastroesophageal reflux.
Topics: Adult; Aged; Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Laryngismus; Middle Aged; Omeprazol | 1996 |
Adult asthma and gastro-oesophageal reflux: the effects of omeprazole therapy on asthma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Asthma; Cross-Over Studies; Double-Bl | 1996 |
Effects of omeprazole on mechanisms of gastroesophageal reflux in childhood.
Topics: Anti-Ulcer Agents; Child; Child, Preschool; Controlled Clinical Trials as Topic; Esophagitis, Peptic | 1997 |
Efficacy of a pectin-based anti-reflux agent on acid reflux and recurrence of symptoms and oesophagitis in gastro-oesophageal reflux disease.
Topics: Aged; Anti-Ulcer Agents; Antidiarrheals; Cross-Over Studies; Double-Blind Method; Endoscopy, Digesti | 1997 |
Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux--the "sensitive oesophagus".
Topics: Adult; Aged; Anti-Ulcer Agents; Cross-Over Studies; Double-Blind Method; Esophagus; Female; Gastroes | 1997 |
Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice.
Topics: Anti-Ulcer Agents; Double-Blind Method; Drug Administration Schedule; Family Practice; Female; Gastr | 1997 |
Lifetime costs of surgical versus medical treatment of severe gastro-oesophageal reflux disease in Finland.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Distribution; Aged; Chronic Disease; Cost of Ill | 1997 |
Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Cimetidine; Double-Blind Method; Esophagitis; Female; Ga | 1997 |
Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride.
Topics: Adult; Anti-Ulcer Agents; Cisapride; Double-Blind Method; Enzyme Inhibitors; Esophagitis; Female; Ga | 1997 |
Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice.
Topics: Anti-Ulcer Agents; Double-Blind Method; Drug Administration Schedule; Female; Gastroesophageal Reflu | 1997 |
Omeprazole as a diagnostic tool in gastroesophageal reflux disease.
Topics: Adult; Aged; Chi-Square Distribution; Double-Blind Method; Female; Gastric Acidity Determination; Ga | 1997 |
Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux.
Topics: Chest Pain; Double-Blind Method; Esophagus; Female; Follow-Up Studies; Gastric Acidity Determination | 1997 |
The ambulatory pH study is normal, but the patient is not--the importance of the symptoms index.
Topics: Adult; Anti-Ulcer Agents; Cross-Over Studies; Double-Blind Method; Esophagus; Female; Gastroesophage | 1998 |
One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Esophagoscopy; Female; Gastroesophageal Reflux; H | 1998 |
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double | 1998 |
Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Endoscopy; Esophagitis; Female; Fol | 1998 |
Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Dose-Respo | 1998 |
[Drug therapy of gastroesophageal reflux (a prospective controlled clinical trial)].
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Domperidone; Dose-Response Relationship, Drug; Fe | 1998 |
Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Europe; Female; Follow-Up Studies; | 1998 |
[Reflux esophagitis; is the preventive eradication of Helicobacter pylori needed in patients on omeprazole?].
Topics: Enzyme Inhibitors; Esophagitis, Peptic; Female; Gastritis, Atrophic; Gastroesophageal Reflux; Helico | 1998 |
No effects of high-dose omeprazole in patients with severe airway hyperresponsiveness and (a)symptomatic gastro-oesophageal reflux.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Bronchoconstrictor Agents; Dose-Respo | 1998 |
The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain.
Topics: Adult; Aged; Aged, 80 and over; Chest Pain; Double-Blind Method; Enzyme Inhibitors; Female; Gastroes | 1998 |
One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Enz | 1997 |
Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Enzyme Inhibitors; Esophagitis; G | 1997 |
Omeprazole improves peak expiratory flow rate and quality of life in asthmatics with gastroesophageal reflux.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Asthma; C | 1998 |
Dose-response relationship of lansoprazole to gastric acid antisecretory effects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Cross-Over | 1998 |
Omeprazole is more effective than cimetidine in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis.
Topics: Administration, Oral; Anti-Ulcer Agents; Chi-Square Distribution; Cimetidine; Double-Blind Method; E | 1998 |
A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Deglutition | 1998 |
Effect of omeprazole in patients with chest pain and normal coronary anatomy: initial experience.
Topics: Adult; Chest Pain; Coronary Angiography; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; | 1998 |
Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection.
Topics: Aged; Anti-Ulcer Agents; Area Under Curve; Gastric Emptying; Gastrins; Gastroesophageal Reflux; Heli | 1998 |
Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Barrett Esophagus; Bile Reflux; Bilirubin; Drug A | 1998 |
Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cross-Over Studies; Double-Blind | 1998 |
Outcome of open antireflux surgery as assessed in a Nordic multicentre prospective clinical trial. Nordic GORD-Study Group.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Chronic Disease; Female; Finland; Gastroesophageal Reflu | 1998 |
Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Circadian Rhythm; Female; Gastric Acid; Gastro | 1998 |
Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily.
Topics: Adult; Circadian Rhythm; Cross-Over Studies; Dose-Response Relationship, Drug; Gastric Acidity Deter | 1998 |
Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 1999 |
Correlation of ambulatory 24-hour esophageal pH monitoring results with symptom improvement in patients with noncardiac chest pain due to gastroesophageal reflux disease.
Topics: Anti-Ulcer Agents; Chest Pain; Esophagus; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Conc | 1999 |
Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients.
Topics: Adult; Aged; Chromogranin A; Chromogranins; Drug Tolerance; Esophagitis; Female; Gastric Acid; Gastr | 1998 |
Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Cross-Over Studies; Double-Blind Method; Esoph | 1998 |
Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Female; Gastroesophageal Reflux; Humans; Male; | 1999 |
Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group.
Topics: Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Esophagitis, Peptic; Female; G | 1999 |
Omeprazole or ranitidine for intermittent treatment of GERD?
Topics: Adult; Anti-Ulcer Agents; Double-Blind Method; Female; Follow-Up Studies; Gastroesophageal Reflux; H | 1999 |
Efficacy of omeprazole versus ranitidine for symptomatic treatment of poorly responsive acid reflux disease-a prospective, controlled trial.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Female; Gastroesophageal Reflux; Histamine H2 A | 1999 |
On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Denmark; Double-Blind Method; Drug Administration Schedule; Esophagi | 1999 |
The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy.
Topics: Adult; Aged; Barrett Esophagus; Double-Blind Method; Esophagus; Female; Gastroesophageal Reflux; Hel | 1999 |
Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Esophagitis, Peptic; Female; Gastro | 1999 |
Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Atrophy; Esophagitis; Female; Gastric Mucosa; Gastrins; | 1999 |
Is the esophageal squamous epithelial barrier function impaired in patients with gastroesophageal reflux disease?
Topics: Adolescent; Adult; Aged; Analysis of Variance; Enzyme Inhibitors; Epithelium; Esophagus; Female; Fun | 1999 |
Patients with functional dyspepsia responding to omeprazole have a characteristic gastro-oesophageal reflux pattern.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Female; Gastroesophageal Reflux; Hel | 1999 |
The effect of omeprazole on gastro-oesophageal reflux and symptoms during strenuous exercise.
Topics: Adult; Anti-Ulcer Agents; Diet; Double-Blind Method; Exercise; Female; Gastric Acidity Determination | 1999 |
Omeprazole therapy decreases the need for dilatation of peptic oesophageal strictures.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Dilatation; Enzyme Inhibitors; Esophageal Stenosi | 1999 |
Post-prandial ranitidine is superior to post-prandial omeprazole in control of gastric acidity in healthy volunteers.
Topics: Adolescent; Adult; Analysis of Variance; Anti-Ulcer Agents; Cross-Over Studies; Enzyme Inhibitors; F | 1999 |
Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study.
Topics: Adult; Aged; Anti-Ulcer Agents; Barrett Esophagus; Double-Blind Method; Esophagoscopy; Female; Follo | 1999 |
Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease.
Topics: Adult; Aged; Anti-Ulcer Agents; Arizona; Cost-Benefit Analysis; Cross-Over Studies; Diagnosis, Diffe | 1999 |
Gastroesophageal reflux in asthmatics: A double-blind, placebo-controlled crossover study with omeprazole.
Topics: Adult; Aged; Anti-Ulcer Agents; Asthma; Circadian Rhythm; Cross-Over Studies; Double-Blind Method; E | 1999 |
A prospective evaluation of esophageal testing and a double-blind, randomized study of omeprazole in a diagnostic and therapeutic algorithm for chronic cough.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Chronic Disease; Cough; Double-Blind Method; | 1999 |
Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1999 |
Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease.
Topics: Algorithms; Anti-Ulcer Agents; Cost-Benefit Analysis; Double-Blind Method; Drug Administration Sched | 1999 |
Treatment with lansoprazole also induces hypertrophy of the parietal cells of the stomach.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cell Count; Double-Blind Method; Female; | 2000 |
Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Double-Blind Method; Endosonograph | 2000 |
Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazo | 2000 |
Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: a randomized, double-blind, parallel, and multicentre study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 2000 |
Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Case-Control Studies; Clarithrom | 2000 |
Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Benzimidazoles; Dose-Respon | 2000 |
Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Circadian Rhythm; Cross-Over Stud | 2000 |
Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis.
Topics: Anti-Ulcer Agents; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Gas | 2000 |
Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Aged, 80 and over; Antacids; A | 2000 |
Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease.
Topics: Adult; Anti-Ulcer Agents; Cross-Over Studies; Double-Blind Method; Esomeprazole; Female; Gastroesoph | 2000 |
Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia.
Topics: Adult; Costs and Cost Analysis; Female; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; M | 2000 |
Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Antacids; Benzimidazoles; D | 2000 |
Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study Group.
Topics: Adult; Aged; Enzyme Inhibitors; Female; Follow-Up Studies; Fundoplication; Gastroesophageal Reflux; | 2000 |
Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Analysis of Variance; Benzimidazoles; Dose-Res | 2000 |
A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Analysis of Variance; Anti-Ulc | 2000 |
High dose proton pump inhibitor response as an initial strategy for a clinical diagnosis of gastro-oesophageal reflux disease (GERD). Swedish multi-centre group in primary health care.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Gastroesophageal Reflux; Humans; Mi | 2000 |
Identifying responders to acid suppression in dyspepsia using a random starting day trial.
Topics: Adult; Aged; Anti-Ulcer Agents; Drug Administration Schedule; Dyspepsia; Female; Gastroesophageal Re | 2000 |
Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Benzimidazoles; Do | 2000 |
Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 2000 |
Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group.
Topics: Administration, Oral; Adolescent; Age Factors; Anti-Ulcer Agents; Area Under Curve; Child; Child, Pr | 2000 |
Chronic cough and gastro-oesophageal reflux: a double-blind placebo-controlled study with omeprazole.
Topics: Adult; Aged; Anti-Ulcer Agents; Cough; Cross-Over Studies; Double-Blind Method; Female; Gastroesopha | 2000 |
Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group.
Topics: Adolescent; Anti-Ulcer Agents; Child; Child, Preschool; Chronic Disease; Dose-Response Relationship, | 2000 |
Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-ce
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Drug Administration Schedul | 2000 |
Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Child; Child, Preschool; Enzyme Inhibitors; Eso | 2000 |
Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Double-Blind Method; | 2000 |
Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, C | 2000 |
Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Dr | 2000 |
Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Biopsy, Needle; Confidence Intervals; Dose-Res | 2001 |
Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Double-Blind Method; Drug Administra | 2000 |
Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus.
Topics: Adult; Aged; Barrett Esophagus; Biopsy; Cell Division; Double-Blind Method; Enzyme Inhibitors; Gastr | 2000 |
Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months.
Topics: Administration, Oral; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Drug Administration Sched | 2001 |
Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
Topics: Adult; Aged; Double-Blind Method; Enzyme Inhibitors; Esomeprazole; Esophagitis; Female; Gastroesopha | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mg.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Circadian Rhythm; Cross-Over Studies; Dose-Response | 2001 |
Comparison of pantoprazole 20 mg to ranitidine 150 mg b.i.d. in the treatment of mild gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Benzimidazoles; Dose-Response | 2001 |
Asthma and gastro-oesophageal reflux: can the response to anti-reflux therapy be predicted?
Topics: Adult; Aged; Anti-Ulcer Agents; Asthma; Body Mass Index; Confidence Intervals; Cross-Over Studies; D | 2001 |
Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Analysis of Variance; Anti-Bacterial Agents; A | 2001 |
Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind M | 2001 |
Long-term management of gastro-eosophageal reflux disease with omeprazole or open antireflux surgery.
Topics: Dose-Response Relationship, Drug; Female; Follow-Up Studies; Fundoplication; Gastroesophageal Reflux | 2001 |
Effectiveness of acid suppression in preventing gastroesophageal reflux disease (GERD) after successful treatment of Helicobacter pylori infection.
Topics: Adult; Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Female; Gastric Acid; Gastroesophageal Reflux | 2001 |
High-dose proton-pump inhibitors as a diagnostic test of gastro-oesophageal reflux disease in endoscopic-negative patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cross-Over Studies; Double- | 2001 |
Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; | 2001 |
No clinical benefit of adding cisapride to pantoprazole for treatment of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cisapride; Double-Blind Method; Drug Therap | 2001 |
Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Rel | 2001 |
Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2001 |
Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Ulcer Agents; Area Under Curve; Child; Chi | 2001 |
The cost of long term therapy for gastro-oesophageal reflux disease: a randomised trial comparing omeprazole and open antireflux surgery.
Topics: Aged; Anti-Ulcer Agents; Confidence Intervals; Cost of Illness; Female; Fundoplication; Gastroesopha | 2001 |
Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease.
Topics: Adult; Aged; Clarithromycin; Double-Blind Method; Female; Gastroesophageal Reflux; Helicobacter Infe | 2001 |
Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Drug Administration Schedule; Endoscopy; Enzyme Inhib | 2001 |
Quantitative assessment of gastric corpus atrophy in subjects using omeprazole: a randomized follow-up study.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Atrophy; Enzyme Inhibitors; Female; Gastric M | 2001 |
Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2001 |
Health-Related quality-of-life and quality-days incrementally gained in symptomatic nonerosive GERD patients treated with lansoprazole or ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Double-Blind Method; Drug Adminis | 2001 |
Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cyt | 2001 |
Control of nocturnal gastric acidity: a role for low dose bedtime ranitidine to supplement daily omeprazole.
Topics: Anti-Ulcer Agents; Cross-Over Studies; Drug Administration Schedule; Female; Gastric Acid; Gastric A | 2002 |
Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Esophagus; | 2002 |
Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough.
Topics: Adult; Aged; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Gastric Acid; Gastroesophageal Re | 2002 |
Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Esophagitis | 2002 |
Integrated acidity and rabeprazole pharmacology.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Pept | 2002 |
A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 2002 |
Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Co | 2002 |
Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Gastro | 2002 |
Role of GERD in chronic resistant sinusitis: a prospective, open label, pilot trial.
Topics: Adult; Chronic Disease; Drug Resistance; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; | 2002 |
Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease.
Topics: Adult; Aged; Anti-Ulcer Agents; Cross-Over Studies; Drug Tolerance; Esomeprazole; Female; Gastric Ju | 2002 |
Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2002 |
Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Dose-Response Relationship, Drug; Do | 2002 |
Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis.
Topics: Adult; Aged; Barrett Esophagus; Drug Administration Schedule; Esophageal Motility Disorders; Esophag | 1992 |
Comparison of omeprazole and ranitidine in treatment of refractory gastroesophageal reflux disease in patients with gastric acid hypersecretion.
Topics: Barrett Esophagus; Drug Administration Schedule; Esophagitis, Peptic; Female; Gastric Acid; Gastroes | 1992 |
Cost and quality effects of alternative treatments for persistent gastroesophageal reflux disease.
Topics: Adult; Aged; Aged, 80 and over; Clinical Protocols; Costs and Cost Analysis; Decision Trees; Follow- | 1992 |
Effect of different doses of omeprazole on 24-hour oesophageal acid exposure in patients with gastro-oesophageal reflux.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Esophagus; Female; Gastroesophag | 1991 |
The medical management of reflux esophagitis. Role of antacids and acid inhibition.
Topics: Antacids; Esophagitis, Peptic; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Omeprazole | 1990 |
Omeprazole.
Topics: Animals; Carcinoid Tumor; Clinical Trials as Topic; Gastric Acid; Gastroesophageal Reflux; Humans; O | 1990 |
Pathophysiology and treatment of gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Cisapride; Clinical Trials as Topic; Esophagitis, Peptic; Esophagogastric Junctio | 1989 |
A "significant" new drug for erosive esophagitis and gastroesophageal reflux disease.
Topics: Clinical Trials as Topic; Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Omeprazole | 1989 |
The effect of omeprazole or ranitidine treatment on 24-hour esophageal acidity in patients with reflux esophagitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Circadian Rhythm; Clinical Trials as Topic; Double-Blind | 1988 |
505 other studies available for omeprazole and Gastroesophageal Reflux
| Article | Year |
|---|---|
Omeprazole-induced Visual Hallucinations: A Case Report.
Topics: Aged; Gastroesophageal Reflux; Hallucinations; Humans; Male; Mental Disorders; Omeprazole; Proton Pu | 2021 |
Proton pump inhibitors associated with rapid eye movement sleep behaviour disorder.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Female; Gastroesophageal Reflux; Humans; Lansoprazole | 2021 |
Nocturnal acid breakthrough and esophageal acidification during treatment with dexlansoprazole as compared to omeprazole in patients with gastroesophageal reflux disease.
Topics: Dexlansoprazole; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Hydr | 2022 |
Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis; Gastroesoph | 2022 |
Intrauterine exposure to omeprazole increases the risk of teeth morphological anomalies in the offspring of a murine model.
Topics: Animals; Disease Models, Animal; Female; Gastroesophageal Reflux; Humans; Mice; Odontogenesis; Omepr | 2023 |
Mixed-methods feasibility study to inform a randomised controlled trial of proton pump inhibitors to reduce strictures following neonatal surgery for oesophageal atresia.
Topics: Adult; Attitude of Health Personnel; Chemoprevention; Constriction, Pathologic; Esophageal Atresia; | 2023 |
The Role of Endoplasmic Reticulum Stress in Gastroesophageal Reflux Disease Symptoms and Treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Endoplasmic Reticulum Stress; Female; Gastroesophage | 2023 |
Clarifications on the safety of dexrabeprazole vs. omeprazole in the treatment of gastroesophageal reflux disease.
Topics: Gastroesophageal Reflux; Humans; Omeprazole; Rabeprazole | 2023 |
Reply to the letter to the editor "Clarifications on the safety of dexrabeprazole vs. omeprazole in the treatment of gastroesophageal reflux disease".
Topics: Gastroesophageal Reflux; Humans; Omeprazole; Rabeprazole | 2023 |
Vanishing gastric hyperplastic polyps.
Topics: Aged; Anti-Ulcer Agents; Drug Substitution; Gastroesophageal Reflux; Humans; Male; Omeprazole; Polyp | 2019 |
Impact of fundoplication for gastroesophageal reflux in the outcome of benign tracheal stenosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Fundoplication; Gastroesophageal Reflux; Humans; | 2019 |
Bilateral Anterior and Intermediate Uveitis Associated With Omeprazole.
Topics: Adult; Female; Fluprednisolone; Gastroesophageal Reflux; Glucocorticoids; Humans; Male; Omeprazole; | 2020 |
Night sweats as a manifestation of gastroesophageal reflux disease.
Topics: Adult; Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Male; Omeprazole; Sweat; Treatment Outcom | 2020 |
Over-the-counter antacids linked to severe hypokalaemia in the context of threatened preterm labour.
Topics: Adult; Antacids; Cardiotocography; Drug Overdose; Female; Gastroesophageal Reflux; Humans; Hypokalem | 2021 |
Nutritional Optic Neuropathy From Chronic Omeprazole Use.
Topics: Adult; Contrast Sensitivity; Female; Gastroesophageal Reflux; Humans; Omeprazole; Optic Disk; Optic | 2021 |
No association between chronic use of ranitidine, compared with omeprazole or famotidine, and gastrointestinal malignancies.
Topics: Animals; Famotidine; Gastroesophageal Reflux; Gastrointestinal Neoplasms; Humans; Omeprazole; Raniti | 2021 |
An Interesting Case of "Refractory" Hypomagnesemia.
Topics: Aged, 80 and over; Gastric Mucosa; Gastroesophageal Reflux; Humans; Magnesium Deficiency; Male; Omep | 2017 |
Gastric Hyperplastic Polyps Associated with Proton Pump Inhibitor Use in a Case without a History of Helicobacter pylori Infection.
Topics: Adenomatous Polyps; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; M | 2017 |
The Role of Gastroesophageal Reflux in Provoking High Blood Pressure Episodes in Patients With Hypertension.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Electric Impe | 2018 |
Persistent severe hypomagnesemia caused by proton pump inhibitor resolved after laparoscopic fundoplication.
Topics: Administration, Oral; Aged; Fundoplication; Gastroesophageal Reflux; Humans; Infusions, Intravenous; | 2017 |
Treatment of reflux disease during pregnancy and lactation.
Topics: Alginates; Antacids; Female; Gastroesophageal Reflux; Glucuronic Acid; Hexuronic Acids; Humans; Lact | 2017 |
Empirical treatment of outpatients with gastroesophageal reflux disease with proton pump inhibitors: A survey of Chinese patients (the ENLIGHT Study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Asian People; Esomeprazole; Female | 2018 |
Optimal PPI Dosing for Improving GERD Symptoms: Is Timing Everything?
Topics: Gastroesophageal Reflux; Humans; Omeprazole | 2019 |
Comparative Study of Alginate and Omeprazole in Symptomatic Treatment of Non-erosive Gastroesophageal Reflux Disease.
Topics: Adult; Alginates; Bangladesh; Drug Monitoring; Female; Gastroesophageal Reflux; Gastrointestinal Age | 2018 |
The effect of Heweijiangni-decoction on esophageal morphology in a rat model of OVA-induced visceral hypersensitivity followed by acid exposure.
Topics: Animals; Desmosomes; Disease Models, Animal; Drugs, Chinese Herbal; Esophagus; Extracellular Space; | 2019 |
Reliving 25 years of Experience with Omeprazole in Acid-peptic Diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Omepraz | 2018 |
Gastroesophageal reflux disease and its association with bronchiolitis obliterans syndrome in allogeneic hematopoietic stem cell transplant recipients.
Topics: Adult; Bronchiolitis Obliterans; Esophageal pH Monitoring; Female; Gastroesophageal Reflux; Hematopo | 2013 |
Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Substitution; Esomeprazole; Gastroesophageal Reflux; H | 2013 |
Therapeutic efficacy of baclofen in refractory gastroesophageal reflux-induced chronic cough.
Topics: Adult; Baclofen; Capsaicin; Cohort Studies; Cough; Domperidone; Esophageal pH Monitoring; Female; Ga | 2013 |
Nocturnal vocalization.
Topics: Adult; Continuous Positive Airway Pressure; Female; Gastroesophageal Reflux; Hiccup; Humans; Omepraz | 2014 |
Protective effects of D-002 on experimentally induced gastroesophageal reflux in rats.
Topics: Administration, Oral; Animals; Anti-Ulcer Agents; Antioxidants; Disease Models, Animal; Esophagus; F | 2014 |
Gastric acid-dependent diseases: a twentieth-century revolution.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Gastric Acid; Gastroesophageal | 2014 |
Comparison of clinical characteristics of chronic cough due to non-acid and acid gastroesophageal reflux.
Topics: Adult; Anti-Ulcer Agents; Baclofen; Capsaicin; Chronic Disease; Cough; Domperidone; Esophageal pH Mo | 2015 |
Acid reflux directly causes sleep disturbances in rat with chronic esophagitis.
Topics: Animals; Chronic Disease; Esophagitis, Peptic; Esophagus; Gastric Acid; Gastric Juice; Gastroesophag | 2014 |
Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Interactions; Erlotinib Hydrochloride; Female; Gastric Acid; Ga | 2015 |
Occupational contact dermatitis caused by omeprazole in a veterinary medicament.
Topics: Animals; Dermatitis, Allergic Contact; Dermatitis, Occupational; Gastroesophageal Reflux; Horse Dise | 2014 |
[Comparison of the effectiveness of omeprazole and pantoprazole treatment of gastroesophageal reflux disease in patients with asthma].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Asthma; Female; | 2013 |
Endoscopic therapies for gastroesophageal reflux disease: back in the game?
Topics: Female; Fundoplication; Gastroesophageal Reflux; Humans; Male; Omeprazole; Proton Pump Inhibitors | 2015 |
Prescribing efficiency of proton pump inhibitors in China: influence and future directions.
Topics: Administration, Oral; China; Drug Costs; Drug Utilization; Drugs, Generic; Forecasting; Gastroesopha | 2015 |
Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies.
Topics: Aged; Chromogranin A; Esomeprazole; Female; Gastrins; Gastroesophageal Reflux; Humans; Laparoscopy; | 2015 |
Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies.
Topics: Aged; Chromogranin A; Esomeprazole; Female; Gastrins; Gastroesophageal Reflux; Humans; Laparoscopy; | 2015 |
Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies.
Topics: Aged; Chromogranin A; Esomeprazole; Female; Gastrins; Gastroesophageal Reflux; Humans; Laparoscopy; | 2015 |
Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies.
Topics: Aged; Chromogranin A; Esomeprazole; Female; Gastrins; Gastroesophageal Reflux; Humans; Laparoscopy; | 2015 |
Letter: proton pump inhibitors, hypergastrinaemia and the risk of gastric neoplasia.
Topics: Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male; Omeprazole; Proton Pump Inhibitors | 2015 |
Alginate beads as a carrier for omeprazole/SBA-15 inclusion compound: A step towards the development of personalized paediatric dosage forms.
Topics: Alginates; Drug Carriers; Drug Liberation; Gastroesophageal Reflux; Glucuronic Acid; Hexuronic Acids | 2015 |
A jackhammer in the gullet: high amplitude oesophageal contractions as a cause of atypical chest pain.
Topics: Anti-Ulcer Agents; Chest Pain; Esophageal Motility Disorders; Gastroesophageal Reflux; Humans; Male; | 2015 |
Comparative efficacy of esomeprazole and omeprazole: Racemate to single enantiomer switch.
Topics: Esomeprazole; Gastroesophageal Reflux; Helicobacter Infections; Humans; Omeprazole; Proton Pump Inhi | 2015 |
A Case of Anaphylaxis After Garlic Ingestion: Is Alliinase the Only Culprit Allergen?
Topics: Anaphylaxis; Carbon-Sulfur Lyases; Food Hypersensitivity; Garlic; Gastroesophageal Reflux; Humans; M | 2015 |
Quiz Page March 2016: A 60-Year-Old Man With Fever, Night Sweats, and Acute Kidney Injury.
Topics: Biopsy; Creatinine; Diagnosis, Differential; Gastroesophageal Reflux; Glucocorticoids; Humans; Kidne | 2016 |
Association of Acute Gastroesophageal Reflux Disease With Esophageal Histologic Changes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biopsy; Eosinophils; Esophagitis, Peptic; Esophagus; Female | 2016 |
Role of altered esophageal intraluminal baseline impedance levels in patients with gatroesophageal reflux disease refractory to proton pump inhibitors.
Topics: Electric Impedance; Esophagus; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; | 2016 |
Dose-Finding Study of Omeprazole on Gastric pH in Neonates with Gastro-Esophageal Acid Reflux Using a Bayesian Sequential Approach.
Topics: Administration, Oral; Anti-Ulcer Agents; Bayes Theorem; Dose-Response Relationship, Drug; Esophageal | 2016 |
Gastro-oesophageal reflux disease in 20 dogs (2012 to 2014).
Topics: Animals; Dog Diseases; Dogs; Esophagoscopy; Female; Gastroesophageal Reflux; Male; Omeprazole | 2017 |
Effect of Roux-en-Y surgery and medical intervention on Barrett's-type changes: an in vivo model.
Topics: Anastomosis, Roux-en-Y; Animals; Barrett Esophagus; Disease Models, Animal; Gastroesophageal Reflux; | 2008 |
Acid reflux detection and symptom-reflux association using 4-day wireless pH recording combining 48-hour periods off and on PPI therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Esophageal pH Monitoring; F | 2008 |
Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Child; Clinical Trials as Topic; Databases, Bibliographic; | 2009 |
Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs).
Topics: Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Down-Regulation; Drug Administration Schedu | 2009 |
N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease.
Topics: Aminopyridines; Animals; Anti-Ulcer Agents; Benzopyrans; Disease Models, Animal; Dogs; Enzyme Inhibi | 2009 |
Gastroesophageal scintigraphy in the evaluation of adult patients with chronic cough due to gastroesophageal reflux disease.
Topics: Adult; Aged; Case-Control Studies; Chronic Disease; Cough; Esophagitis, Peptic; Esophagus; Female; G | 2008 |
[Analysis of actual costs in long-term therapy of reflux disease. Use of pantoprazole counts].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Costs and Cost Analysis; Drugs, Generic; | 2008 |
I was recently diagnosed with "dyspepesia." Is this a fancy term for heartburn? Are there other ways of preventing and easing symptoms besides yoga classes to reduce stress and Prilosec for reflux?
Topics: Diet; Dyspepsia; Enzyme Inhibitors; Gastroesophageal Reflux; Helicobacter pylori; Humans; Omeprazole | 2008 |
Effect of alpha-tocopherol, N-acetylcysteine and omeprazole on esophageal adenocarcinoma formation in a rat surgical model.
Topics: Acetylcysteine; Adenocarcinoma; alpha-Tocopherol; Animals; Disease Models, Animal; Esophageal Neopla | 2009 |
[Proton pump inhibition: more than only reflux therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Chest Pain; Clopidogrel; Comorbi | 2008 |
Evaluation of use of proton pump inhibitors in Greece.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Drug Prescriptions; Drug Utilization; Gastroesophage | 2009 |
Silent acid reflux and asthma control.
Topics: Asthma; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors; Treatment Failure | 2009 |
[Therapy of gastric acid-induced illnesses in general practice. The first pantoprazole generic drug has arrived].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biological Availability; Cost-Benefit An | 2009 |
Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat.
Topics: Drug Administration Schedule; Dyspepsia; Evidence-Based Medicine; Gastric Acid; Gastric Mucosa; Gast | 2009 |
Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis.
Topics: Adult; Aged; Enzyme Inhibitors; Europe; Female; Follow-Up Studies; Gastroesophageal Reflux; Humans; | 2009 |
Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily.
Topics: Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Duodenogastric Reflux; Esophageal pH M | 2009 |
Gastroesophageal reflux leads to esophageal cancer in a surgical model with mice.
Topics: Adenocarcinoma; Animals; Anti-Ulcer Agents; Carcinoma, Squamous Cell; Cyclin-Dependent Kinase Inhibi | 2009 |
Oesophageal acid hypersensitivity is not a contraindication to Nissen fundoplication.
Topics: Adult; Aged, 80 and over; Contraindications; Drug Resistance; Endoscopy, Gastrointestinal; Esophagit | 2009 |
Long-term use of proton pump inhibitors: are they really safe? A case of delayed acute interstitial nephritis.
Topics: Aged; Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Male; Nephritis, Interstitial; Omeprazole | 2009 |
PPI-delayed diagnosis of gastrinoma: oncologic victim of pharmacologic success.
Topics: Anti-Ulcer Agents; Appendectomy; Barrett Esophagus; Delayed Diagnosis; Gastrinoma; Gastroesophageal | 2010 |
Case reports--resolution of Barrett's disease and esophageal epithelial atypia after gastric bypass and LAP-BAND.
Topics: Anti-Ulcer Agents; Barrett Esophagus; Esophagitis; Esophagoscopy; Gastrectomy; Gastric Bypass; Gastr | 2009 |
Inappropriate use of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Cross-Sectional Studies; Dyspepsia | 2010 |
[Why some proton pump inhibitors are more equal than others].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Deglutition Disorders; Drugs, Generic; Female; Gastroesopha | 2009 |
The effect of omeprazole on oesophageal pH in dogs during anaesthesia.
Topics: Anesthesia, General; Animals; Dogs; Esophageal pH Monitoring; Female; Gastroesophageal Reflux; Male; | 2009 |
Omeprazole-induced cough in a patient with gastroesophageal reflux disease.
Topics: Aged; Cough; Female; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors | 2010 |
Patient satisfaction with switching to esomeprazole from existing proton pump inhibitor therapy for gastro-oesophageal reflux disease: an observational, multicentre study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Esomeprazole; Female; Gastroesophagea | 2009 |
Treating silent reflux disease does not improve poorly controlled asthma.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Asthma; Esophageal pH Monitoring; Female; Gastroesophageal Ref | 2010 |
[Comparative study of esomeprazole and omeprazole using for initialism therapy for elderly-senile and young-adulthood patients with GERD].
Topics: Adult; Aged; Anti-Ulcer Agents; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male; Middle | 2009 |
Omeprazole-induced subacute cutaneous lupus erythematosus.
Topics: Anti-Ulcer Agents; Drug Eruptions; Female; Gastroesophageal Reflux; Humans; Lupus Erythematosus, Cut | 2010 |
Diagnosis of gastroesophageal reflux disease.
Topics: Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Omeprazole; Treatment Outcome | 2010 |
A dispensing error resulting in possible fluoxetine overdose and subsequent discontinuation syndrome in a child.
Topics: Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug Overdose; Fluoxetine; Gastroesophageal Ref | 2010 |
Editorial: just how "difficult" is it to withdraw PPI treatment?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dyspepsia; Esophagitis; Gastric Acid; Gastroesophageal Refl | 2010 |
Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis.
Topics: Adolescent; Adult; Aged; Alleles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 | 2010 |
Novel approaches to inhibition of gastric acid secretion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; H | 2010 |
De novo erosive esophagitis in duodenal ulcer patients related to pre-existing reflux symptoms, smoking, and patient age, but not to Helicobacter pylori eradication: a one-year follow-up study.
Topics: Adult; Age Factors; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Cl | 2010 |
Patients with gastroesophageal reflux disease and respiratory manifestations do not present lung function disorders during cardiopulmonary exercise test.
Topics: Adult; Anti-Ulcer Agents; Cough; Exercise Test; Female; Gastroesophageal Reflux; Gastroscopy; Heart | 2011 |
Treatment strategies for acid reflux: EncomPASSing practical solutions for primary care.
Topics: Cost-Benefit Analysis; Gastroesophageal Reflux; Humans; Omeprazole; Primary Health Care; Randomized | 2010 |
"War and Peace" with Barrett's esophagus.
Topics: Adenocarcinoma; Aged; Anti-Ulcer Agents; Antihypertensive Agents; Aspirin; Barrett Esophagus; Celeco | 2011 |
Endoscopic jejunal biopsy culture: a simple and effective method to study jejunal microflora.
Topics: Adult; Bacteria; Bacteriological Techniques; Biopsy; Candida; Endoscopy, Gastrointestinal; Female; G | 2010 |
[Dynamics of inflammatory periodontal diseases under the influence of gastroesophageal reflux disease therapy].
Topics: Adult; Alginates; Chronic Disease; Chronic Periodontitis; Drug Therapy, Combination; Enzyme Inhibito | 2010 |
It is difficult to discontinue PPI treatment in patients with GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Dyspepsia; Esophagitis; Gastric A | 2011 |
Proton pump inhibitor step-down therapy for GERD: a multi-center study in Japan.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Chi-Square Distribution; Drug Administration Schedul | 2011 |
Eosinophilic esophagitis in patients with typical gastroesophageal reflux disease symptoms refractory to proton pump inhibitor.
Topics: Adolescent; Adult; Aged; Diagnosis, Differential; Eosinophilic Esophagitis; Female; Gastroesophageal | 2011 |
Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Esomeprazole; E | 2011 |
The reason for failure of on-demand PPI therapy in NERD patients.
Topics: Female; Gastroesophageal Reflux; Humans; Irritable Bowel Syndrome; Male; Omeprazole; Proton Pump Inh | 2011 |
Low levels of adherence with proton pump inhibitor therapy contribute to therapeutic failure in gastroesophageal reflux disease.
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Gastroesophageal Reflux; Humans; Ma | 2012 |
[Gastric acid suppression of a new oral powder omeprazole suspension for infants with gastroesophageal reflux disease. A pilot study].
Topics: Anti-Ulcer Agents; Esophageal pH Monitoring; Female; Gastroesophageal Reflux; Humans; Infant; Male; | 2011 |
Proton pump inhibitors omeprazole, lansoprazole and pantoprazole induce relaxation in the rat lower oesophageal sphincter.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Angiotensins; Animals; Carbachol; Electric Stimulation; Eso | 2011 |
Assessment and treatment of gastroesophageal reflux in healthy infants with apneic episodes: a retrospective analysis of 87 consecutive patients.
Topics: Cisapride; Enzyme Inhibitors; Esophageal pH Monitoring; Esophagoscopy; Female; Follow-Up Studies; Fu | 2011 |
The safety of fetal exposure to proton-pump inhibitors during pregnancy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abnormalities, Drug-Induced; Adult; Cohort Studies; Databas | 2012 |
The usefulness of the original questionnaire in the evaluation of quality of life in patients with gastroesophageal reflux disease.
Topics: Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Omeprazole; Quality of Life; Reproducibility of | 2011 |
Evolution of GERD over 5 years.
Topics: Antacids; Anti-Ulcer Agents; Female; Gastroesophageal Reflux; Humans; Male; Omeprazole | 2012 |
Combatting the cough that won't quit.
Topics: Algorithms; Anti-Ulcer Agents; Chronic Disease; Cough; Diagnosis, Differential; Family Practice; Fem | 2012 |
Control of intra-oesophageal pH in patients with Barrett's oesophagus on omeprazole-sodium bicarbonate therapy.
Topics: Aged; Barrett Esophagus; Body Mass Index; Cohort Studies; Female; Gastroesophageal Reflux; Humans; H | 2012 |
Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD.
Topics: Adult; Cells, Cultured; Chemokine CCL26; Chemokines, CC; Enzyme-Linked Immunosorbent Assay; Eosinoph | 2013 |
[Factors affecting efficacy of gastroesophageal reflux disease treatment with proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Female; Gastroesophageal Reflux; Humans; Lansoprazol | 2012 |
Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Esomeprazole; Esophagitis, Peptic; Female; Gastroeso | 2012 |
[Adverse events associated with long-term use of proton pump inhibitors].
Topics: Anti-Ulcer Agents; Bacterial Infections; Congenital Abnormalities; Dyspepsia; Fractures, Bone; Gastr | 2012 |
[Efficacy and safety of OTC omeprazole].
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastroesophageal Refl | 2012 |
An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2002 |
Proton pump inhibitors: an update.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Interactions; Esomeprazole; Gastroesop | 2002 |
Assessment of the afferent vagal nerve in patients with gastroesophageal reflux.
Topics: Adult; Anti-Ulcer Agents; Cerebral Cortex; Drug Administration Schedule; Electric Stimulation; Esoph | 2002 |
Early relief of upper gastrointestinal dyspeptic symptoms: a survey of empirical therapy with pantoprazole in Canadian clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Canad | 2002 |
Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Benzimidazoles; Child; Child, Pres | 2002 |
Functional dyspepsia: bye-bye to PPIs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; China; Dyspepsia; Gastroesophageal R | 2002 |
[Effectiveness of pariet (rabeprazole) in the treatment of gastroesophageal reflux disease (at the reflux-esophagitis stage)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2002 |
Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aryl Hydrocarbon Hydroxylases; Confidence Intervals; | 2002 |
Prospective study on the incidence of chronic ear complaints related to gastroesophageal reflux and on the outcome of antireflux therapy.
Topics: Adult; Aged; Anti-Ulcer Agents; Chronic Disease; Cohort Studies; Enzyme Inhibitors; Female; Gastroes | 2002 |
Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy.
Topics: Adult; Aged; Anti-Ulcer Agents; Barrett Esophagus; Cohort Studies; Female; Gastroesophageal Reflux; | 2002 |
[Pharma clinics medication of the month. Esomeprazole].
Topics: Cost Control; Drug Costs; Duodenal Ulcer; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; | 2002 |
Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 2002 |
[Typical and atypical symptoms of laryngopharyngeal reflux disease].
Topics: Adult; Anti-Ulcer Agents; Diagnosis, Differential; Esophagus; Female; Gastroesophageal Reflux; Heart | 2002 |
Severe esophagitis healed in less than a week with intravenous pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Enzyme Inhibitors; Esophagitis; Fema | 2003 |
Persistent gastroesophageal reflux disease symptoms on standard proton-pump inhibitor therapy.
Topics: Adult; Aged; Diazepam; Drug Therapy, Combination; Enzyme Inhibitors; Follow-Up Studies; Gastroesopha | 2002 |
[Ongoing treatment with omeprazole and appearance of oropharyngeal candidiasis].
Topics: Aged; Anti-Ulcer Agents; Antifungal Agents; Candida albicans; Candidiasis, Oral; Female; Fluconazole | 2002 |
[A case for proton pump blocker... When cough comes from the stomach].
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antirheumatic Age | 2002 |
Diagnostic test with omeprazole in patients with posterior laryngitis.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Diet; Endoscopy, Gastrointestinal; Esophagitis; Female; | 2003 |
Omeprazole-induced acute interstitial nephritis.
Topics: Aged; Female; Gastroesophageal Reflux; Humans; Nephritis, Interstitial; Omeprazole | 2003 |
Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Chronic Disease; Cisapride; | 2003 |
[Pantoprazole-induced hepatitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdomen; Abdominal Pain; Anti-Ulcer Agents; Benzimidazoles; | 2003 |
Reflux symptoms in general practice: diagnostic evaluation of the Carlsson-Dent gastro-oesophageal reflux disease questionnaire.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Female; Gastroesophageal Reflux; Huma | 2003 |
Complications of medical management of dental erosion.
Topics: Adult; Enzyme Inhibitors; Gastritis; Gastroesophageal Reflux; Humans; Male; Omeprazole; Proton Pump | 2003 |
Nonoperative treatment of laryngeal granuloma.
Topics: Anti-Ulcer Agents; Gastroesophageal Reflux; Granuloma; Humans; Laryngeal Diseases; Laryngoscopy; Mal | 2003 |
Lansoprazole overutilization: methods for step-down therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Costs; Drug Utilization Review; Enz | 2003 |
Globus sensation and gastroesophageal reflux.
Topics: Adult; Aged; Deglutition Disorders; Diagnostic Techniques, Digestive System; Enzyme Inhibitors; Fema | 2003 |
Oesophageal acid-peptic strictures in the histamine H2 receptor antagonist and proton pump inhibitor era.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Catheterization; Esophageal Stenosis; Female; Gas | 2003 |
Acid exposure and altered acid clearance in GERD patients treated for Helicobacter pylori infection.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Thera | 2003 |
A proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Asthma; Benzimidazoles; Female; Ga | 2003 |
The comparison of an empiric proton pump inhibitor trial vs 24-hour double-probe Ph monitoring in laryngopharyngeal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Enzyme Inhibitors; Female; Gastroesophageal Re | 2003 |
Pharyngolaryngeal reflux in outpatient clinical practice: personal experience.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Enzyme Inhibitors; Feasibility Studies; Female; Gas | 2003 |
Long-term observation of reflux oesophagitis developing after Helicobacter pylori eradication therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Esophagitis, Peptic; Female; | 2003 |
Adverse reactions to pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anaphylaxis; Benzimidazoles; Enzyme Inhibitors; Fema | 2003 |
Minimal surgery for treatment of GERD.
Topics: Barrett Esophagus; Combined Modality Therapy; Enzyme Inhibitors; Fundoplication; Gastroesophageal Re | 2003 |
[References for reflux therapy. Preventing nocturnal acid recurrence].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Chronotherapy; Delayed-A | 2003 |
Impact of Maine's Medicaid drug formulary change on non-Medicaid markets: spillover effects of a restrictive drug formulary.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Utilization; Enzyme Inhibitors; Formul | 2003 |
Asthma-like syndrome in a teenager.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Albuterol; Amoxicillin; Androstadienes; Anti-Ba | 2003 |
Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity.
Topics: Adult; Anti-Ulcer Agents; Clinical Trials as Topic; Data Interpretation, Statistical; Female; Gastro | 2003 |
[Heartburn without esophagitis. Symptoms more important than the finding?].
Topics: Androstadienes; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ul | 2003 |
Manifestations of gastroesophageal reflux and response to omeprazole therapy in patients with chronic posterior laryngitis: an evaluation based on clinical practice.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Chronic Disease; Female; Gastroesophageal Reflux; Humans | 2003 |
Helicobacter pylori eradication does not exacerbate gastro-oesophageal reflux disease.
Topics: Esophagus; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-I | 2004 |
Acute interstitial nephritis due to pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Administration, Oral; Aged; Benzimidazoles; | 2004 |
Outcome of laparoscopic Nissen-Rossetti fundoplication in children with gastroesophageal reflux disease and supraesophageal symptoms.
Topics: Adolescent; Anti-Ulcer Agents; Asthma; Child; Child, Preschool; Combined Modality Therapy; Domperido | 2004 |
Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost Control; Cost-Benefit Analysis; Databa | 2004 |
Adverse events following discharge from the hospital.
Topics: Anti-Ulcer Agents; Gastroesophageal Reflux; Health Maintenance Organizations; Humans; Male; Middle A | 2004 |
[Efficacy of controloc in the treatment of acid-dependent diseases].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroes | 2003 |
Eosinophilic infiltration of the esophagus: gastroesophageal reflux versus eosinophilic esophagitis in children--discussion on daily practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biopsy; Child; Cimetidine; Diagnosis, Differential; Enzyme | 2004 |
[Long-term course of reflux symptoms following Helicobacter pylori eradication].
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromyci | 2004 |
pH probe positioning for 24-hour pH-metry by manometry or pH step-up.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Enzyme Inhibitors; Female; Gas | 2004 |
Omeprazole may delay the diagnosis of pyloric stenosis.
Topics: Anti-Ulcer Agents; Drug Administration Schedule; Gastroesophageal Reflux; Humans; Infant, Newborn; M | 2004 |
Not a usual suspect; rabeprazole therapy presenting as a severe neuropsychiatric illness: case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Brain; Diagnosis, Differential; Gast | 2003 |
[When sour does not make merry at all . Fast relief for patients with reflux].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Gastr | 2003 |
Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Barrett Esophagus; Benzimidazoles; | 2004 |
H pylori infection and reflux oesophagitis.
Topics: Cohort Studies; Drug Therapy, Combination; Esophagitis; Gastroesophageal Reflux; Gastrointestinal Ag | 2004 |
[Stubborn reflux pain, inconspicuous esophagus. Which therapy brings the fastest relief?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Eso | 2004 |
[Graded therapy in reflux disease. "In severe cases 40 mg., in milder 20 mg."].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2004 |
By the way, doctor. I've been taking Prilosec for esophageal reflux. My doctor says I may need to take it indefinitely. Is that safe?
Topics: Antacids; Female; Gastroesophageal Reflux; Humans; Omeprazole; Time Factors | 2004 |
Early epigastric pain after PPI administration: exacerbation of Helicobacter pylori corpus gastritis?
Topics: Abdominal Pain; Anti-Ulcer Agents; Dyspepsia; Gastritis; Gastroesophageal Reflux; Helicobacter Infec | 2004 |
GERD 2003: issues from the past and a consensus for the future.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Gas | 2004 |
[Effectiveness of omeprazole therapy in children with gastroesophageal reflux diseases(GERD)].
Topics: Adolescent; Anti-Ulcer Agents; Child; Child, Preschool; Female; Gastroesophageal Reflux; Humans; Hyd | 2004 |
Evaluation of treatment for gastro-oesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and Helicobacter pylori infection in Japan.
Topics: Anti-Ulcer Agents; Female; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Hu | 2004 |
Patients with chest pain and occult gastroesophageal reflux demonstrate visceral pain hypersensitivity which may be partially responsive to acid suppression.
Topics: Acids; Adult; Chest Pain; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Pa | 2004 |
Pantoprazole for sleepiness associated with acid reflux and obstructive sleep disordered breathing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Arousal; Benzimidazoles; Circadia | 2004 |
Pachydermia is not diagnostic of active laryngopharyngeal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2004 |
Recurrent anaphylaxis linked to pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anaphylaxis; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylas | 2004 |
Oesophageal pH monitoring is of limited value in the diagnosis of "reflux-cough".
Topics: Anti-Ulcer Agents; Cough; Esophagus; Follow-Up Studies; Gastroesophageal Reflux; Humans; Hydrogen-Io | 2004 |
Omeprazole does not reduce gastroesophageal reflux: new insights using multichannel intraluminal impedance technology.
Topics: Adult; Anti-Ulcer Agents; Catheterization; Electric Impedance; Esophagus; Female; Gastroesophageal R | 2004 |
[Erosion caused by gastric reflux in children. Discussion of etiology, clinical appearance and therapy in two cases].
Topics: Adolescent; Anti-Ulcer Agents; Child; Fluorides, Topical; Gastroesophageal Reflux; Humans; Male; Ome | 2004 |
[The best strategies against reflux disease. Acid stomach and the sequelae].
Topics: Anti-Ulcer Agents; Barrett Esophagus; Chest Pain; Esophagitis; Gastroesophageal Reflux; Helicobacter | 2004 |
[Attention! Cough, asthma and Co. are often caused by reflux].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Asthma; Benzimidazoles; Clinical | 2004 |
[Paradigm change in reflux disease. In reflux patients listening to is often more important than endoscopy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2004 |
Treatment of gastric hemorrhage by pulverized omeprazole and antacid--concomitant administration via a nasogastric tube.
Topics: Adolescent; Antacids; Anti-Ulcer Agents; Cimetidine; Drug Therapy, Combination; Gastroesophageal Ref | 2004 |
Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Circadian Rhythm; Gastri | 2004 |
Persistent cough following pulmonary resection: observational and empiric study of possible causes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzamides; Carcinoma, Non-Small-Cell Lung; Chronic D | 2005 |
Persistent cough following pulmonary resection: observational and empiric study of possible causes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzamides; Carcinoma, Non-Small-Cell Lung; Chronic D | 2005 |
Persistent cough following pulmonary resection: observational and empiric study of possible causes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzamides; Carcinoma, Non-Small-Cell Lung; Chronic D | 2005 |
Persistent cough following pulmonary resection: observational and empiric study of possible causes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzamides; Carcinoma, Non-Small-Cell Lung; Chronic D | 2005 |
Validation of the Reflux Disease Questionnaire for a German population.
Topics: Adult; Aged; Anti-Ulcer Agents; Cross-Cultural Comparison; Dyspepsia; Female; Gastroesophageal Reflu | 2005 |
Rebound acid hypersecretion after long-term inhibition of gastric acid secretion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Enterochromaffin- | 2005 |
[Gastroesophageal reflux disease refractory to esomeprazole].
Topics: Adult; Anti-Ulcer Agents; Esomeprazole; Gastric Acidity Determination; Gastroesophageal Reflux; Huma | 2005 |
Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment.
Topics: Adult; Biopsy; Epithelial Cells; Esophagitis; Female; Gastroesophageal Reflux; Heartburn; Humans; Ma | 2005 |
H+/K+-ATPase (proton pump) inhibitors dampen increased cough reflex: more than gastric acid suppression.
Topics: Anti-Ulcer Agents; Cough; Depression, Chemical; Gastric Acid; Gastroesophageal Reflux; Humans; Omepr | 2005 |
Lack of interaction between atazanavir and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Atazanavir Sulfate; Contraindicat | 2005 |
Helicobacter pylori infection in patients with erosive esophagitis is associated with rapid heartburn relief and lack of relapse after treatment with pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Case-Control Studies; Chi-Squa | 2005 |
Long-term acid suppression by omeprazole in gastro-oesophageal reflux disease patients does not lead to anti-gastric autoantibody production.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Antibody Formation; Autoantibodies; Blotting, Wes | 2005 |
Symptom association probability and symptom sensitivity index: preferable but still suboptimal predictors of response to high dose omeprazole.
Topics: Adult; Drug Administration Schedule; Female; Gastroesophageal Reflux; Heartburn; Humans; Hydrogen-Io | 2005 |
Rabeprazole controls GERD symptoms in a patient for whom treatment with lansoprazole failed: first report of "cluster GERD.".
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal Reflux; | 2005 |
[Basic principles of successful GERD (gastroesophageal reflux disease) therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 2005 |
Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl | 2005 |
Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cohort Studies; Drug Admini | 2005 |
Lansoprazole-associated collagenous colitis: a case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biopsy; Colitis; Collagen; Colonoscopy; Diagnosis, Differen | 2005 |
[Pharmacogenomical aspects of gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida | 2005 |
Long-term omeprazole and esomeprazole treatment does not significantly increase gastric epithelial cell proliferation and epithelial growth factor receptor expression and has no effect on apoptosis and p53 expression.
Topics: Adult; Apoptosis; Cell Proliferation; Epithelial Cells; ErbB Receptors; Esomeprazole; Female; Gastri | 2005 |
The effect of gastro-oesophageal reflux and omeprazole on key sleep parameters.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Case-Control Studies; Female; Gastroesophageal Reflux; Humans; | 2005 |
Frequency of gastroesophageal reflux disease in nonatopic children with asthma-like airway disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Asthmatic Agents; Anti-Ulcer Agents; Asthma; Child; Ch | 2006 |
Does gastro-esophageal reflux provoke the myocardial ischemia in patients with CAD?
Topics: Adult; Aged; Anti-Ulcer Agents; Circadian Rhythm; Coronary Artery Disease; Electrocardiography, Ambu | 2005 |
A decade-long sour-taste sensation successfully treated with a proton-pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Administration Schedule; Enzyme Inhibitors; Female; Ga | 2005 |
Nasal pain disrupting sleep as a presenting symptom of extraesophageal acid reflux in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child, Preschool; Diet; Gastroesophageal | 2005 |
Balanced perspective essential in erosive oesophagitis treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Esoph | 2005 |
Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esomeprazole; Gastroesop | 2005 |
Development and validation of the Gastroesophageal Reflux Disease Treatment Satisfaction Questionnaire.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2005 |
Four-day Bravo pH capsule monitoring with and without proton pump inhibitor therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Benzimidazoles; Ca | 2005 |
[Acid inhibitors for asthma patients].
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Anti-Ulcer Agents; Asthma; Child; Eosinoph | 2005 |
Voice disorders and gastroesophageal reflux.
Topics: Adolescent; Adult; Aged; Case-Control Studies; Enzyme Inhibitors; Esophagoscopy; Female; Gastroesoph | 2005 |
Factors influencing the shift of patients from one proton pump inhibitor to another: the effect of direct-to-consumer advertising.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Advertising; Cohort Studies; Cost Sharing; Drug Utilization | 2005 |
Clinical implications of immediate-release PPI therapy in the management of GERD and upper GI bleeding. Introduction.
Topics: Enzyme Inhibitors; Gastroesophageal Reflux; Gastrointestinal Hemorrhage; Humans; Omeprazole; Proton | 2005 |
[The impact of rabeprazole treatment on the quality of life in patients with reflux esophagitis and non-erosive reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2005 |
Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Gastric Acidity Determination; Ga | 2005 |
Sensitive quantification of omeprazole and its metabolites in human plasma by liquid chromatography-mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Esomeprazole; Gastroesophageal Reflux; Humans; Omeprazole; Sen | 2006 |
[Gastroesophageal reflux and obstructive sleep apnea syndrome].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Female; Gastroesophageal Reflux; Hum | 2005 |
What is the relationship between gastro-oesophageal reflux and obstructive sleep apnoea?
Topics: Anti-Ulcer Agents; Causality; Comorbidity; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump | 2006 |
All PPIs equivalent for treatment of GERD.
Topics: Anti-Ulcer Agents; Dose-Response Relationship, Drug; Gastroesophageal Reflux; Humans; Omeprazole; Pr | 2005 |
[Oral cavity manifestations of gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esophagus; Female; Follo | 2005 |
Asthma and gastroesophageal reflux disease: effect of long-term pantoprazole therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Asthma; Benzimidazoles; Female; F | 2005 |
Efficacy of a proton pump inhibitor given in the early postoperative period to relieve symptoms of hiatal hernia after open heart surgery.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Benzimidazoles; Cardiac Sur | 2006 |
Gastrointestinal tract.
Topics: Adult; Endoscopy, Digestive System; Enzyme Inhibitors; Gastroesophageal Reflux; Gastrointestinal Tra | 2005 |
The effects of changing temperature correction factors on measures of acidity calculated from gastric and oesophageal pH recordings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Catheterization; Esophag | 2006 |
[Reflux therapy in the elderly].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal R | 2005 |
Determinants of long-term outcome of patients with reflux-related ear, nose, and throat symptoms.
Topics: Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Gastroesophageal Reflux; | 2006 |
Proton pump inhibitor failure in gastro-oesophageal reflux disease--what about eosinophilic oesophagitis?
Topics: Adult; Eosinophilia; Esophagitis; Esophagoscopy; Gastroesophageal Reflux; Humans; Male; Omeprazole; | 2006 |
Gastro-oesophageal reflux disease in 'difficult-to-control' asthma: prevalence and response to treatment with acid suppressive therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Asthma; Cohort Studies; Female; Forced Expiratory | 2006 |
Proton pump inhibitors and acute interstitial nephritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Kidney Injury; Adult; Age Distribution; Aged; Aged, 8 | 2006 |
Treatment of oesophageal bile reflux in children: the results of a prospective study with omeprazole.
Topics: Adolescent; Anti-Ulcer Agents; Bile Reflux; Child; Child, Preschool; Esophagitis; Female; Gastroesop | 2006 |
Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children.
Topics: Achlorhydria; Acute Disease; Anti-Ulcer Agents; Child, Preschool; Community-Acquired Infections; Gas | 2006 |
Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Administration Schedule; Enzyme Inhibi | 2006 |
Presenting symptoms of nonerosive and erosive esophagitis in pediatric patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Anorexia; Anti-Ulcer Agents; Ch | 2006 |
Efficacy of low-dose lansoprazole in the treatment of non-erosive gastrooesophageal reflux disease. Influence of infection by Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Double-Blind Method; Female; Gastroesophageal Reflux; Helic | 2006 |
Should we bravo?
Topics: Cohort Studies; Equipment Design; Equipment Safety; Esophageal pH Monitoring; Esophagoscopy; Female; | 2006 |
Gastroesophageal reflux disease and asthma: the role of proton pump inhibitors.
Topics: Adult; Asthma; Gastroesophageal Reflux; Humans; Male; Omeprazole; Proton Pump Inhibitors | 2006 |
Co-prescription of alginate based formulations & proton pump inhibitors (PPIs) in gastro-oesophageal reflux disease: time for rethink?
Topics: Alginates; Antacids; Drug Interactions; Drug Therapy, Combination; Gastroesophageal Reflux; Humans; | 2006 |
Impact of malnutrition on gastrointestinal disorders and gross motor abilities in children with cerebral palsy.
Topics: Adolescent; Body Mass Index; Cerebral Palsy; Child; Child Nutrition Disorders; Child, Preschool; Enz | 2007 |
Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Enzyme Inhibitors; Esophageal pH Monitoring; Female; Fol | 2006 |
By the way, doctor. I've been taking Prilosec for over a year for GERD. Recently, I read that long-term use of proton pump inhibitors increases the risk of certain gastric cancers. Your opinion?
Topics: Anti-Ulcer Agents; Female; Gastroesophageal Reflux; Humans; Omeprazole; Stomach Neoplasms | 2006 |
[Effects of proton pump inhibitor on airway hyperresponsiveness in asthmatics with gastroesophageal reflux].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Female; Gastroesophageal Reflux; | 2006 |
Severe laryngeal hyperkeratosis secondaryto laryngopharyngeal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Therapy, Combination; Gastroesophageal | 2006 |
Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastresophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aminopyrine; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2006 |
Esophageal intramural pseudodiverticulosis with esophageal strictures successfully treated with dilation therapy.
Topics: Aged; Antifungal Agents; Candidiasis; Catheterization; Chronic Disease; Deglutition Disorders; Diagn | 2006 |
Treatment of laryngopharyngeal reflux improves asthma symptoms in asthmatics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Asthma; Benzimidazoles; Combined | 2006 |
Multichannel intraluminal impedance in the evaluation of patients with persistent globus on proton pump inhibitor therapy.
Topics: Adult; Aged; Case-Control Studies; Deglutition Disorders; Electric Impedance; Enzyme Inhibitors; Eso | 2006 |
Potential relationship between gastroesophageal reflux disease and atrial arrhythmias.
Topics: Aged; Arrhythmias, Cardiac; Comorbidity; Electrocardiography, Ambulatory; Enzyme Inhibitors; Esophag | 2006 |
The role of proton-pump inhibitor therapy in patients with gastroesophageal reflux disease and difficult-to-control asthma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Gastroesophageal Reflux; Humans; | 2006 |
Excessively high doses of omeprazole being used in infants.
Topics: Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Infant | 2006 |
Proton pump inhibitors.
Topics: Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Nephritis, Interstitial; Omeprazole; Proton Pump | 2006 |
[Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease].
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Female; Gastroesophageal Reflux; Gen | 2006 |
A 59-year-old woman with gastroesophageal reflux disease and barrett esophagus, 4 years later.
Topics: Barrett Esophagus; Enzyme Inhibitors; Esophagoscopy; Female; Gastroesophageal Reflux; Humans; Middle | 2006 |
[The influence of gastroesophageal reflux on the course and therapy of bronchial asthma].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Gastroesophageal Reflux; Histami | 2006 |
Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment.
Topics: Administration, Oral; Adult; Anti-Ulcer Agents; Cross-Over Studies; Dose-Response Relationship, Drug | 2007 |
Laser eustachian tuboplasty: two-year results.
Topics: Adult; Anti-Ulcer Agents; Eustachian Tube; Female; Follow-Up Studies; Gastroesophageal Reflux; Heari | 2007 |
Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Distribution; Child; Child, Preschool; Cohort Studies; | 2007 |
Comparative drug effects: the case of GERD therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Disease Management; Gastroesophageal Reflux; Heal | 2007 |
The management of upper gastrointestinal symptoms: is endoscopy indicated?
Topics: Age Factors; Antacids; Anti-Ulcer Agents; Dyspepsia; Endoscopy, Digestive System; Gastroesophageal R | 2007 |
Proton pump inhibitors for GERD in children.
Topics: Anti-Ulcer Agents; Child; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pum | 2007 |
Autoimmune haemolytic anaemia associated with use of omeprazole.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Anti-Ulcer Agents; Female; Gastroesophageal Reflux; Humans; Ome | 2007 |
[A case of gastroesophageal reflux disease with marked eosinophilia].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Eosinophilia; Esophagitis, Peptic; Female; Gastroesop | 2007 |
Autoimmune haemolytic anaemia due to Omeprazole.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Anti-Ulcer Agents; Female; Gastroesophageal Reflux; Humans; Ome | 2007 |
Ecabet sodium prevents esophageal lesions induced by the reflux of gastric juice in rats.
Topics: Abietanes; Animals; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug Synergism; Drug Therap | 2007 |
Is this medicine really involved in a drug interaction?
Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Digoxin; Drug Interactions; Drug | 2007 |
Omeprazole-associated digoxin toxicity.
Topics: Aged; Atrial Fibrillation; Cardiotonic Agents; Digoxin; Drug Interactions; Enzyme Inhibitors; Female | 2007 |
Severe systemic adverse reaction to proton pump inhibitors in an infant.
Topics: Enzyme Inhibitors; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Infant; Lung Diseases; Ome | 2007 |
Getting categorical on GERD.
Topics: Anti-Ulcer Agents; Barrett Esophagus; Disease Progression; Esophageal Neoplasms; Esophagitis; Esopha | 2007 |
[Characteristics of a combined course of duodenal ulcer and gastroesophageal reflux disease].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antidepressive Agents, Second-Generation; Cla | 2007 |
Responsiveness of measures of heartburn improvement in non-erosive reflux disease.
Topics: Adult; Aged; Esophageal pH Monitoring; Female; Gastroesophageal Reflux; Heartburn; Humans; Male; Mid | 2007 |
'Poppy seeds' in stomach aspirates: is oral omeprazole extemporaneous dispersion bioavailable?
Topics: Anti-Ulcer Agents; Biological Availability; Chemistry, Pharmaceutical; Gastroesophageal Reflux; Huma | 2008 |
I was recently diagnosed with "dyspepsia". Is this just a fancy term for heartburn? Are there other ways of preventing and easing symptoms besides yoga classes to reduce stress and Prilosec for reflux?
Topics: Anti-Ulcer Agents; Dyspepsia; Gastroesophageal Reflux; Humans; Meditation; Omeprazole; Stress, Physi | 2007 |
Duodenogastro-esophageal reflux in children with refractory gastro-esophageal reflux disease.
Topics: Adolescent; Anti-Ulcer Agents; Breath Tests; Child; Duodenum; Endoscopy, Digestive System; Endoscopy | 2007 |
Treatment interruptus: the need for withdrawal.
Topics: Anti-Ulcer Agents; Child; Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Omeprazole; Ranitidi | 2007 |
Prospective Acid Reflux Study of Iran (PARSI): methodology and study design.
Topics: Biopsy; Comorbidity; Drug Administration Schedule; Esophagogastric Junction; Esophagus; Feasibility | 2007 |
Proton pump inhibitor utilization patterns in infants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Anti-Ulcer Agents; Drug Administration Schedul | 2007 |
Laparoscopic partial posterior (Toupet) fundoplication improves esophageal bolus propagation on scintigraphy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Cross-Over Studies; Esophageal Sphincter, Lowe | 2008 |
EMANCIPATE study: drawing conclusions may be difficult in the absence of fundamental information.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Omepraz | 2008 |
EMANCIPATE versus EXPO: different results can be explained by differing study designs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Omepraz | 2008 |
Severe hypomagnesaemia in long-term users of proton-pump inhibitors.
Topics: Aged; Female; Gastroesophageal Reflux; Humans; Hypocalcemia; Magnesium Deficiency; Male; Middle Aged | 2008 |
[Drug treatment and surgical indications in gastroesophageal reflux].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Fundoplication | 2007 |
Symptom-focused results after laparoscopic fundoplication for refractory gastroesophageal reflux disease--a prospective study.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Female; Follow-Up Stud | 2008 |
Idiopathic tracheal stenosis: successful outcome with antigastroesophageal reflux disease therapy.
Topics: Administration, Oral; Adult; Biopsy, Needle; Bronchoscopy; Dose-Response Relationship, Drug; Drug Ad | 2008 |
Gastroesophageal reflux disease after Helicobacter pylori eradication in gastric ulcer patients: a one-year follow-up study.
Topics: Activities of Daily Living; Adult; Aged; Anti-Ulcer Agents; Data Interpretation, Statistical; Esopha | 2008 |
Case of the month. Gastroesophageal reflux disease (GERD), heart failure, valvular heart disease.
Topics: Aortic Valve; Aortic Valve Stenosis; Female; Gastroesophageal Reflux; Heart Failure; Humans; Middle | 2008 |
Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Circadian Rhythm; Esophageal pH Monitoring; Esophagus; Gast | 2008 |
[General practitioners' management of gastroesophageal reflux in France in 2005: a pharmacoeconomic study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Costs and Cost Analysis; Esomepra | 2008 |
[Association of gastroesophageal reflux and chronic laryngitis].
Topics: Adult; Aged; Anti-Ulcer Agents; Chronic Disease; Endoscopy, Digestive System; Female; Gastroesophage | 1995 |
Omeprazole for the treatment of posterior laryngitis.
Topics: Anti-Ulcer Agents; Drug Administration Schedule; Esophagus; Gastroesophageal Reflux; Humans; Hydroge | 1995 |
Role of gastroesophageal reflux disease in patients with cervical symptoms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Barium Sulfate; Biopsy; Cineradiograp | 1995 |
Control of gastric acid with high dose H2-receptor antagonists after omeprazole failure: report of two cases.
Topics: Adult; Anti-Ulcer Agents; Cimetidine; Drug Resistance; Female; Gastric Acid; Gastroesophageal Reflux | 1995 |
Gastric mucosal histamine storing cells. Evidence for different roles of mast cells and enterochromaffin-like cells in humans.
Topics: Aged; Biopsy; Enterochromaffin Cells; Female; Gastrectomy; Gastric Mucosa; Gastrins; Gastroesophagea | 1995 |
[Delayed increase of serum gastrin level during prolonged treatment with omeprazole: two cases].
Topics: Adult; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Female; Gastrins; Gastroesophageal Reflu | 1995 |
Outcomes of antireflux therapy for the treatment of chronic laryngitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Chronic Disease; Famotidine; Female; Gastroesopha | 1995 |
Gastroesophageal reflux laryngitis resistant to omeprazole therapy.
Topics: Adult; Aged; Female; Gastroesophageal Reflux; Humans; Laryngitis; Male; Middle Aged; Omeprazole; Ret | 1995 |
[A case of chronic persistent cough caused by gastro-esophageal reflux].
Topics: Aged; Chronic Disease; Cimetidine; Cough; Female; Gastroesophageal Reflux; Histamine H2 Antagonists; | 1995 |
Treatment of pyrosis does not insure adequate control of gastric acid reflux.
Topics: Barrett Esophagus; Chronic Disease; Esophagitis; Gastroesophageal Reflux; Heartburn; Humans; Hydroge | 1995 |
Chronic cough and hoarseness in patients with severe gastroesophageal reflux disease. Diagnosis and response to therapy.
Topics: Case-Control Studies; Chronic Disease; Cough; Female; Fundoplication; Gastroesophageal Reflux; Heart | 1995 |
Observation of gastric glandular cysts in the corpus mucosa of the stomach under omeprazole treatment.
Topics: Adult; Aged; Cysts; Diagnosis, Differential; Female; Gastric Mucosa; Gastroesophageal Reflux; Humans | 1995 |
Baclofen therapy for chronic hiccup.
Topics: Anti-Ulcer Agents; Baclofen; Chronic Disease; Cisapride; Dose-Response Relationship, Drug; Female; G | 1995 |
Omeprazole and dry mouth.
Topics: Aged; Aged, 80 and over; Candida albicans; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Con | 1995 |
Omeprazole, serum gastrin, and gastric acid suppression.
Topics: Gastric Acid; Gastrins; Gastroesophageal Reflux; Humans; Omeprazole | 1995 |
Oesophageal motility and gastro-oesophageal reflux before and after healing of reflux oesophagitis. A study using 24 hour ambulatory pH and pressure monitoring.
Topics: Adult; Aged; Aged, 80 and over; Esophagitis, Peptic; Esophagus; Female; Follow-Up Studies; Gastroeso | 1994 |
Management of Acid-Related Diseases: Focus on Pantoprazole. Proceedings of the 1st International Symposium on Pantoprazole. Berlin, Germany, 1 May 1993.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Benzimidazoles; Gastroe | 1994 |
24-hour pH monitoring in symptomatic patients without erosive esophagitis who did not respond to antireflux treatment.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Esophagitis; Esophagus; Female; Gastroesophageal | 1994 |
Omeprazole failure in a patient with gastroesophageal reflux disease.
Topics: Gastric Acid; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole | 1994 |
Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus.
Topics: Aged; Barrett Esophagus; Esophagus; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Mal | 1994 |
Diagnosis and treatment of patients with gastroesophageal reflux and noncardiac chest pain.
Topics: Adult; Aged; Aged, 80 and over; Barium Sulfate; Chest Pain; Diagnosis, Differential; Esophagoscopy; | 1994 |
Economic analysis of alternative treatments for persistent gastro-oesophageal reflux disease.
Topics: Cost-Benefit Analysis; Decision Trees; Drug Costs; Gastroesophageal Reflux; Humans; Omeprazole; Rani | 1994 |
Comparison of omeprazole and famotidine on esophageal pH in patients with moderate to severe esophagitis: a cross-over study.
Topics: Adult; Aged; Esophagitis; Esophagus; Famotidine; Female; Gastric Acid; Gastroesophageal Reflux; Huma | 1994 |
The extent and pattern of gastro-oesophageal reflux in patients with scleroderma oesophagus: the effect of low-dose omeprazole.
Topics: Adult; Aged; Deglutition Disorders; Dose-Response Relationship, Drug; Esophagus; Female; Gastroesoph | 1993 |
Optimal dose of omeprazole in infants and children.
Topics: Adolescent; Child; Child, Preschool; Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Infant; O | 1994 |
[Retrosternal pain. Clinical conference about a subject with esophagitis].
Topics: Esophagitis, Peptic; Esophagoscopy; Female; Gastroesophageal Reflux; Heartburn; Humans; Manometry; M | 1993 |
Omeprazole dosing: AM vs. PM: does sunset make a difference?
Topics: Drug Administration Schedule; Duodenal Ulcer; Gastric Acidity Determination; Gastrins; Gastroesophag | 1993 |
Unusual presentation of mucosal hypersensitivity secondary to gastroesophageal reflux disease.
Topics: Adolescent; Deglutition Disorders; Enteral Nutrition; Eosinophils; Esophagitis, Peptic; Esophagus; F | 1993 |
Surgery for uncomplicated gastro-oesophageal reflux.
Topics: Esophagitis; Gastroesophageal Reflux; Humans; Omeprazole | 1993 |
Wrong-way swallowing as a possible cause of bronchitis in patients with gastroesophageal reflux disease.
Topics: Bronchitis; Chronic Disease; Cough; Deglutition Disorders; Female; Gastroesophageal Reflux; Hernia, | 1993 |
[Gastroesophageal reflux (round table II)].
Topics: Antacids; Anti-Ulcer Agents; Gastroesophageal Reflux; Gastrointestinal Motility; Histamine H2 Antago | 1995 |
[Gastroesophageal reflux (round table I)].
Topics: Anti-Ulcer Agents; Diagnosis, Differential; Esophagitis; Gastric Acid; Gastroesophageal Reflux; Hist | 1995 |
Gastroesophageal reflux-induced cough syncope.
Topics: Adult; Cisapride; Cough; Drug Therapy, Combination; Gastroesophageal Reflux; Humans; Male; Monitorin | 1995 |
Dysphonia as an atypical presentation of gastro-oesophageal reflux.
Topics: Adult; Anti-Ulcer Agents; Chronic Disease; Female; Gastroesophageal Reflux; Humans; Male; Middle Age | 1995 |
[Effect of prolonged treatment with proton pump inhibitors on serum gastrin levels and the fundus mucosa. Preliminary results].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Duodenal Ulcer; Enzyme Inhi | 1995 |
Esophageal motility disorders and their coexistence with pathologic acid reflux in patients with noncardiac chest pain.
Topics: Adult; Aged; Analysis of Variance; Anti-Ulcer Agents; Chest Pain; Diagnosis, Differential; Esophagea | 1995 |
Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome.
Topics: Adult; Aged; Anti-Ulcer Agents; Asthma; Barium Sulfate; Contrast Media; Esophagus; Female; Forced Ex | 1996 |
Morning or evening dosage of omeprazole for gastro-oesophageal reflux disease?
Topics: Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Omeprazole; Time Factors | 1996 |
Pulmonary symptoms associated with gastroesophageal reflux: use of ambulatory pH monitoring to diagnose and to direct therapy.
Topics: Anti-Ulcer Agents; Asthma; Cough; Esophagus; Female; Gastroesophageal Reflux; Histamine H2 Antagonis | 1996 |
Omeprazole works best when used properly.
Topics: Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Omeprazole; Proton P | 1996 |
Monitoring of omeprazole treatment in gastro-oesophageal reflux disease.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Female; Gastroe | 1996 |
Epigastric pain unrelieved by omeprazole.
Topics: Abdominal Pain; Adult; Anti-Ulcer Agents; Barrett Esophagus; Diagnosis, Differential; Gastroesophage | 1996 |
Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms: testing while on therapy identifies the need for more aggressive anti-reflux therapy.
Topics: Drug Administration Schedule; Enzyme Inhibitors; Esophagus; Gastroesophageal Reflux; Humans; Hydroge | 1996 |
Omeprazole to treat asthma?
Topics: Adult; Anti-Ulcer Agents; Asthma; Gastroesophageal Reflux; Humans; Omeprazole | 1996 |
Cobalamin deficiency with megaloblastic anaemia in one patient under long-term omeprazole therapy.
Topics: Anemia, Megaloblastic; Enzyme Inhibitors; Gastroesophageal Reflux; Hematinics; Humans; Malabsorption | 1996 |
Cost effectiveness of medical versus surgical treatment in patients with severe or refractory gastroesophageal reflux disease in the Netherlands.
Topics: Anti-Ulcer Agents; Cost-Benefit Analysis; Fundoplication; Gastroesophageal Reflux; Health Care Costs | 1996 |
Is the only good H. pylori a dead H. pylori?
Topics: Anti-Ulcer Agents; Cohort Studies; Follow-Up Studies; Fundoplication; Gastroesophageal Reflux; Helic | 1996 |
Subjective, laryngoscopic, and acoustic measurements of laryngeal reflux before and after treatment with omeprazole.
Topics: Adult; Aged; Anti-Ulcer Agents; Female; Gastroesophageal Reflux; Humans; Larynx; Male; Middle Aged; | 1996 |
Pilot study of the oral omeprazole test for reflux laryngitis.
Topics: Administration, Oral; Adult; Aged; Drug Administration Schedule; Female; Gastroesophageal Reflux; Hu | 1997 |
Effect of omeprazole on the course of associated esophagitis and laryngitis.
Topics: Adult; Aged; Anti-Ulcer Agents; Chronic Disease; Esophagitis, Peptic; Esophagoscopy; Female; Follow- | 1996 |
Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Barrett Esophag | 1997 |
Medical treatment of gastroesophageal reflux disease does not prevent the development of Barrett's metaplasia and poor esophageal body motility.
Topics: Anti-Ulcer Agents; Barrett Esophagus; Dose-Response Relationship, Drug; Esophageal Motility Disorder | 1997 |
Incidence of antireflux surgery in Finland 1988-1993. Influence of proton-pump inhibitors and laparoscopic technique.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Enzyme Inhibitors; Female; Finland; Fundoplicatio | 1997 |
Video time lapse endoscopy.
Topics: Anti-Ulcer Agents; Endoscopy, Digestive System; Esophagitis; Gastroesophageal Reflux; Humans; Image | 1997 |
Gastroesophageal reflux disease in intellectually disabled individuals: leads for diagnosis and the effect of omeprazole therapy.
Topics: Adolescent; Adult; Aged; Anemia, Iron-Deficiency; Anti-Ulcer Agents; Child; Child, Preschool; Depres | 1997 |
A prospective follow-up study of 5669 users of lansoprazole in daily practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 1997 |
Treatment versus management of gastroesophageal reflux disease.
Topics: Diagnostic Errors; Gastroesophageal Reflux; Humans; Omeprazole | 1997 |
Omeprazole maintenance therapy for GERD.
Topics: Adult; Anti-Ulcer Agents; Controlled Clinical Trials as Topic; Double-Blind Method; Gastroesophageal | 1997 |
Laryngeal manifestations of gastroesophageal reflux before and after treatment with omeprazole.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Barium Sulfate; Contrast Media; Deglutition; Enzy | 1997 |
Acid-suppressing drugs during pregnancy.
Topics: Abnormalities, Drug-Induced; Anti-Ulcer Agents; Cohort Studies; Female; Fetus; Gastroesophageal Refl | 1997 |
Unresolved issues in gastroesophageal reflux-related ear, nose, and throat problems.
Topics: Animals; Anti-Ulcer Agents; Esophagus; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion C | 1997 |
Empiric trial of high-dose omeprazole in patients with posterior laryngitis: a prospective study.
Topics: Anti-Ulcer Agents; Cough; Deglutition Disorders; Female; Follow-Up Studies; Gastroesophageal Reflux; | 1997 |
Acid control and regression of Barrett's esophagus: is the glass half full or half empty?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Circadian Rhythm; Dru | 1997 |
Respiratory symptoms in patients with gastroesophageal reflux disease following medical therapy and following antireflux surgery.
Topics: Adult; Aged; Anti-Ulcer Agents; Cisapride; Drug Therapy, Combination; Female; Gastroesophageal Reflu | 1997 |
[Reflux disease of the gastrointestinal tract. Acute therapy and long-term care in daily practice. 2. Therapeutic procedure--diagnosis--therapy-diagram].
Topics: Amoxicillin; Clarithromycin; Dose-Response Relationship, Drug; Gastroesophageal Reflux; Helicobacter | 1997 |
Antireflux surgery in children: time for a harder look.
Topics: Child; Enzyme Inhibitors; Fundoplication; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump I | 1998 |
[Laparoscopic interventions in gastroesophageal reflux--a cost-benefit analysis].
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Cost-Benefit Analysis; Female; Gastroesophageal Reflux; | 1997 |
Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis.
Topics: Anti-Ulcer Agents; Cisapride; Cost-Benefit Analysis; Databases, Factual; Family Practice; Gastroesop | 1998 |
Rectal omeprazole in the treatment of reflux pain in esophageal cancer.
Topics: Administration, Rectal; Aged; Anti-Ulcer Agents; Esophageal Neoplasms; Female; Gastroesophageal Refl | 1998 |
Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation.
Topics: Adult; Female; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lactation; Milk, Human; Om | 1998 |
Empirical therapy versus diagnostic tests in gastroesophageal reflux disease: a medical decision analysis.
Topics: Cost of Illness; Decision Support Techniques; Drug Therapy; Duodenal Ulcer; Enzyme Inhibitors; Esoph | 1998 |
Furunculosis associated with repeated courses of omeprazole therapy.
Topics: Disease Susceptibility; Furunculosis; Gastroesophageal Reflux; Humans; Male; Omeprazole | 1998 |
Reflux and vocal disorders in singers with bulimia.
Topics: Adult; Anti-Ulcer Agents; Bulimia; Cisapride; Female; Gastroesophageal Reflux; Humans; Omeprazole; P | 1998 |
Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Barrett Esophagus; Esophagus; Fema | 1998 |
Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Circadian Rhythm; Female; G | 1998 |
The acid suppression test for unexplained chest pain.
Topics: Chest Pain; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Omeprazo | 1998 |
Outcomes of atypical symptoms attributed to gastroesophageal reflux treated by laparoscopic fundoplication.
Topics: Adult; Aged; Aged, 80 and over; Esophagus; Female; Fundoplication; Gastroesophageal Reflux; Histamin | 1998 |
[Reflux symptoms--are trials with acid pump inhibitors useful in the diagnosis?].
Topics: Antacids; Anti-Ulcer Agents; Clinical Trials as Topic; Gastric Acidity Determination; Gastroesophage | 1998 |
Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics.
Topics: Endoscopy, Digestive System; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Male; Micro | 1998 |
Omeprazole: therapy of choice in intellectually disabled children.
Topics: Adolescent; Adolescent, Institutionalized; Anti-Ulcer Agents; Child; Child, Institutionalized; Child | 1998 |
The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease.
Topics: Anti-Ulcer Agents; Dyspepsia; Endoscopy, Digestive System; Esophagitis, Peptic; Gastric Acidity Dete | 1998 |
CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection.
Topics: Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P | 1998 |
[Proton-pump inhibitor Rabeprazole: faster acid- and symptom-control].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroes | 1998 |
The utility of endoscopy in the management of patients with gastroesophageal reflux symptoms.
Topics: Adolescent; Adult; Aged; Barrett Esophagus; Esophagoscopy; Evaluation Studies as Topic; Female; Gast | 1998 |
High-dose omeprazole in patients with noncardiac chest pain.
Topics: Anti-Ulcer Agents; Chest Pain; Gastroesophageal Reflux; Humans; Omeprazole | 1999 |
Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Enzyme I | 1999 |
Cost effectiveness of treatment for gastro-oesophageal reflux.
Topics: Anti-Ulcer Agents; Cisapride; Cost-Benefit Analysis; Gastroesophageal Reflux; Histamine H2 Antagonis | 1998 |
Omeprazole in asthma.
Topics: Asthma; Gastroesophageal Reflux; Humans; Omeprazole; Peak Expiratory Flow Rate | 1999 |
[Should antisecretory agents be prescribed before endoscopy in cases with symptoms suggestive of gastroesophageal reflux?].
Topics: Anti-Ulcer Agents; Endoscopy; Gastroesophageal Reflux; Humans; Omeprazole; Patient Selection; Premed | 1999 |
Omeprazole test and 24-hour esophageal pH monitoring in diagnosing GERD.
Topics: Anti-Ulcer Agents; Esophagus; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Omeprazol | 1999 |
[Benign proximal esophageal stenosis--mostly a complication of gastroesophageal reflux disease].
Topics: Anti-Ulcer Agents; Diagnosis, Differential; Dilatation; Endoscopy, Digestive System; Esophageal Sten | 1999 |
Clinical and economic factors in the selection of drugs for gastroesophageal reflux disease.
Topics: Cimetidine; Cost-Benefit Analysis; Endoscopy; Gastroesophageal Reflux; Humans; Omeprazole; Ranitidin | 1993 |
Does Helicobacter pylori affect the management of gastroesophageal reflux disease?
Topics: Enzyme Inhibitors; Gastritis; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; | 1999 |
Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease.
Topics: Anti-Ulcer Agents; Case-Control Studies; Esophagitis, Peptic; Follow-Up Studies; Gastroesophageal Re | 1999 |
The effect of medical therapy and antireflux surgery on dysphagia in patients with gastroesophageal reflux disease without esophageal stricture.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cisapride; | 1999 |
Gastroesophageal reflux: A critical factor in pediatric subglottic stenosis.
Topics: Child, Preschool; Cisapride; Drug Monitoring; Fundoplication; Gastroesophageal Reflux; Gastrointesti | 1999 |
Gastroesophageal reflux disease as a cause of death: analysis of fatal cases under conservative treatment.
Topics: Aged; Anti-Ulcer Agents; Cause of Death; Esophagitis, Peptic; Female; Finland; Gastroesophageal Refl | 1999 |
The cost-effectiveness of strategies to assess gastroesophageal reflux as an exacerbating factor in asthma.
Topics: Asthma; Cost-Benefit Analysis; Drug Costs; Gastroesophageal Reflux; Health Care Costs; Humans; Hydro | 1999 |
The efficacy of extended-interval dosing of omeprazole in keeping gastroesophageal reflux disease patients symptom free.
Topics: Clinical Trials as Topic; Drug Administration Schedule; Enzyme Inhibitors; Gastroesophageal Reflux; | 1999 |
Nocturnal gastric acid breakthrough on proton pump inhibitors.
Topics: Circadian Rhythm; Drug Administration Schedule; Gastric Acid; Gastroesophageal Reflux; Helicobacter | 1999 |
Fixed drug eruption in hands caused by omeprazole.
Topics: Adult; Diagnosis, Differential; Drug Eruptions; Enzyme Inhibitors; Female; Gastroesophageal Reflux; | 1999 |
Gastroesophageal reflux disease and a HAPPI quality of life.
Topics: Gastroesophageal Reflux; Heartburn; Humans; Omeprazole; Proton Pump Inhibitors; Quality of Life | 1999 |
Supraesophageal manifestations of gastroesophageal reflux disease.
Topics: Adult; Anti-Ulcer Agents; Cough; Domperidone; Dopamine Antagonists; Endoscopy, Gastrointestinal; Fem | 1999 |
Omeprazole for asthma with gastro-oesophageal reflux.
Topics: Anti-Ulcer Agents; Asthma; Gastroesophageal Reflux; Humans; Omeprazole | 1999 |
[Role of 24 hour intraesophageal pH monitoring in diagnosis of gastroesophageal reflux and assessment of drug effectiveness].
Topics: Adult; Anti-Ulcer Agents; Circadian Rhythm; Esophagus; Famotidine; Female; Follow-Up Studies; Gastro | 1999 |
Development of a health-related quality-of-life questionnaire for individuals with gastroesophageal reflux disease: a validation study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Female; Gastroesophageal Re | 1999 |
The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain.
Topics: Anti-Ulcer Agents; Chest Pain; Cost-Benefit Analysis; Decision Trees; Diagnosis, Differential; Esoph | 1999 |
Cost-effectiveness of testing for gastroesophageal reflux disease: what do patients, physicians, and health insurers want?
Topics: Anti-Ulcer Agents; Chest Pain; Cost-Benefit Analysis; Diagnosis, Differential; Esophagoscopy; Gastro | 1999 |
Fundic gland polyps under omeprazole treatment.
Topics: Anti-Ulcer Agents; Gastric Fundus; Gastroesophageal Reflux; Humans; Omeprazole; Polyps; Stomach Neop | 1999 |
Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; California; Cost Savings; C | 1999 |
Atrophic gastritis during long-term omeprazole therapy affects serum vitamin B12 levels.
Topics: Absorption; Anti-Ulcer Agents; Cohort Studies; Drug Administration Schedule; Female; Gastritis, Atro | 1999 |
[Diagnostic omeprazole test in suspected reflux-associated chronic cough].
Topics: Adult; Aged; Cough; Diagnosis, Differential; Enzyme Inhibitors; Esophagitis; Female; Gastroesophagea | 1999 |
Rabeprazole is latest entrant in proton-pump-inhibitor class.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroes | 1999 |
Accurately diagnosing and successfully treating chronic cough due to gastroesophageal reflux disease can be difficult.
Topics: Antacids; Asthma; Chronic Disease; Consensus Development Conferences as Topic; Cough; Diagnosis, Dif | 1999 |
Helicobacter pylori and omeprazole therapy in GERD.
Topics: Enzyme Inhibitors; Esophagitis, Peptic; Gastroesophageal Reflux; Helicobacter Infections; Helicobact | 1999 |
Rabeprazole sodium.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroes | 1999 |
24-h pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Barrett Esophagus; Child; Enzyme Inhibitors; Female; Gas | 1999 |
Gastro-oesophageal reflux: clinical profiles and outcome.
Topics: Adolescent; Child; Child, Preschool; Cisapride; Esophagoscopy; Female; Fundoplication; Gastroesophag | 1999 |
Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Femal | 2000 |
[Congress of the American College of Surgeons (ACS). San Francisco, 10-15 October 1999].
Topics: Anti-Ulcer Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cholang | 1999 |
Concordance between use of proton pump inhibitors and prescribing guidelines.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Drug Utilization Review; Enzyme Inhibitors; Female; | 2000 |
Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Barrett Esophagus; Child; Drug Resist | 2000 |
[Award winning drug].
Topics: Antacids; Anti-Ulcer Agents; Esophageal Neoplasms; Gastric Acidity Determination; Gastroesophageal R | 1999 |
The acid test for formulary policy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Costs and Cost Analysis; Formularies as | 1999 |
Ex juvantibus approach for chronic posterior laryngitis: results of short-term pantoprazole therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Chronic Disease; | 1999 |
The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis.
Topics: Adult; Aged; Anti-Ulcer Agents; Esophagitis; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion C | 2000 |
Clinical and fiscal impact of lansoprazole intolerance in veterans with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Costs and Cost Analysis; Enzyme Inhibitors; Female; G | 2000 |
Clinical evolution of laryngeal granulomas: treatment and prognosis.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Antiemetics; Botulinum Toxins, Type A; Combined Modality | 1999 |
A surgical nirvana for GERD sufferers?
Topics: Gastroesophageal Reflux; Humans; Laparoscopy; Omeprazole; Quality of Life; Retreatment; Surveys and | 2000 |
Pantoprazole (Protonix).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Clinical Trials as Topic; Dose-Response Rel | 2000 |
pH monitoring in patients with benign voice disorders.
Topics: Adult; Aged; Anti-Ulcer Agents; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; | 2000 |
Longitudinal oesophageal muscle and pharyngo-oesophageal dysphagia--a deductive study.
Topics: Anti-Ulcer Agents; Bronchitis; Deglutition Disorders; Esophagogastric Junction; Esophagus; Gastroeso | 2000 |
Reversible renal failure after treatment with omeprazole.
Topics: Acute Kidney Injury; Aged; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Male; Nephritis, Inte | 2000 |
How do we offer clinical relief to patients with gastro-oesophageal reflux disease?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; | 2000 |
Should we eradicate Helicobacter pylori in patients with recurrent gastro-oesophageal reflux disease?
Topics: Esophagitis; Gastritis; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Human | 2000 |
Controlling acid reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration | 1999 |
[Diagnosis and therapy of laryngitis gastrica].
Topics: Adult; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Ga | 2000 |
Presumed laryngo-pharyngeal reflux: investigate or treat?
Topics: Anti-Ulcer Agents; Clinical Protocols; Diagnosis, Differential; Female; Gastroesophageal Reflux; Hum | 2000 |
Long-term safety and efficacy of omeprazole in gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Barrett Esophagus; Drug Administration Schedule; Esophageal Neoplasms; Esophagiti | 2000 |
Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Female; Gastroesophageal Re | 2000 |
Rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adenosine Triphosphatases; Anti-Ulcer Agent | 1999 |
Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders.
Topics: Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Biomarkers, Tumor; Chromogranin A; Chromogranins; | 2000 |
Laryngopharyngeal sensory deficits in patients with laryngopharyngeal reflux and dysphagia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Deglutition Disorders; Fema | 2000 |
Omeprazole in oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Carcinoid Tumor; Female; Gastroesophageal Reflux; Humans; Middle Aged; Omeprazole | 2000 |
Parietal cell protrusions with fundic gland cysts and fundic gland polyps: are they related or simply similar but distinguishable?
Topics: Cysts; Gastric Fundus; Gastric Mucosa; Gastrins; Gastroesophageal Reflux; Humans; Omeprazole; Pariet | 2000 |
Asymptomatic giardiasis--an association with proton pump inhibitors?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Gastroesophageal Reflux; Giardias | 2000 |
Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Decision Trees; Drug | 2000 |
Proton pump inhibitors: cost-effective agents for management of reflux-induced esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Decision Support Tec | 2000 |
Treatment strategies for gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cytochrome P-450 Enzyme System; Drug Intera | 2000 |
Long-term effects of omeprazole on the gastric mucosa.
Topics: Anti-Ulcer Agents; Gastric Mucosa; Gastroesophageal Reflux; Humans; Omeprazole; Parietal Cells, Gast | 2000 |
Long-term omeprazole treatment and risk of gastric cancer.
Topics: Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Omeprazole; Risk Factors; Stomach Neoplasms | 2000 |
Efficacy and safety of long-term omeprazole treatment.
Topics: Anti-Ulcer Agents; Gastric Mucosa; Gastroesophageal Reflux; Humans; Omeprazole; Time Factors | 2000 |
Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease.
Topics: Aged; Anti-Ulcer Agents; Enzyme Inhibitors; Esophagitis, Peptic; Female; Follow-Up Studies; Gastroes | 2001 |
Dyspepsia responsive to acid suppression therapy: reflux disease or duodenal hypersensitivity?
Topics: Antacids; Duodenum; Dyspepsia; Gastric Acid; Gastroesophageal Reflux; Histamine H2 Antagonists; Huma | 2000 |
[Heartburn. Only a harmless symptom?].
Topics: Esophagitis, Peptic; Gastroesophageal Reflux; Heartburn; Humans; Omeprazole; Proton Pump Inhibitors | 2001 |
From the Food and Drug Administration.
Topics: Anti-Ulcer Agents; Diphtheria-Tetanus-acellular Pertussis Vaccines; Epidermolysis Bullosa Dystrophic | 2001 |
Reproducibility, validity, and responsiveness of a disease-specific symptom questionnaire for gastroesophageal reflux disease.
Topics: Anti-Ulcer Agents; Case-Control Studies; Female; Fundoplication; Gastroesophageal Reflux; Health Sta | 2000 |
Black esophagus: a view in the dark.
Topics: Acute Disease; Aged; Anti-Ulcer Agents; Esophageal Diseases; Esophagus; Gastric Outlet Obstruction; | 2000 |
Antireflux surgery in children suffering from reflux-associated respiratory disease?
Topics: Adolescent; Anti-Ulcer Agents; Child; Child, Preschool; Female; Gastroesophageal Reflux; Humans; Inf | 2001 |
Which patients with ulcer- or reflux-like dyspepsia will respond favorably to omeprazole?
Topics: Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Omeprazole; Patient Selection; Peptic Ulcer; Tre | 2001 |
Stability of gastric secretory inhibition during 6-month treatment with omeprazole in patients with gastroesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Female; Gastric Acid; Gastric Acidity Determination; Gastroesophageal Reflu | 2001 |
Omeprazole maintenance therapy for gastroesophageal reflux disease after failure of fundoplication.
Topics: Child; Child, Preschool; Enzyme Inhibitors; Esophagitis, Peptic; Female; Follow-Up Studies; Fundopli | 2001 |
Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole.
Topics: Adult; Aged; Anti-Ulcer Agents; Electric Impedance; Enzyme Inhibitors; Female; Gastric Acid; Gastric | 2001 |
Restoration of enamel and dentin erosion due to gastroesophageal reflux disease: a case report.
Topics: Adult; Ceramics; Composite Resins; Crowns; Dental Enamel; Dental Restoration, Permanent; Dental Vene | 2001 |
Laryngopharyngeal reflux symptoms improve before changes in physical findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studie | 2001 |
Laryngopharyngeal reflux symptoms improve before changes in physical findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studie | 2001 |
Laryngopharyngeal reflux symptoms improve before changes in physical findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studie | 2001 |
Laryngopharyngeal reflux symptoms improve before changes in physical findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studie | 2001 |
Pathological documentation of complete elimination of Barrett's metaplasia following endoscopic multipolar electrocoagulation therapy.
Topics: Adult; Anti-Ulcer Agents; Barrett Esophagus; Chemotherapy, Adjuvant; Electrocoagulation; Esophagecto | 2001 |
Treatment of gastroesophageal reflux disease: to step or not to step.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Gastroesophageal Reflux; Heartburn; Hist | 2001 |
Surgery versus medical therapy for gastroesophageal reflux disease.
Topics: Anti-Ulcer Agents; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Laparoscopy; Omeprazole; Prot | 2001 |
Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors.
Topics: Anti-Ulcer Agents; Campylobacter Infections; Gastric Acid; Gastroenteritis; Gastroesophageal Reflux; | 2001 |
Adenocarcinoma of the rat esophagus in the presence of a proton pump inhibitor: a pilot study.
Topics: Adenocarcinoma; Animals; Disease Models, Animal; Esophageal Neoplasms; Esophagostomy; Gastroesophage | 2001 |
Chronic middle ear disease and gastroesophageal reflux disease: a causal relation?
Topics: Adult; Aged; Anti-Ulcer Agents; Chronic Disease; Combined Modality Therapy; Endoscopy; Female; Gastr | 2001 |
Impact of a formulary change in proton pump inhibitors on health care costs and patients' symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Female; Formularies as Topic; Gastroesophageal Reflux; Heal | 2001 |
Sporadic fundic gland polyps, GERD and omeprazole usage: is there a little piece of information missed?
Topics: Anti-Ulcer Agents; Gastric Fundus; Gastroesophageal Reflux; Humans; Omeprazole; Polyps | 2001 |
Strategies for diagnosis and short and long term treatment: respondent overview.
Topics: Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors | 2001 |
The treatment of gastroesophageal reflux disease with proton-pump inhibitors and its implications on managed care--pharmacoeconomics and its application to antisecretory drugs: a case study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; California; Clinical Trials as Topic; En | 2001 |
Duodenal fat intensifies the perception of heartburn.
Topics: Adult; Aged; Analysis of Variance; Anti-Ulcer Agents; Dietary Fats; Dose-Response Relationship, Drug | 2001 |
Efficacy of medical therapy and antireflux surgery to prevent Barrett's metaplasia in patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Barrett Esophagus; Benzimid | 2001 |
[Laryngeal manifestations of gastroesophageal reflux disease (GERD) in pediatric patients: the usefulness of therapeutic (proton pump inhibitor (PPI)) trials].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Child; Child, Preschool; Gastroesophageal Reflux; Humans; I | 2001 |
Effect of aggressive therapy on laryngeal symptoms and voice characteristics in patients with gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cisapride; Gastroesophag | 2001 |
Optimizing acid-suppression therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Duode | 2001 |
Clinical efficacy of proton pump inhibitor therapy in neurologically impaired children with gastroesophageal reflux: prospective study.
Topics: Child; Child, Preschool; Drug Administration Schedule; Female; Follow-Up Studies; Gastroesophageal R | 2001 |
Treatment of erosive oesophagitis with omeprazole: a comparison with different delivery system.
Topics: Anti-Ulcer Agents; Drug Delivery Systems; Esophagitis; Gastroesophageal Reflux; Helicobacter Infecti | 2001 |
[The relationship between obstructive sleep apnea and gastroesophageal reflux and the effect of antireflux therapy].
Topics: Adult; Anti-Ulcer Agents; Cisapride; Drug Therapy, Combination; Female; Gastroesophageal Reflux; Hum | 1999 |
Laryngospasm: an atypical manifestation of severe gastroesophageal reflux disease (GERD).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Enzyme Inhibito | 2001 |
Gastroesophageal reflux and obstructive sleep apnea.
Topics: Adult; Chemoreceptor Cells; Gastroesophageal Reflux; Humans; Larynx; Male; Middle Aged; Omeprazole; | 2001 |
[Lansoprazole-associated collagenous colitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Colitis; Collagen; Female; Gastroesophageal Reflux; | 2001 |
Cervical osteophyte induced dysphagia.
Topics: Anti-Ulcer Agents; Cervical Vertebrae; Cisapride; Deglutition Disorders; Esophageal Stenosis; Gastro | 2001 |
In support of "step-up therapy" for gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Drug Administration Sched | 2002 |
[Pharma-clinics medication of the month. Rabeprazole (Pariet)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Clinical Trials as Topic; Duodenal Ulcer; E | 2002 |
Spontaneous resolution of multiple fundic gland polyps after cessation of treatment with lansoprazole and Nissen fundoplication: a case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Enzyme Inhibitors; Female; Fundoplication; Gastric Fu | 2002 |
Proton pump inhibitors or surgery for gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Enzyme Inhibit | 2002 |
Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Enzyme Inhibitors; Female; Fundop | 2002 |
Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies.
Topics: Adult; Cost-Benefit Analysis; Enzyme Inhibitors; Esomeprazole; Esophagitis; Female; Gastroesophageal | 2002 |
Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor.
Topics: Aged; Cimetidine; Creatinine; Enzyme Inhibitors; Female; Folic Acid; Gastroesophageal Reflux; Histam | 2002 |
Is lansoprazole (Prevacid) or omeprazole (Prilosec) more effective in treating erosive esophagitis?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Evidence-Based Medicine; Gastroes | 2002 |
Pantoprazole IV (Protonix IV).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Clinical Trials as Topic; Drug Approval; Fe | 2002 |
Discussion on simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole.
Topics: Anti-Ulcer Agents; Electric Impedance; Enzyme Inhibitors; Esophagus; Gastroesophageal Reflux; Humans | 2002 |
Esomeprazole: a review of its use in the management of acid-related disorders in the US.
Topics: Animals; Anti-Ulcer Agents; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Gastrointestin | 2002 |
Laryngeal manifestations of gastroesophageal reflux disease in children.
Topics: Child; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Laryn | 2002 |
High dose Omeprazole in esophagitis with stenosis after surgical treatment of esophageal atresia.
Topics: Esophageal Atresia; Esophageal Stenosis; Esophagitis; Gastroesophageal Reflux; Humans; Omeprazole | 2002 |
Protection against aspiration with the Proseal laryngeal mask airway.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anesthesia, General; Female; Follow-Up Studies; Gastr | 2002 |
[Clinical management of reflux laryngitis].
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Diagnosis, Differential; Female; Gastroesophageal Reflux | 2002 |
Cisapride and gastroesophageal reflux disease.
Topics: Cisapride; Drug Therapy, Combination; Gastroesophageal Reflux; Omeprazole; Piperidines; Ranitidine | 1992 |
[Respiratory manifestations and gastroesophageal reflux].
Topics: Adult; Aged; Antacids; Cough; Diet; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omep | 1992 |
Omeprazole.
Topics: Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Omeprazole; Peptic Ulcer; Risk Factors; S | 1991 |
Medical therapy for gastroesophageal reflux disease. Not all treatments are equal!
Topics: Drug Administration Schedule; Famotidine; Gastroesophageal Reflux; Humans; Omeprazole | 1991 |
[Prolonged drug therapy of reflux disease if surgery is contraindicated].
Topics: Gastroesophageal Reflux; Omeprazole; Time Factors | 1991 |
[Barrett's esophagus and omeprazole].
Topics: Barrett Esophagus; Female; Gastroesophageal Reflux; Humans; Middle Aged; Omeprazole | 1991 |
Comparative tolerability profile of omeprazole in clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Aspartate Aminotransferases; Cimet | 1991 |
Omeprazole.
Topics: Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Omeprazole | 1991 |
Omeprazole.
Topics: Duodenal Ulcer; Esophagitis; Gastroesophageal Reflux; Humans; Omeprazole; Stomach Ulcer | 1991 |
Combined gastric and oesophageal 24-hour pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole.
Topics: Adult; Aged; Aged, 80 and over; Drug Resistance; Esophagus; Female; Gastric Acid; Gastrins; Gastroes | 1990 |
Is gastric acid hypersecretion the only reason for refractory gastroesophageal reflux disease?
Topics: Gastric Acid; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Omeprazole | 1990 |
Effect of omeprazole and high doses of ranitidine on gastric acidity and gastroesophageal reflux in patients with moderate-severe esophagitis.
Topics: Adult; Esophagitis, Peptic; Esophagus; Female; Gastric Acidity Determination; Gastroesophageal Reflu | 1990 |
Omeprazole: a new approach to gastric acid suppression.
Topics: Esophagitis, Peptic; Gastric Acid; Gastroesophageal Reflux; Humans; Omeprazole; Zollinger-Ellison Sy | 1990 |
Omeprazole.
Topics: Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Omeprazole | 1990 |
Effect of omeprazole on gastroesophageal reflux in Barrett's esophagus.
Topics: Barrett Esophagus; Esophagitis, Peptic; Esophagogastric Junction; Female; Gastric Acidity Determinat | 1989 |
Summary of the 34th meeting of the Food and Drug Administration Gastrointestinal Drugs Advisory Committee. March 15 and 16, 1989 (omeprazole and domperidone).
Topics: Animals; Diabetes Complications; Domperidone; Duodenal Ulcer; Gastroesophageal Reflux; Humans; Omepr | 1989 |
Beneficial effect of omeprazole in a patient with severe bronchial asthma and gastro-oesophageal reflux.
Topics: Adult; Asthma; Domperidone; Gastroesophageal Reflux; Humans; Male; Omeprazole; Ranitidine; Recurrenc | 1988 |
Barrett's ulcer: response to standard dose ranitidine, high dose ranitidine, and omeprazole.
Topics: Barrett Esophagus; Drug Administration Schedule; Drug Therapy, Combination; Esophageal Diseases; Eso | 1988 |